{"21ed4da4b3dfde07b7b086728deab4e569b1739e": [["Such system generally consists of a discrete algorithm or controller that interacts with a continuous process or plant in order to control its behaviour.", [["a continuous process", "TREATMENT", 89, 109]]], ["The controller can retrieve information from the plant through sensors and may alter its behaviour with actuators.IntroductionBecause of this hybridation, CPS are often regarded as quite hard to trust.", [["this hybridation", "PROBLEM", 137, 153]]], ["However, their versatility, adaptability and price made them unavoidable in our everyday life, from Internet of Things (IoT) to smart systems (e.g. home automation, smart factories and so on), including, of course, critical systems such as transportation and medical devices.", [["transportation and medical devices", "TREATMENT", 240, 274]]], ["Being able to formally model and certify CPS is thus a major challenge nowadays.IntroductionThe design of formal modelling approaches for CPS development and/or certification has been addressed in various ways.", [["formal modelling approaches", "TREATMENT", 106, 133], ["CPS development", "TREATMENT", 138, 153]]], ["In [4] , Alur defines the hybrid automata formalism to model hybrid systems.", [["hybrid automata formalism", "OBSERVATION", 26, 51]]], ["Hybrid model-checkers such as HyTech, d/dt, PHaVer or SpaceEx can then be used to establish properties such as reachability.IntroductionIn terms of modelling techniques, [18] have proposed HybridCSP as a hybrid extension of CSP [17] .", [["HyTech", "CHEMICAL", 30, 36], ["HyTech", "SIMPLE_CHEMICAL", 30, 36], ["PHaVer", "SIMPLE_CHEMICAL", 44, 50], ["SpaceEx", "SIMPLE_CHEMICAL", 54, 61], ["PHaVer", "PROTEIN", 44, 50], ["Hybrid model", "TEST", 0, 12], ["HyTech", "TEST", 30, 36], ["dt", "PROBLEM", 40, 42], ["PHaVer", "TREATMENT", 44, 50], ["SpaceEx", "TREATMENT", 54, 61]]], ["[7] proposes a continuous extension of Action System.", [["a continuous extension of Action System", "TREATMENT", 13, 52]]], ["In the same manner, [8] proposes an hybrid extension to the Event-B method.IntroductionProof-based approaches have also been used to try and formally prove CPS.", [["an hybrid extension", "PROBLEM", 33, 52]]], ["[9] use Coq to that extent, starting from an annotated C program.", [["Coq", "PROTEIN", 8, 11], ["Coq", "TREATMENT", 8, 11]]], ["[21] uses a special formalism (hybrid programs) to model and to prove hybrid systems using KeYmaera.", [["a special formalism (hybrid programs", "TREATMENT", 10, 46], ["KeYmaera", "TREATMENT", 91, 99]]], ["Event-B has been used for modelling similar systems in [23] and [10] .IntroductionHowever, all these approaches still require formal modelling expertise, where the developer needs to establish correctness using complex proof systems involving discrete and continuous mathematics features and proof rules.", [["[23]", "SIMPLE_CHEMICAL", 55, 59], ["[10]", "SIMPLE_CHEMICAL", 64, 68]]], ["As a consequence, the use of these methods on a large scale is hindered, in particular in formal system engineering.", [["these methods", "TREATMENT", 29, 42], ["a large scale", "TREATMENT", 46, 59]]], ["So, easing CPS formal modelling and verification activities in presence of both discrete and continuous behaviours is still a challenge.IntroductionTo address this challenge, we propose a systematic correct-by-construction approach to design hybrid systems based on the definition of architecture patterns.", [["hybrid systems", "CELL_LINE", 242, 256], ["CPS formal modelling", "TEST", 11, 31], ["verification activities", "TEST", 36, 59], ["design hybrid systems", "TREATMENT", 235, 256]]], ["Proof obligations, in particular regarding well-definedness, may need to be discharged in order to inherit all the properties of the generic pattern.IntroductionIn our previous work [14] , we used Event-B to design and formalise commonly used architecture patterns (AP) for centralised hybrid systems.", [["centralised hybrid systems", "CELL_LINE", 274, 300], ["centralised hybrid systems", "PROBLEM", 274, 300]]], ["In this paper, we extend these architecture patterns to model distributed hybrid systems i.e. systems that manage multiple autonomous subsystems, linked together by a communication network.", [["autonomous subsystems", "OBSERVATION", 123, 144]]], ["A case study is given as a possible instantiation of this pattern, involving independent liquid tanks enforcing a global invariant that expresses safety properties.", [["A case study", "TEST", 0, 12], ["independent liquid tanks", "TREATMENT", 77, 101]]], ["3 presents hybrid modelling features needed for hybrid system development.", [["hybrid modelling features", "PROBLEM", 11, 36], ["hybrid system development", "PROBLEM", 48, 73]]], ["Section 6 introduces a case study to support our work, which is solved in Sect.", [["a case study", "TEST", 21, 33]]], ["8 provides an assessment of the approach, and Sect.", [["an assessment", "TEST", 11, 24]]], ["9 concludes the paper and discusses possible future research directions.IntroductionThe design process consists of a series of refinements of an abstract model leading to the final concrete model.", [["an abstract model", "TREATMENT", 142, 159]]], ["Event-B machines formalize models described as state-transitions systems and a set of proof obligations are automatically generated for each model.IntroductionNotation.", [["B machines", "TREATMENT", 6, 16], ["a set of proof obligations", "TREATMENT", 77, 103]]], ["Model structureContextMachine RefinementHybrid Systems Modelling FeaturesModelling hybrid systems requires handling of continuous behaviours.", [["Modelling hybrid systems", "PROBLEM", 73, 97]]], ["These concepts such as differential equations and their associated properties have been modelled through an intensive use of Event-B theories and have been used to model various case studies found in [13] [14] [15] .Hybrid Systems Modelling FeaturesIn order to deal with continuous objects, theories have been defined for continuous functions, (ordinary) differential equations as well as for their properties.", [["[13] [14] [15]", "SIMPLE_CHEMICAL", 200, 214], ["differential equations", "TEST", 23, 45], ["differential equations", "TEST", 355, 377]]], ["We thus introduce dense time t \u2208 R + , modeled as a continuously evolving variable.VARIABLES t INVARIANTSSystem State.", [["dense", "OBSERVATION_MODIFIER", 18, 23], ["variable", "OBSERVATION_MODIFIER", 74, 82]]], ["According to the architecture of hybrid systems, we have identified two types of states.VARIABLES t INVARIANTS-Discrete state x s \u2208 STATES , variable that represents the controller's internal state.", [["Discrete", "OBSERVATION_MODIFIER", 111, 119], ["state x s", "OBSERVATION_MODIFIER", 120, 129]]], ["It evolves in a pointwise manner with instantaneous changes. -Continuous state x p \u2208 R + \u2192 S represents the plant's state and evolves continuously.", [["instantaneous changes", "PROBLEM", 38, 59], ["instantaneous changes", "OBSERVATION", 38, 59]]], ["It is modelled as a function of time with values in space S.Hybrid Modeling Features.Modeling hybrid systems requires the introduction of multiple specific features which are defined below.Hybrid Modeling Features.-DE(S) type for differential equations which solutions evolve over set S ode(f, \u03b7 0 , t 0 ) represents the ODE 1\u03b7 (t) = f (\u03b7(t), t) with initial condition \u03b7(t 0 ) = \u03b7 0 Other, more specialised expressions and predicates are defined (FlowEquation, FlowODE ) in additional theories.", [["Modeling hybrid systems", "PROBLEM", 85, 108], ["Hybrid Modeling Features", "PROBLEM", 189, 213], ["differential equations", "PROBLEM", 230, 252], ["initial condition", "PROBLEM", 351, 368], ["hybrid systems", "OBSERVATION", 94, 108]]], ["Note that all these definitions use algebraic datatypes together with axioms, theorems and proof rules.Hybrid Modeling Features.In the following, we use x to denote the union of discrete and continuous state variables.Hybrid Modeling Features.Continuous Assignment.", [["Hybrid Modeling Features", "PROBLEM", 103, 127], ["Hybrid Modeling Features", "PROBLEM", 218, 242]]], ["Updating such variables thus requires to 1) make the time progress from t to t > t, and 2) append to the already existing function a new piece corresponding to its extended behavior (on [t, t ]) while ensuring its \"past\" (i.e. whatever happened on [0, t]) remains unchanged.Hybrid Modeling Features.Similarly to the classic Event-B's before-after predicate (BAP ), we define a continuous before-after predicate (CBAP ) operator, denoted :| t\u2192t , as follows:Hybrid Modeling Features..", [["Hybrid Modeling Features", "PROBLEM", 274, 298], ["unchanged", "OBSERVATION_MODIFIER", 264, 273]]], ["The operator consists of 3 parts: past preservation and coherence at assignment point (PP), before-after predicate on the added section (PR), and local invariant preservation (LI).", [["PR", "PROTEIN", 137, 139], ["PP", "TEST", 87, 89], ["the added section (PR)", "TREATMENT", 118, 140]]], ["The discrete state variables x s do not change in the interval [t, t ] but the predicate P may use it for control purposes.Hybrid Modeling Features.Note that this operator is well-defined if and only if t > t, as otherwise the interval [t, t ] would not be well-defined.Hybrid Modeling Features.From the above definition, shortcuts can be introduced for readability purposes:Architecture Patterns for Modelling Hybrid SystemsOne of the most common architectures found in CPS (see Fig. 2 ) is a discrete software controller, which interacts by some means (e.g. actuators) with a plant and its physical environment (continuous physical phenomenon) in a closed-loop schema.", [["P", "DNA", 89, 90], ["Hybrid Modeling Features", "PROBLEM", 123, 147], ["Hybrid Modeling Features", "PROBLEM", 270, 294], ["readability purposes", "TEST", 354, 374], ["continuous physical phenomenon", "TREATMENT", 614, 644], ["a closed-loop schema", "TREATMENT", 649, 669], ["discrete", "OBSERVATION_MODIFIER", 4, 12], ["discrete", "OBSERVATION_MODIFIER", 494, 502], ["software", "OBSERVATION", 503, 511], ["loop schema", "OBSERVATION", 658, 669]]], ["Sensors, user commands control decision and actuators modify these variables.Architecture Patterns for Modelling Hybrid SystemsIn this paper, we focus on the verification of the correctness of such discrete controllers, which require correct composition of discrete and continuous models.", [["such discrete controllers", "PROBLEM", 193, 218]]], ["We claim that correctness should arise from a design process based on sound abstractions and models of the relevant laws of physics.Architecture Patterns for Modelling Hybrid SystemsHybrid systems may combine the behaviours of multiple separated components (plants or controllers), which can lead to very different control strategies, following the number of controllers and plants to be controlled.", [["a design process", "PROBLEM", 44, 60], ["Modelling Hybrid SystemsHybrid systems", "TREATMENT", 158, 196], ["multiple", "OBSERVATION_MODIFIER", 227, 235]]], ["Therefore, the generic architecture given in Fig. 2 should be refined into three types of architecture patterns:Architecture Patterns for Modelling Hybrid Systems-Single-to-Single AP corresponds to hybrid systems with one controller and one plant.", [["Modelling Hybrid Systems", "PROBLEM", 138, 162]]], ["Examples of hybrid systems corresponding to this pattern addressed in the literature include the automatic car braking [15] , the signalised left-turn assist [13] , heating systems [16] , etc. -Single-to-Many AP describes hybrid systems with one controller and many plants (more than one).", [["hybrid systems", "PROBLEM", 12, 26], ["heating systems", "TREATMENT", 165, 180], ["left", "ANATOMY_MODIFIER", 141, 145], ["many", "OBSERVATION_MODIFIER", 261, 265], ["plants", "OBSERVATION", 266, 272]]], ["This pattern corresponds to centralised control.", [["centralised control", "TREATMENT", 28, 47], ["centralised control", "OBSERVATION", 28, 47]]], ["An example of hybrid system corresponding to this pattern is the control of a global volume distributed over several tanks formalised with hybrid automata and with Event-B in [14] . -Many-to-Many AP characterises hybrid systems with many controllers and many plants.", [["hybrid system", "PROBLEM", 14, 27], ["hybrid automata", "PROBLEM", 139, 154], ["Many AP characterises hybrid systems", "PROBLEM", 191, 227], ["hybrid system", "OBSERVATION", 14, 27], ["global", "OBSERVATION_MODIFIER", 78, 84], ["volume", "OBSERVATION_MODIFIER", 85, 91], ["hybrid automata", "OBSERVATION", 139, 154], ["many", "OBSERVATION_MODIFIER", 254, 258], ["plants", "OBSERVATION", 259, 265]]], ["Examples of such systems are UAV or rover fleet control modelled in Event-B [22] .Architecture Patterns for Modelling Hybrid SystemsAll the patterns defined above refine the one of Fig. 2 .", [["rover fleet control", "TREATMENT", 36, 55], ["Modelling Hybrid Systems", "PROBLEM", 108, 132]]], ["The controller and the plant components may be refined to one or many components.", [["The controller and the plant components", "TREATMENT", 0, 39], ["many", "OBSERVATION_MODIFIER", 65, 69], ["components", "OBSERVATION_MODIFIER", 70, 80]]], ["The single-to-many AP defines a controller with one discrete state able to build a global continuous state aggregating the many states of each and every plants.Architecture Patterns for Modelling Hybrid SystemsFinally, the many-to-many AP allows to define distributed hybrid systems where each component has a partial view of all the other systems.", [["AP", "PROTEIN", 19, 21], ["Modelling Hybrid SystemsFinally", "PROBLEM", 186, 217], ["a partial view", "TEST", 308, 322], ["hybrid systems", "OBSERVATION", 268, 282]]], ["Then, the correctness of this approximation shall be ensured to establish global invariants.", [["global invariants", "OBSERVATION", 74, 91]]], ["In other words, local invariants associated to each hybrid system contribute to ensure the global invariant of the whole system composed of all the hybrid systems.Architecture Patterns for Modelling Hybrid SystemsNote: it is worth noticing that the case of many-to-many AP may be defined as a set of hybrid systems corresponding to either single-to-single AP or singleto-many AP.", [["AP", "CANCER", 270, 272], ["hybrid systems", "CELL_LINE", 300, 314], ["local invariants", "PROBLEM", 16, 32], ["each hybrid system", "PROBLEM", 47, 65]]], ["In the last case, single-to-many is abstracted by a single-to-single system, providing modular verification.Methodology for Hybrid System DesignThe pattern presented in Sect.", [["modular verification", "TEST", 87, 107]]], ["4 served as a basis for setting up a methodology for hybrid system design.", [["hybrid system design", "PROBLEM", 53, 73]]], ["Discrete models can be derived in the same manner [6] .Methodology for Hybrid System DesignNote that the generic model introduces typically continuous concepts such as differential equations and dense time.", [["Hybrid System", "TREATMENT", 71, 84]]], ["It therefore heavily relies on the theory extension of Event-B implemented as a plug-in (see Sect.", [["a plug", "PROBLEM", 78, 84]]], ["Discrete events are instantaneous.", [["Discrete events", "PROBLEM", 0, 15], ["instantaneous", "OBSERVATION_MODIFIER", 20, 33]]], ["Transition events (corresponding to command arrow and the Ctrl box of Fig. 2 ) model internal changes in the controller.", [["Ctrl box", "DNA", 58, 66], ["Transition events", "PROBLEM", 0, 17], ["model internal changes in the controller", "PROBLEM", 79, 119], ["internal changes", "OBSERVATION", 85, 101]]], ["It updates the state of the automaton (act1).A Generic Event-B Model for Hybrid Systemsa c t 1 : xs :\u2208 s END Sense.", [["act1", "GENE_OR_GENE_PRODUCT", 39, 43], ["act1", "DNA", 39, 43]]], ["Sensing events (corresponding to sense arrow of Fig. 2 ) model changes in the controller induced by the reading of the plant's state, generally obtained from sensors.", [["Sensing events", "PROBLEM", 0, 14], ["model changes", "PROBLEM", 57, 70]]], ["The purpose is to change state x s in action act1 of the mode automaton.A Generic Event-B Model for Hybrid Systemsa c t 1 : t, xp :\u223c t\u2192t eq & END Behave.", [["act1", "GENE_OR_GENE_PRODUCT", 45, 49], ["act1", "PROTEIN", 45, 49]]], ["Behave events (corresponding to the environment arrow of Fig. 2) represent changes in the plant due to the environment: rain, wind, etc. These events enforce, in action act1, the dynamics of the plant to comply with a differential equation under solvability condition (gdr2) but without any condition on the state of the mode automaton.", [["act1", "GENE_OR_GENE_PRODUCT", 169, 173], ["act1", "PROTEIN", 169, 173], ["any condition", "PROBLEM", 287, 300]]], ["These events enforce, in action act1, the dynamics of the plant to comply with a differential equation under solvability condition (gdr2) and a constraint H on the plant evolution domain (gdr5 and gdr6).", [["act1", "GENE_OR_GENE_PRODUCT", 32, 36], ["gdr5", "GENE_OR_GENE_PRODUCT", 188, 192], ["act1", "PROTEIN", 32, 36], ["gdr2", "PROTEIN", 132, 136], ["plant evolution domain", "PROTEIN", 164, 186], ["gdr5", "PROTEIN", 188, 192], ["gdr6", "PROTEIN", 197, 201]]], ["Moreover, unlike for Behave, since Actuate results from a change in the controller, it is guarded by a predicate on the mode automaton (gdr4).A Generic Event-B Model for Hybrid SystemsAs mentioned above, both Behave and Actuate are continuous events.", [["Hybrid SystemsAs", "PROBLEM", 170, 186]]], ["Both events enforce plant behaviour by setting up a corresponding differential equation.SemanticsThe semantics of hybrid models we use is close to the one of Hybrid Event-B [8] , hybrid programs in [21] or continuous action systems [7, 20] .SemanticsIn classical Event-B semantics, each model is associated with a discrete statetransition system, in which transitions are the fired machine events and states consist of the machine's variables.", [["hybrid models", "TREATMENT", 114, 127], ["hybrid programs", "TREATMENT", 179, 194], ["continuous action systems", "TEST", 206, 231], ["a discrete statetransition system", "PROBLEM", 312, 345]]], ["In order to properly handle the modelling of continuous behaviours, the semantics of Event-B is enhanced to handle modelling of continuous phenomena which are, in nature, different from discrete behaviours.", [["continuous phenomena", "PROBLEM", 128, 148], ["continuous phenomena", "OBSERVATION", 128, 148], ["discrete", "OBSERVATION_MODIFIER", 186, 194]]], ["We have identified two categories of events: discrete (instantaneous) events, which use discrete assignments operators such as :| and := and continuous (not instantaneous) events that span over some duration and use continuous assignment operators, namely :| t\u2192t and := t\u2192t .", [["t\u2192t", "PROTEIN", 259, 262], ["t\u2192t", "PROTEIN", 270, 273]]], ["Note that, if several (continuous or discrete) events guards are enabled, these enabled events are fired non deterministically.SemanticsA model is then defined as follows.", [["several (continuous or discrete) events guards", "PROBLEM", 14, 60], ["SemanticsA model", "TEST", 127, 143]]], ["In this case, discrete events are preemptive.", [["preemptive", "OBSERVATION", 34, 44]]], ["This protocol ensures that when the conditions (events' guards) are met, the controller is able to trigger control actions (Sense or Transition) that may or may not change the continuous behaviour of the plant (through triggering an Actuate event).", [["This protocol", "TREATMENT", 0, 13]]], ["Unlike Actuate, the Behave event neither requires control action to be triggered nor any plant evolution constraint H. Sensing actions using the Sense event will re-establish the correct plant behaviour via the control loop in order to further trigger an Actuate event.The Generic Model in RodinThe generic model is the entry point for the method.", [["the control loop", "TREATMENT", 207, 223], ["an Actuate event", "PROBLEM", 252, 268], ["the method", "TREATMENT", 336, 346]]], ["This approach has been successfully applied to various case studies.", [["This approach", "TREATMENT", 0, 13], ["various case studies", "TEST", 47, 67]]], ["[13, 15] show a class of systems with one controller and one plant while [14] demonstrates the possible use of the method for a system with one controller and several plants.The Generic Model in RodinModels for the generic approach, including the above-mentioned case studies can be found at https://www.irit.fr/~Guillaume.Dupont/models.php.Case Study: The Water Tank ProblemWe now illustrate our approach for formally verifying hybrid systems patterns with a well-known control theory problem: keeping the volume of liquid inside a tank between specific bounds proposed by [5] .Abstract SystemThe problem is depicted on Fig. 3 and can be described as follows: one or more tanks are filled with a liquid and connected to an input and an output pump.Abstract SystemA controller can access the global volume V of all tanks and may control their pumps to start filling or emptying them.", [["the method", "TREATMENT", 111, 121], ["case studies", "TEST", 263, 275], ["the volume of liquid", "TREATMENT", 503, 523], ["a liquid", "TREATMENT", 695, 703], ["an output pump", "TREATMENT", 734, 748], ["all tanks", "TREATMENT", 811, 820], ["their pumps", "TREATMENT", 837, 848], ["several", "OBSERVATION_MODIFIER", 159, 166], ["plants", "OBSERVATION", 167, 173], ["output pump", "OBSERVATION", 737, 748]]], ["The goal of the controller is to keep the whole volume between V low and V high .", [["V high", "OBSERVATION_MODIFIER", 73, 79]]], ["Let V , be the volume of the tanks (continuous state being controlled).", [["Let V", "GENE_OR_GENE_PRODUCT", 0, 5], ["the tanks", "TREATMENT", 25, 34]]], ["V is physically bounded by 0 and V max , such that V high \u2264 V max , and it shall satisfy the following properties:Abstract SystemSAF1 The volume never overflows nor underflows:Abstract SystemThe variation of the volume is bounded (to avoid excessive turmoil in the tank): |V (t)| < \u0394V max At this level, it is not needed to know the specific characteristics of the tanks (i.e. their shapes, their number, the behaviour of the pumps, the way the controller accesses V and so on).", [["V", "GENE_OR_GENE_PRODUCT", 0, 1], ["SystemSAF1", "GENE_OR_GENE_PRODUCT", 123, 133], ["SystemSAF1", "PROTEIN", 123, 133], ["excessive turmoil in the tank", "PROBLEM", 240, 269], ["the pumps", "TREATMENT", 422, 431], ["variation", "OBSERVATION_MODIFIER", 195, 204], ["volume", "OBSERVATION_MODIFIER", 212, 218]]], ["The system is later refined for specific tanks and using specific architecture patterns.Architecture Patterns as Abstract System RefinementsThe system formerly introduced can be refined to illustrate the three architecture patterns identified in Sect.", [["specific tanks", "TREATMENT", 32, 46]]], ["4 and depicted on Fig. 4 .", [["on Fig", "OBSERVATION_MODIFIER", 15, 21]]], ["Single-to-Single Architecture Pattern.", [["-to-Single Architecture", "OBSERVATION_MODIFIER", 6, 29]]], ["Within a refinement, the abstract model of Fig. 3 is instantiated by a concrete system composed of one controller managing one cylinder-shaped tank (see Fig. 4a ).", [["Fig", "OBSERVATION_MODIFIER", 43, 46]]], ["The abstract plant's volume is refined using the gluing invariant V = B \u00b7 h, where B is the surface of the cylinder's base and h is the height of liquid in the tank (easier to measure than the direct volume).", [["surface", "ANATOMY", 92, 99], ["surface", "CELLULAR_COMPONENT", 92, 99], ["B", "PROTEIN", 83, 84], ["The abstract plant's volume", "TEST", 0, 27], ["surface", "OBSERVATION_MODIFIER", 92, 99], ["base", "ANATOMY_MODIFIER", 118, 122], ["tank", "ANATOMY", 160, 164]]], ["Constraints on h are strengthened by the well-definedness condition V max \u2264 B \u00b7 H max , ensuring that the cylinder can contain (at least) volume V max .Architecture Patterns as Abstract System RefinementsAs a matter of simplification, the pumps are associated with a fixed flow rate and are either open (full flow) or closed (no flow), with no intermediate state.", [["the pumps", "TREATMENT", 235, 244], ["a fixed flow rate", "PROBLEM", 265, 282], ["fixed flow", "OBSERVATION", 267, 277], ["no", "UNCERTAINTY", 326, 328], ["flow", "OBSERVATION", 329, 333], ["no", "UNCERTAINTY", 341, 343], ["intermediate state", "OBSERVATION", 344, 362]]], ["Therefore, a differential equation for the system is\u1e23 = in \u00b7 \u03b4 in + out \u00b7 \u03b4 out , where in, out are the states of the pumps and \u03b4 in , \u03b4 out are their respective flows.", [["\u03b4", "PROTEIN", 128, 129], ["a differential equation", "TEST", 11, 34], ["the pumps", "TREATMENT", 114, 123], ["respective flows", "OBSERVATION", 151, 167]]], ["This pattern has been previously instantiated in [13, 15] .Architecture Patterns as Abstract System RefinementsSingle-to-Many Architecture Pattern.", [["-to-Many Architecture", "OBSERVATION_MODIFIER", 117, 138]]], ["The same case study can be used to illustrate the second architecture pattern, which involves a single controller and many plants.", [["The same case study", "TEST", 0, 19], ["many", "OBSERVATION_MODIFIER", 118, 122], ["plants", "OBSERVATION", 123, 129]]], ["Figure 4b depicts a simplified case for two cylinder tanks, but it scales to any number of tanks of various shapes provided the differential equations that governs these plants are known.", [["two cylinder tanks", "TREATMENT", 40, 58], ["the differential equations", "PROBLEM", 124, 150]]], ["For two cylindrical tanks, the gluing invariant is V = B 1 \u00b7h 1 +B 2 \u00b7h 2 where B 1 and B 2 are the surface of the cylinders bases and h 1 and h 2 are the height of liquid in the tanks.", [["surface", "ANATOMY", 100, 107], ["B 1", "GENE_OR_GENE_PRODUCT", 80, 83], ["B 2", "GENE_OR_GENE_PRODUCT", 88, 91], ["two cylindrical tanks", "TREATMENT", 4, 25], ["the gluing invariant", "TEST", 27, 47], ["+B", "TEST", 64, 66], ["the cylinders bases", "TEST", 111, 130], ["cylinders", "ANATOMY_MODIFIER", 115, 124], ["bases", "ANATOMY_MODIFIER", 125, 130]]], ["The associated differential equations given as witnesses for instantiation are defined by a linear combination.Architecture Patterns as Abstract System RefinementsHowever, the interesting property in this instantiation relates to the feasibility of the refinement.", [["The associated differential equations", "PROBLEM", 0, 37], ["instantiation", "PROBLEM", 61, 74], ["linear", "OBSERVATION_MODIFIER", 92, 98]]], ["Indeed, an additional well-definedness condition, expressed as an invariant, states that V max \u2264 B 1 \u00b7 H 1,max + B 2 \u00b7 H 2,max as to guarantee that the maximum abstract volume can be contained by the two cylinders representing the concrete plant.Architecture Patterns as Abstract System RefinementsThis pattern has been thoroughly instantiated and studied in [14] .Architecture Patterns as Abstract System RefinementsNote: All the Event-B models corresponding to the two architecture patterns discussed above are available at https://www.irit.fr/~Guillaume.Dupont/ models.php.", [["Event-B models", "DNA", 431, 445], ["V max \u2264 B", "TEST", 89, 98], ["max", "TEST", 107, 110], ["concrete plant", "OBSERVATION", 231, 245]]], ["We did not discuss them in this paper due to space limitations.", [["space limitations", "PROBLEM", 45, 62]]], ["The details of the Event-B models are given below for the case study of the water tank following the instantiation of this specific architecture pattern from Fig. 4c .Application of the Many-to-Many Architecture PatternRefinement Strategy.", [["the water tank", "TREATMENT", 72, 86]]], ["Depending on the number of components (controllers/plants), the generic parts for controller and plant are refined.Application of the Many-to-Many Architecture PatternNote that the instantiation of the generic model is achieved by providing witnesses to the parameters of the generic events of the Event-B models, i.e. providing a witness for an existential proof obligation.Application of the Many-to-Many Architecture PatternTwo refinements leading to the final Event-B model are defined.", [["an existential proof obligation", "TREATMENT", 343, 374]]], ["Then, the final instantiated architecture pattern of Fig. 4c is modelled as a refinement of this model, providing witnesses for generic parameters.", [["this model", "TREATMENT", 92, 102], ["Fig. 4c", "OBSERVATION", 53, 60]]], ["7.1 and 7.2.Abstract Tank ModelMachine State.", [["Tank ModelMachine", "OBSERVATION", 21, 38]]], ["The controlled variable is the volume V .", [["variable", "OBSERVATION_MODIFIER", 15, 23], ["volume V", "OBSERVATION", 31, 39]]], ["6.1 (SAF1 and SAF2), this quantity shall remain between V low and V high and its derivative (V ) shall be bounded by the \u0394V max constant.", [["SAF1", "TEST", 5, 9], ["SAF2", "TEST", 14, 18]]], ["The system operates in 4 modes: Emptying (volume decreases), Filling (volume increases), Normal (volume varies in an arbitrary way between V low and V high ) and Stable (volume does not vary) defining the set STATES.Abstract Tank Modela c t 1 : xs := Normal END Transition and Sense.", [["Filling (volume increases", "TEST", 61, 86], ["Normal", "OBSERVATION", 89, 95], ["Stable", "OBSERVATION_MODIFIER", 162, 168], ["END", "OBSERVATION_MODIFIER", 258, 261], ["Transition", "OBSERVATION_MODIFIER", 262, 272]]], ["When the volume reaches V low (resp.", [["low", "OBSERVATION_MODIFIER", 26, 29]]], ["Transition events are guarded by a stricter version of the safety invariant as to prevent the system from deliberately going into an unsafe mode.Abstract Tank ModelBehave and Actuate.", [["Transition events", "PROBLEM", 0, 17]]], ["The system performs actuation on the pumps.", [["the pumps", "TREATMENT", 33, 42]]], ["At this level, the shape of the tank(s) and the behaviour of the pumps are not known yet.", [["shape", "OBSERVATION_MODIFIER", 19, 24]]], ["The only constraint the actuation shall enforce is that whenever the system is in a specific state, the provided differential equation for actuation is such that its solutions have the expected behaviour (e.g. decreasing solutions when in Emptying mode, increasing solutions when in Filling mode, etc.).", [["decreasing solutions", "TREATMENT", 210, 230], ["Emptying mode", "TREATMENT", 239, 252], ["increasing solutions", "TREATMENT", 254, 274]]], ["This constraint is captured by the FlowEq(x s , D, e) predicate of guard grd3 and is defined in a theory, where x s is the controller's state, D is the domain on which the predicated behaviour is expected to be true and e is the given equation.Many-to-many ModelThe model presented below corresponds to the system depicted on Fig. 4c .Many-to-many ModelMachine State.", [["grd3", "GENE_OR_GENE_PRODUCT", 73, 77], ["guard grd3", "PROTEIN", 67, 77], ["guard grd3", "TREATMENT", 67, 77]]], ["Each tank has its own volume, V 1 and V 2 (see Fig. 4c ) behaving as a global invariant.", [["global invariant", "OBSERVATION", 71, 87]]], ["The abstract volume V is hence refined using the gluing invariant V = V 1 + V 2 , and the safety invariant becomesMany-to-many Model, and in order to have a coherent refinement we need to have V max \u2264 V 1,max +V 2,max .", [["The abstract volume V", "TEST", 0, 21], ["the gluing invariant V", "TEST", 45, 67], ["V max \u2264 V", "TEST", 193, 202], ["volume V", "OBSERVATION", 13, 21]]], ["The controller discrete abstract state x s is glued (inv02) with the two discrete controllers states using the guess_gs operator.Many-to-many ModelEach tank is controlled by an independent controller.", [["the guess_gs operator", "TREATMENT", 107, 128], ["discrete", "OBSERVATION_MODIFIER", 15, 23], ["abstract", "OBSERVATION", 24, 32]]], ["To model this situation, two additional continuous variables, V sim 1 (resp.", [["V sim 1", "GENE_OR_GENE_PRODUCT", 62, 69]]], ["This enforcement is used to prove the initially defined global invariant.Many-to-many ModelBehave and Actuate.", [["global invariant", "OBSERVATION", 56, 72]]], ["The system's actuation is established using continuous refinement as presented in [14] : the witness for e (abstract differential equation) is a predicate that links the solutions of e 1 and e 2 (concrete differential equations) such that the sum V * 1 + V * 2 of any pair of solutions (V * 1 , V * 2 ) of (e 1 , e 2 ) is a solution of e, in addition to having the relevant general constraints (namely, a correct behaviour as per the system's current state).", [["The system's actuation", "TREATMENT", 0, 22]]], ["The witness for V is given to establish the invariant after actuation.AssessmentThe work presented in this paper showed that the generic model proposed in [15] applies to different architecture patterns of hybrid systems.", [["hybrid systems", "OBSERVATION", 206, 220]]], ["Below, we provide an assessment of the approach with respect to the proof effort and set up methodology.", [["an assessment", "TEST", 18, 31]]], ["The abstract tank model generated 107 proof obligations, most of which are invariant (about 40%) or well-definedness (about 21%) related.", [["abstract tank", "OBSERVATION", 4, 17], ["invariant", "OBSERVATION_MODIFIER", 75, 84]]], ["Welldefinedness also appears often in proofs subgoals.", [["Welldefinedness", "DISEASE", 0, 15]]], ["Feasibility POs, related to solution existence, are those difficult to prove.AssessmentAs for the many-to-many model, it yields 156 proof obligations, among which a good proportion (53%) consists of invariant POs alone.", [["POs", "GENE_OR_GENE_PRODUCT", 209, 212], ["POs", "PROTEIN", 209, 212], ["AssessmentAs", "TEST", 77, 89]]], ["The model also yields quite a few guard strengthening POs (around 15%) that ensure that the controllers behave properly despite the estimation it makes of the system.", [["a few guard strengthening POs", "TREATMENT", 28, 57]]], ["But the hardest POs to discharge are the one regarding refinement (witness well-definedness and feasibility, and simulation).AssessmentA great interest of the proposed methodology is there: the only complex proofs to carry on are related to refinement.", [["Assessment", "TEST", 125, 135]]], ["Proofs for complicated invariants and so on have been realised at the abstract level and are done once and for all.AssessmentTool Support.", [["complicated invariants", "PROBLEM", 11, 33], ["AssessmentTool Support", "TREATMENT", 115, 137]]], ["Because of our heavy use of the theory plug-in in Rodin, proof automation (including SMTs and external provers) is nearly nonexistent for discharging the generated POs.", [["the theory plug", "PROBLEM", 28, 43], ["SMTs and external provers", "TREATMENT", 85, 110], ["heavy", "OBSERVATION_MODIFIER", 15, 20], ["plug", "OBSERVATION", 39, 43]]], ["The use of patterns as methodological basis is not new in system engineering.", [["not", "UNCERTAINTY", 47, 50], ["new", "OBSERVATION_MODIFIER", 51, 54]]], ["The availability of architecture patterns offers a methodological guide to system designers, who simply need to identify which pattern matches the hybrid system under design and instantiate it with refinements and witnesses.AssessmentThe generic model offers a framework that is formally proven once and for all.", [["Assessment", "TEST", 224, 234]]], ["It corresponds to a customisation of Event-B to offer resources for modelling controllers, plants, sensing and actuation, integrating both discrete and continuous behaviours.", [["modelling controllers", "TREATMENT", 68, 89], ["actuation", "TREATMENT", 111, 120]]], ["This generic model is used as a ground model for further designs.AssessmentEach defined architecture pattern is formalised as an instance of the generic model.", [["Assessment", "TEST", 65, 75]]], ["For example, it has been used to state that the cylinders given as refinement are capable of storing an abstractly specified volume of liquid V max .Conclusion and Future WorkThis paper presented a framework for modelling hybrid systems.", [["the cylinders", "TREATMENT", 44, 57], ["modelling hybrid systems", "TREATMENT", 212, 236]]], ["It relies on a formal model of different hybrid systems architecture patterns formalised with the Event-B method using the Rodin platform.", [["the Rodin platform", "TREATMENT", 119, 137]]], ["Because this framework is formalised at a generic level, it offers a systematic methodology for hybrid systems development and verification.Conclusion and Future WorkThe approach extensively uses the mathematical extensions capabilities offered by the theory plug-in of Event-B, allowing to enrich Event-B models with continuous behaviours.", [["the mathematical extensions capabilities", "TREATMENT", 196, 236], ["plug", "OBSERVATION", 259, 263]]], ["Data types for reals, continuous functions, differential equations and so on have been defined within a sound Event-B theory.", [["differential equations", "TEST", 44, 66]]], ["Although the definition of generic architecture patterns has reduced the number and the complexity of proof obligations and their proofs, the proof effort still needs to be reduced.", [["generic architecture", "OBSERVATION", 27, 47], ["reduced", "OBSERVATION_MODIFIER", 61, 68]]], ["Providing other sound domain theories contributes to such a reduction.", [["a reduction", "TREATMENT", 58, 69]]], ["One of the main extensions to our work consists in enriching the proposed framework with other theories.", [["main", "OBSERVATION_MODIFIER", 11, 15]]]], "PMC7122153": [["HistoryThe history of retroviruses and our understanding of cancer are intertwined and illuminated by some of the most important scientific breakthroughs in the last century.", [["cancer", "ANATOMY", 60, 66], ["cancer", "DISEASE", 60, 66], ["retroviruses", "ORGANISM", 22, 34], ["cancer", "CANCER", 60, 66], ["retroviruses", "PROBLEM", 22, 34], ["cancer", "PROBLEM", 60, 66], ["retroviruses", "OBSERVATION", 22, 34], ["cancer", "OBSERVATION", 60, 66]]], ["In 1908, Danish scientists Vilhelm Ellerman and Oluf Bang discovered an infectious pathogen that could be transmitted from one chicken to another, a non-cellular pathogen capable of causing cancer.", [["cancer", "ANATOMY", 190, 196], ["cancer", "DISEASE", 190, 196], ["chicken", "ORGANISM", 127, 134], ["cancer", "CANCER", 190, 196], ["chicken", "SPECIES", 127, 134], ["chicken", "SPECIES", 127, 134], ["an infectious pathogen", "PROBLEM", 69, 91], ["a non-cellular pathogen", "PROBLEM", 147, 170], ["cancer", "PROBLEM", 190, 196], ["infectious", "OBSERVATION_MODIFIER", 72, 82], ["cancer", "OBSERVATION", 190, 196]]], ["The agent was able to pass through filters designed for cells and bacteria, leading them to the observation that a non-cellular pathogen was inducing cancer (Ellerman and Bang, 1908).", [["cells", "ANATOMY", 56, 61], ["cancer", "ANATOMY", 150, 156], ["cancer", "DISEASE", 150, 156], ["cells", "CELL", 56, 61], ["cancer", "CANCER", 150, 156], ["cells", "PROBLEM", 56, 61], ["bacteria", "PROBLEM", 66, 74], ["a non-cellular pathogen", "PROBLEM", 113, 136], ["cancer", "PROBLEM", 150, 156], ["cancer", "OBSERVATION", 150, 156]]], ["A few years later, in 1911, Peyton Rous from Rockefeller University made a related observation by identifying a similar pathogen, naming it the Rous sarcoma virus (RSV).", [["Rous sarcoma", "DISEASE", 144, 156], ["Peyton Rous", "ORGANISM", 28, 39], ["Rous sarcoma virus", "ORGANISM", 144, 162], ["RSV", "ORGANISM", 164, 167], ["Rous", "SPECIES", 35, 39], ["Rous sarcoma virus", "SPECIES", 144, 162], ["Rous sarcoma virus", "SPECIES", 144, 162], ["RSV", "SPECIES", 164, 167], ["a similar pathogen", "PROBLEM", 110, 128], ["the Rous sarcoma virus", "PROBLEM", 140, 162]]], ["Peyton Rous was awarded the Nobel Prize for his discovery, the first identifiable retrovirus (Rous, 1911).HistoryBetween 1911 and 1960, many other cancer-causing viruses were identified and cataloged.", [["cancer", "ANATOMY", 147, 153], ["cancer", "DISEASE", 147, 153], ["Peyton Rous", "ORGANISM", 0, 11], ["retrovirus", "ORGANISM", 82, 92], ["Rous", "ORGANISM", 94, 98], ["cancer", "CANCER", 147, 153], ["Rous", "SPECIES", 7, 11], ["Rous", "SPECIES", 94, 98], ["many other cancer", "PROBLEM", 136, 153], ["viruses", "PROBLEM", 162, 169], ["retrovirus", "OBSERVATION", 82, 92], ["cancer", "OBSERVATION", 147, 153], ["viruses", "OBSERVATION", 162, 169]]], ["The viruses were named after either the species that were their hosts or the tumor types that they caused.", [["tumor", "ANATOMY", 77, 82], ["tumor", "DISEASE", 77, 82], ["tumor", "CANCER", 77, 82], ["The viruses", "PROBLEM", 0, 11], ["the species", "PROBLEM", 36, 47], ["viruses", "OBSERVATION", 4, 11], ["tumor", "OBSERVATION", 77, 82]]], ["It became apparent, even before the mechanisms were understood, that these viruses were highly specific to the target hosts that they are able to infect.", [["these viruses", "PROBLEM", 69, 82]]], ["This newfound study of cancer-causing viruses brought about an understanding of this universal phenomenon that could be observed in mammalian and avian organisms.", [["cancer", "ANATOMY", 23, 29], ["cancer", "DISEASE", 23, 29], ["cancer", "CANCER", 23, 29], ["This newfound study", "TEST", 0, 19], ["cancer", "PROBLEM", 23, 29], ["viruses", "PROBLEM", 38, 45], ["this universal phenomenon", "PROBLEM", 80, 105], ["cancer", "OBSERVATION", 23, 29]]], ["The concept that cancer was caused by an infectious agent was a natural thought process that followed the discoveries of multiple external agents responsible for disease throughout the eighteenth and nineteenth centuries, including the vaccination work against smallpox by Edward Jenner in 1796.", [["cancer", "ANATOMY", 17, 23], ["cancer", "DISEASE", 17, 23], ["smallpox", "DISEASE", 261, 269], ["cancer", "CANCER", 17, 23], ["cancer", "PROBLEM", 17, 23], ["an infectious agent", "PROBLEM", 38, 57], ["multiple external agents", "TREATMENT", 121, 145], ["disease", "PROBLEM", 162, 169], ["cancer", "OBSERVATION", 17, 23], ["infectious", "OBSERVATION", 41, 51]]], ["The concept of cancer being caused by an infectious agent had the unwanted consequence of sending researchers on the wrong track, since we now know that most human cancers are not caused by viruses but rather from \u201cwithin\u201d (see below).HistoryThe structure and function of DNA, proposed by James Watson and Francis Crick in 1953, postulated that information flowed in a set pattern that would begin from DNA transcribed to RNA, which would be the blueprint to form proteins.", [["cancer", "ANATOMY", 15, 21], ["cancers", "ANATOMY", 164, 171], ["cancer", "DISEASE", 15, 21], ["cancers", "DISEASE", 164, 171], ["cancer", "CANCER", 15, 21], ["human", "ORGANISM", 158, 163], ["cancers", "CANCER", 164, 171], ["DNA", "CELLULAR_COMPONENT", 272, 275], ["DNA", "CELLULAR_COMPONENT", 403, 406], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 158, 163], ["cancer", "PROBLEM", 15, 21], ["an infectious agent", "PROBLEM", 38, 57], ["most human cancers", "PROBLEM", 153, 171], ["viruses", "PROBLEM", 190, 197], ["cancer", "OBSERVATION", 15, 21], ["infectious", "OBSERVATION", 41, 51], ["cancers", "OBSERVATION", 164, 171], ["viruses", "OBSERVATION", 190, 197]]], ["This central dogma was widely accepted to be invariant in every organism and implied that something that changed a cell\u2019s phenotype (such as a virus) would necessarily require that its genetic information be stored in the form of DNA (Watson and Crick, 1953).", [["cell", "ANATOMY", 115, 119], ["cell", "CELL", 115, 119], ["DNA", "CELLULAR_COMPONENT", 230, 233], ["a cell\u2019s phenotype", "PROBLEM", 113, 131], ["central dogma", "OBSERVATION", 5, 18], ["invariant", "OBSERVATION_MODIFIER", 45, 54]]], ["However, in 1959, Howard Temin found the first exception to this rule while doing research for his PhD thesis on RSV and other viruses that would soon be compiled into a family known as Retroviridae.", [["RSV", "ORGANISM", 113, 116], ["RSV", "SPECIES", 113, 116], ["RSV", "PROBLEM", 113, 116], ["other viruses", "PROBLEM", 121, 134], ["Retroviridae", "TREATMENT", 186, 198]]], ["His viral stocks were absent of DNA and appeared to use RNA as their genome, implying that retroviruses did not replicate themselves in the set pattern described in the Central Dogma.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["retroviruses", "ORGANISM", 91, 103], ["His viral stocks", "TEST", 0, 16], ["DNA", "PROBLEM", 32, 35], ["RNA", "TREATMENT", 56, 59], ["viral stocks", "OBSERVATION", 4, 16], ["retroviruses", "OBSERVATION", 91, 103], ["Central Dogma", "OBSERVATION", 169, 182]]], ["As a graduate student, Temin had managed to prove that there were viruses that could replicate through a process he called reverse transcription.", [["viruses", "PROBLEM", 66, 73]]], ["The reason it was called as such was due to the fact that replication seemed to occur in reverse, using a single strand of RNA to form double-stranded DNA (Temin and Rubin, 1958).", [["DNA", "CELLULAR_COMPONENT", 151, 154], ["double-stranded DNA", "DNA", 135, 154], ["a single strand of RNA", "TREATMENT", 104, 126]]], ["Furthermore, before Temin\u2019s work, it was unclear whether a virus was a quantal unit or a solution with transforming potential.", [["a virus", "PROBLEM", 57, 64], ["a solution", "TREATMENT", 87, 97]]], ["He proved that viruses were actually particles capable of transforming the phenotype of an infected cell and all of its progeny.", [["cell", "ANATOMY", 100, 104], ["progeny", "ANATOMY", 120, 127], ["cell", "CELL", 100, 104], ["viruses", "PROBLEM", 15, 22], ["an infected cell", "PROBLEM", 88, 104], ["viruses", "OBSERVATION", 15, 22], ["infected cell", "OBSERVATION", 91, 104]]], ["Temin also proved the existence of the enzyme that was responsible for reverse transcription, which he called reverse transcriptase.", [["Temin", "GENE_OR_GENE_PRODUCT", 0, 5], ["reverse transcriptase", "PROTEIN", 110, 131], ["the enzyme", "TEST", 35, 45]]], ["This enzyme was isolated by David Baltimore, who shared the Nobel Prize with Howard Temin for this work (Temin, 1964).HistoryThe nature of the transforming potential of retroviruses became evident after the technology to identify the specific sequence of nucleic acids was invented.", [["nucleic acids", "CHEMICAL", 255, 268], ["retroviruses", "ORGANISM", 169, 181], ["nucleic acids", "SIMPLE_CHEMICAL", 255, 268], ["This enzyme", "TEST", 0, 11], ["retroviruses", "PROBLEM", 169, 181], ["nucleic acids", "TREATMENT", 255, 268], ["retroviruses", "OBSERVATION", 169, 181]]], ["In the 1970s, Harold Varmus, Mike Bishop, and colleagues identified the general structure of retroviral genomes as having two repeated sequences on the ends and three viral genes, gag, pol, and env.", [["retroviral", "ORGANISM", 93, 103], ["gag", "GENE_OR_GENE_PRODUCT", 180, 183], ["pol", "GENE_OR_GENE_PRODUCT", 185, 188], ["env", "GENE_OR_GENE_PRODUCT", 194, 197], ["retroviral genomes", "DNA", 93, 111], ["viral genes", "DNA", 167, 178], ["gag", "DNA", 180, 183], ["pol", "DNA", 185, 188], ["env", "DNA", 194, 197], ["retroviral genomes", "OBSERVATION", 93, 111]]], ["However, in the case of the tumor-forming viruses, there was another gene downstream of env that turned out to be responsible for the induction of the transformed phenotype.", [["tumor", "ANATOMY", 28, 33], ["tumor", "DISEASE", 28, 33], ["tumor", "CANCER", 28, 33], ["env", "GENE_OR_GENE_PRODUCT", 88, 91], ["env", "DNA", 88, 91], ["the tumor-forming viruses", "PROBLEM", 24, 49], ["another gene downstream of env", "PROBLEM", 61, 91], ["the transformed phenotype", "PROBLEM", 147, 172], ["tumor", "OBSERVATION", 28, 33], ["viruses", "OBSERVATION", 42, 49]]], ["In the case of RSV, the gene was called Src and referred to as an oncogene because it caused cancer (Stehelin et al., 1976).", [["cancer", "ANATOMY", 93, 99], ["cancer", "DISEASE", 93, 99], ["RSV", "ORGANISM", 15, 18], ["Src", "GENE_OR_GENE_PRODUCT", 40, 43], ["cancer", "CANCER", 93, 99], ["Src", "PROTEIN", 40, 43], ["oncogene", "DNA", 66, 74], ["RSV", "SPECIES", 15, 18], ["RSV", "PROBLEM", 15, 18], ["cancer", "PROBLEM", 93, 99], ["RSV", "OBSERVATION", 15, 18], ["cancer", "OBSERVATION", 93, 99]]], ["Further experiments showed that this fourth gene was different from virus to virus, and unlike the other viral genes, the oncogene was closely related to a cellular gene found in the cells of the host animal that the virus previously infected.", [["cellular", "ANATOMY", 156, 164], ["cells", "ANATOMY", 183, 188], ["cellular", "CELL", 156, 164], ["cells", "CELL", 183, 188], ["fourth gene", "DNA", 37, 48], ["viral genes", "DNA", 105, 116], ["oncogene", "DNA", 122, 130], ["cellular gene", "DNA", 156, 169], ["Further experiments", "TEST", 0, 19], ["virus to virus", "PROBLEM", 68, 82], ["the other viral genes", "PROBLEM", 95, 116], ["a cellular gene", "PROBLEM", 154, 169], ["the virus", "PROBLEM", 213, 222], ["viral genes", "OBSERVATION", 105, 116]]], ["These oncogenes appeared to be stolen from the host genome and then expressed either in the wrong cell type or in an unregulated manner by the virus leading to the formation of cancer (Kurth, 1983).", [["cell", "ANATOMY", 98, 102], ["cancer", "ANATOMY", 177, 183], ["cancer", "DISEASE", 177, 183], ["cell type", "CELL", 98, 107], ["cancer", "CANCER", 177, 183], ["oncogenes", "DNA", 6, 15], ["host genome", "DNA", 47, 58], ["the virus", "PROBLEM", 139, 148], ["cancer", "PROBLEM", 177, 183], ["host genome", "OBSERVATION", 47, 58], ["cancer", "OBSERVATION", 177, 183]]], ["The realization that our own genes caused cancer and that cancer was a product formed from within us changed the way we think about this disease and led to Varmus and Bishop being awarded the Nobel Prize for their work (Bishop, 1983).HistoryThe collection of genes expressed as oncogenes from the known retroviruses was then catalogued, and the functions of the normal cellular homologues (proto-oncogenes) were identified.", [["cancer", "ANATOMY", 42, 48], ["cancer", "ANATOMY", 58, 64], ["cellular", "ANATOMY", 369, 377], ["cancer", "DISEASE", 42, 48], ["cancer", "DISEASE", 58, 64], ["cancer", "CANCER", 42, 48], ["cancer", "CANCER", 58, 64], ["retroviruses", "ORGANISM", 303, 315], ["cellular", "CELL", 369, 377], ["proto-", "GENE_OR_GENE_PRODUCT", 390, 396], ["oncogenes", "DNA", 278, 287], ["normal cellular homologues", "DNA", 362, 388], ["proto-oncogenes", "DNA", 390, 405], ["cancer", "PROBLEM", 42, 48], ["cancer", "PROBLEM", 58, 64], ["this disease", "PROBLEM", 132, 144], ["the known retroviruses", "PROBLEM", 293, 315], ["cancer", "OBSERVATION", 42, 48], ["cancer", "OBSERVATION", 58, 64], ["retroviruses", "OBSERVATION", 303, 315]]], ["These cellular proto-oncogenes were found to encode the components of signal transduction pathways involved in both the proliferation and the inhibition of apoptosis.", [["cellular", "ANATOMY", 6, 14], ["cellular", "CELL", 6, 14], ["cellular proto-oncogenes", "DNA", 6, 30], ["signal transduction pathways", "PROBLEM", 70, 98], ["apoptosis", "PROBLEM", 156, 165], ["cellular proto-oncogenes", "OBSERVATION", 6, 30], ["proliferation", "OBSERVATION", 120, 133], ["apoptosis", "OBSERVATION", 156, 165]]], ["These gene products cover the entire spectrum from overexpression of ligands such as PDGF (v-SIS) to mutant active receptors such as EGFR (v-erbB), to constitutively active downstream components such as Ras and Akt, and transcription factors such as Myc, Jun, and Fos (Pech et al., 1989).", [["PDGF", "GENE_OR_GENE_PRODUCT", 85, 89], ["v-SIS", "GENE_OR_GENE_PRODUCT", 91, 96], ["EGFR", "GENE_OR_GENE_PRODUCT", 133, 137], ["v-erbB", "GENE_OR_GENE_PRODUCT", 139, 145], ["Ras", "GENE_OR_GENE_PRODUCT", 203, 206], ["Akt", "GENE_OR_GENE_PRODUCT", 211, 214], ["Myc", "GENE_OR_GENE_PRODUCT", 250, 253], ["Jun", "GENE_OR_GENE_PRODUCT", 255, 258], ["Fos", "GENE_OR_GENE_PRODUCT", 264, 267], ["PDGF", "PROTEIN", 85, 89], ["v-SIS", "PROTEIN", 91, 96], ["mutant active receptors", "PROTEIN", 101, 124], ["EGFR", "PROTEIN", 133, 137], ["v-erbB", "PROTEIN", 139, 145], ["Ras", "PROTEIN", 203, 206], ["Akt", "PROTEIN", 211, 214], ["transcription factors", "PROTEIN", 220, 241], ["Myc", "PROTEIN", 250, 253], ["Jun", "PROTEIN", 255, 258], ["Fos", "PROTEIN", 264, 267], ["These gene products", "TREATMENT", 0, 19], ["overexpression of ligands", "TREATMENT", 51, 76], ["PDGF (v-SIS", "TREATMENT", 85, 96], ["mutant active receptors", "PROBLEM", 101, 124], ["EGFR (v-erbB)", "PROBLEM", 133, 146], ["constitutively active downstream components", "PROBLEM", 151, 194]]], ["Because of their natural ability to function as tumor-inducing agents, retroviruses became prime candidates for the creation of genetically engineered tumorigenic vectors that could be designed to transfer any gene and test its ability to induce tumor formation.", [["tumor", "ANATOMY", 48, 53], ["tumor", "ANATOMY", 246, 251], ["tumor", "DISEASE", 48, 53], ["tumor", "DISEASE", 246, 251], ["tumor", "CANCER", 48, 53], ["retroviruses", "ORGANISM", 71, 83], ["tumor", "CANCER", 246, 251], ["tumor-inducing agents", "TREATMENT", 48, 69], ["retroviruses", "TREATMENT", 71, 83], ["genetically engineered tumorigenic vectors", "TREATMENT", 128, 170], ["tumor formation", "PROBLEM", 246, 261], ["tumor", "OBSERVATION", 246, 251]]], ["In the 1990s, RSV was turned into a viral vector by Steve Hughes.", [["RSV", "ORGANISM", 14, 17], ["RSV", "SPECIES", 14, 17], ["RSV", "PROBLEM", 14, 17]]], ["The Src gene was replaced by any gene of interest that was less than 2.5 kb (due to packaging constraints) and became known as the replication-competent ALV splice acceptor, or RCAS in short (Petropoulos and Hughes, 1991).RCASThe most commonly used version of RCAS is based on the subgroup A avian leukosis (ALV) viruses.", [["avian leukosis (ALV) viruses", "DISEASE", 292, 320], ["Src", "GENE_OR_GENE_PRODUCT", 4, 7], ["ALV", "ORGANISM", 153, 156], ["A", "ORGANISM", 290, 291], ["avian leukosis (ALV) viruses", "ORGANISM", 292, 320], ["Src gene", "DNA", 4, 12], ["avian leukosis", "SPECIES", 292, 306], ["A avian leukosis", "SPECIES", 290, 306], ["ALV", "SPECIES", 308, 311], ["version of RCAS", "TREATMENT", 249, 264], ["the subgroup A avian leukosis (ALV) viruses", "PROBLEM", 277, 320], ["ALV splice", "OBSERVATION", 153, 163], ["avian leukosis", "OBSERVATION", 292, 306]]], ["The cell surface receptor that permits ALV-A subgroup infection of host cells is limited to birds (Coffin et al., 1997).", [["cell surface", "ANATOMY", 4, 16], ["cells", "ANATOMY", 72, 77], ["infection", "DISEASE", 54, 63], ["cell", "CELL", 4, 8], ["ALV-A", "ORGANISM", 39, 44], ["host cells", "CELL", 67, 77], ["birds", "ORGANISM", 92, 97], ["cell surface receptor", "PROTEIN", 4, 25], ["host cells", "CELL_TYPE", 67, 77], ["The cell surface receptor", "TEST", 0, 25], ["ALV", "PROBLEM", 39, 42], ["A subgroup infection of host cells", "PROBLEM", 43, 77], ["cell", "OBSERVATION", 4, 8], ["surface", "OBSERVATION_MODIFIER", 9, 16], ["ALV", "ANATOMY", 39, 42], ["infection", "OBSERVATION", 54, 63], ["host cells", "OBSERVATION", 67, 77]]], ["The genetic locus that encodes the receptor for subgroup A viruses is referred to as tv-a, or tumor virus-a.", [["tumor", "ANATOMY", 94, 99], ["tumor", "DISEASE", 94, 99], ["tv-a", "GENE_OR_GENE_PRODUCT", 85, 89], ["tumor", "CANCER", 94, 99], ["subgroup A viruses", "PROBLEM", 48, 66], ["tumor virus", "PROBLEM", 94, 105], ["viruses", "OBSERVATION", 59, 66]]], ["This gene was cloned from quail cells by Bates, Young, and Varmus using expression cloning from quail DNA into mouse cells and identified by its ability to confer susceptibility to RCAS infection (Bates et al., 1993).", [["quail cells", "ANATOMY", 26, 37], ["cells", "ANATOMY", 117, 122], ["RCAS infection", "DISEASE", 181, 195], ["quail cells", "CELL", 26, 37], ["Varmus", "GENE_OR_GENE_PRODUCT", 59, 65], ["quail", "ORGANISM", 96, 101], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["mouse", "ORGANISM", 111, 116], ["cells", "CELL", 117, 122], ["quail cells", "CELL_TYPE", 26, 37], ["quail DNA", "DNA", 96, 105], ["mouse cells", "CELL_TYPE", 111, 122], ["quail", "SPECIES", 26, 31], ["quail", "SPECIES", 96, 101], ["mouse", "SPECIES", 111, 116], ["quail", "SPECIES", 26, 31], ["quail", "SPECIES", 96, 101], ["mouse", "SPECIES", 111, 116], ["expression cloning", "TREATMENT", 72, 90], ["quail DNA into mouse cells", "TREATMENT", 96, 122], ["RCAS infection", "PROBLEM", 181, 195]]], ["When expressed in mammalian cells, this gene product, tv-a, allows the infection by RCAS vectors and subsequent expression of whatever gene is inserted downstream of the env gene.", [["cells", "ANATOMY", 28, 33], ["infection", "DISEASE", 71, 80], ["mammalian cells", "CELL", 18, 33], ["tv-a", "GENE_OR_GENE_PRODUCT", 54, 58], ["RCAS", "GENE_OR_GENE_PRODUCT", 84, 88], ["env", "GENE_OR_GENE_PRODUCT", 170, 173], ["mammalian cells", "CELL_TYPE", 18, 33], ["tv-a", "PROTEIN", 54, 58], ["RCAS vectors", "DNA", 84, 96], ["env gene", "DNA", 170, 178], ["the infection", "PROBLEM", 67, 80], ["RCAS vectors", "TREATMENT", 84, 96], ["mammalian cells", "OBSERVATION", 18, 33], ["infection", "OBSERVATION", 71, 80], ["env gene", "OBSERVATION", 170, 178]]], ["Furthermore, due to splicing differences between avian and mammalian cells, the mRNAs that encode the viral gene products gag, pol, and env are unstable and produce essentially no protein.", [["mammalian cells", "ANATOMY", 59, 74], ["avian", "ORGANISM", 49, 54], ["mammalian cells", "CELL", 59, 74], ["gag", "GENE_OR_GENE_PRODUCT", 122, 125], ["pol", "GENE_OR_GENE_PRODUCT", 127, 130], ["env", "GENE_OR_GENE_PRODUCT", 136, 139], ["avian and mammalian cells", "CELL_TYPE", 49, 74], ["mRNAs", "RNA", 80, 85], ["viral gene products gag, pol, and env", "DNA", 102, 139], ["splicing differences between avian and mammalian cells", "PROBLEM", 20, 74], ["mammalian cells", "OBSERVATION", 59, 74], ["viral gene", "OBSERVATION", 102, 112]]], ["The overall result is receptor-mediated gene targeting to mammalian cells engineered to express tv-a.", [["cells", "ANATOMY", 68, 73], ["mammalian cells", "CELL", 58, 73], ["tv", "GENE_OR_GENE_PRODUCT", 96, 98], ["mammalian cells", "CELL_TYPE", 58, 73], ["tv", "PROTEIN", 96, 98]]], ["Federspiel and Hughes were the first to demonstrate the specificity of this system in transgenic mice.", [["mice", "ORGANISM", 97, 101], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101]]], ["They showed that RCAS vectors expressing the marker gene alkaline phosphatase would specifically infect myocytes of mice transgenic for expression of tv-a from a muscle-specific promoter (Federspiel et al., 1994).Retroviral Life CycleThe life cycle of a retrovirus is comprised of a series of steps through which the virus replicates itself and its genetic information (Figure 2.1 and Color Plate 4).", [["myocytes", "ANATOMY", 104, 112], ["muscle", "ANATOMY", 162, 168], ["RCAS", "GENE_OR_GENE_PRODUCT", 17, 21], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 57, 77], ["myocytes", "CELL", 104, 112], ["mice", "ORGANISM", 116, 120], ["tv-a", "GENE_OR_GENE_PRODUCT", 150, 154], ["muscle", "ORGAN", 162, 168], ["Retroviral", "ORGANISM", 213, 223], ["retrovirus", "ORGANISM", 254, 264], ["RCAS vectors", "DNA", 17, 29], ["alkaline phosphatase", "PROTEIN", 57, 77], ["tv-a", "PROTEIN", 150, 154], ["muscle-specific promoter", "DNA", 162, 186], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["RCAS vectors", "TREATMENT", 17, 29], ["the marker gene alkaline phosphatase", "TEST", 41, 77], ["Retroviral Life Cycle", "TREATMENT", 213, 234], ["a retrovirus", "PROBLEM", 252, 264], ["the virus", "PROBLEM", 313, 322], ["Figure", "TEST", 370, 376], ["Color Plate", "TEST", 385, 396], ["muscle", "ANATOMY", 162, 168], ["retrovirus", "OBSERVATION", 254, 264]]], ["Genetically engineered retroviruses are called \u201cecotropic\u201d when they can only infect host cells of the same species as the natural hosts of the wild-type virus and \u201cxenotropic\u201d when they can only infect cells from species that differ from its natural host.", [["cells", "ANATOMY", 90, 95], ["cells", "ANATOMY", 203, 208], ["retroviruses", "ORGANISM", 23, 35], ["host cells", "CELL", 85, 95], ["wild-type virus", "ORGANISM", 144, 159], ["xenotropic", "ORGANISM", 165, 175], ["cells", "CELL", 203, 208], ["host cells", "CELL_TYPE", 85, 95], ["type virus", "PROBLEM", 149, 159], ["xenotropic\u201d", "TREATMENT", 165, 176], ["retroviruses", "OBSERVATION", 23, 35]]], ["\u201cAmphotropic\u201d viruses are capable of infecting both host cells and cells of other species (Katen et al., 2001).", [["cells", "ANATOMY", 57, 62], ["cells", "ANATOMY", 67, 72], ["Amphotropic\u201d viruses", "ORGANISM", 1, 21], ["cells", "CELL", 57, 62], ["cells", "CELL", 67, 72], ["host cells", "CELL_TYPE", 52, 62], ["Amphotropic\u201d viruses", "TREATMENT", 1, 21], ["other species", "PROBLEM", 76, 89], ["Amphotropic\u201d viruses", "OBSERVATION", 1, 21], ["host cells", "OBSERVATION", 52, 62]]], ["It is largely due to the polytropic characteristics of amphotropic viruses that diseases can transfer from one species to another.", [["amphotropic viruses", "ORGANISM", 55, 74], ["amphotropic viruses", "PROBLEM", 55, 74], ["amphotropic viruses", "OBSERVATION", 55, 74]]], ["Two examples of cross-species disease transfer are seen in the HIV virus (monkey to human) and the virus that causes SARS (avian to human) (Marx et al., 2001).", [["SARS", "DISEASE", 117, 121], ["HIV virus", "ORGANISM", 63, 72], ["monkey", "ORGANISM", 74, 80], ["human", "ORGANISM", 84, 89], ["human", "ORGANISM", 132, 137], ["HIV virus", "SPECIES", 63, 72], ["monkey", "SPECIES", 74, 80], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 132, 137], ["HIV virus", "SPECIES", 63, 72], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 132, 137], ["cross-species disease transfer", "PROBLEM", 16, 46], ["the HIV virus", "PROBLEM", 59, 72], ["the virus", "PROBLEM", 95, 104], ["SARS", "PROBLEM", 117, 121], ["cross-species disease", "OBSERVATION", 16, 37]]], ["Retroviruses have two identical copies of single-stranded RNA, called a capsid and an outer envelope comprised of glycoproteins used in the docking of the virus to the host cell.", [["outer envelope", "ANATOMY", 86, 100], ["cell", "ANATOMY", 173, 177], ["Retroviruses", "ORGANISM", 0, 12], ["host cell", "CELL", 168, 177], ["single-stranded RNA", "RNA", 42, 61], ["glycoproteins", "PROTEIN", 114, 127], ["host cell", "CELL_TYPE", 168, 177], ["single-stranded RNA", "PROBLEM", 42, 61], ["a capsid", "PROBLEM", 70, 78], ["an outer envelope", "TREATMENT", 83, 100], ["glycoproteins", "TREATMENT", 114, 127], ["single-stranded RNA", "OBSERVATION_MODIFIER", 42, 61], ["glycoproteins", "OBSERVATION", 114, 127], ["virus", "OBSERVATION", 155, 160], ["host cell", "OBSERVATION", 168, 177]]], ["The envelope glycoproteins interact in a highly specific manner, allowing them to dock only to a corresponding receptor protein on the membrane of the cell.", [["membrane", "ANATOMY", 135, 143], ["cell", "ANATOMY", 151, 155], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["cell", "CELL", 151, 155], ["envelope glycoproteins", "PROTEIN", 4, 26], ["receptor protein", "PROTEIN", 111, 127], ["The envelope glycoproteins", "TREATMENT", 0, 26], ["envelope", "OBSERVATION_MODIFIER", 4, 12], ["glycoproteins", "OBSERVATION", 13, 26], ["cell", "ANATOMY", 151, 155]]], ["For example, avian sarcoma and leucosis viruses and mouse mammary tumor virus infect in a species-specific manner (DeLarco and Todaro, 1976).", [["sarcoma", "ANATOMY", 19, 26], ["mammary tumor", "ANATOMY", 58, 71], ["avian sarcoma", "DISEASE", 13, 26], ["mammary tumor", "DISEASE", 58, 71], ["avian", "ORGANISM", 13, 18], ["sarcoma", "CANCER", 19, 26], ["leucosis viruses", "ORGANISM", 31, 47], ["mouse", "ORGANISM", 52, 57], ["mammary tumor virus", "ORGANISM", 58, 77], ["avian", "SPECIES", 13, 18], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 52, 57], ["avian sarcoma", "PROBLEM", 13, 26], ["leucosis viruses", "PROBLEM", 31, 47], ["mouse mammary tumor virus infect", "PROBLEM", 52, 84], ["avian", "OBSERVATION_MODIFIER", 13, 18], ["sarcoma", "OBSERVATION", 19, 26], ["leucosis viruses", "OBSERVATION", 31, 47], ["mammary", "ANATOMY", 58, 65], ["tumor", "OBSERVATION", 66, 71], ["virus infect", "OBSERVATION", 72, 84]]]], "PMC7490491": [["IntroductionIn March 2020, New York City (NYC) became the epicenter of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["coronavirus disease", "DISEASE", 75, 94], ["COVID-19", "CHEMICAL", 101, 109], ["pandemic", "DISEASE", 111, 119], ["acute respiratory syndrome coronavirus", "DISEASE", 137, 175], ["coronavirus", "ORGANISM", 75, 86], ["SARS-CoV-2", "ORGANISM", 179, 189], ["severe acute respiratory syndrome coronavirus", "SPECIES", 130, 175], ["SARS-CoV-2", "SPECIES", 179, 189], ["the coronavirus disease", "PROBLEM", 71, 94], ["COVID", "TEST", 101, 106], ["pandemic", "PROBLEM", 111, 119], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 130, 175], ["CoV", "TEST", 184, 187], ["coronavirus", "ANATOMY", 75, 86], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["respiratory syndrome", "OBSERVATION", 143, 163]]], ["To date, there have been 385,760 positive cases in New York state [1].IntroductionPatients with end-stage kidney disease (ESKD), including those on peritoneal dialysis (PD), have multiple comorbidities and a weakened immune system, making them more susceptible to infection than the general population [2].", [["kidney", "ANATOMY", 106, 112], ["peritoneal", "ANATOMY", 148, 158], ["immune system", "ANATOMY", 217, 230], ["end-stage kidney disease", "DISEASE", 96, 120], ["ESKD", "DISEASE", 122, 126], ["PD", "DISEASE", 169, 171], ["infection", "DISEASE", 264, 273], ["kidney", "ORGAN", 106, 112], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 148, 158], ["end-stage kidney disease", "PROBLEM", 96, 120], ["ESKD)", "PROBLEM", 122, 127], ["peritoneal dialysis", "TREATMENT", 148, 167], ["PD", "TREATMENT", 169, 171], ["multiple comorbidities", "PROBLEM", 179, 201], ["a weakened immune system", "PROBLEM", 206, 230], ["infection", "PROBLEM", 264, 273], ["stage", "OBSERVATION_MODIFIER", 100, 105], ["kidney", "ANATOMY", 106, 112], ["disease", "OBSERVATION", 113, 120], ["ESKD", "OBSERVATION", 122, 126], ["peritoneal", "ANATOMY", 148, 158], ["dialysis", "OBSERVATION", 159, 167], ["multiple", "OBSERVATION_MODIFIER", 179, 187], ["comorbidities", "OBSERVATION", 188, 201], ["infection", "OBSERVATION", 264, 273]]], ["During the COVID-19 pandemic, outpatient home dialysis center policies and procedures changed in order to practice better infection control and to decrease community spread.", [["infection", "DISEASE", 122, 131], ["the COVID", "TEST", 7, 16], ["outpatient home dialysis center policies", "TREATMENT", 30, 70], ["procedures", "TREATMENT", 75, 85], ["better infection control", "TREATMENT", 115, 139]]], ["This pandemic has affected the ESKD population, with high mortality rates reported among patients on hemodialysis (HD) [3].", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["the ESKD population", "PROBLEM", 27, 46], ["high mortality rates", "PROBLEM", 53, 73], ["hemodialysis (HD)", "TREATMENT", 101, 118], ["ESKD", "OBSERVATION_MODIFIER", 31, 35]]], ["However, the degree to which it has affected the PD population in the United States (US) has not yet been elucidated [4, 5].", [["PD", "DISEASE", 49, 51], ["degree", "OBSERVATION_MODIFIER", 13, 19]]], ["Herein, we describe the clinical characteristics, presentations, clinical course, and outcomes of ESKD patients on PD hospitalized with COVID-19.MethodsThis is a case series of patients with ESKD on chronic PD hospitalized with COVID-19 in 13 hospitals of a large health system in the New York City area.", [["ESKD", "DISEASE", 98, 102], ["PD", "DISEASE", 115, 117], ["ESKD", "DISEASE", 191, 195], ["PD", "DISEASE", 207, 209], ["COVID-19", "CHEMICAL", 136, 144], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 177, 185], ["PD", "TREATMENT", 115, 117], ["COVID", "TEST", 136, 141], ["ESKD", "PROBLEM", 191, 195], ["chronic PD", "TREATMENT", 199, 209], ["COVID", "TEST", 228, 233], ["large", "OBSERVATION_MODIFIER", 258, 263]]], ["All adult patients (age \u2265 18 years) with prevalent ESKD on PD who tested positive by PCR testing of a nasopharyngeal sample for COVID-19 from March 1, 2020, to April 27, 2020, were eligible.", [["nasopharyngeal sample", "ANATOMY", 102, 123], ["ESKD", "DISEASE", 51, 55], ["PD", "DISEASE", 59, 61], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["prevalent ESKD", "PROBLEM", 41, 55], ["PD", "TREATMENT", 59, 61], ["PCR testing", "TEST", 85, 96], ["a nasopharyngeal sample", "TEST", 100, 123], ["COVID", "TEST", 128, 133], ["nasopharyngeal", "ANATOMY", 102, 116]]], ["The patients were followed up through June 15, 2020.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["For patients who had multiple qualifying hospital admissions, we included only the first hospitalization.MethodsFor hospitalized patients, we identified patients with ESKD on PD through the following mechanisms: (1) presence of provider-entered discrete comorbidity of ESKD (International Classification of Diseases, Tenth Revision [ICD-10] code N18.6); (2) independent adjudication of the ESKD diagnosis and PD status through manual chart review of hospital admission and nephrology consultation notes to ensure patients had prevalent ESKD (J.S.H.); and (3) presence of dialysis orders specifically for the PD procedure.MethodsWe collected data on patient demographics, baseline history of comorbid conditions, medications, dialysis-specific data elements, and details of the hospital admissions.", [["ESKD", "DISEASE", 167, 171], ["PD", "DISEASE", 175, 177], ["ESKD", "DISEASE", 269, 273], ["ESKD", "DISEASE", 390, 394], ["PD", "DISEASE", 409, 411], ["ESKD", "DISEASE", 536, 540], ["PD", "DISEASE", 608, 610], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 153, 161], ["patients", "ORGANISM", 513, 521], ["patient", "ORGANISM", 649, 656], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 513, 521], ["patient", "SPECIES", 649, 656], ["ESKD", "PROBLEM", 167, 171], ["PD", "TREATMENT", 175, 177], ["ESKD", "PROBLEM", 269, 273], ["Diseases", "PROBLEM", 307, 315], ["Tenth Revision", "TREATMENT", 317, 331], ["ICD", "TREATMENT", 333, 336], ["dialysis orders", "TREATMENT", 571, 586], ["the PD procedure", "TREATMENT", 604, 620], ["comorbid conditions", "PROBLEM", 691, 710], ["medications", "TREATMENT", 712, 723], ["dialysis", "TREATMENT", 725, 733], ["ESKD", "OBSERVATION", 269, 273]]], ["Comorbid conditions and home medications were determined from provider-entered past medical history and admission medication reconciliation.", [["Comorbid conditions", "PROBLEM", 0, 19], ["home medications", "TREATMENT", 24, 40], ["admission medication reconciliation", "TREATMENT", 104, 139]]], ["Clinical presentation, imaging findings, episode of peritonitis, modality of PD, PD orders, and ventilatory settings were collected using manual chart review (M.S., D.M., and N.N.U.).", [["peritonitis", "DISEASE", 52, 63], ["PD", "DISEASE", 77, 79], ["PD", "DISEASE", 81, 83], ["imaging findings", "TEST", 23, 39], ["peritonitis", "PROBLEM", 52, 63], ["PD", "TREATMENT", 77, 79], ["PD orders", "TREATMENT", 81, 90], ["ventilatory settings", "TREATMENT", 96, 116], ["peritonitis", "OBSERVATION", 52, 63]]], ["We collected details during hospital admission such as intensive care unit (ICU) stay, need for mechanical ventilation, vasopressor support, hospital length of stay, death, discharge, and baseline laboratory test results within 48 h of hospital admission.", [["death", "DISEASE", 166, 171], ["mechanical ventilation", "TREATMENT", 96, 118], ["vasopressor support", "TREATMENT", 120, 139], ["death", "PROBLEM", 166, 171]]], ["Due to the COVID-19 pandemic, many additional ICUs were created in nontraditional hospital areas and units.", [["the COVID", "TEST", 7, 16], ["pandemic", "PROBLEM", 20, 28]]], ["Hence, ICU stay was defined as either one of the following: need for invasive mechanical ventilation, need for vasopressor or inotrope support, under the care of an ICU service, or in a known ICU location.", [["invasive mechanical ventilation", "TREATMENT", 69, 100], ["vasopressor", "TREATMENT", 111, 122], ["inotrope support", "TREATMENT", 126, 142]]], ["As the overall number of patients receiving PD was small, only descriptive statistical analysis was performed.", [["PD", "DISEASE", 44, 46], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["PD", "TREATMENT", 44, 46], ["descriptive statistical analysis", "TEST", 63, 95]]], ["The Institutional Review Board of Northwell Health approved the study protocol before the commencement of the study.ResultsWe identified 11 patients with ESKD on PD hospitalized with COVID-19 (out of a total of 419 hospitalized patients with ESKD [2.6%]).", [["ESKD", "DISEASE", 154, 158], ["PD", "DISEASE", 162, 164], ["ESKD", "DISEASE", 242, 246], ["patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 228, 236], ["the study protocol", "TEST", 60, 78], ["the study", "TEST", 106, 115], ["ESKD", "PROBLEM", 154, 158], ["PD", "TREATMENT", 162, 164], ["COVID", "TEST", 183, 188], ["ESKD", "TEST", 242, 246]]], ["The median age was 54 years, with 4 (36%) patients aged less than 40, 3 (27%) aged 50\u201359, and 3 (27%) aged 60\u201369 years.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["The patients were on an average of 8 home medications, 2 were on angiotensin-converting enzyme inhibitors, and 1 was on immunosuppressive medications (prednisone and tacrolimus).", [["angiotensin", "CHEMICAL", 65, 76], ["prednisone", "CHEMICAL", 151, 161], ["tacrolimus", "CHEMICAL", 166, 176], ["prednisone", "CHEMICAL", 151, 161], ["tacrolimus", "CHEMICAL", 166, 176], ["patients", "ORGANISM", 4, 12], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 65, 94], ["prednisone", "SIMPLE_CHEMICAL", 151, 161], ["tacrolimus", "SIMPLE_CHEMICAL", 166, 176], ["patients", "SPECIES", 4, 12], ["8 home medications", "TREATMENT", 35, 53], ["angiotensin", "TREATMENT", 65, 76], ["enzyme inhibitors", "TREATMENT", 88, 105], ["immunosuppressive medications", "TREATMENT", 120, 149], ["prednisone", "TREATMENT", 151, 161], ["tacrolimus", "TREATMENT", 166, 176]]], ["Five of the 11 patients received erythropoietin-stimulating agents during the hospitalization.ResultsTen patients had hypertension, 5 had diabetes mellitus, 2 had systemic lupus erythematosus, 1 had coronary artery disease, 1 had asthma, and 1 had a history of a prior failed kidney transplant.", [["coronary artery", "ANATOMY", 199, 214], ["kidney", "ANATOMY", 276, 282], ["hypertension", "DISEASE", 118, 130], ["diabetes mellitus", "DISEASE", 138, 155], ["systemic lupus erythematosus", "DISEASE", 163, 191], ["coronary artery disease", "DISEASE", 199, 222], ["asthma", "DISEASE", 230, 236], ["patients", "ORGANISM", 15, 23], ["erythropoietin-stimulating agents", "SIMPLE_CHEMICAL", 33, 66], ["patients", "ORGANISM", 105, 113], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 199, 214], ["kidney", "ORGAN", 276, 282], ["erythropoietin", "PROTEIN", 33, 47], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 105, 113], ["erythropoietin-stimulating agents", "TREATMENT", 33, 66], ["hypertension", "PROBLEM", 118, 130], ["diabetes mellitus", "PROBLEM", 138, 155], ["systemic lupus erythematosus", "PROBLEM", 163, 191], ["coronary artery disease", "PROBLEM", 199, 222], ["asthma", "PROBLEM", 230, 236], ["a prior failed kidney transplant", "TREATMENT", 261, 293], ["hypertension", "OBSERVATION", 118, 130], ["systemic", "OBSERVATION_MODIFIER", 163, 171], ["lupus erythematosus", "OBSERVATION", 172, 191], ["coronary artery", "ANATOMY", 199, 214], ["disease", "OBSERVATION", 215, 222], ["asthma", "OBSERVATION", 230, 236], ["kidney", "ANATOMY", 276, 282], ["transplant", "OBSERVATION", 283, 293]]], ["None of the patients had any underlying malignancy.", [["malignancy", "DISEASE", 40, 50], ["patients", "ORGANISM", 12, 20], ["malignancy", "CANCER", 40, 50], ["patients", "SPECIES", 12, 20], ["any underlying malignancy", "PROBLEM", 25, 50], ["malignancy", "OBSERVATION", 40, 50]]], ["Four (36%) patients were overweight, and another 4 (36%) were obese.", [["overweight", "DISEASE", 25, 35], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["obese", "PROBLEM", 62, 67], ["obese", "OBSERVATION", 62, 67]]], ["Nine reported no smoking history, and 2 were former smokers.", [["no", "UNCERTAINTY", 14, 16]]], ["Table 1 summarizes the baseline demographics and characteristics of these patients.ResultsThe most commonly reported presenting symptoms were fever (present in 7 of 11 [64%]) and diarrhea (6 of 11 [55%]), followed by shortness of breath (5 of 11 [45%]), cough (5 of 11 [45%]), and myalgias (4 of 11 [36%]).", [["fever", "DISEASE", 142, 147], ["diarrhea", "DISEASE", 179, 187], ["shortness of breath", "DISEASE", 217, 236], ["cough", "DISEASE", 254, 259], ["myalgias", "DISEASE", 281, 289], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["presenting symptoms", "PROBLEM", 117, 136], ["fever", "PROBLEM", 142, 147], ["diarrhea", "PROBLEM", 179, 187], ["shortness of breath", "PROBLEM", 217, 236], ["cough", "PROBLEM", 254, 259], ["myalgias", "PROBLEM", 281, 289]]], ["Less commonly reported symptoms included vomiting in 2 (18%), abdominal pain in 2 (18%), agitation in 1 (9%), vertigo in 1 (9%), and loss of taste or smell in 1 (9%).", [["abdominal", "ANATOMY", 62, 71], ["vomiting", "DISEASE", 41, 49], ["abdominal pain", "DISEASE", 62, 76], ["agitation", "DISEASE", 89, 98], ["vertigo", "DISEASE", 110, 117], ["loss of taste or smell", "DISEASE", 133, 155], ["abdominal", "ORGANISM_SUBDIVISION", 62, 71], ["symptoms", "PROBLEM", 23, 31], ["vomiting", "PROBLEM", 41, 49], ["abdominal pain", "PROBLEM", 62, 76], ["agitation", "PROBLEM", 89, 98], ["vertigo", "PROBLEM", 110, 117], ["loss of taste or smell", "PROBLEM", 133, 155], ["abdominal", "ANATOMY", 62, 71], ["pain", "OBSERVATION", 72, 76], ["vertigo", "OBSERVATION", 110, 117]]], ["Seven patients reported positive SARS-CoV-2 exposure from a member of their household.ResultsInitial chest radiographs showed bilateral opacities in the majority, 9 of 11 patients (82%).", [["chest", "ANATOMY", 101, 106], ["opacities", "DISEASE", 136, 145], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 171, 179], ["positive SARS", "PROBLEM", 24, 37], ["ResultsInitial chest radiographs", "TEST", 86, 118], ["bilateral opacities", "PROBLEM", 126, 145], ["positive", "OBSERVATION_MODIFIER", 24, 32], ["SARS", "OBSERVATION", 33, 37], ["chest", "ANATOMY", 101, 106], ["bilateral", "ANATOMY_MODIFIER", 126, 135], ["opacities", "OBSERVATION", 136, 145], ["majority", "ANATOMY_MODIFIER", 153, 161]]], ["One patient had unilobar pneumonia, and another had no acute findings on chest radiograph.", [["chest", "ANATOMY", 73, 78], ["pneumonia", "DISEASE", 25, 34], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["unilobar pneumonia", "PROBLEM", 16, 34], ["acute findings", "PROBLEM", 55, 69], ["chest radiograph", "TEST", 73, 89], ["unilobar", "OBSERVATION_MODIFIER", 16, 24], ["pneumonia", "OBSERVATION", 25, 34], ["no", "UNCERTAINTY", 52, 54], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["findings", "OBSERVATION", 61, 69], ["chest", "ANATOMY", 73, 78]]], ["Table 2 summarizes the clinical presentation, imaging findings, and outcomes of these patients.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["imaging findings", "TEST", 46, 62]]], ["Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000510259) summarize the pertinent laboratory data within the 48 hours of admission for these patients and the inpatient orders for PD.ResultsThe hospital course was complicated by ICU stay in 3 of 11 patients (27%), all of whom required mechanical ventilation.", [["PD", "DISEASE", 204, 206], ["patients", "ORGANISM", 166, 174], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 166, 174], ["patients", "SPECIES", 273, 281], ["PD", "TREATMENT", 204, 206], ["mechanical ventilation", "TREATMENT", 310, 332], ["mechanical ventilation", "OBSERVATION", 310, 332]]], ["Among the patients ventilated and who were on PD, one had a decrease in the plateau pressure from 36 to 29 cm H2O and another had no significant change in plateau pressure, which remained at 20 cm H2O despite being on PD.", [["PD", "DISEASE", 46, 48], ["H2O", "CHEMICAL", 110, 113], ["H2O", "CHEMICAL", 197, 200], ["PD", "DISEASE", 218, 220], ["H2O", "CHEMICAL", 110, 113], ["H2O", "CHEMICAL", 197, 200], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["PD", "TREATMENT", 46, 48], ["the plateau pressure", "TEST", 72, 92], ["significant change in plateau pressure", "PROBLEM", 133, 171], ["PD", "TREATMENT", 218, 220], ["decrease", "OBSERVATION_MODIFIER", 60, 68], ["plateau pressure", "OBSERVATION", 76, 92], ["29 cm", "OBSERVATION_MODIFIER", 104, 109], ["no", "UNCERTAINTY", 130, 132], ["significant", "OBSERVATION_MODIFIER", 133, 144], ["change", "OBSERVATION", 145, 151], ["plateau pressure", "OBSERVATION", 155, 171], ["20 cm", "OBSERVATION_MODIFIER", 191, 196]]], ["Seven patients received continuous ambulatory PD (CAPD), and 4 patients were on automated PD during the hospitalization.", [["PD", "DISEASE", 46, 48], ["PD", "DISEASE", 90, 92], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 63, 71], ["continuous ambulatory PD (CAPD", "TREATMENT", 24, 54], ["automated PD", "TREATMENT", 80, 92]]], ["One patient in the ICU received HD temporarily for one day due to severe hyperkalemia, with subsequent transition back to CAPD.ResultsThree patients were diagnosed with culture-negative peritonitis during hospitalization.", [["hyperkalemia", "DISEASE", 73, 85], ["peritonitis", "DISEASE", 186, 197], ["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 140, 148], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 140, 148], ["HD", "TREATMENT", 32, 34], ["severe hyperkalemia", "PROBLEM", 66, 85], ["CAPD", "TREATMENT", 122, 126], ["culture", "TEST", 169, 176], ["peritonitis", "PROBLEM", 186, 197], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["hyperkalemia", "OBSERVATION", 73, 85], ["negative", "OBSERVATION_MODIFIER", 177, 185], ["peritonitis", "OBSERVATION", 186, 197]]], ["None of the 3 patients with peritonitis died.", [["peritonitis", "DISEASE", 28, 39], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["peritonitis", "PROBLEM", 28, 39], ["peritonitis", "OBSERVATION", 28, 39]]], ["Table 2 shows the cell counts of the patients treated for peritonitis and their antibiotic course and duration.ResultsThe length of hospital stay ranged from 2 to 23 days, with the average length of stay being 9 days.", [["cell", "ANATOMY", 18, 22], ["peritonitis", "DISEASE", 58, 69], ["cell", "CELL", 18, 22], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["the cell counts", "TEST", 14, 29], ["peritonitis", "PROBLEM", 58, 69], ["their antibiotic course", "TREATMENT", 74, 97], ["peritonitis", "OBSERVATION", 58, 69], ["length", "OBSERVATION_MODIFIER", 122, 128]]], ["Two of the 11 (18%) patients expired, both of whom required mechanical ventilation and died within 4 days of admission (Table 2).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["mechanical ventilation", "TREATMENT", 60, 82], ["mechanical ventilation", "OBSERVATION", 60, 82]]], ["Both patients continued on CAPD until the day of expiration.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["CAPD", "TREATMENT", 27, 31]]], ["Nine patients (82%) were discharged home, and one was readmitted for worsening pneumonia.DiscussionIn this report, we describe the characteristics, presentation, and outcomes of ESKD patients on chronic PD hospitalized with COVID-19.", [["pneumonia", "DISEASE", 79, 88], ["ESKD", "DISEASE", 178, 182], ["PD", "DISEASE", 203, 205], ["COVID-19", "CHEMICAL", 224, 232], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 183, 191], ["worsening pneumonia", "PROBLEM", 69, 88], ["chronic PD", "TREATMENT", 195, 205], ["COVID", "TEST", 224, 229], ["worsening", "OBSERVATION_MODIFIER", 69, 78], ["pneumonia", "OBSERVATION", 79, 88]]], ["Of 419 hospitalized patients with ESKD, 11 were on chronic PD therapy (2.6%).", [["ESKD", "DISEASE", 34, 38], ["PD", "DISEASE", 59, 61], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["ESKD", "PROBLEM", 34, 38], ["chronic PD therapy", "TREATMENT", 51, 69]]], ["Among those 11, three patients required mechanical ventilation, two of whom died.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["mechanical ventilation", "TREATMENT", 40, 62], ["mechanical ventilation", "OBSERVATION", 40, 62]]], ["Of the entire cohort, 9 of the 11 patients (82%) were discharged alive.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["All but one patient were continued on PD without any significant electrolyte or volume-related concerns, and two of the patients on ventilator had either no change or improvement in their plateau pressures, making PD a viable option for those with COVID-19 infection and on mechanical ventilation.DiscussionLike all patients with ESKD, those on PD carry an increased risk of infection due to their immunosuppressed state and comorbid conditions.", [["PD", "DISEASE", 38, 40], ["PD", "DISEASE", 214, 216], ["infection", "DISEASE", 257, 266], ["ESKD", "DISEASE", 330, 334], ["PD", "DISEASE", 345, 347], ["infection", "DISEASE", 375, 384], ["patient", "ORGANISM", 12, 19], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 316, 324], ["patient", "SPECIES", 12, 19], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 316, 324], ["PD", "TREATMENT", 38, 40], ["ventilator", "TREATMENT", 132, 142], ["their plateau pressures", "TEST", 182, 205], ["COVID-19 infection", "PROBLEM", 248, 266], ["mechanical ventilation", "TREATMENT", 274, 296], ["ESKD", "TREATMENT", 330, 334], ["PD", "TREATMENT", 345, 347], ["infection", "PROBLEM", 375, 384], ["their immunosuppressed state", "PROBLEM", 392, 420], ["comorbid conditions", "PROBLEM", 425, 444], ["plateau pressures", "OBSERVATION", 188, 205], ["infection", "OBSERVATION", 257, 266], ["mechanical ventilation", "OBSERVATION", 274, 296], ["infection", "OBSERVATION", 375, 384]]], ["While some established risk factors for severe illness with COVID-19 such as advanced age, diabetes mellitus, and hypertension were present in our cohort, others such as heart disease, obesity, and cancer were less common or absent entirely [6].", [["heart", "ANATOMY", 170, 175], ["cancer", "ANATOMY", 198, 204], ["illness", "DISEASE", 47, 54], ["diabetes mellitus", "DISEASE", 91, 108], ["hypertension", "DISEASE", 114, 126], ["heart disease", "DISEASE", 170, 183], ["obesity", "DISEASE", 185, 192], ["cancer", "DISEASE", 198, 204], ["heart", "ORGAN", 170, 175], ["cancer", "CANCER", 198, 204], ["severe illness", "PROBLEM", 40, 54], ["COVID", "TREATMENT", 60, 65], ["diabetes mellitus", "PROBLEM", 91, 108], ["hypertension", "PROBLEM", 114, 126], ["heart disease", "PROBLEM", 170, 183], ["obesity", "PROBLEM", 185, 192], ["cancer", "PROBLEM", 198, 204], ["hypertension", "OBSERVATION", 114, 126], ["heart", "ANATOMY", 170, 175], ["disease", "OBSERVATION", 176, 183], ["obesity", "OBSERVATION", 185, 192], ["cancer", "OBSERVATION", 198, 204]]], ["Despite the risk factors, they seemed to do fairly well.DiscussionData for hospitalized patients on HD are slowly emerging, yet there are no reports of the burden of illness of COVID-19 in the PD population.", [["illness", "DISEASE", 166, 173], ["COVID-19", "CHEMICAL", 177, 185], ["PD", "DISEASE", 193, 195], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["the risk factors", "PROBLEM", 8, 24], ["HD", "TREATMENT", 100, 102], ["COVID", "TEST", 177, 182]]], ["Most studies from Europe, the US, and China show a high mortality rate for HD patients [3, 4, 5, 7].", [["HD", "DISEASE", 75, 77], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["the US", "TEST", 26, 32], ["a high mortality rate", "PROBLEM", 49, 70]]], ["In one single center study from the US, only 2 of 59 hospitalized patients with ESKD and COVID-19 were on PD [3].", [["ESKD", "DISEASE", 80, 84], ["PD", "DISEASE", 106, 108], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["the US", "TEST", 32, 38], ["ESKD", "TEST", 80, 84], ["COVID", "TEST", 89, 94]]], ["We did not observe a large number of patients hospitalized with this illness possibly owing to the ability of PD patients to perform dialysis at home and socially distance from others as opposed to in-center HD patients, PD patients being highly trained toward proper hygiene, and new policies and procedures that were put in place by outpatient PD units in an effort to decrease risk.", [["PD", "DISEASE", 110, 112], ["PD", "DISEASE", 221, 223], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 211, 219], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 211, 219], ["patients", "SPECIES", 224, 232], ["dialysis", "TREATMENT", 133, 141], ["procedures", "TREATMENT", 298, 308], ["outpatient PD units", "TREATMENT", 335, 354], ["large", "OBSERVATION_MODIFIER", 21, 26]]], ["In our population of admitted patients on PD, most did not require mechanical ventilation and were discharged home.", [["PD", "DISEASE", 42, 44], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["PD", "TREATMENT", 42, 44], ["mechanical ventilation", "TREATMENT", 67, 89], ["mechanical ventilation", "OBSERVATION", 67, 89]]], ["Despite that, given our small sample size, definitive conclusions regarding mortality in hospitalized patients on PD with COVID-19 are not possible.DiscussionCommonly reported symptoms associated with COVID-19 include fever, cough, and shortness of breath [8].", [["PD", "DISEASE", 114, 116], ["fever", "DISEASE", 218, 223], ["cough", "DISEASE", 225, 230], ["shortness of breath", "DISEASE", 236, 255], ["COVID-19", "CHEMICAL", 122, 130], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["our small sample size", "PROBLEM", 20, 41], ["PD", "TREATMENT", 114, 116], ["COVID", "TREATMENT", 122, 127], ["symptoms", "PROBLEM", 176, 184], ["COVID", "TEST", 201, 206], ["fever", "PROBLEM", 218, 223], ["cough", "PROBLEM", 225, 230], ["shortness of breath", "PROBLEM", 236, 255], ["small", "OBSERVATION_MODIFIER", 24, 29], ["size", "OBSERVATION_MODIFIER", 37, 41], ["not possible", "UNCERTAINTY", 135, 147], ["cough", "OBSERVATION", 225, 230]]], ["While fever was a common presentation, more than half of our patients also presented with diarrhea.", [["fever", "DISEASE", 6, 11], ["diarrhea", "DISEASE", 90, 98], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["fever", "PROBLEM", 6, 11], ["diarrhea", "PROBLEM", 90, 98], ["diarrhea", "OBSERVATION", 90, 98]]], ["One patient presented with diarrhea, abdominal pain, and myalgias, and another presented with only diarrhea and abdominal pain.", [["abdominal", "ANATOMY", 37, 46], ["abdominal", "ANATOMY", 112, 121], ["diarrhea", "DISEASE", 27, 35], ["abdominal pain", "DISEASE", 37, 51], ["myalgias", "DISEASE", 57, 65], ["diarrhea", "DISEASE", 99, 107], ["abdominal pain", "DISEASE", 112, 126], ["patient", "ORGANISM", 4, 11], ["abdominal", "ORGANISM_SUBDIVISION", 37, 46], ["abdominal", "ORGANISM_SUBDIVISION", 112, 121], ["patient", "SPECIES", 4, 11], ["diarrhea", "PROBLEM", 27, 35], ["abdominal pain", "PROBLEM", 37, 51], ["myalgias", "PROBLEM", 57, 65], ["diarrhea", "PROBLEM", 99, 107], ["abdominal pain", "PROBLEM", 112, 126], ["diarrhea", "OBSERVATION", 27, 35], ["abdominal", "ANATOMY", 37, 46], ["pain", "OBSERVATION", 47, 51], ["myalgias", "OBSERVATION", 57, 65], ["diarrhea", "OBSERVATION", 99, 107], ["abdominal", "ANATOMY", 112, 121], ["pain", "OBSERVATION", 122, 126]]], ["Neither of these patients had the typical cough or shortness of breath.", [["cough", "DISEASE", 42, 47], ["shortness of breath", "DISEASE", 51, 70], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["the typical cough", "PROBLEM", 30, 47], ["shortness of breath", "PROBLEM", 51, 70], ["typical", "OBSERVATION_MODIFIER", 34, 41], ["cough", "OBSERVATION", 42, 47]]], ["Our findings suggest the importance of assessing atypical symptoms of COVID-19, especially gastrointestinal symptoms in the PD population, and taking appropriate infection control precautions and diagnostic measures when these atypical symptoms are identified.DiscussionInterestingly, 3 patients were diagnosed with culture-negative peritonitis during their hospitalization.", [["gastrointestinal", "ANATOMY", 91, 107], ["gastrointestinal symptoms", "DISEASE", 91, 116], ["PD", "DISEASE", 124, 126], ["infection", "DISEASE", 162, 171], ["peritonitis", "DISEASE", 333, 344], ["gastrointestinal", "ORGAN", 91, 107], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["atypical symptoms", "PROBLEM", 49, 66], ["COVID", "TEST", 70, 75], ["gastrointestinal symptoms", "PROBLEM", 91, 116], ["the PD population", "TREATMENT", 120, 137], ["appropriate infection control precautions", "TREATMENT", 150, 191], ["diagnostic measures", "TEST", 196, 215], ["these atypical symptoms", "PROBLEM", 221, 244], ["culture", "TEST", 316, 323], ["peritonitis", "PROBLEM", 333, 344], ["peritonitis", "OBSERVATION", 333, 344]]], ["None of these patients died.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Owing to the temporal relationship of the COVID-19 illness and peritonitis, it is possible that SARS-CoV-2 might have been responsible for the peritonitis.", [["illness", "DISEASE", 51, 58], ["peritonitis", "DISEASE", 63, 74], ["SARS", "DISEASE", 96, 100], ["peritonitis", "DISEASE", 143, 154], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 96, 106], ["SARS-CoV", "SPECIES", 96, 104], ["the COVID-19 illness", "PROBLEM", 38, 58], ["peritonitis", "PROBLEM", 63, 74], ["SARS", "PROBLEM", 96, 100], ["CoV", "PROBLEM", 101, 104], ["the peritonitis", "PROBLEM", 139, 154], ["peritonitis", "OBSERVATION", 63, 74], ["peritonitis", "OBSERVATION", 143, 154]]], ["Whether this is a direct effect of the virus, hematogenous spread, touch contamination, the effect of inflammatory mediators, superimposed bacterial translocation due to diarrhea, or another issue remains uncertain, although Vischini et al. [9] previously reported peritoneal dialysate being positive for SARS-CoV-2 in a COVID-19 patient.DiscussionLimitations of this case series include the small sample size and the observational nature of the data collection from the electronic medical record.", [["peritoneal", "ANATOMY", 265, 275], ["diarrhea", "DISEASE", 170, 178], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 265, 275], ["dialysate", "ORGANISM_SUBSTANCE", 276, 285], ["SARS-CoV-2", "ORGANISM", 305, 315], ["patient", "ORGANISM", 330, 337], ["inflammatory mediators", "PROTEIN", 102, 124], ["patient", "SPECIES", 330, 337], ["SARS-CoV", "SPECIES", 305, 313], ["the virus", "PROBLEM", 35, 44], ["hematogenous spread", "PROBLEM", 46, 65], ["touch contamination", "PROBLEM", 67, 86], ["inflammatory mediators", "PROBLEM", 102, 124], ["superimposed bacterial translocation", "PROBLEM", 126, 162], ["diarrhea", "PROBLEM", 170, 178], ["peritoneal dialysate", "TEST", 265, 285], ["SARS", "PROBLEM", 305, 309], ["CoV", "TEST", 310, 313], ["hematogenous", "OBSERVATION_MODIFIER", 46, 58], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114], ["bacterial translocation", "OBSERVATION", 139, 162], ["peritoneal", "ANATOMY", 265, 275], ["small", "OBSERVATION_MODIFIER", 392, 397]]], ["The study was unable to obtain prevalence data as several different outpatient units admit to our enterprise hospitals and our electronic medical record system was not able to capture that.", [["The study", "TEST", 0, 9], ["prevalence data", "TEST", 31, 46]]], ["However, these data come from a diverse population of over 11,000 patients hospitalized at 13 hospitals in the New York area, the epicenter of the COVID-19 outbreak.ConclusionIn conclusion, we describe a series of patients with ESKD on chronic PD hospitalized with COVID-19 disease during the peak of the pandemic.", [["ESKD", "DISEASE", 228, 232], ["PD", "DISEASE", 244, 246], ["COVID-19 disease", "DISEASE", 265, 281], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 214, 222], ["the COVID", "TEST", 143, 152], ["ESKD", "PROBLEM", 228, 232], ["chronic PD", "TREATMENT", 236, 246], ["COVID-19 disease", "PROBLEM", 265, 281], ["the pandemic", "PROBLEM", 301, 313]]], ["We found that most patients had a relatively mild course and were discharged home.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["course", "OBSERVATION_MODIFIER", 50, 56]]], ["Further studies are needed to understand the absolute risk of infection in patients on PD and the spectrum of the burden of illness including presentation, complications of illness, and outcomes.Statement of EthicsThis study was approved by the Northwell IRB (COVID IRB # 529).Conflict of Interest StatementK.D.J. is a consultant for Astex Pharmaceuticals and Natera.Funding SourcesNo funding was needed for this study.Author ContributionsM.S., N.N.U., and D.M. made substantial contributions to the study concept and design.", [["infection", "DISEASE", 62, 71], ["PD", "DISEASE", 87, 89], ["illness", "DISEASE", 124, 131], ["illness", "DISEASE", 173, 180], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Further studies", "TEST", 0, 15], ["infection", "PROBLEM", 62, 71], ["PD", "TREATMENT", 87, 89], ["illness", "PROBLEM", 124, 131], ["illness", "PROBLEM", 173, 180], ["Astex Pharmaceuticals", "TREATMENT", 334, 355], ["Natera", "TREATMENT", 360, 366], ["this study", "TEST", 408, 418], ["the study", "TEST", 496, 505], ["infection", "OBSERVATION", 62, 71]]], ["J.S.H. was responsible for data extraction.", [["data extraction", "TREATMENT", 27, 42]]], ["J.N. and J.S.H. made substantial contributions to data acquisition, analysis, and interpretation.", [["data acquisition", "TEST", 50, 66], ["analysis", "TEST", 68, 76]]]], "6e7eeeb52aaa159588050577530502dad2fcc5e1": [["Seasonal hyperacute panuveitis (SHAPU) is a potentially blinding ocular disease occurring in Nepal that principally affects young children.", [["ocular", "ANATOMY", 65, 71], ["hyperacute panuveitis", "DISEASE", 9, 30], ["SHAPU", "DISEASE", 32, 37], ["ocular disease", "DISEASE", 65, 79], ["children", "ORGANISM", 130, 138], ["children", "SPECIES", 130, 138], ["Seasonal hyperacute panuveitis", "PROBLEM", 0, 30], ["a potentially blinding ocular disease", "PROBLEM", 42, 79], ["hyperacute", "OBSERVATION_MODIFIER", 9, 19], ["panuveitis", "OBSERVATION", 20, 30], ["potentially", "UNCERTAINTY", 44, 55], ["blinding", "OBSERVATION_MODIFIER", 56, 64], ["ocular disease", "OBSERVATION", 65, 79]]], ["Random amplification of partially purified vitreous fluid (VF)-derived nucleic acid revealed the presence of human anelloviruses in VF of SHAPU patients.", [["vitreous fluid", "ANATOMY", 43, 57], ["nucleic acid", "CHEMICAL", 71, 83], ["VF", "DISEASE", 132, 134], ["vitreous fluid", "ORGANISM_SUBSTANCE", 43, 57], ["human", "ORGANISM", 109, 114], ["anelloviruses", "CANCER", 115, 128], ["patients", "ORGANISM", 144, 152], ["human", "SPECIES", 109, 114], ["patients", "SPECIES", 144, 152], ["human", "SPECIES", 109, 114], ["partially purified vitreous fluid (VF", "TEST", 24, 61], ["nucleic acid", "TEST", 71, 83], ["human anelloviruses", "PROBLEM", 109, 128], ["vitreous fluid", "OBSERVATION", 43, 57]]], ["In a comparative study of patients with different ocular pathologies, SHAPU patients were at highest risk of harboring anelloviruses in their eyes.", [["ocular", "ANATOMY", 50, 56], ["eyes", "ANATOMY", 142, 146], ["ocular pathologies", "DISEASE", 50, 68], ["anelloviruses", "DISEASE", 119, 132], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 76, 84], ["anelloviruses", "CANCER", 119, 132], ["eyes", "ORGAN", 142, 146], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 76, 84], ["a comparative study", "TEST", 3, 22], ["different ocular pathologies", "PROBLEM", 40, 68], ["harboring anelloviruses in their eyes", "PROBLEM", 109, 146], ["ocular", "ANATOMY", 50, 56], ["pathologies", "OBSERVATION", 57, 68], ["harboring anelloviruses", "OBSERVATION", 109, 132], ["eyes", "ANATOMY", 142, 146]]], ["The majority of SHAPU patients had multiple anelloviruses in their VF.", [["SHAPU", "DISEASE", 16, 21], ["VF", "DISEASE", 67, 69], ["SHAPU", "CANCER", 16, 21], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["multiple anelloviruses in their VF", "PROBLEM", 35, 69], ["multiple", "OBSERVATION_MODIFIER", 35, 43], ["anelloviruses", "OBSERVATION", 44, 57]]], ["The ocular anellovirus load in SHAPU and non-SHAPU patients did not differ and no SHAPU-specific anellovirus variant was detected.", [["ocular", "ANATOMY", 4, 10], ["SHAPU", "ANATOMY", 31, 36], ["ocular anellovirus", "MULTI-TISSUE_STRUCTURE", 4, 22], ["SHAPU", "CANCER", 31, 36], ["patients", "ORGANISM", 51, 59], ["SHAPU", "GENE_OR_GENE_PRODUCT", 82, 87], ["anellovirus", "GENE_OR_GENE_PRODUCT", 97, 108], ["SHAPU", "PROTEIN", 82, 87], ["anellovirus variant", "PROTEIN", 97, 116], ["patients", "SPECIES", 51, 59], ["The ocular anellovirus load", "TEST", 0, 27], ["SHAPU-specific anellovirus variant", "PROBLEM", 82, 116], ["ocular", "ANATOMY", 4, 10], ["anellovirus load", "OBSERVATION", 11, 27], ["anellovirus variant", "OBSERVATION", 97, 116]]], ["Analysis of paired serum and VF samples from SHAPU and non-SHAPU patients showed that the anellovirus detected in VF samples most likely originated from the systemic viral pool during viremia, potentially through breakdown of the blood-ocular barrier.", [["serum", "ANATOMY", 19, 24], ["VF samples", "ANATOMY", 29, 39], ["SHAPU", "ANATOMY", 45, 50], ["VF samples", "ANATOMY", 114, 124], ["blood", "ANATOMY", 230, 235], ["ocular", "ANATOMY", 236, 242], ["viremia", "DISEASE", 184, 191], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["VF samples", "CANCER", 29, 39], ["SHAPU", "CANCER", 45, 50], ["patients", "ORGANISM", 65, 73], ["anellovirus", "GENE_OR_GENE_PRODUCT", 90, 101], ["VF samples", "CANCER", 114, 124], ["blood", "ORGANISM_SUBSTANCE", 230, 235], ["ocular barrier", "MULTI-TISSUE_STRUCTURE", 236, 250], ["patients", "SPECIES", 65, 73], ["paired serum", "TEST", 12, 24], ["VF samples", "TEST", 29, 39], ["SHAPU", "TEST", 45, 50], ["the anellovirus", "PROBLEM", 86, 101], ["VF samples", "PROBLEM", 114, 124], ["the systemic viral pool", "PROBLEM", 153, 176], ["viremia", "PROBLEM", 184, 191], ["the blood-ocular barrier", "TREATMENT", 226, 250], ["most likely", "UNCERTAINTY", 125, 136], ["systemic", "OBSERVATION_MODIFIER", 157, 165], ["viral pool", "OBSERVATION", 166, 176], ["viremia", "OBSERVATION", 184, 191], ["ocular", "ANATOMY", 236, 242]]], ["The detection of anelloviruses in VF samples of uveitis patients, profoundly so in SHAPU patients, is imperative and warrants elucidation of its clinical significance.", [["VF samples", "ANATOMY", 34, 44], ["VF", "DISEASE", 34, 36], ["uveitis", "DISEASE", 48, 55], ["anelloviruses", "GENE_OR_GENE_PRODUCT", 17, 30], ["VF samples", "CANCER", 34, 44], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 89, 97], ["The detection", "TEST", 0, 13], ["anelloviruses", "PROBLEM", 17, 30], ["uveitis", "PROBLEM", 48, 55], ["uveitis", "OBSERVATION", 48, 55]]]], "fd504c3894072f5974f805be10adfb9eb6b2dbed": [["| INTRODUCTIONSwine acute diarrhoea syndrome coronavirus (SADS-CoV) is a newly discovered coronavirus which is an enveloped, positive and singlestranded sense RNA virus with a genome size of approximately 27 kb (Gong et al., 2017; Pan et al., 2017; Zhou et al., 2018) .| INTRODUCTIONSADS-CoV belongs to the family Coronaviridae which contains four genera, Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus (Woo, Huang, Lau, & Yuen, 2010; Woo et al., 2012) .", [["acute diarrhoea syndrome coronavirus", "DISEASE", 20, 56], ["coronavirus", "DISEASE", 90, 101], ["INTRODUCTIONSwine acute diarrhoea syndrome coronavirus", "ORGANISM", 2, 56], ["SADS-CoV", "ORGANISM", 58, 66], ["coronavirus", "ORGANISM", 90, 101], ["INTRODUCTIONSADS-CoV", "GENE_OR_GENE_PRODUCT", 271, 291], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 356, 372], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 374, 389], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 391, 407], ["INTRODUCTIONSwine acute diarrhoea syndrome coronavirus", "SPECIES", 2, 56], ["SADS-CoV", "SPECIES", 58, 66], ["INTRODUCTIONSADS-CoV", "SPECIES", 271, 291], ["acute diarrhoea syndrome", "PROBLEM", 20, 44], ["coronavirus (SADS-CoV", "PROBLEM", 45, 66], ["a newly discovered coronavirus", "PROBLEM", 71, 101], ["singlestranded sense RNA virus", "PROBLEM", 138, 168], ["Coronaviridae", "TREATMENT", 314, 327], ["Alphacoronavirus", "TREATMENT", 356, 372], ["Betacoronavirus", "TREATMENT", 374, 389], ["Gammacoronavirus", "TREATMENT", 391, 407], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["diarrhoea syndrome coronavirus", "OBSERVATION", 26, 56], ["coronavirus", "OBSERVATION", 90, 101], ["size", "OBSERVATION_MODIFIER", 183, 187]]], ["So far, six coronaviruses have been identified from pigs, which include porcine epidemic diarrhoea virus (PEDV), porcine respiratory coronavirus (PRCV), SADS-CoV and transmissible gastroenteritis virus (TGEV) that all belong to the Alphacoronavirus genus, as well as one betacoronavirus, porcine hemagglutinating encephalomyelitis virus (PHEV) and one deltacoronavirus, porcine deltacoronavirus (PDCoV) (Lin, Saif, Marthaler, & Wang, 2016; Wesley, Woods, & Cheung, 1991; Woo et al., 2010) .", [["porcine epidemic diarrhoea virus", "DISEASE", 72, 104], ["porcine respiratory coronavirus", "DISEASE", 113, 144], ["transmissible gastroenteritis virus", "DISEASE", 166, 201], ["hemagglutinating encephalomyelitis", "DISEASE", 296, 330], ["coronaviruses", "ORGANISM", 12, 25], ["pigs", "ORGANISM", 52, 56], ["porcine epidemic diarrhoea virus", "ORGANISM", 72, 104], ["porcine respiratory coronavirus", "ORGANISM", 113, 144], ["SADS-CoV", "ORGANISM", 153, 161], ["transmissible gastroenteritis virus", "ORGANISM", 166, 201], ["TGEV", "ORGANISM", 203, 207], ["Alphacoronavirus genus", "ORGANISM", 232, 254], ["porcine hemagglutinating encephalomyelitis virus", "ORGANISM", 288, 336], ["PHEV", "ORGANISM", 338, 342], ["porcine deltacoronavirus", "ORGANISM", 370, 394], ["pigs", "SPECIES", 52, 56], ["porcine epidemic diarrhoea virus", "SPECIES", 72, 104], ["porcine respiratory coronavirus", "SPECIES", 113, 144], ["SADS-CoV", "SPECIES", 153, 161], ["transmissible gastroenteritis virus", "SPECIES", 166, 201], ["porcine hemagglutinating encephalomyelitis virus", "SPECIES", 288, 336], ["porcine", "SPECIES", 370, 377], ["pigs", "SPECIES", 52, 56], ["porcine epidemic diarrhoea virus", "SPECIES", 72, 104], ["PEDV", "SPECIES", 106, 110], ["porcine respiratory coronavirus", "SPECIES", 113, 144], ["PRCV", "SPECIES", 146, 150], ["SADS-CoV", "SPECIES", 153, 161], ["transmissible gastroenteritis virus", "SPECIES", 166, 201], ["TGEV", "SPECIES", 203, 207], ["porcine hemagglutinating encephalomyelitis virus", "SPECIES", 288, 336], ["PHEV", "SPECIES", 338, 342], ["porcine deltacoronavirus (PDCoV) (Lin, Saif, Marthaler, & Wang, 2016; Wesley, Woods, & Cheung, 1991; Woo et al., 2010", "SPECIES", 370, 487], ["six coronaviruses", "PROBLEM", 8, 25], ["porcine epidemic diarrhoea virus", "PROBLEM", 72, 104], ["PEDV", "PROBLEM", 106, 110], ["porcine respiratory coronavirus (PRCV)", "PROBLEM", 113, 151], ["SADS", "PROBLEM", 153, 157], ["CoV", "PROBLEM", 158, 161], ["transmissible gastroenteritis virus (TGEV", "PROBLEM", 166, 207], ["porcine hemagglutinating encephalomyelitis virus", "PROBLEM", 288, 336], ["porcine deltacoronavirus", "TREATMENT", 370, 394], ["respiratory coronavirus", "OBSERVATION", 121, 144], ["gastroenteritis virus", "OBSERVATION", 180, 201], ["Alphacoronavirus genus", "ANATOMY", 232, 254], ["hemagglutinating encephalomyelitis", "OBSERVATION", 296, 330]]], ["Among these viruses, SADS-CoV is the most newly discovered coronavirus, which has been first reported in 2017 in China and is considered to be an HKU2-related coronavirus with a bat-origin (Gong et al., 2017; Zhou et al., 2018) .", [["coronavirus", "DISEASE", 159, 170], ["SADS-CoV", "ORGANISM", 21, 29], ["coronavirus", "ORGANISM", 59, 70], ["HKU2", "GENE_OR_GENE_PRODUCT", 146, 150], ["coronavirus", "ORGANISM", 159, 170], ["SADS-CoV", "SPECIES", 21, 29], ["these viruses", "PROBLEM", 6, 19], ["SADS", "PROBLEM", 21, 25], ["coronavirus", "PROBLEM", 59, 70], ["an HKU2-related coronavirus", "PROBLEM", 143, 170], ["viruses", "OBSERVATION", 12, 19], ["coronavirus", "OBSERVATION", 59, 70], ["coronavirus", "OBSERVATION", 159, 170]]], ["In January 2017, SADS-CoV was detected in a swine farm and subsequently spread rapidly to three other farms in *These authors contributed equally to this work.", [["SADS-CoV", "ORGANISM", 17, 25], ["swine", "SPECIES", 44, 49], ["SADS-CoV", "SPECIES", 17, 25], ["swine", "SPECIES", 44, 49], ["SADS", "PROBLEM", 17, 21]]], ["Guangdong Province and caused the fatal swine acute diarrhoea syndrome (SADS) characterized by the clinical signs with severe, acute diarrhoea and rapid weight loss of piglets.", [["swine acute diarrhoea syndrome", "DISEASE", 40, 70], ["SADS", "DISEASE", 72, 76], ["diarrhoea", "DISEASE", 133, 142], ["weight loss", "DISEASE", 153, 164], ["piglets", "ORGANISM", 168, 175], ["swine", "SPECIES", 40, 45], ["piglets", "SPECIES", 168, 175], ["the fatal swine acute diarrhoea syndrome", "PROBLEM", 30, 70], ["acute diarrhoea", "PROBLEM", 127, 142], ["rapid weight loss of piglets", "PROBLEM", 147, 175], ["fatal", "OBSERVATION_MODIFIER", 34, 39], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["diarrhoea syndrome", "OBSERVATION", 52, 70], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["diarrhoea", "OBSERVATION", 133, 142], ["rapid", "OBSERVATION_MODIFIER", 147, 152], ["weight loss", "OBSERVATION", 153, 164]]], ["The symptoms of SADS-CoV are similar to those that caused by other swine enteric coronaviruses such as PDCoV and PEDV, but SADS-CoV is more harmful than these viruses because it has led to the death of almost 25,000 piglets in a short time and resulted in more significant economic losses (Dong et al., 2015; Sun, Wang, Wei, Chen, & Feng, 2016; Zhou et al., 2018) .", [["PEDV", "CHEMICAL", 113, 117], ["death", "DISEASE", 193, 198], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["swine enteric coronaviruses", "ORGANISM", 67, 94], ["SADS-CoV", "ORGANISM", 123, 131], ["piglets", "ORGANISM", 216, 223], ["swine", "SPECIES", 67, 72], ["piglets", "SPECIES", 216, 223], ["SADS-CoV", "SPECIES", 16, 24], ["swine", "SPECIES", 67, 72], ["PDCoV", "SPECIES", 103, 108], ["PEDV", "SPECIES", 113, 117], ["SADS-CoV", "SPECIES", 123, 131], ["The symptoms", "PROBLEM", 0, 12], ["SADS", "PROBLEM", 16, 20], ["CoV", "PROBLEM", 21, 24], ["other swine enteric coronaviruses", "PROBLEM", 61, 94], ["PDCoV", "PROBLEM", 103, 108], ["PEDV", "PROBLEM", 113, 117], ["SADS", "PROBLEM", 123, 127], ["CoV", "PROBLEM", 128, 131], ["these viruses", "PROBLEM", 153, 166], ["significant economic losses", "PROBLEM", 261, 288], ["coronaviruses", "OBSERVATION", 81, 94], ["significant", "OBSERVATION_MODIFIER", 261, 272], ["economic losses", "OBSERVATION", 273, 288]]], ["So, it is urgent to investigate the molecular epidemiology and transmission patterns of SADS-CoV for establishing effective controls for this new coronavirus.| INTRODUCTIONIn the present study, we performed the retrospective PCR testing on diarrheal samples from 45 swine farms in Guangdong Province to evaluate the emergence and the distribution of SADS-CoV in pigs in China.", [["samples", "ANATOMY", 250, 257], ["coronavirus", "DISEASE", 146, 157], ["diarrheal", "DISEASE", 240, 249], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["coronavirus", "ORGANISM", 146, 157], ["SADS-CoV", "ORGANISM", 350, 358], ["pigs", "ORGANISM", 362, 366], ["swine", "SPECIES", 266, 271], ["pigs", "SPECIES", 362, 366], ["SADS-CoV", "SPECIES", 88, 96], ["swine", "SPECIES", 266, 271], ["SADS-CoV", "SPECIES", 350, 358], ["pigs", "SPECIES", 362, 366], ["SADS", "PROBLEM", 88, 92], ["this new coronavirus", "PROBLEM", 137, 157], ["the present study", "TEST", 175, 192], ["the retrospective PCR testing", "TEST", 207, 236], ["diarrheal samples", "TEST", 240, 257], ["SADS", "PROBLEM", 350, 354], ["CoV", "OBSERVATION", 355, 358]]], ["The prevalence and co-infection information of SADS-CoV from eleven SADS-CoV-positive farms was provided.", [["SADS-CoV", "ORGANISM", 47, 55], ["SADS-CoV", "ORGANISM", 68, 76], ["SADS-CoV", "SPECIES", 47, 55], ["SADS", "TEST", 47, 51], ["CoV", "PROBLEM", 52, 55], ["eleven SADS", "TEST", 61, 72], ["CoV", "TEST", 73, 76]]], ["The sequences of SADS-CoV, including two complete genomes, five nucleocapsid protein (N) genes and five spike protein (S) genes, were also identified and characterized to investigate the phylogenetic relationships of SADS-CoV.| Nucleic acid extraction and molecular diagnosisSamples were homogenized in phosphate-buffered saline (PBS) (20% w/v), frozen and thawed three times, then centrifuged for 10 min at 10,000 g.", [["Nucleic acid", "CHEMICAL", 228, 240], ["phosphate", "CHEMICAL", 303, 312], ["phosphate", "CHEMICAL", 303, 312], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 64, 88], ["spike protein (S)", "GENE_OR_GENE_PRODUCT", 104, 121], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 303, 328], ["SADS", "DNA", 17, 21], ["CoV", "DNA", 22, 25], ["nucleocapsid protein (N) genes", "DNA", 64, 94], ["spike protein (S) genes", "DNA", 104, 127], ["SADS-CoV", "SPECIES", 17, 25], ["SADS", "TEST", 17, 21], ["CoV", "TEST", 22, 25], ["five nucleocapsid protein", "TEST", 59, 84], ["five spike protein", "TEST", 99, 117], ["Nucleic acid extraction", "TREATMENT", 228, 251], ["phosphate", "TEST", 303, 312], ["buffered saline (PBS", "TREATMENT", 313, 333], ["frozen", "TREATMENT", 346, 352], ["acid", "OBSERVATION_MODIFIER", 236, 240]]], ["Viral nucleic acid was extracted following the manufacturer's recommendations of AxyPrep TM Body Fluid Viral DNA/RNA Miniprep Kit (Axygen Scientific, Inc).", [["nucleic acid", "CHEMICAL", 6, 18], ["Viral nucleic acid", "PROBLEM", 0, 18], ["AxyPrep TM", "TREATMENT", 81, 91], ["nucleic acid", "OBSERVATION", 6, 18]]], ["The virus nucleic acid was stored at \u221280\u00b0C until PCR was performed.", [["nucleic acid", "CHEMICAL", 10, 22], ["C", "GENE_OR_GENE_PRODUCT", 41, 42], ["The virus nucleic acid", "TEST", 0, 22], ["PCR", "TEST", 49, 52]]], ["A pair of primers (forward primer 5\u2032-GGTCCCTGTGACCGAAGTTTTAG-3\u2032, reverse primer 5\u2032-GCGTTCTGCGATAAAGCTTAAAACTATTA-3\u2032) was designed to detected SADS-CoV based on the conserved N gene of this virus.| Nucleic acid extraction and molecular diagnosisOne step RT-PCR using PrimeScript \u2122 One Step RT-PCR Kit Ver.2 with Dye Plus (Takara, Biotechnology, Dalian, China) was carried out to amplify the target fragments by the following thermal profile of 50\u00b0C for 30 min, 94\u00b0C for 3 min, 35 cycles of denaturation at 94\u00b0C for 30 s, annealing at 55\u00b0C for 30 s, an extension at 72\u00b0C for 30 s, and a final step of 72\u00b0C for 5 min.", [["fragments", "ANATOMY", 397, 406], ["Nucleic acid", "CHEMICAL", 197, 209], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 142, 150], ["forward primer 5", "DNA", 19, 35], ["reverse primer", "DNA", 65, 79], ["SADS-CoV", "DNA", 142, 150], ["N gene", "DNA", 174, 180], ["target fragments", "DNA", 390, 406], ["SADS-CoV", "SPECIES", 142, 150], ["A pair of primers (forward primer", "TREATMENT", 0, 33], ["GGTCCCTGTGACCGAAGTTTTAG", "TEST", 37, 60], ["GCGTTCTGCGATAAAGCTTAAAACTATTA", "TEST", 83, 112], ["SADS", "PROBLEM", 142, 146], ["this virus", "PROBLEM", 184, 194], ["Nucleic acid extraction", "TREATMENT", 197, 220], ["PrimeScript", "TREATMENT", 266, 277], ["denaturation", "TREATMENT", 489, 501]]], ["Four other diarrheal pathogens including PEDV, PDCoV, rotavirus (RV), and TGEV from SADS-CoVpositive farms were also tested by RT-PCR according to the previously described methods (Liu, Zhu, Liao, Xu, & Zhou, 2015; Mai et al., 2017; Stevenson et al., 2013) .| Amplification of the N gene, the S gene, and the complete genome of SADS-CoVSpecific primer pairs based on reported SADS-CoV strains (GenBank accession numbers: MF094681-MF094684) were designed for S genes, N genes and complete genome amplifications, respectively (Table S1 ).", [["diarrheal pathogens", "DISEASE", 11, 30], ["PEDV", "GENE_OR_GENE_PRODUCT", 41, 45], ["PDCoV", "GENE_OR_GENE_PRODUCT", 47, 52], ["rotavirus", "ORGANISM", 54, 63], ["TGEV", "ORGANISM", 74, 78], ["SADS", "GENE_OR_GENE_PRODUCT", 328, 332], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 376, 384], ["N gene", "DNA", 281, 287], ["S gene", "DNA", 293, 299], ["SADS", "DNA", 328, 332], ["CoVSpecific primer pairs", "DNA", 333, 357], ["SADS-CoV strains", "DNA", 376, 392], ["S genes", "DNA", 458, 465], ["N genes", "DNA", 467, 474], ["TGEV", "SPECIES", 74, 78], ["PEDV", "SPECIES", 41, 45], ["PDCoV", "SPECIES", 47, 52], ["rotavirus", "SPECIES", 54, 63], ["RV", "SPECIES", 65, 67], ["TGEV", "SPECIES", 74, 78], ["SADS-CoV", "SPECIES", 376, 384], ["Four other diarrheal pathogens", "PROBLEM", 0, 30], ["PEDV", "PROBLEM", 41, 45], ["PDCoV", "PROBLEM", 47, 52], ["rotavirus", "PROBLEM", 54, 63], ["TGEV", "PROBLEM", 74, 78], ["SADS", "PROBLEM", 84, 88], ["CoVpositive farms", "PROBLEM", 89, 106], ["PCR", "TEST", 130, 133], ["the N gene", "TREATMENT", 277, 287], ["SADS", "PROBLEM", 328, 332], ["CoVSpecific primer pairs", "PROBLEM", 333, 357], ["CoV strains", "PROBLEM", 381, 392], ["diarrheal", "OBSERVATION_MODIFIER", 11, 20], ["pathogens", "OBSERVATION", 21, 30], ["RV", "ANATOMY", 65, 67]]], ["PCR assays were performed with the following thermal profile: 95\u00b0C for 5 min, 35 cycles of 95\u00b0C for 30 s, 50\u00b0C for 30 s, and 72\u00b0C for 1 min 15 s, followed by a final 10 min extension at 72\u00b0C. The products were purified following the manufacturer's| Sequence alignment and phylogenetic analysisThe nucleotide sequences were assembled and aligned using the DNASTAR program (DNAStar V7.1, Madison, WI, USA).", [["nucleotide", "CHEMICAL", 297, 307], ["PCR assays", "TEST", 0, 10], ["thermal profile", "TEST", 45, 60], ["Sequence alignment", "TEST", 249, 267], ["phylogenetic analysis", "TEST", 272, 293], ["The nucleotide sequences", "TEST", 293, 317]]], ["Phylogenetic trees were constructed using the neighbour-joining method in MEGA 7.0 software with bootstrap analysis of 1,000 replicates.", [["Phylogenetic trees", "PROBLEM", 0, 18], ["bootstrap analysis", "TEST", 97, 115]]], ["Percentages of replicate trees in which the associated taxa clustered are shown as nearby branches (Chenna et al., 2003; Kumar, Stecher, & Tamura, 2016; Tamura, Nei, & Kumar, 2004 ).| Sequence identities and phylogenetic analysesThe two complete genomes (accession number MG605090 and F I G U R E 4 Phylogenetic analysis of the S genes of SADS-CoV and reference coronavirus species.", [["SADS-CoV", "GENE_OR_GENE_PRODUCT", 339, 347], ["coronavirus species", "ORGANISM", 362, 381], ["S genes", "DNA", 328, 335], ["SADS-CoV", "DNA", 339, 347], ["SADS-CoV", "SPECIES", 339, 347], ["Sequence identities", "TEST", 184, 203], ["phylogenetic analyses", "TEST", 208, 229], ["Phylogenetic analysis", "TEST", 299, 320], ["SADS", "PROBLEM", 339, 343], ["CoV", "PROBLEM", 344, 347], ["reference coronavirus species", "PROBLEM", 352, 381], ["replicate trees", "OBSERVATION", 15, 30], ["branches", "ANATOMY_MODIFIER", 90, 98], ["two", "OBSERVATION_MODIFIER", 233, 236], ["complete", "OBSERVATION_MODIFIER", 237, 245], ["genomes", "OBSERVATION", 246, 253], ["coronavirus species", "OBSERVATION", 362, 381]]], ["The tree was constructed as per Figure 2 above.", [["tree", "ANATOMY_MODIFIER", 4, 8]]], ["Five new sequences of S genes studied in this work were indicated with \"black solid circles\" diarrhoea samples.", [["samples", "ANATOMY", 103, 110], ["diarrhoea", "DISEASE", 93, 102], ["S genes", "DNA", 22, 29], ["Five new sequences of S genes", "TEST", 0, 29], ["diarrhoea samples", "PROBLEM", 93, 110]]], ["Our results showed that the first SADS-CoV positive sample was collected in August 2016 from the farm LS with a history of diarrhoea, as well as from other two farms TP and ZW, which indicates that SADS-CoV has emerged in pigs in China at least since August 2016.", [["sample", "ANATOMY", 52, 58], ["diarrhoea", "DISEASE", 123, 132], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["TP", "GENE_OR_GENE_PRODUCT", 166, 168], ["SADS-CoV", "ORGANISM", 198, 206], ["pigs", "ORGANISM", 222, 226], ["pigs", "SPECIES", 222, 226], ["SADS-CoV", "SPECIES", 198, 206], ["pigs", "SPECIES", 222, 226], ["the first SADS", "TEST", 24, 38], ["CoV positive sample", "PROBLEM", 39, 58], ["diarrhoea", "PROBLEM", 123, 132], ["SADS", "PROBLEM", 198, 202], ["CoV", "PROBLEM", 203, 206], ["diarrhoea", "OBSERVATION", 123, 132]]], ["As the same time, clinical signs of SADS-CoV during the retrospective investigation included sever and acute vomiting and diarrhoea, leading to death in piglets that were less than 5 days of age with a mortality rate of around 50%.", [["vomiting", "DISEASE", 109, 117], ["diarrhoea", "DISEASE", 122, 131], ["death", "DISEASE", 144, 149], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["piglets", "ORGANISM", 153, 160], ["piglets", "SPECIES", 153, 160], ["SADS-CoV", "SPECIES", 36, 44], ["SADS", "PROBLEM", 36, 40], ["CoV", "PROBLEM", 41, 44], ["the retrospective investigation", "TEST", 52, 83], ["sever and acute vomiting", "PROBLEM", 93, 117], ["diarrhoea", "PROBLEM", 122, 131], ["death", "PROBLEM", 144, 149], ["a mortality rate", "TEST", 200, 216], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["vomiting", "OBSERVATION", 109, 117], ["diarrhoea", "OBSERVATION", 122, 131]]], ["These clinical presentations were similar to those signs in the large scale outbreak of SADS-CoV reported by Zhou et al. (2018) , except the mortality rate in piglets later increased to 90%.| Sequence identities and phylogenetic analysesBased on the rates of infection documented in our work, it revealed that PEDV (78.25%) was still the primary cause of the porcine diarrhoea, which is consistent with previous studies that PEDV has been considered to be the major pathogen responsible for the porcine diarrhoea epidemic in China since 2010 (Ge et al., 2013; Sun et al., 2012; Zhao et al., 2016) .", [["SADS", "DISEASE", 88, 92], ["infection", "DISEASE", 259, 268], ["porcine diarrhoea", "DISEASE", 359, 376], ["PEDV", "CHEMICAL", 425, 429], ["porcine diarrhoea", "DISEASE", 495, 512], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["piglets", "ORGANISM", 159, 166], ["porcine", "ORGANISM", 359, 366], ["porcine", "ORGANISM", 495, 502], ["piglets", "SPECIES", 159, 166], ["porcine", "SPECIES", 359, 366], ["porcine", "SPECIES", 495, 502], ["SADS-CoV", "SPECIES", 88, 96], ["PEDV", "SPECIES", 310, 314], ["porcine", "SPECIES", 359, 366], ["PEDV", "SPECIES", 425, 429], ["those signs", "TEST", 45, 56], ["the mortality rate", "TEST", 137, 155], ["Sequence identities", "TEST", 192, 211], ["phylogenetic analyses", "TEST", 216, 237], ["infection", "PROBLEM", 259, 268], ["PEDV", "PROBLEM", 310, 314], ["the porcine diarrhoea", "PROBLEM", 355, 376], ["previous studies", "TEST", 403, 419], ["PEDV", "PROBLEM", 425, 429], ["the porcine diarrhoea", "PROBLEM", 491, 512], ["large", "OBSERVATION_MODIFIER", 64, 69], ["infection", "OBSERVATION", 259, 268], ["porcine diarrhoea", "OBSERVATION", 359, 376], ["consistent with", "UNCERTAINTY", 387, 402]]], ["The phylogenetic relationships of SADS-CoV sequences were also identified in this study.", [["SADS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["SADS-CoV sequences", "DNA", 34, 52], ["SADS-CoV", "SPECIES", 34, 42], ["SADS-CoV sequences", "TEST", 34, 52], ["this study", "TEST", 77, 87]]], ["The results showed that all SADS-CoV sequences clustered together to form an independent branch and separated from other viral sequences in the genus Alphacoronavirus.| Sequence identities and phylogenetic analysesOur results also indicated that both the complete genomes, N genes and S genes of all SADS-CoV strains shared the highest nucleotides identifies with those corresponding sequences of four bat coronavirus HKU2 strains.", [["SADS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 300, 308], ["bat coronavirus", "ORGANISM", 402, 417], ["HKU2", "GENE_OR_GENE_PRODUCT", 418, 422], ["SADS-CoV sequences", "DNA", 28, 46], ["viral sequences", "DNA", 121, 136], ["N genes", "DNA", 273, 280], ["S genes", "DNA", 285, 292], ["bat coronavirus", "SPECIES", 402, 417], ["SADS-CoV", "SPECIES", 28, 36], ["SADS-CoV", "SPECIES", 300, 308], ["bat coronavirus", "SPECIES", 402, 417], ["all SADS", "TEST", 24, 32], ["CoV sequences", "TEST", 33, 46], ["other viral sequences", "TEST", 115, 136], ["Sequence identities", "TEST", 169, 188], ["phylogenetic analyses", "TEST", 193, 214], ["all SADS", "PROBLEM", 296, 304], ["CoV strains", "PROBLEM", 305, 316], ["four bat coronavirus HKU2 strains", "PROBLEM", 397, 430], ["branch", "OBSERVATION_MODIFIER", 89, 95], ["genus Alphacoronavirus", "ANATOMY", 144, 166]]], ["In this work, The phylogenetic trees of full length genomes and S genes of SADS-CoV sequences showed that the SADS-CoV branch clustered with these four HKU2 strains, which is same to previous results (Gong et al., 2017; Pan et al., 2017; Zhou et al., 2018) .", [["SADS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 110, 118], ["HKU2", "GENE_OR_GENE_PRODUCT", 152, 156], ["S genes", "DNA", 64, 71], ["SADS-CoV sequences", "DNA", 75, 93], ["SADS-CoV branch", "DNA", 110, 125], ["SADS-CoV", "SPECIES", 75, 83], ["SADS-CoV", "SPECIES", 110, 118], ["SADS", "TEST", 75, 79], ["CoV sequences", "TEST", 80, 93], ["the SADS", "TEST", 106, 114], ["these four HKU2 strains", "PROBLEM", 141, 164]]], ["Besides the genomes and S genes, the tree of N genes in our study revealed the identical result too.", [["S genes", "DNA", 24, 31], ["N genes", "DNA", 45, 52], ["our study", "TEST", 56, 65]]], ["So far, a total of eight full-length genomes of SADS-CoV have been reported in Guangdong| Sequence identities and phylogenetic analysesProvince of China (Gong et al., 2017; Pan et al., 2017; Zhou et al., 2018 ; this study).", [["SADS-CoV", "GENE_OR_GENE_PRODUCT", 48, 56], ["SADS", "DNA", 48, 52], ["SADS-CoV", "SPECIES", 48, 56], ["Guangdong|", "SPECIES", 79, 89], ["SADS", "PROBLEM", 48, 52], ["Sequence identities", "TEST", 90, 109], ["this study", "TEST", 211, 221]]], ["The two new genomes of SADS-CoV sequences in this work shared 100% nucleotides identities with the sequence MF167434 published by Gong et al. (2017) and our four previously reported sequences (Zhou et al., 2018) , and shared 99.8% nucleotides identities with the sequence MF370205 studied by Pan et al. (2017) .", [["nucleotides", "CHEMICAL", 67, 78], ["nucleotides", "CHEMICAL", 231, 242], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["SADS-CoV sequences", "DNA", 23, 41], ["SADS-CoV", "SPECIES", 23, 31], ["SADS", "TEST", 23, 27], ["CoV sequences", "TEST", 28, 41], ["the sequence", "TEST", 95, 107], ["the sequence", "TEST", 259, 271], ["two", "OBSERVATION_MODIFIER", 4, 7], ["new", "OBSERVATION_MODIFIER", 8, 11]]], ["The results suggest that these eight SADS-CoV sequences may come from the same origin.", [["SADS-CoV", "GENE_OR_GENE_PRODUCT", 37, 45], ["SADS-CoV sequences", "DNA", 37, 55], ["SADS-CoV", "SPECIES", 37, 45], ["these eight SADS", "TEST", 25, 41], ["CoV sequences", "TEST", 42, 55]]], ["Only the phylogenetic tree of S genes in our work showed that sequences of the AlphaCoV were divided into two sublineages, AlphaCoV1 which contained all SADS-CoV sequences and AlphaCoV2, clustering together with sequences of the BeltaCoV and the DelatCov, respectively.", [["AlphaCoV", "GENE_OR_GENE_PRODUCT", 79, 87], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 153, 161], ["AlphaCoV2", "GENE_OR_GENE_PRODUCT", 176, 185], ["S genes", "DNA", 30, 37], ["AlphaCoV", "DNA", 79, 87], ["AlphaCoV1", "DNA", 123, 132], ["SADS-CoV sequences", "DNA", 153, 171], ["AlphaCoV2", "DNA", 176, 185], ["BeltaCoV", "DNA", 229, 237], ["DelatCov", "DNA", 246, 254], ["SADS-CoV", "SPECIES", 153, 161], ["the AlphaCoV", "TEST", 75, 87], ["all SADS", "TEST", 149, 157], ["CoV sequences", "TEST", 158, 171], ["AlphaCoV2", "TEST", 176, 185], ["the BeltaCoV", "TREATMENT", 225, 237], ["phylogenetic", "OBSERVATION_MODIFIER", 9, 21], ["tree", "OBSERVATION_MODIFIER", 22, 26]]], ["And this result was consistent with the study of Pan et al. (2017) .", [["the study", "TEST", 36, 45]]], ["As a newly discovered coronavirus, the availability of SADS-CoV sequences data is limited which prevents better understandings of the molecular epidemiology of this virus.", [["coronavirus", "ORGANISM", 22, 33], ["SADS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["SADS-CoV sequences", "DNA", 55, 73], ["a newly discovered coronavirus", "PROBLEM", 3, 33], ["SADS-CoV sequences data", "TEST", 55, 78], ["this virus", "PROBLEM", 160, 170], ["coronavirus", "OBSERVATION", 22, 33]]], ["Meanwhile, being a RNA virus, SADS-CoV may mutate rapidly and exhibit high genetic differences (Drummond, Pybus, Rambaut, Forsberg, & Rodrigo, 2003; K\u00fchnert, Wu, & Drummond, 2011CONFLI CT OF INTERESTThe authors declare no conflict of interests with any organization.JingyunMa https://orcid.org/0000-0001-6285-312XJingyunInfectious Diseases, 23, 1607-1609. https://doi.org/10.3201/eid2309.", [["SADS-CoV", "GENE_OR_GENE_PRODUCT", 30, 38], ["SADS-CoV", "SPECIES", 30, 38], ["a RNA virus", "PROBLEM", 17, 28], ["SADS", "PROBLEM", 30, 34], ["high genetic differences", "PROBLEM", 70, 94], ["Drummond", "TEST", 96, 104], ["JingyunMa", "PROBLEM", 266, 275]]]], "cc73c35f25b7ced0ace59dd6f6ee381c492c8ae6": [["IntroductionIn recent decades, there has been a significant increase in life expectancy.", [["a significant increase in life expectancy", "PROBLEM", 46, 87], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["increase", "OBSERVATION_MODIFIER", 60, 68]]], ["In the UK, the proportion of the population aged 65 years and over has increased, from 15.9% in 1998 to 18 .3% in 2018, and is projected to reach 24.2% by 2038.", [["increased", "OBSERVATION_MODIFIER", 71, 80]]], ["1 This dramatic demographic transition presents both opportunities and challenges to society.", [["dramatic", "OBSERVATION_MODIFIER", 7, 15]]], ["With increasing numbers of the population now being in middle and older ages, many more people live with chronic long-term conditions such as cardiovascular diseases, cancers, chronic respiratory diseases, type 2 diabetes, and of course, dental caries, periodontal disease, tooth loss and a range of other oral conditions.", [["cardiovascular", "ANATOMY", 142, 156], ["cancers", "ANATOMY", 167, 174], ["respiratory", "ANATOMY", 184, 195], ["periodontal", "ANATOMY", 253, 264], ["tooth", "ANATOMY", 274, 279], ["oral", "ANATOMY", 306, 310], ["cardiovascular diseases", "DISEASE", 142, 165], ["cancers", "DISEASE", 167, 174], ["chronic respiratory diseases", "DISEASE", 176, 204], ["type 2 diabetes", "DISEASE", 206, 221], ["caries", "DISEASE", 245, 251], ["periodontal disease", "DISEASE", 253, 272], ["tooth loss", "DISEASE", 274, 284], ["people", "ORGANISM", 88, 94], ["cardiovascular", "ANATOMICAL_SYSTEM", 142, 156], ["cancers", "CANCER", 167, 174], ["tooth", "ORGAN", 274, 279], ["oral", "ORGANISM_SUBDIVISION", 306, 310], ["people", "SPECIES", 88, 94], ["chronic long-term conditions", "PROBLEM", 105, 133], ["cardiovascular diseases", "PROBLEM", 142, 165], ["cancers", "PROBLEM", 167, 174], ["chronic respiratory diseases", "PROBLEM", 176, 204], ["type 2 diabetes", "PROBLEM", 206, 221], ["dental caries", "PROBLEM", 238, 251], ["periodontal disease", "PROBLEM", 253, 272], ["tooth loss", "PROBLEM", 274, 284], ["increasing", "OBSERVATION_MODIFIER", 5, 15], ["numbers", "OBSERVATION_MODIFIER", 16, 23], ["population", "OBSERVATION_MODIFIER", 31, 41], ["middle", "ANATOMY_MODIFIER", 55, 61], ["chronic", "OBSERVATION_MODIFIER", 105, 112], ["long-term", "OBSERVATION_MODIFIER", 113, 122], ["cardiovascular", "ANATOMY", 142, 156], ["diseases", "OBSERVATION", 157, 165], ["cancers", "OBSERVATION", 167, 174], ["chronic", "OBSERVATION_MODIFIER", 176, 183], ["respiratory diseases", "OBSERVATION", 184, 204], ["diabetes", "OBSERVATION", 213, 221], ["periodontal", "ANATOMY", 253, 264], ["disease", "OBSERVATION", 265, 272], ["tooth loss", "OBSERVATION", 274, 284]]], ["In response to this demographic change, a significant shift in focus is now beginning to take place in medicine, with increasing attention being placed on the issue of multimorbidity.", [["multimorbidity", "DISEASE", 168, 182], ["this demographic change", "PROBLEM", 15, 38], ["a significant shift", "PROBLEM", 40, 59], ["multimorbidity", "PROBLEM", 168, 182], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["shift", "OBSERVATION", 54, 59], ["increasing", "OBSERVATION_MODIFIER", 118, 128], ["multimorbidity", "OBSERVATION", 168, 182]]], ["The coexistence of two or more chronic conditions has profound future implications for medical training, clinical practice and research.", [["more chronic conditions", "PROBLEM", 26, 49], ["medical training", "TREATMENT", 87, 103], ["chronic", "OBSERVATION_MODIFIER", 31, 38]]], ["2, 3 What is the relevance of multimorbidity to oral health and dentistry?", [["oral", "ANATOMY", 48, 52], ["oral", "ORGANISM_SUBDIVISION", 48, 52]]], ["This paper will present an overview of multimorbidity in terms of its meaning, impact and causes, and will highlight the implications of multimorbidity for future training of oral health professionals, practice of clinical dentistry and dental research.Defining multimorbidityOf course, the coexistence of chronic conditions is not a new concept, but research and clinical practice have been hampered due to a lack of a consensus and precise definition of multimorbidity in the medical literature.", [["oral", "ANATOMY", 175, 179], ["multimorbidity", "DISEASE", 456, 470], ["oral", "ORGANISM_SUBDIVISION", 175, 179], ["multimorbidity", "PROBLEM", 39, 53], ["future training", "TREATMENT", 156, 171], ["oral health professionals", "TREATMENT", 175, 200], ["clinical dentistry", "TREATMENT", 214, 232], ["chronic conditions", "PROBLEM", 306, 324], ["multimorbidity", "PROBLEM", 456, 470], ["multimorbidity", "OBSERVATION", 39, 53], ["multimorbidity", "OBSERVATION", 262, 276], ["chronic", "OBSERVATION_MODIFIER", 306, 313], ["conditions", "OBSERVATION", 314, 324], ["multimorbidity", "OBSERVATION", 456, 470]]], ["4, 5 Various august bodies have recently defined multimorbidity in a range of subtly different ways.", [["multimorbidity", "OBSERVATION", 49, 63]]], ["The World Health Organisation (WHO) defines multimorbidity as 'being affected by two or more chronic health conditions in the same individual.' 6 The National Institute for Health and Care Excellence (NICE), in their clinical guidelines for optimising care for people with multimorbidity, described this as the presence of two or more chronic health conditions, including: \u2022 Defined physical and mental health conditions \u2022 Ongoing conditions such as learning disability \u2022 Symptom complexes such as frailty and chronic pain \u2022 Sensory impairment such as sight or hearing loss \u2022 Alcohol and substance misuse.Defining multimorbidityThe Academy of Medical Sciences in their recent report 2 came up with the following definition of multimorbidity as 'the coexistence of two or more chronic conditions each of which is either: \u2022 A physical non-communicable disease of long duration such as cardiovascular disease or cancer \u2022 A mental health condition of long duration such as mood disorder or dementia \u2022 An infectious disease of long duration such as HIV or hepatitis C' .Defining multimorbidityThis paper highlights the increasing importance of multimorbidity and presents an overview of its prevalence, impact and determinants.Defining multimorbidityNone of these definitions explicitly include reference to oral conditions but clearly dental caries, periodontal diseases and many other conditions affecting the teeth and mouth are chronic, long-term, non-communicable diseases that affect a significant proportion of the adult and elderly population.", [["cardiovascular", "ANATOMY", 883, 897], ["cancer", "ANATOMY", 909, 915], ["oral", "ANATOMY", 1303, 1307], ["periodontal", "ANATOMY", 1346, 1357], ["teeth", "ANATOMY", 1407, 1412], ["mouth", "ANATOMY", 1417, 1422], ["learning disability", "DISEASE", 450, 469], ["frailty", "DISEASE", 498, 505], ["chronic pain", "DISEASE", 510, 522], ["Sensory impairment", "DISEASE", 525, 543], ["hearing loss", "DISEASE", 561, 573], ["Alcohol", "CHEMICAL", 576, 583], ["substance misuse", "DISEASE", 588, 604], ["multimorbidity", "DISEASE", 726, 740], ["cardiovascular disease", "DISEASE", 883, 905], ["cancer", "DISEASE", 909, 915], ["mood disorder", "DISEASE", 969, 982], ["dementia", "DISEASE", 986, 994], ["HIV or hepatitis C", "DISEASE", 1044, 1062], ["dental caries", "DISEASE", 1331, 1344], ["periodontal diseases", "DISEASE", 1346, 1366], ["people", "ORGANISM", 261, 267], ["cancer", "CANCER", 909, 915], ["hepatitis C", "ORGANISM", 1051, 1062], ["oral", "ORGANISM_SUBDIVISION", 1303, 1307], ["teeth", "ORGAN", 1407, 1412], ["mouth", "ORGANISM_SUBDIVISION", 1417, 1422], ["people", "SPECIES", 261, 267], ["HIV", "SPECIES", 1044, 1047], ["HIV", "SPECIES", 1044, 1047], ["multimorbidity", "PROBLEM", 44, 58], ["multimorbidity", "PROBLEM", 273, 287], ["Defined physical and mental health conditions", "PROBLEM", 375, 420], ["Ongoing conditions", "PROBLEM", 423, 441], ["Symptom complexes", "PROBLEM", 472, 489], ["chronic pain", "PROBLEM", 510, 522], ["Sensory impairment", "PROBLEM", 525, 543], ["hearing loss", "PROBLEM", 561, 573], ["multimorbidity", "PROBLEM", 726, 740], ["A physical non-communicable disease of long duration", "PROBLEM", 822, 874], ["cardiovascular disease", "PROBLEM", 883, 905], ["cancer", "PROBLEM", 909, 915], ["A mental health condition", "PROBLEM", 918, 943], ["mood disorder", "PROBLEM", 969, 982], ["dementia", "PROBLEM", 986, 994], ["An infectious disease of long duration", "PROBLEM", 997, 1035], ["HIV", "PROBLEM", 1044, 1047], ["hepatitis C'", "PROBLEM", 1051, 1063], ["multimorbidity", "PROBLEM", 1139, 1153], ["oral conditions", "PROBLEM", 1303, 1318], ["dental caries", "PROBLEM", 1331, 1344], ["periodontal diseases", "PROBLEM", 1346, 1366], ["non-communicable diseases", "PROBLEM", 1447, 1472], ["chronic", "OBSERVATION_MODIFIER", 335, 342], ["chronic", "OBSERVATION_MODIFIER", 510, 517], ["multimorbidity", "OBSERVATION", 614, 628], ["cancer", "OBSERVATION", 909, 915], ["infectious", "OBSERVATION", 1000, 1010], ["long duration", "OBSERVATION_MODIFIER", 1022, 1035], ["multimorbidity", "OBSERVATION", 1074, 1088], ["increasing", "OBSERVATION_MODIFIER", 1114, 1124], ["multimorbidity", "OBSERVATION", 1139, 1153], ["multimorbidity", "OBSERVATION", 1231, 1245], ["periodontal", "ANATOMY", 1346, 1357], ["diseases", "OBSERVATION", 1358, 1366], ["teeth", "ANATOMY", 1407, 1412], ["mouth", "ANATOMY", 1417, 1422], ["chronic", "OBSERVATION_MODIFIER", 1427, 1434], ["long-term", "OBSERVATION_MODIFIER", 1436, 1445]]], ["7 Comorbidity and multimorbidity are neither synonymous nor mutually exclusive conceptsthey provide two different perspectives through which to consider an individual with more than one health condition at the same time.", [["Comorbidity", "PROBLEM", 2, 13], ["multimorbidity", "PROBLEM", 18, 32]]], ["8 Comorbidity is the coexistence of other health conditions with an index condition that is the specific focus of attention.", [["Comorbidity", "PROBLEM", 2, 13], ["an index condition", "PROBLEM", 65, 83]]], ["In contrast, multimorbidity is the coexistence of several health conditions, where none are considered an index condition that is the specific focus of attention.", [["multimorbidity", "DISEASE", 13, 27], ["an index condition", "PROBLEM", 103, 121], ["multimorbidity", "OBSERVATION", 13, 27]]], ["Multimorbidity is therefore a broader and more heterogeneous concept which can be used to describe a wide array of people experiencing a multitude of different combinations of conditions at the same time.", [["Multimorbidity", "DISEASE", 0, 14], ["people", "ORGANISM", 115, 121], ["people", "SPECIES", 115, 121], ["more heterogeneous", "OBSERVATION_MODIFIER", 42, 60]]], ["The concept is also a more patient-centred concept, in that it also acknowledges that the impact of experiencing more than one chronic condition is influenced not only by health-related characteristics but also by the broader behavioural, socioeconomic, cultural and environmental context.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["chronic", "OBSERVATION_MODIFIER", 127, 134], ["condition", "OBSERVATION", 135, 144]]], ["The global COVID-19 pandemic acutely highlights the significance of multimorbidity, with severity and mortality risk greatly increased among those who have multiple underlying health conditions.", [["multimorbidity", "DISEASE", 68, 82], ["The global COVID", "TEST", 0, 16], ["multimorbidity", "PROBLEM", 68, 82], ["severity", "PROBLEM", 89, 97], ["mortality risk", "PROBLEM", 102, 116], ["multimorbidity", "OBSERVATION", 68, 82], ["increased", "OBSERVATION_MODIFIER", 125, 134]]], ["9, 10 Prevalence and impact of multimorbidity Despite differing definitions and measurement methods, the available evidence would suggest that multimorbidity is very common, is likely to be on the increase and has a major impact in terms of quality of life, increased risk of mortality and financial costs to the NHS.", [["multimorbidity", "DISEASE", 143, 157], ["multimorbidity", "TREATMENT", 31, 45], ["measurement methods", "TEST", 80, 99], ["multimorbidity", "PROBLEM", 143, 157], ["multimorbidity", "OBSERVATION", 31, 45], ["multimorbidity", "OBSERVATION", 143, 157], ["likely to be", "UNCERTAINTY", 177, 189]]], ["2 Precise estimates of the prevalence of multimorbidity vary widely depending on the exact number of conditions included, whether highly prevalent conditions are considered and the age profile of the population involved.", [["multimorbidity", "DISEASE", 41, 55], ["multimorbidity", "PROBLEM", 41, 55], ["multimorbidity", "OBSERVATION", 41, 55]]], ["A recent study across several low-, middle-and high-income countries showed that the prevalence of multimorbidity across 12 health conditions including edentulism ranged from 34-62% in the 50-59-year-old age group and 50-92% in the 80+ years group.", [["multimorbidity", "DISEASE", 99, 113], ["edentulism", "DISEASE", 152, 162], ["A recent study", "TEST", 0, 14], ["multimorbidity across 12 health conditions", "PROBLEM", 99, 141], ["edentulism", "TEST", 152, 162]]], ["11 Analysis by the Health Foundation estimated that 14 million people in England were living with two or more long-term health conditions.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69]]], ["12 Although in general the prevalence of multimorbidity is strongly related to age, 11, 13 it is not restricted to older people as many younger people are also affected by the coexistence of health conditions.", [["multimorbidity", "DISEASE", 41, 55], ["people", "ORGANISM", 121, 127], ["people", "ORGANISM", 144, 150], ["people", "SPECIES", 121, 127], ["people", "SPECIES", 144, 150], ["multimorbidity", "PROBLEM", 41, 55], ["multimorbidity", "OBSERVATION", 41, 55]]], ["In fact, in some populations, the absolute number of people affected by multimorbidity is greater among those under 65 years due to the population age structure.", [["multimorbidity", "DISEASE", 72, 86], ["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["some", "OBSERVATION_MODIFIER", 12, 16], ["populations", "OBSERVATION_MODIFIER", 17, 28], ["absolute", "OBSERVATION_MODIFIER", 34, 42], ["number", "OBSERVATION_MODIFIER", 43, 49], ["greater", "OBSERVATION_MODIFIER", 90, 97]]], ["2 The prevalence is also affected by broader socioeconomic factors -socially disadvantaged people experience multimorbidity at an earlier age than their more affluent contemporaries.", [["multimorbidity", "DISEASE", 109, 123], ["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97]]], ["12, 14 Data from longitudinal studies have highlighted that the prevalence of multimorbidity has increased in the last 20 years in many countries including the UK.", [["multimorbidity", "DISEASE", 78, 92], ["UK", "GENE_OR_GENE_PRODUCT", 160, 162], ["longitudinal studies", "TEST", 17, 37], ["multimorbidity", "PROBLEM", 78, 92], ["multimorbidity", "OBSERVATION", 78, 92], ["increased", "OBSERVATION_MODIFIER", 97, 106]]], ["2 In a large UK study of 230,000 primary care patients over a four-year period, the prevalence of multimorbidity (coexistence of five or more conditions) quadrupled from 6% to 24%.", [["multimorbidity", "DISEASE", 98, 112], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["multimorbidity", "PROBLEM", 98, 112], ["large", "OBSERVATION_MODIFIER", 7, 12], ["multimorbidity", "OBSERVATION", 98, 112]]], ["15 Multimorbidity is therefore increasingly becoming the norm, rather than the exception.Defining multimorbidityExtensive research has shown the negative impact of multimorbidity on peoples' lives and its broader societal effects.", [["Multimorbidity", "DISEASE", 3, 17], ["Multimorbidity", "OBSERVATION", 3, 17], ["multimorbidity", "OBSERVATION", 98, 112], ["negative", "OBSERVATION_MODIFIER", 145, 153], ["impact", "OBSERVATION_MODIFIER", 154, 160], ["multimorbidity", "OBSERVATION", 164, 178]]], ["The coexistence of multiple chronic conditions is associated with reduced wellbeing and quality of life, and an increased risk of disability, functional decline and mortality.", [["disability", "DISEASE", 130, 140], ["multiple chronic conditions", "PROBLEM", 19, 46], ["reduced wellbeing and quality of life", "PROBLEM", 66, 103], ["an increased risk of disability", "PROBLEM", 109, 140], ["functional decline", "PROBLEM", 142, 160], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["chronic", "OBSERVATION_MODIFIER", 28, 35], ["conditions", "OBSERVATION", 36, 46], ["reduced", "OBSERVATION_MODIFIER", 66, 73], ["increased", "OBSERVATION_MODIFIER", 112, 121]]], ["2 People living with multiple conditions experience a greater treatment burden -the time and energy needed to access treatment from multiple providers of often uncoordinated care and complying with complex care plans involving multiple medications.", [["People", "ORGANISM", 2, 8], ["People", "SPECIES", 2, 8], ["treatment", "TREATMENT", 117, 126], ["multiple medications", "TREATMENT", 227, 247]]], ["The Health Foundation Report showed that patients with multimorbidities were prescribed on average 20.6 different medications compared to 5.6 medications for patients diagnosed with only one condition.", [["multimorbidities", "DISEASE", 55, 71], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 158, 166], ["multimorbidities", "PROBLEM", 55, 71], ["different medications", "TREATMENT", 104, 125], ["medications", "TREATMENT", 142, 153]]], ["12 Carers and family members of people affected by multimorbidity also experience a range of negative health outcomes, including both mental and physical health conditions and increased mortality.", [["multimorbidity", "DISEASE", 51, 65], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["increased mortality", "PROBLEM", 176, 195], ["increased", "OBSERVATION_MODIFIER", 176, 185], ["mortality", "OBSERVATION", 186, 195]]], ["2 Finally, the economic burden of multimorbidity on the NHS and other healthcare systems is significant, with both an increased number of primary care visits and hospital admissions, both planned and unplanned.", [["multimorbidity", "DISEASE", 34, 48], ["multimorbidity", "PROBLEM", 34, 48], ["economic", "OBSERVATION_MODIFIER", 15, 23], ["burden", "OBSERVATION_MODIFIER", 24, 30], ["multimorbidity", "OBSERVATION", 34, 48], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["increased", "OBSERVATION_MODIFIER", 118, 127]]], ["2, 12 Considering the burden that multimorbidities place on patients' quality of life, it is not surprising that oral healthcare and maintenance are not always a high priority in this group.", [["oral", "ANATOMY", 113, 117], ["multimorbidities", "DISEASE", 34, 50], ["patients", "ORGANISM", 60, 68], ["oral", "ORGANISM_SUBDIVISION", 113, 117], ["patients", "SPECIES", 60, 68]]], ["16Determinants of multimorbiditySeveral studies have shown, in different populations and diverse countries, a strong association between increasing age and higher rates of multimorbidity.", [["multimorbidity", "DISEASE", 18, 32], ["multimorbidity", "DISEASE", 172, 186], ["multimorbidity", "PROBLEM", 18, 32], ["Several studies", "TEST", 32, 47], ["multimorbidity", "PROBLEM", 172, 186], ["multimorbidity", "OBSERVATION", 18, 32], ["diverse", "OBSERVATION_MODIFIER", 89, 96]]], ["2 Indeed, multimorbidity is typically the norm among many older people.", [["people", "ORGANISM", 64, 70], ["people", "SPECIES", 64, 70], ["multimorbidity", "OBSERVATION", 10, 24]]], ["However, multimorbidity is not unique to older people and there is evidence that the increasing prevalence of multimorbidity cannot be explained only by an ageing population.", [["multimorbidity", "DISEASE", 9, 23], ["multimorbidity", "DISEASE", 110, 124], ["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["multimorbidity", "PROBLEM", 9, 23], ["multimorbidity", "PROBLEM", 110, 124], ["multimorbidity", "OBSERVATION", 9, 23], ["not unique", "UNCERTAINTY", 27, 37], ["increasing", "OBSERVATION_MODIFIER", 85, 95], ["multimorbidity", "OBSERVATION", 110, 124]]], ["2 Limited detailed research has, however, been conducted to uncover the underlying causes of multimorbidity and, as most of the previous studies have been cross-sectional in nature, it has been difficult to assess the direction of association between risk factors and multiple chronic conditions.", [["multimorbidity", "DISEASE", 93, 107], ["multimorbidity", "PROBLEM", 93, 107], ["the previous studies", "TEST", 124, 144], ["risk factors", "PROBLEM", 251, 263], ["multiple chronic conditions", "PROBLEM", 268, 295], ["multimorbidity", "OBSERVATION", 93, 107], ["multiple", "OBSERVATION_MODIFIER", 268, 276], ["chronic", "OBSERVATION_MODIFIER", 277, 284], ["conditions", "OBSERVATION", 285, 295]]], ["Some evidence suggests that multimorbidity is more common among women than men, 17 but it is unclear if this is due to the fact that women are more likely to attend health services and therefore have a condition diagnosed, or whether this is because women may suffer more adverse effects of poverty and income inequality and hence experience multiple health problems.", [["multimorbidity", "DISEASE", 28, 42], ["women", "ORGANISM", 64, 69], ["men", "ORGANISM", 75, 78], ["women", "ORGANISM", 133, 138], ["women", "ORGANISM", 250, 255], ["women", "SPECIES", 64, 69], ["men", "SPECIES", 75, 78], ["women", "SPECIES", 133, 138], ["women", "SPECIES", 250, 255], ["multimorbidity", "PROBLEM", 28, 42], ["multiple health problems", "PROBLEM", 342, 366], ["multimorbidity", "OBSERVATION", 28, 42]]], ["Socioeconomic status is certainly strongly linked to higher rates of multimorbidity.", [["multimorbidity", "DISEASE", 69, 83]]], ["12, 17 A Scottish study showed that people living in the most deprived neighbourhoods were almost twice as likely to have poor mental health and other conditions, and to experience the onset of multimorbidity 10-15 years earlier than those living in more affluent areas.", [["multimorbidity", "DISEASE", 194, 208], ["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["A Scottish study", "TEST", 7, 23], ["poor mental health and other conditions", "PROBLEM", 122, 161], ["multimorbidity", "PROBLEM", 194, 208]]], ["18 Health-related behaviours such as smoking, alcohol consumption, poor nutrition and physical inactivity are identified as common risk factors for a range of chronic diseases 19 and are also associated with increased multimorbidity risk.", [["smoking", "CHEMICAL", 37, 44], ["alcohol", "CHEMICAL", 46, 53], ["physical inactivity", "DISEASE", 86, 105], ["chronic diseases", "DISEASE", 159, 175], ["alcohol", "CHEMICAL", 46, 53], ["alcohol", "SIMPLE_CHEMICAL", 46, 53], ["chronic diseases", "PROBLEM", 159, 175], ["increased multimorbidity risk", "PROBLEM", 208, 237], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["diseases", "OBSERVATION", 167, 175], ["increased", "OBSERVATION_MODIFIER", 208, 217], ["multimorbidity", "OBSERVATION", 218, 232]]], ["2 Behavioural risk factors including specific oral health-related behaviours such as tooth brushing and dental attendance have been shown to cluster together in certain patterns, 20,21 and these clusters are strongly associated with socioeconomic status and psychosocial factors.", [["oral", "ANATOMY", 46, 50], ["tooth", "ANATOMY", 85, 90], ["oral", "ORGANISM_SUBDIVISION", 46, 50], ["tooth", "ORGAN", 85, 90], ["Behavioural risk factors", "PROBLEM", 2, 26], ["related behaviours", "PROBLEM", 58, 76], ["psychosocial factors", "PROBLEM", 258, 278]]], ["20, 21, 22 The available evidence suggests that the mechanisms underlying multimorbidity include shared biological (chronic inflammatory processes), behavioural, social and broader socioeconomic factors.", [["multimorbidity", "DISEASE", 74, 88], ["the mechanisms underlying multimorbidity", "PROBLEM", 48, 88], ["shared biological (chronic inflammatory processes", "PROBLEM", 97, 146], ["multimorbidity", "OBSERVATION", 74, 88], ["chronic", "OBSERVATION_MODIFIER", 116, 123], ["inflammatory", "OBSERVATION", 124, 136]]], ["More longitudinal studies are, however, needed to tease out the direction of the relationships between multimorbidity and potential risk factors, and to establish the causal mechanisms.Association between oral and general healthOver the last few decades, there have been an increasing number of studies exploring the nature and the direction of the associations between oral and general health.", [["oral", "ANATOMY", 205, 209], ["oral", "ANATOMY", 370, 374], ["multimorbidity", "DISEASE", 103, 117], ["oral", "ORGANISM_SUBDIVISION", 205, 209], ["oral", "ORGANISM_SUBDIVISION", 370, 374], ["More longitudinal studies", "TEST", 0, 25], ["increasing", "OBSERVATION_MODIFIER", 274, 284]]], ["Most of the research to date has assessed comorbidity between a specific oral disease and another specific systemic condition.", [["oral", "ANATOMY", 73, 77], ["oral disease", "DISEASE", 73, 85], ["oral", "ORGANISM_SUBDIVISION", 73, 77], ["comorbidity", "PROBLEM", 42, 53], ["a specific oral disease", "PROBLEM", 62, 85]]], ["Although there is no unified overarching theory to explain the potential association between a variety of oral and general health conditions, the associations are underpinned by shared biological mechanisms and by the wider social determinants of non-communicable diseases.", [["oral", "ANATOMY", 106, 110], ["non-communicable diseases", "DISEASE", 247, 272], ["oral", "ORGANISM_SUBDIVISION", 106, 110], ["non-communicable diseases", "PROBLEM", 247, 272], ["no", "UNCERTAINTY", 18, 20], ["non-communicable diseases", "OBSERVATION", 247, 272]]], ["18 The strength of the evidence supporting these associations is varied from strong (diabetes) to weak (pregnancy outcomes).", [["diabetes", "DISEASE", 85, 93], ["strong (diabetes)", "PROBLEM", 77, 94], ["weak (pregnancy outcomes", "PROBLEM", 98, 122]]], ["23, 24, 25 In terms of biological mechanisms, there are three main processes associated with periodontal pathogenesis that may play a role in the immune response associated with certain chronic conditions; namely infection, inflammation and adaptive immunity.", [["periodontal", "ANATOMY", 93, 104], ["infection", "DISEASE", 213, 222], ["inflammation", "DISEASE", 224, 236], ["periodontal pathogenesis", "PROBLEM", 93, 117], ["certain chronic conditions", "PROBLEM", 178, 204], ["namely infection", "PROBLEM", 206, 222], ["inflammation", "PROBLEM", 224, 236], ["biological mechanisms", "OBSERVATION", 23, 44], ["periodontal", "ANATOMY", 93, 104], ["pathogenesis", "OBSERVATION", 105, 117], ["infection", "OBSERVATION", 213, 222]]], ["26 Over time, sustained localised inflammation in the periodontal tissue can trigger the initiation of a systemic inflammatory response that could contribute to the pathogenesis of certain systemic conditions with an inflammatory component, such as diabetes, cardiovascular disease and rheumatoid arthritis.", [["periodontal tissue", "ANATOMY", 54, 72], ["cardiovascular", "ANATOMY", 259, 273], ["inflammation", "DISEASE", 34, 46], ["diabetes", "DISEASE", 249, 257], ["cardiovascular disease", "DISEASE", 259, 281], ["rheumatoid arthritis", "DISEASE", 286, 306], ["periodontal tissue", "TISSUE", 54, 72], ["sustained localised inflammation in the periodontal tissue", "PROBLEM", 14, 72], ["a systemic inflammatory response", "PROBLEM", 103, 135], ["certain systemic conditions", "PROBLEM", 181, 208], ["an inflammatory component", "PROBLEM", 214, 239], ["diabetes", "PROBLEM", 249, 257], ["cardiovascular disease", "PROBLEM", 259, 281], ["rheumatoid arthritis", "PROBLEM", 286, 306], ["localised", "OBSERVATION_MODIFIER", 24, 33], ["inflammation", "OBSERVATION", 34, 46], ["periodontal tissue", "ANATOMY", 54, 72], ["systemic", "OBSERVATION_MODIFIER", 105, 113], ["inflammatory", "OBSERVATION", 114, 126], ["inflammatory", "OBSERVATION_MODIFIER", 217, 229], ["diabetes", "OBSERVATION", 249, 257], ["cardiovascular disease", "OBSERVATION", 259, 281], ["rheumatoid arthritis", "OBSERVATION", 286, 306]]], ["27, 28 Although the immune response to the presence of periodontal bacteria is genetically driven, wider risk factors may play a crucial role in how these traits are manifested.", [["periodontal bacteria", "PROBLEM", 55, 75], ["periodontal", "ANATOMY", 55, 66], ["bacteria", "OBSERVATION", 67, 75]]], ["24 The individual immune response is influenced by wider behavioural, environmental and societal risk factors, such as high-sugar diet, smoking and alcohol consumption, as well as societal factors such as socioeconomic status, psychosocial factors and access to care.", [["smoking", "CHEMICAL", 136, 143], ["alcohol", "CHEMICAL", 148, 155], ["sugar", "CHEMICAL", 124, 129], ["alcohol", "CHEMICAL", 148, 155], ["alcohol", "SIMPLE_CHEMICAL", 148, 155], ["psychosocial factors", "PROBLEM", 227, 247], ["immune response", "OBSERVATION", 18, 33]]], ["18 To our knowledge, there are no robust longitudinal studies investigating the relationship between oral and general health in the context of multimorbidities, but there are several studies examining the associations between oral diseases and certain specific systemic conditions.", [["oral", "ANATOMY", 101, 105], ["oral", "ANATOMY", 226, 230], ["multimorbidities", "DISEASE", 143, 159], ["oral diseases", "DISEASE", 226, 239], ["oral", "ORGANISM_SUBDIVISION", 101, 105], ["oral", "ORGANISM_SUBDIVISION", 226, 230], ["several studies", "TEST", 175, 190], ["oral diseases", "PROBLEM", 226, 239]]], ["29 Epidemiological data from systematic reviews of observational studies show that there is a bidirectional relationship between diabetes and periodontal disease.", [["periodontal", "ANATOMY", 142, 153], ["diabetes", "DISEASE", 129, 137], ["periodontal disease", "DISEASE", 142, 161], ["Epidemiological data", "TEST", 3, 23], ["observational studies", "TEST", 51, 72], ["diabetes", "PROBLEM", 129, 137], ["periodontal disease", "PROBLEM", 142, 161], ["diabetes", "OBSERVATION", 129, 137], ["periodontal disease", "OBSERVATION", 142, 161]]], ["Systemically healthy people with periodontitis present poor glycaemic control and an increased risk for developing diabetes, while patients with diabetes and periodontitis present a higher prevalence of complications secondary to diabetes.", [["periodontitis", "DISEASE", 33, 46], ["diabetes", "DISEASE", 115, 123], ["diabetes", "DISEASE", 145, 153], ["periodontitis", "DISEASE", 158, 171], ["diabetes", "DISEASE", 230, 238], ["people", "ORGANISM", 21, 27], ["patients", "ORGANISM", 131, 139], ["people", "SPECIES", 21, 27], ["patients", "SPECIES", 131, 139], ["periodontitis", "PROBLEM", 33, 46], ["developing diabetes", "PROBLEM", 104, 123], ["diabetes", "PROBLEM", 145, 153], ["periodontitis", "PROBLEM", 158, 171], ["complications", "PROBLEM", 203, 216], ["diabetes", "PROBLEM", 230, 238], ["periodontitis", "OBSERVATION", 33, 46], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["diabetes", "OBSERVATION", 115, 123], ["periodontitis", "OBSERVATION", 158, 171], ["diabetes", "OBSERVATION", 230, 238]]], ["25, 30 Two Cochrane reviews of randomised controlled trials reported a positive impact of non-surgical periodontal treatment on patients' short-term glycaemic control.", [["periodontal", "ANATOMY", 103, 114], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["randomised controlled trials", "TREATMENT", 31, 59], ["non-surgical periodontal treatment", "TREATMENT", 90, 124], ["patients' short-term glycaemic control", "TREATMENT", 128, 166]]], ["31, 32 The clinical significance of this has been compared to adding an additional drug to the patient's treatment regime, but without the additional side effects associated with polypharmacy.", [["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["an additional drug", "TREATMENT", 69, 87], ["the patient's treatment regime", "TREATMENT", 91, 121], ["polypharmacy", "TREATMENT", 179, 191]]], ["25 Furthermore, the associations between periodontitis and cardiovascular disease have also been extensively investigated.", [["cardiovascular", "ANATOMY", 59, 73], ["periodontitis", "DISEASE", 41, 54], ["cardiovascular disease", "DISEASE", 59, 81], ["cardiovascular", "ANATOMICAL_SYSTEM", 59, 73], ["periodontitis", "PROBLEM", 41, 54], ["cardiovascular disease", "PROBLEM", 59, 81], ["periodontitis", "OBSERVATION", 41, 54], ["cardiovascular", "ANATOMY", 59, 73], ["disease", "OBSERVATION", 74, 81]]], ["Cardiovascular disease is often clustered with other systemic conditions in patients with multimorbidities, leading to increased mortality risk.", [["Cardiovascular", "ANATOMY", 0, 14], ["Cardiovascular disease", "DISEASE", 0, 22], ["multimorbidities", "DISEASE", 90, 106], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Cardiovascular disease", "PROBLEM", 0, 22], ["other systemic conditions", "PROBLEM", 47, 72], ["multimorbidities", "PROBLEM", 90, 106], ["increased mortality risk", "PROBLEM", 119, 143], ["disease", "OBSERVATION", 15, 22], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["mortality", "OBSERVATION", 129, 138]]], ["The incidence of coronary heart disease, cerebrovascular disease and peripheral arterial disease has been associated with the prevalence and severity of periodontitis, independently of other risk factors.", [["coronary", "ANATOMY", 17, 25], ["heart", "ANATOMY", 26, 31], ["cerebrovascular", "ANATOMY", 41, 56], ["peripheral arterial", "ANATOMY", 69, 88], ["coronary heart disease", "DISEASE", 17, 39], ["cerebrovascular disease", "DISEASE", 41, 64], ["peripheral arterial disease", "DISEASE", 69, 96], ["periodontitis", "DISEASE", 153, 166], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 17, 31], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 41, 56], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 69, 88], ["coronary heart disease", "PROBLEM", 17, 39], ["cerebrovascular disease", "PROBLEM", 41, 64], ["peripheral arterial disease", "PROBLEM", 69, 96], ["periodontitis", "PROBLEM", 153, 166], ["other risk factors", "PROBLEM", 185, 203], ["coronary heart", "ANATOMY", 17, 31], ["disease", "OBSERVATION", 32, 39], ["cerebrovascular disease", "OBSERVATION", 41, 64], ["peripheral", "ANATOMY_MODIFIER", 69, 79], ["arterial", "ANATOMY", 80, 88], ["disease", "OBSERVATION", 89, 96], ["severity", "OBSERVATION_MODIFIER", 141, 149], ["periodontitis", "OBSERVATION", 153, 166]]], ["33, 34 Evidence supports the positive impact of periodontal treatment on surrogate cardiovascular outcomes such as decreased levels of systemic inflammatory markers and improved endothelial function in the short term, 35 but there is no evidence on the impact of periodontal treatment on long-term cardiovascular endpoints.", [["periodontal", "ANATOMY", 48, 59], ["cardiovascular", "ANATOMY", 83, 97], ["endothelial", "ANATOMY", 178, 189], ["periodontal", "ANATOMY", 263, 274], ["cardiovascular", "ANATOMY", 298, 312], ["cardiovascular", "ANATOMICAL_SYSTEM", 83, 97], ["endothelial", "CELL", 178, 189], ["cardiovascular", "ANATOMICAL_SYSTEM", 298, 312], ["systemic inflammatory markers", "PROTEIN", 135, 164], ["periodontal treatment", "TREATMENT", 48, 69], ["surrogate cardiovascular outcomes", "PROBLEM", 73, 106], ["decreased levels of systemic inflammatory markers", "PROBLEM", 115, 164], ["periodontal treatment", "TREATMENT", 263, 284], ["long-term cardiovascular endpoints", "TREATMENT", 288, 322], ["positive", "OBSERVATION_MODIFIER", 29, 37], ["impact", "OBSERVATION_MODIFIER", 38, 44], ["periodontal treatment", "OBSERVATION", 48, 69], ["systemic", "OBSERVATION_MODIFIER", 135, 143], ["inflammatory", "OBSERVATION", 144, 156], ["endothelial function", "OBSERVATION", 178, 198], ["short term", "OBSERVATION_MODIFIER", 206, 216], ["no evidence on", "UNCERTAINTY", 234, 248], ["periodontal", "OBSERVATION", 263, 274]]], ["36, 37 Findings from observational studies and systematic reviews suggest that periodontal disease is also associated with the prevalence and severity of rheumatoid arthritis.", [["periodontal", "ANATOMY", 79, 90], ["periodontal disease", "DISEASE", 79, 98], ["rheumatoid arthritis", "DISEASE", 154, 174], ["observational studies", "TEST", 21, 42], ["systematic reviews", "TEST", 47, 65], ["periodontal disease", "PROBLEM", 79, 98], ["rheumatoid arthritis", "PROBLEM", 154, 174], ["periodontal disease", "OBSERVATION", 79, 98], ["rheumatoid arthritis", "OBSERVATION", 154, 174]]], ["38, 39 Additionally, patients with rheumatoid arthritis are more likely to be edentulous compared with healthy subjects.", [["rheumatoid arthritis", "DISEASE", 35, 55], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["rheumatoid arthritis", "PROBLEM", 35, 55], ["edentulous", "PROBLEM", 78, 88], ["rheumatoid", "OBSERVATION_MODIFIER", 35, 45], ["arthritis", "OBSERVATION", 46, 55], ["more likely to be", "UNCERTAINTY", 60, 77], ["edentulous", "OBSERVATION", 78, 88]]], ["39 A number of small, interventional studies suggest that non-surgical periodontal treatment could lead to a reduction of rheumatoid disease activity scores and of serum levels of inflammatory markers in the short term.", [["periodontal", "ANATOMY", 71, 82], ["serum", "ANATOMY", 164, 169], ["serum", "ORGANISM_SUBSTANCE", 164, 169], ["inflammatory markers", "PROTEIN", 180, 200], ["interventional studies", "TEST", 22, 44], ["non-surgical periodontal treatment", "TREATMENT", 58, 92], ["rheumatoid disease activity scores", "PROBLEM", 122, 156], ["serum levels", "TEST", 164, 176], ["inflammatory markers", "PROBLEM", 180, 200], ["small", "OBSERVATION_MODIFIER", 15, 20], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["rheumatoid disease", "OBSERVATION", 122, 140], ["inflammatory", "OBSERVATION", 180, 192], ["short term", "OBSERVATION_MODIFIER", 208, 218]]], ["40, 41 Patients with chronic kidney disease and periodontitis have a significantly increased mortality risk, independent of other risk factors, compared to patients without periodontitis.", [["kidney", "ANATOMY", 29, 35], ["chronic kidney disease", "DISEASE", 21, 43], ["periodontitis", "DISEASE", 48, 61], ["periodontitis", "DISEASE", 173, 186], ["Patients", "ORGANISM", 7, 15], ["kidney", "ORGAN", 29, 35], ["patients", "ORGANISM", 156, 164], ["Patients", "SPECIES", 7, 15], ["patients", "SPECIES", 156, 164], ["chronic kidney disease", "PROBLEM", 21, 43], ["periodontitis", "PROBLEM", 48, 61], ["a significantly increased mortality risk", "PROBLEM", 67, 107], ["other risk factors", "PROBLEM", 124, 142], ["periodontitis", "PROBLEM", 173, 186], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["kidney", "ANATOMY", 29, 35], ["disease", "OBSERVATION", 36, 43], ["periodontitis", "OBSERVATION", 48, 61], ["significantly", "OBSERVATION_MODIFIER", 69, 82], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["mortality", "OBSERVATION", 93, 102], ["without", "UNCERTAINTY", 165, 172], ["periodontitis", "OBSERVATION", 173, 186]]], ["42 Emerging evidence from systematic reviews suggests an association between periodontitis and low birth weight.", [["periodontitis", "DISEASE", 77, 90], ["low birth weight", "DISEASE", 95, 111], ["systematic reviews", "TEST", 26, 44], ["periodontitis", "PROBLEM", 77, 90], ["low birth weight", "PROBLEM", 95, 111], ["periodontitis", "OBSERVATION", 77, 90], ["low", "OBSERVATION_MODIFIER", 95, 98]]], ["43, 44 It is unclear if periodontal treatment during pregnancy has an impact on preterm birth, but low-quality evidence suggests that periodontal treatment may reduce low birth weight.", [["periodontal", "ANATOMY", 24, 35], ["periodontal", "ANATOMY", 134, 145], ["preterm birth", "DISEASE", 80, 93], ["low birth weight", "DISEASE", 167, 183], ["periodontal treatment", "TREATMENT", 24, 45], ["preterm birth", "PROBLEM", 80, 93], ["periodontal treatment", "TREATMENT", 134, 155], ["low birth weight", "PROBLEM", 167, 183], ["unclear if", "UNCERTAINTY", 13, 23]]], ["23 The findings of a number of systematic reviews suggest an association between periodontitis and chronic obstructive pulmonary disease (COPD).", [["pulmonary", "ANATOMY", 119, 128], ["periodontitis", "DISEASE", 81, 94], ["chronic obstructive pulmonary disease", "DISEASE", 99, 136], ["COPD", "DISEASE", 138, 142], ["pulmonary", "ORGAN", 119, 128], ["periodontitis", "PROBLEM", 81, 94], ["chronic obstructive pulmonary disease", "PROBLEM", 99, 136], ["COPD)", "PROBLEM", 138, 143], ["periodontitis", "OBSERVATION", 81, 94], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["obstructive", "OBSERVATION_MODIFIER", 107, 118], ["pulmonary", "ANATOMY", 119, 128], ["disease", "OBSERVATION", 129, 136], ["COPD", "OBSERVATION", 138, 142]]], ["45, 46 Additionally, periodontitis severity has been associated with an increased mortality risk from pneumonia in the elderly.", [["periodontitis", "DISEASE", 21, 34], ["pneumonia", "DISEASE", 102, 111], ["periodontitis severity", "PROBLEM", 21, 43], ["an increased mortality risk", "PROBLEM", 69, 96], ["pneumonia", "PROBLEM", 102, 111], ["periodontitis", "OBSERVATION", 21, 34], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["mortality", "OBSERVATION", 82, 91], ["pneumonia", "OBSERVATION", 102, 111]]], ["47 The findings from a Cochrane review highlighted the beneficial role of using antibacterial mouthwash or gel in reducing the incidence of ventilator-associated pneumonia in critically ill patients.", [["pneumonia", "DISEASE", 162, 171], ["critically ill", "DISEASE", 175, 189], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["antibacterial mouthwash", "TREATMENT", 80, 103], ["gel", "TREATMENT", 107, 110], ["ventilator-associated pneumonia", "PROBLEM", 140, 171], ["ventilator", "OBSERVATION", 140, 150], ["pneumonia", "OBSERVATION", 162, 171]]], ["48 It is important to acknowledge the limitations of the existing literature on periodontal disease and other health conditions.", [["periodontal", "ANATOMY", 80, 91], ["periodontal disease", "DISEASE", 80, 99], ["periodontal disease and other health conditions", "PROBLEM", 80, 127], ["periodontal", "ANATOMY", 80, 91], ["disease", "OBSERVATION", 92, 99]]], ["Most of the interventional studies investigating the impact of periodontal treatment on various systemic outcomes were based on delivering non-surgical periodontal treatment in secondary care settings and they shared a number of limitations, such as heterogeneity of definitions for periodontal disease and criteria for treatment success, short follow-up time and the use of surrogate outcomes.", [["periodontal", "ANATOMY", 63, 74], ["periodontal", "ANATOMY", 152, 163], ["periodontal", "ANATOMY", 283, 294], ["periodontal disease", "DISEASE", 283, 302], ["the interventional studies", "TEST", 8, 34], ["periodontal treatment", "TREATMENT", 63, 84], ["various systemic outcomes", "TREATMENT", 88, 113], ["non-surgical periodontal treatment", "TREATMENT", 139, 173], ["secondary care settings", "TREATMENT", 177, 200], ["periodontal disease", "PROBLEM", 283, 302], ["treatment success", "TREATMENT", 320, 337], ["periodontal", "OBSERVATION", 63, 74]]], ["29, 49 Besides periodontal disease, there are also other dental conditions that have been associated with systemic diseases.", [["periodontal", "ANATOMY", 15, 26], ["periodontal disease", "DISEASE", 15, 34], ["systemic diseases", "DISEASE", 106, 123], ["periodontal disease", "PROBLEM", 15, 34], ["other dental conditions", "PROBLEM", 51, 74], ["systemic diseases", "PROBLEM", 106, 123], ["periodontal", "ANATOMY", 15, 26], ["disease", "OBSERVATION", 27, 34], ["associated with", "UNCERTAINTY", 90, 105], ["systemic", "OBSERVATION_MODIFIER", 106, 114], ["diseases", "OBSERVATION", 115, 123]]], ["Data from systematic reviews exploring the associations between oral health and cognitive decline present conflicting results, likely due to methodological limitations.", [["oral", "ANATOMY", 64, 68], ["cognitive decline", "DISEASE", 80, 97], ["oral", "ORGANISM_SUBDIVISION", 64, 68], ["cognitive decline", "PROBLEM", 80, 97], ["methodological limitations", "PROBLEM", 141, 167], ["likely due to", "UNCERTAINTY", 127, 140]]], ["50 There are some suggestions that poor oral health and severe tooth loss might be associated with increased risk of developing cognitive impairment and dementia.", [["oral", "ANATOMY", 40, 44], ["tooth", "ANATOMY", 63, 68], ["tooth loss", "DISEASE", 63, 73], ["cognitive impairment", "DISEASE", 128, 148], ["dementia", "DISEASE", 153, 161], ["oral", "ORGANISM_SUBDIVISION", 40, 44], ["tooth", "ORGAN", 63, 68], ["poor oral health", "PROBLEM", 35, 51], ["severe tooth loss", "PROBLEM", 56, 73], ["developing cognitive impairment", "PROBLEM", 117, 148], ["dementia", "PROBLEM", 153, 161], ["poor", "OBSERVATION_MODIFIER", 35, 39], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["tooth loss", "OBSERVATION", 63, 73], ["cognitive impairment", "OBSERVATION", 128, 148], ["dementia", "OBSERVATION", 153, 161]]], ["51 Most epidemiological studies on cancer prognosis have been focusing on cancers in isolation, but often cancers are associated with multimorbidity.", [["cancer", "ANATOMY", 35, 41], ["cancers", "ANATOMY", 74, 81], ["cancers", "ANATOMY", 106, 113], ["cancer", "DISEASE", 35, 41], ["cancers", "DISEASE", 74, 81], ["cancers", "DISEASE", 106, 113], ["multimorbidity", "DISEASE", 134, 148], ["cancer", "CANCER", 35, 41], ["cancers", "CANCER", 74, 81], ["cancers", "CANCER", 106, 113], ["Most epidemiological studies", "TEST", 3, 31], ["cancer prognosis", "PROBLEM", 35, 51], ["cancers in isolation", "PROBLEM", 74, 94], ["often cancers", "PROBLEM", 100, 113], ["multimorbidity", "PROBLEM", 134, 148], ["cancers", "OBSERVATION", 106, 113]]], ["52, 53 It is estimated that 82% of cancer patients present with at least one additional condition.", [["cancer", "ANATOMY", 35, 41], ["cancer", "DISEASE", 35, 41], ["cancer", "CANCER", 35, 41], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["cancer", "OBSERVATION", 35, 41]]], ["12 Head and neck cancers are no exception from this and are among the ten most prevalent forms of cancer in the UK, and have presented an increased incidence rate by nearly one-third in the last 20 years.", [["Head and neck cancers", "ANATOMY", 3, 24], ["cancer", "ANATOMY", 98, 104], ["Head and neck cancers", "DISEASE", 3, 24], ["cancer", "DISEASE", 98, 104], ["Head and neck cancers", "CANCER", 3, 24], ["cancer", "CANCER", 98, 104], ["Head and neck cancers", "PROBLEM", 3, 24], ["cancer", "PROBLEM", 98, 104], ["an increased incidence rate", "PROBLEM", 135, 162], ["Head", "ANATOMY", 3, 7], ["neck", "ANATOMY", 12, 16], ["cancers", "OBSERVATION", 17, 24], ["no", "UNCERTAINTY", 29, 31], ["cancer", "OBSERVATION", 98, 104], ["increased", "OBSERVATION_MODIFIER", 138, 147]]], ["54 When describing the bidirectional relationship between oral and general health, it is important to also consider how certain systemic conditions may affect oral health.", [["oral", "ANATOMY", 58, 62], ["oral", "ANATOMY", 159, 163], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["oral", "ORGANISM_SUBDIVISION", 159, 163]]], ["For example, poorly controlled diabetes has been associated with an increased risk of periodontal disease, and certain musculoskeletal conditions like osteoarthritis and rheumatoid arthritis may negatively impact on people's ability to maintain good oral health.", [["periodontal", "ANATOMY", 86, 97], ["musculoskeletal", "ANATOMY", 119, 134], ["oral", "ANATOMY", 250, 254], ["diabetes", "DISEASE", 31, 39], ["periodontal disease", "DISEASE", 86, 105], ["osteoarthritis", "DISEASE", 151, 165], ["rheumatoid arthritis", "DISEASE", 170, 190], ["periodontal", "ORGAN", 86, 97], ["people", "ORGANISM", 216, 222], ["oral", "ORGANISM_SUBDIVISION", 250, 254], ["people", "SPECIES", 216, 222], ["poorly controlled diabetes", "PROBLEM", 13, 39], ["periodontal disease", "PROBLEM", 86, 105], ["certain musculoskeletal conditions", "PROBLEM", 111, 145], ["osteoarthritis", "PROBLEM", 151, 165], ["rheumatoid arthritis", "PROBLEM", 170, 190], ["poorly controlled", "OBSERVATION_MODIFIER", 13, 30], ["diabetes", "OBSERVATION", 31, 39], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["periodontal disease", "OBSERVATION", 86, 105], ["musculoskeletal", "ANATOMY", 119, 134], ["osteoarthritis", "OBSERVATION", 151, 165], ["rheumatoid", "OBSERVATION_MODIFIER", 170, 180], ["arthritis", "OBSERVATION", 181, 190]]], ["25, 55 Data from systematic reviews and meta-analysis suggests that people with anxiety and depressive disorders present a greater risk of dental caries.", [["anxiety", "DISEASE", 80, 87], ["depressive disorders", "DISEASE", 92, 112], ["caries", "DISEASE", 146, 152], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["systematic reviews", "TEST", 17, 35], ["meta-analysis", "TEST", 40, 53], ["anxiety", "PROBLEM", 80, 87], ["depressive disorders", "PROBLEM", 92, 112], ["dental caries", "PROBLEM", 139, 152], ["greater", "OBSERVATION_MODIFIER", 123, 130], ["dental caries", "OBSERVATION", 139, 152]]], ["The reasons for this could be multifactorial: decreased interest in maintaining good oral hygiene, an increased risk in smoking and consuming sugary foods and drinks, as well as the side effects of certain psychotropic medications that can cause dry mouth.", [["oral", "ANATOMY", 85, 89], ["smoking", "CHEMICAL", 120, 127], ["dry mouth", "DISEASE", 246, 255], ["oral", "ORGANISM_SUBDIVISION", 85, 89], ["mouth", "ORGANISM_SUBDIVISION", 250, 255], ["certain psychotropic medications", "TREATMENT", 198, 230], ["dry mouth", "PROBLEM", 246, 255], ["decreased", "OBSERVATION", 46, 55], ["good", "OBSERVATION_MODIFIER", 80, 84]]], ["56Implications of multimorbidity for oral health and dentistryAs multimorbidity is becoming the norm, rather than the exception, a profound shift is needed in the training of oral health professionals, the practice and delivery of dental care, and the focus of dental research.Training oral health professionalsOver the last 30 years, considerable efforts have been made to better integrate the training of oral health professionals within the wider healthcare educational system.", [["oral", "ANATOMY", 37, 41], ["oral", "ANATOMY", 175, 179], ["oral", "ANATOMY", 286, 290], ["oral", "ANATOMY", 407, 411], ["oral", "ORGANISM_SUBDIVISION", 37, 41], ["oral", "ORGANISM_SUBDIVISION", 175, 179], ["oral", "ORGANISM_SUBDIVISION", 286, 290], ["oral", "ORGANISM_SUBDIVISION", 407, 411], ["a profound shift", "PROBLEM", 129, 145], ["dental care", "TREATMENT", 231, 242], ["profound", "OBSERVATION_MODIFIER", 131, 139], ["shift", "OBSERVATION", 140, 145]]], ["This siloed approach to professional education needs to radically change if the future oral health workforce is going to be equipped with the knowledge, skills and competencies needed to provide high-quality and integrated care to the everincreasing numbers of patients with multiple health conditions.", [["oral", "ANATOMY", 87, 91], ["oral", "ORGANISM_SUBDIVISION", 87, 91], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 261, 269], ["professional education", "TREATMENT", 24, 46]]], ["57 Truly integrated models of education and training are needed which include a significant focus on multimorbidity (in terms of common social determinants, pathogenesis, treatment modalities and impact), and the best ways of addressing and supporting the (oral) health needs of patients with multiple conditions.", [["oral", "ANATOMY", 257, 261], ["oral", "ORGANISM_SUBDIVISION", 257, 261], ["patients", "ORGANISM", 279, 287], ["patients", "SPECIES", 279, 287], ["education and training", "TREATMENT", 30, 52], ["treatment modalities", "TREATMENT", 171, 191]]], ["Greater emphasis needs to be placed on training oral health professionals to be active and core members of multidisciplinary health teams working in primary care, community or hospital settings.", [["oral", "ANATOMY", 48, 52], ["oral", "ORGANISM_SUBDIVISION", 48, 52]]], ["Undergraduate and continuing professional development training also needs to equip oral health professionals with highly developed communication skills to enable them to communicate effectively with other health professionals, as well as with patients and their families living with complex health needs.", [["oral", "ANATOMY", 83, 87], ["oral", "ORGANISM_SUBDIVISION", 83, 87], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["continuing professional development training", "TREATMENT", 18, 62]]], ["It is also very important that core oral health input is included in the curriculum and assessment of medical, pharmacy and nursing students to ensure that they are better informed and equipped to deal with oral health problems, and when appropriate to refer patients to oral health professionals.", [["oral", "ANATOMY", 36, 40], ["oral", "ANATOMY", 207, 211], ["oral", "ANATOMY", 271, 275], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["oral", "ORGANISM_SUBDIVISION", 207, 211], ["patients", "ORGANISM", 259, 267], ["oral", "ORGANISM_SUBDIVISION", 271, 275], ["patients", "SPECIES", 259, 267]]], ["58Clinical practice including preventionA move towards greater horizontal service integration and the provision of coordinated care delivered by multidisciplinary teams (including oral health professionals working in primary, community and hospital settings) requires a radical system-level reform and redesign in how health and dental services are commissioned, remunerated and delivered.", [["oral", "ANATOMY", 180, 184], ["oral", "ORGANISM_SUBDIVISION", 180, 184], ["58Clinical practice", "TREATMENT", 0, 19], ["preventionA", "TREATMENT", 30, 41], ["a radical system", "TREATMENT", 268, 284]]], ["A Cochrane review of interventions treating multimorbidity highlighted that patient-level interventions such as educational support and patient self-management had little or no impact, whereas 'whole system' and organisationallevel interventions promoting integrated case management and the enhanced use of multidisciplinary teams (which specifically targeted particular combinations of conditions including depression and functional difficulties) had more promising results.", [["multimorbidity", "DISEASE", 44, 58], ["depression", "DISEASE", 408, 418], ["patient", "ORGANISM", 76, 83], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 76, 83], ["patient", "SPECIES", 136, 143], ["interventions", "TREATMENT", 21, 34], ["multimorbidity", "PROBLEM", 44, 58], ["patient-level interventions", "TREATMENT", 76, 103], ["educational support", "TREATMENT", 112, 131], ["organisationallevel interventions", "TREATMENT", 212, 245], ["integrated case management", "TREATMENT", 256, 282], ["depression", "PROBLEM", 408, 418], ["functional difficulties", "PROBLEM", 423, 446]]], ["59 Innovative financing strategies need to be tested and adopted to create a stimulus and incentive to promote the coordination and integration of care for multimorbid patients across the health and social care system.", [["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["Innovative financing strategies", "TREATMENT", 3, 34]]], ["60 Integrated information systems also need to be created with unified electronic health records that capture all aspects of a patient's care journey across primary, community, hospital and social care settings.Clinical practice including preventionWith increasing numbers of individuals in the general population living with multiple health conditions, oral health professionals working in general dental practice will have an absolutely fundamental role in providing care and treatment for these patients.", [["oral", "ANATOMY", 354, 358], ["patient", "ORGANISM", 127, 134], ["oral", "ORGANISM_SUBDIVISION", 354, 358], ["patients", "ORGANISM", 498, 506], ["patient", "SPECIES", 127, 134], ["patients", "SPECIES", 498, 506], ["Clinical practice", "TREATMENT", 211, 228], ["treatment", "TREATMENT", 478, 487], ["increasing", "OBSERVATION_MODIFIER", 254, 264], ["numbers", "OBSERVATION_MODIFIER", 265, 272]]], ["As generalists, primary dental care teams will need to adopt a more holistic and systematic approach in how they undertake medical histories, diagnosis and treatment planning, and the provision of appropriate routine dental care for these patients.", [["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 239, 247], ["systematic approach", "TREATMENT", 81, 100], ["treatment planning", "TREATMENT", 156, 174], ["appropriate routine dental care", "TREATMENT", 197, 228]]], ["In multimorbid patients with more complex needs, primary dental care teams will need to liaise and refer these cases to appropriate specialists working in the community or hospital settings.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["For example, in the United States and France, a periodontal assessment has been included in the national guidance for diabetes care.", [["diabetes", "DISEASE", 118, 126], ["a periodontal assessment", "TEST", 46, 70], ["diabetes care", "TREATMENT", 118, 131]]], ["61, 62 In England, the Office of the Chief Dental Officer has recently published a guide to support commissioners to develop more integrated clinical pathways between the medical and dental care of diabetic patients.", [["diabetic", "DISEASE", 198, 206], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215]]], ["63 Multimorbidity also has important implications for the delivery of ongoing evidence-informed preventive care.", [["Multimorbidity", "DISEASE", 3, 17]]], ["It is particularly important that patients living with multiple health conditions receive effective preventive support from their oral health professional and are empowered to undertake appropriate self-care practices to maintain and improve their oral health status.", [["oral", "ANATOMY", 130, 134], ["oral", "ANATOMY", 248, 252], ["patients", "ORGANISM", 34, 42], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["oral", "ORGANISM_SUBDIVISION", 248, 252], ["patients", "SPECIES", 34, 42], ["preventive support", "TREATMENT", 100, 118]]], ["Preventive resources such as Delivering better oral health 64 follow a common risk factor approach in advocating integrated preventive support, covering advice on diet, tobacco and alcohol use.", [["oral", "ANATOMY", 47, 51], ["alcohol", "CHEMICAL", 181, 188], ["alcohol", "CHEMICAL", 181, 188], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["tobacco", "ORGANISM", 169, 176], ["alcohol", "SIMPLE_CHEMICAL", 181, 188], ["tobacco", "SPECIES", 169, 176], ["preventive support", "TREATMENT", 124, 142]]], ["19 More detailed and comprehensive preventive support will also be needed for multimorbid patients experiencing the complications of living with multiple conditions; for example, dry mouth linked to the use of polypharmacy.Research gapsThe Academy of Medical Sciences report on multimorbidity has highlighted a wide range of research gaps in this field 2 and the National Institute of Health Research has identified multimorbidity as a key research priority.", [["dry mouth", "DISEASE", 179, 188], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["dry mouth", "PROBLEM", 179, 188], ["polypharmacy", "TREATMENT", 210, 222], ["Research gaps", "TEST", 223, 236], ["wide", "OBSERVATION_MODIFIER", 311, 315], ["multimorbidity", "OBSERVATION", 416, 430]]], ["65 More longitudinal research is certainly needed to understand more comprehensively the underlying determinants and shared causal pathways between chronic conditions, including oral diseases.", [["oral", "ANATOMY", 178, 182], ["oral diseases", "DISEASE", 178, 191], ["oral", "ORGANISM_SUBDIVISION", 178, 182], ["chronic conditions", "PROBLEM", 148, 166], ["oral diseases", "PROBLEM", 178, 191], ["chronic", "OBSERVATION_MODIFIER", 148, 155]]], ["More interventional studies are also needed to evaluate interventions to prevent multimorbidity and to improve treatment outcomes.", [["multimorbidity", "DISEASE", 81, 95], ["More interventional studies", "TEST", 0, 27], ["interventions", "TREATMENT", 56, 69], ["multimorbidity", "PROBLEM", 81, 95], ["treatment outcomes", "TREATMENT", 111, 129]]], ["Rather than excluding participants with multiple conditions from clinical studies, as currently happens in most clinical trials, future studies should actively focus on their inclusion.", [["participants", "SPECIES", 22, 34], ["clinical studies", "TEST", 65, 81], ["future studies", "TEST", 129, 143]]], ["Oral health outcomes need to be included in future multimorbidity studies to enable more research on how oral conditions cluster with other chronic conditions and the shared pathways.ConclusionMultimorbidity is increasingly common and has a major impact on quality of life, mortality risk and costs to the NHS.", [["Oral", "ANATOMY", 0, 4], ["oral", "ANATOMY", 105, 109], ["Multimorbidity", "DISEASE", 193, 207], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["oral", "ORGANISM_SUBDIVISION", 105, 109], ["multimorbidity studies", "TEST", 51, 73], ["other chronic conditions", "PROBLEM", 134, 158], ["Multimorbidity", "OBSERVATION", 193, 207]]], ["This significant change in the pattern of disease in society has profound implications for the future training of oral health professionals, the practice and delivery of dental care, and dental research.", [["oral", "ANATOMY", 114, 118], ["oral", "ORGANISM_SUBDIVISION", 114, 118], ["This significant change", "PROBLEM", 0, 23], ["disease", "PROBLEM", 42, 49], ["oral health professionals", "TREATMENT", 114, 139], ["dental care", "TREATMENT", 170, 181], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["change", "OBSERVATION", 17, 23], ["pattern", "OBSERVATION_MODIFIER", 31, 38], ["disease", "OBSERVATION", 42, 49]]], ["The dental profession must respond to this challenge.", [["this challenge", "TREATMENT", 38, 52]]]], "PMC7377292": [["TO THE EDITOR\u2014Coronaviruses (CoV) comprise a large family of zoonotic RNA viruses.", [["zoonotic RNA viruses", "DISEASE", 61, 81], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 14, 27], ["CoV", "ORGANISM", 29, 32], ["CoV", "SPECIES", 29, 32], ["zoonotic RNA viruses", "PROBLEM", 61, 81], ["zoonotic RNA viruses", "OBSERVATION", 61, 81]]], ["Among the 7 members known to infect humans, SARS-CoV-2, the causative agent of COVID-19, together with SARS-CoV and MERS-CoV, cause severe respiratory syndrome.", [["respiratory", "ANATOMY", 139, 150], ["SARS", "DISEASE", 44, 48], ["SARS-CoV", "DISEASE", 103, 111], ["respiratory syndrome", "DISEASE", 139, 159], ["humans", "ORGANISM", 36, 42], ["SARS-CoV-2", "ORGANISM", 44, 54], ["COVID-19", "ORGANISM", 79, 87], ["SARS-CoV", "ORGANISM", 103, 111], ["MERS-CoV", "ORGANISM", 116, 124], ["humans", "SPECIES", 36, 42], ["MERS-CoV", "SPECIES", 116, 124], ["humans", "SPECIES", 36, 42], ["SARS-CoV", "SPECIES", 44, 52], ["COVID-19", "SPECIES", 79, 87], ["SARS-CoV", "SPECIES", 103, 111], ["MERS-CoV", "SPECIES", 116, 124], ["COVID", "TEST", 79, 84], ["SARS", "PROBLEM", 103, 107], ["CoV", "PROBLEM", 121, 124], ["severe respiratory syndrome", "PROBLEM", 132, 159], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["respiratory syndrome", "OBSERVATION", 139, 159]]], ["The other 4 members, including NL63, HKU1, OC43, and 229E, are widely circulating in humans but predominantly cause mild respiratory tract illness [1].", [["respiratory tract", "ANATOMY", 121, 138], ["respiratory tract illness", "DISEASE", 121, 146], ["NL63", "GENE_OR_GENE_PRODUCT", 31, 35], ["HKU1", "GENE_OR_GENE_PRODUCT", 37, 41], ["OC43", "GENE_OR_GENE_PRODUCT", 43, 47], ["229E", "GENE_OR_GENE_PRODUCT", 53, 57], ["humans", "ORGANISM", 85, 91], ["NL63", "PROTEIN", 31, 35], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["NL63", "TEST", 31, 35], ["mild respiratory tract illness", "PROBLEM", 116, 146], ["OC43", "ANATOMY", 43, 47], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["respiratory tract", "OBSERVATION", 121, 138]]], ["Thus we call these 4 viruses low-pathogenic human CoVs (LPH-CoV).", [["human", "ORGANISM", 44, 49], ["CoVs", "GENE_OR_GENE_PRODUCT", 50, 54], ["LPH-CoV", "GENE_OR_GENE_PRODUCT", 56, 63], ["LPH", "PROTEIN", 56, 59], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["LPH-CoV", "SPECIES", 56, 63]]], ["Two recent studies by Nickbakhsh et al and Monto et al in The Journal of Infectious Diseases have reported the prevalence of LPH-CoV as 4.0% in western Scotland and 8.3%\u201316.3% in Michigan, United States [2, 3].", [["Infectious Diseases", "DISEASE", 73, 92], ["LPH-CoV", "ORGANISM", 125, 132], ["LPH-CoV", "SPECIES", 125, 132], ["Two recent studies", "TEST", 0, 18], ["LPH", "TEST", 125, 128], ["CoV", "TEST", 129, 132], ["Infectious", "OBSERVATION", 73, 83]]], ["Interestingly, both studies detected the highest frequency of infection in children younger than 5 years.", [["infection", "DISEASE", 62, 71], ["children", "ORGANISM", 75, 83], ["children", "SPECIES", 75, 83], ["both studies", "TEST", 15, 27], ["infection", "PROBLEM", 62, 71], ["highest", "OBSERVATION_MODIFIER", 41, 48], ["infection", "OBSERVATION", 62, 71]]], ["This is the opposite to the COVID-19 pandemic where children are less commonly affected by SARS-CoV-2 [4].", [["SARS", "DISEASE", 91, 95], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 91, 99]]], ["These intriguing findings trigger important hypotheses on whether coinfection with LPH-CoV interferes with SARS-CoV-2 or exposure to LPH-CoV confers cross-protective immunity to some extent.", [["coinfection", "DISEASE", 66, 77], ["LPH-CoV", "ORGANISM", 83, 90], ["SARS-CoV-2", "ORGANISM", 107, 117], ["LPH-CoV", "GENE_OR_GENE_PRODUCT", 133, 140], ["LPH", "PROTEIN", 83, 86], ["LPH", "PROTEIN", 133, 136], ["LPH-CoV", "SPECIES", 83, 90], ["SARS-CoV", "SPECIES", 107, 115], ["LPH-CoV", "SPECIES", 133, 140], ["coinfection", "PROBLEM", 66, 77], ["LPH", "TEST", 83, 86], ["SARS", "PROBLEM", 107, 111], ["CoV", "PROBLEM", 112, 115], ["exposure to LPH", "PROBLEM", 121, 136], ["CoV confers cross-protective immunity", "TREATMENT", 137, 174], ["some extent", "OBSERVATION_MODIFIER", 178, 189]]]], "0d3559dd7dea4ccd3446913601e9c48bc948c141": [["J o u r n a l P r e -p r o o f Currently, there are two major forms of testing in the U.S.: testing for SARS-CoV-2 RNA and serologic testing.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["SARS-CoV", "SPECIES", 104, 112], ["testing", "TEST", 92, 99], ["SARS", "TEST", 104, 108], ["CoV", "TEST", 109, 112], ["serologic testing", "TEST", 123, 140]]], ["1, 2 However, only testing those experiencing symptoms is not a practical way of obtaining a true picture of the infection status of the nation, as the majority of infected individuals do not exhibit symptoms.", [["infection", "DISEASE", 113, 122], ["individuals", "ORGANISM", 173, 184], ["symptoms", "PROBLEM", 46, 54], ["the infection", "PROBLEM", 109, 122], ["infected individuals", "PROBLEM", 164, 184], ["symptoms", "PROBLEM", 200, 208], ["infection", "OBSERVATION", 113, 122], ["infected", "OBSERVATION", 164, 172]]], ["3 Healthcare personnel who are in close contact with ill patients may be asymptomatic themselves and unknowingly transmit the infection to others.", [["infection", "DISEASE", 126, 135], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["the infection", "PROBLEM", 122, 135], ["infection", "OBSERVATION", 126, 135]]], ["A call for new methods of testing and surveillance on a large scale will be important if we hope to control the spread of SARS-CoV-2 infections.", [["SARS", "DISEASE", 122, 126], ["infections", "DISEASE", 133, 143], ["SARS-CoV-2", "ORGANISM", 122, 132], ["SARS-CoV-2", "SPECIES", 122, 132], ["testing", "TEST", 26, 33], ["surveillance", "TEST", 38, 50], ["a large scale", "TREATMENT", 54, 67], ["SARS", "PROBLEM", 122, 126], ["CoV-2 infections", "PROBLEM", 127, 143]]]], "973b709be1f105a101100621ae88d48176de58d0": [["IntroductionHuman immunodeficiency virus type-1 (HIV-1) infection induces apoptosis in several cell types of the infected host.", [["cell", "ANATOMY", 95, 99], ["IntroductionHuman immunodeficiency virus type-1", "CHEMICAL", 0, 47], ["infection", "DISEASE", 56, 65], ["IntroductionHuman immunodeficiency virus type-1", "ORGANISM", 0, 47], ["HIV-1", "ORGANISM", 49, 54], ["cell", "CELL", 95, 99], ["IntroductionHuman immunodeficiency virus type-1", "SPECIES", 0, 47], ["HIV-1", "SPECIES", 49, 54], ["IntroductionHuman immunodeficiency virus type-1", "SPECIES", 0, 47], ["HIV-1", "SPECIES", 49, 54], ["IntroductionHuman immunodeficiency virus type", "TEST", 0, 45], ["HIV", "PROBLEM", 49, 52], ["infection", "PROBLEM", 56, 65], ["apoptosis", "PROBLEM", 74, 83], ["the infected host", "PROBLEM", 109, 126], ["infection", "OBSERVATION", 56, 65], ["several cell", "OBSERVATION_MODIFIER", 87, 99], ["infected host", "OBSERVATION", 113, 126]]], ["CD4+ T cells infected by HIV-1 display a cell cycle arrest at the G2 phase, which eventually leads to cell death.", [["CD4+ T cells", "ANATOMY", 0, 12], ["cell", "ANATOMY", 41, 45], ["cell", "ANATOMY", 102, 106], ["death", "DISEASE", 107, 112], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["HIV-1", "ORGANISM", 25, 30], ["cell", "CELL", 41, 45], ["cell", "CELL", 102, 106], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["HIV-1", "SPECIES", 25, 30], ["HIV-1", "SPECIES", 25, 30], ["CD4", "TEST", 0, 3], ["T cells infected", "PROBLEM", 5, 21], ["HIV", "TEST", 25, 28], ["a cell cycle arrest", "PROBLEM", 39, 58], ["cell death", "PROBLEM", 102, 112], ["cell death", "OBSERVATION", 102, 112]]], ["1, 2 This is thought to contribute to the loss of CD4+ T cells and to the development of immunodeficiency.", [["CD4+ T cells", "ANATOMY", 50, 62], ["immunodeficiency", "DISEASE", 89, 105], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD4", "PROTEIN", 50, 53], ["T cells", "CELL_TYPE", 55, 62], ["the loss of CD4+ T cells", "PROBLEM", 38, 62], ["immunodeficiency", "PROBLEM", 89, 105], ["thought to contribute", "UNCERTAINTY", 13, 34], ["immunodeficiency", "OBSERVATION", 89, 105]]], ["3, 4 A virally encoded accessory protein, Vpr, is a major player in the induction of G2 arrest and apoptosis in CD4+ T cells.", [["CD4+ T cells", "ANATOMY", 112, 124], ["Vpr", "GENE_OR_GENE_PRODUCT", 42, 45], ["CD4", "GENE_OR_GENE_PRODUCT", 112, 115], ["virally encoded accessory protein", "PROTEIN", 7, 40], ["Vpr", "PROTEIN", 42, 45], ["CD4+ T cells", "CELL_TYPE", 112, 124], ["G2 arrest", "PROBLEM", 85, 94], ["apoptosis", "PROBLEM", 99, 108], ["accessory protein", "OBSERVATION", 23, 40], ["G2 arrest", "OBSERVATION", 85, 94]]], ["[5] [6] [7] [8] However, in the central nervous system (CNS), HIV-1 triggers the apoptosis of neurons via a different mechanism.", [["central nervous system", "ANATOMY", 32, 54], ["CNS", "ANATOMY", 56, 59], ["neurons", "ANATOMY", 94, 101], ["[5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 15], ["central nervous system", "ANATOMICAL_SYSTEM", 32, 54], ["CNS", "ANATOMICAL_SYSTEM", 56, 59], ["HIV-1", "ORGANISM", 62, 67], ["neurons", "CELL", 94, 101], ["HIV-1", "SPECIES", 62, 67], ["HIV-1", "SPECIES", 62, 67], ["HIV", "PROBLEM", 62, 65], ["the apoptosis of neurons", "PROBLEM", 77, 101], ["central", "ANATOMY_MODIFIER", 32, 39], ["nervous system", "ANATOMY", 40, 54], ["CNS", "ANATOMY", 56, 59]]], ["Neurons undergo apoptosis as a result of exposure to extracellular viral proteins such as Tat and gp120, and this neurodegeneration can lead to HIV-1 associated dementia (HAD).", [["Neurons", "ANATOMY", 0, 7], ["extracellular", "ANATOMY", 53, 66], ["neurodegeneration", "DISEASE", 114, 131], ["dementia", "DISEASE", 161, 169], ["HAD", "DISEASE", 171, 174], ["Neurons", "CELL", 0, 7], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 66], ["Tat", "GENE_OR_GENE_PRODUCT", 90, 93], ["gp120", "GENE_OR_GENE_PRODUCT", 98, 103], ["HIV-1", "ORGANISM", 144, 149], ["extracellular viral proteins", "PROTEIN", 53, 81], ["Tat", "PROTEIN", 90, 93], ["gp120", "PROTEIN", 98, 103], ["HIV-1", "SPECIES", 144, 149], ["HIV-1", "SPECIES", 144, 149], ["apoptosis", "PROBLEM", 16, 25], ["extracellular viral proteins", "TREATMENT", 53, 81], ["Tat and gp120", "TREATMENT", 90, 103], ["this neurodegeneration", "PROBLEM", 109, 131], ["HIV-1 associated dementia", "PROBLEM", 144, 169], ["apoptosis", "OBSERVATION", 16, 25], ["dementia", "OBSERVATION", 161, 169]]], ["[9] [10] [11] These neurotoxic viral proteins [12] [13] [14] [15] are believed to be secreted from HIV-1 infected microglia, the macrophage of the CNS.IntroductionUnlike CD4+ T cells, macrophage and microglia do not undergo apoptosis upon HIV-1 infection.", [["microglia", "ANATOMY", 114, 123], ["macrophage", "ANATOMY", 129, 139], ["CNS", "ANATOMY", 147, 150], ["CD4+ T cells", "ANATOMY", 170, 182], ["macrophage", "ANATOMY", 184, 194], ["microglia", "ANATOMY", 199, 208], ["neurotoxic", "DISEASE", 20, 30], ["[12] [13] [14] [15]", "CHEMICAL", 46, 65], ["HIV-1 infection", "DISEASE", 239, 254], ["[9] [10] [11]", "SIMPLE_CHEMICAL", 0, 13], ["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 46, 65], ["HIV-1", "ORGANISM", 99, 104], ["microglia", "CELL", 114, 123], ["macrophage", "CELL", 129, 139], ["CNS", "ANATOMICAL_SYSTEM", 147, 150], ["CD4", "GENE_OR_GENE_PRODUCT", 170, 173], ["macrophage", "CELL", 184, 194], ["microglia", "CELL", 199, 208], ["HIV-1", "ORGANISM", 239, 244], ["microglia", "CELL_TYPE", 114, 123], ["macrophage", "CELL_TYPE", 129, 139], ["CD4", "PROTEIN", 170, 173], ["T cells", "CELL_TYPE", 175, 182], ["macrophage", "CELL_TYPE", 184, 194], ["microglia", "CELL_TYPE", 199, 208], ["HIV-1", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 239, 244], ["HIV-1", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 239, 244], ["These neurotoxic viral proteins", "TEST", 14, 45], ["HIV", "TEST", 99, 102], ["infected microglia", "PROBLEM", 105, 123], ["CD4", "TEST", 170, 173], ["T cells", "PROBLEM", 175, 182], ["macrophage", "PROBLEM", 184, 194], ["apoptosis", "PROBLEM", 224, 233], ["HIV", "PROBLEM", 239, 242], ["1 infection", "PROBLEM", 243, 254], ["infected microglia", "OBSERVATION", 105, 123], ["macrophage", "OBSERVATION_MODIFIER", 129, 139], ["CNS", "ANATOMY", 147, 150], ["T cells", "OBSERVATION", 175, 182], ["infection", "OBSERVATION", 245, 254]]], ["16, 17 These two terminally differentiated cell types are infected by macrophage (M)-tropic/R5 viruses at the early stages of viral infection.", [["cell", "ANATOMY", 43, 47], ["macrophage", "ANATOMY", 70, 80], ["viral infection", "DISEASE", 126, 141], ["cell", "CELL", 43, 47], ["macrophage", "CELL", 70, 80], ["(M)-tropic/R5 viruses", "ORGANISM", 81, 102], ["terminally differentiated cell types", "CELL_TYPE", 17, 53], ["tropic/R5 viruses", "PROBLEM", 85, 102], ["viral infection", "PROBLEM", 126, 141], ["two", "OBSERVATION_MODIFIER", 13, 16], ["terminally", "OBSERVATION_MODIFIER", 17, 27], ["differentiated", "OBSERVATION_MODIFIER", 28, 42], ["cell types", "OBSERVATION", 43, 53], ["infected", "OBSERVATION_MODIFIER", 58, 66], ["macrophage", "OBSERVATION_MODIFIER", 70, 80], ["R5 viruses", "OBSERVATION", 92, 102], ["early stages", "OBSERVATION_MODIFIER", 110, 122], ["viral", "OBSERVATION_MODIFIER", 126, 131], ["infection", "OBSERVATION", 132, 141]]], ["[18] [19] [20] [21] Since macro-phage and microglia are non-dividing cells, the cell cycle arrest effect of virus-encoded Vpr, which is mechanistically linked to cell death, has been thought to be insignificant in these HIV-1 target cells.", [["microglia", "ANATOMY", 42, 51], ["cells", "ANATOMY", 69, 74], ["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 162, 166], ["cells", "ANATOMY", 233, 238], ["death", "DISEASE", 167, 172], ["[18] [19] [20] [21]", "SIMPLE_CHEMICAL", 0, 19], ["microglia", "CELL", 42, 51], ["cells", "CELL", 69, 74], ["cell", "CELL", 80, 84], ["Vpr", "GENE_OR_GENE_PRODUCT", 122, 125], ["cell", "CELL", 162, 166], ["HIV-1", "ORGANISM", 220, 225], ["cells", "CELL", 233, 238], ["microglia", "CELL_TYPE", 42, 51], ["non-dividing cells", "CELL_TYPE", 56, 74], ["Vpr", "PROTEIN", 122, 125], ["HIV-1 target cells", "CELL_LINE", 220, 238], ["HIV-1", "SPECIES", 220, 225], ["HIV-1", "SPECIES", 220, 225], ["macro-phage", "TEST", 26, 37], ["non-dividing cells", "PROBLEM", 56, 74], ["the cell cycle arrest effect of virus", "PROBLEM", 76, 113], ["cell death", "PROBLEM", 162, 172], ["microglia", "ANATOMY", 42, 51], ["thought to be", "UNCERTAINTY", 183, 196], ["insignificant", "OBSERVATION_MODIFIER", 197, 210]]], ["This is because Vpr cannot activate the proapoptotic pathway that it activates in T cells, since ATR, Rad17 and Chk1 are not expressed in macrophage.", [["T cells", "ANATOMY", 82, 89], ["macrophage", "ANATOMY", 138, 148], ["Vpr", "GENE_OR_GENE_PRODUCT", 16, 19], ["T cells", "CELL", 82, 89], ["ATR", "GENE_OR_GENE_PRODUCT", 97, 100], ["Rad17", "GENE_OR_GENE_PRODUCT", 102, 107], ["Chk1", "GENE_OR_GENE_PRODUCT", 112, 116], ["macrophage", "CELL", 138, 148], ["Vpr", "PROTEIN", 16, 19], ["T cells", "CELL_TYPE", 82, 89], ["ATR", "PROTEIN", 97, 100], ["Rad17", "PROTEIN", 102, 107], ["Chk1", "PROTEIN", 112, 116], ["macrophage", "CELL_TYPE", 138, 148], ["Vpr", "PROBLEM", 16, 19], ["ATR", "TEST", 97, 100], ["Chk1", "TEST", 112, 116], ["macrophage", "OBSERVATION_MODIFIER", 138, 148]]], ["22 Interestingly, a recent study reported that HIV-1 infected microglia may have a survival advantage, as compared with uninfected microglia in the same patients.", [["microglia", "ANATOMY", 62, 71], ["microglia", "ANATOMY", 131, 140], ["HIV-1", "ORGANISM", 47, 52], ["microglia", "CELL", 62, 71], ["microglia", "CELL", 131, 140], ["patients", "ORGANISM", 153, 161], ["microglia", "CELL_TYPE", 62, 71], ["uninfected microglia", "CELL_TYPE", 120, 140], ["HIV-1", "SPECIES", 47, 52], ["patients", "SPECIES", 153, 161], ["HIV-1", "SPECIES", 47, 52], ["a recent study", "TEST", 18, 32], ["HIV-1 infected microglia", "PROBLEM", 47, 71], ["infected microglia", "OBSERVATION", 53, 71]]], ["23 Since the phenotypic outcomes of HIV-1 infection in CD4+ T cells (apoptosis) and microglia (pro-survival) are opposite, it is of considerable interest to better understand how HIV-1 interacts with microglia.", [["CD4+ T cells", "ANATOMY", 55, 67], ["microglia", "ANATOMY", 84, 93], ["microglia", "ANATOMY", 200, 209], ["HIV-1 infection", "DISEASE", 36, 51], ["HIV-1", "ORGANISM", 36, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 55, 58], ["microglia", "CELL", 84, 93], ["HIV-1", "ORGANISM", 179, 184], ["microglia", "CELL", 200, 209], ["CD4+ T cells", "CELL_TYPE", 55, 67], ["microglia", "CELL_TYPE", 84, 93], ["microglia", "CELL_TYPE", 200, 209], ["HIV-1", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 179, 184], ["HIV", "PROBLEM", 36, 39], ["1 infection", "PROBLEM", 40, 51], ["CD4", "TEST", 55, 58], ["T cells", "PROBLEM", 60, 67], ["apoptosis", "PROBLEM", 69, 78], ["infection", "OBSERVATION", 42, 51]]], ["This may lead to insight into how HIV-1 infected microglia are able to contribute to the persistent production of HIV-1 within the central nervous system.", [["microglia", "ANATOMY", 49, 58], ["central nervous system", "ANATOMY", 131, 153], ["HIV-1", "ORGANISM", 34, 39], ["microglia", "CELL", 49, 58], ["HIV-1", "ORGANISM", 114, 119], ["central nervous system", "ANATOMICAL_SYSTEM", 131, 153], ["microglia", "CELL_TYPE", 49, 58], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 114, 119], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 114, 119], ["1 infected microglia", "PROBLEM", 38, 58], ["HIV", "PROBLEM", 114, 117], ["infected", "OBSERVATION", 40, 48], ["persistent", "OBSERVATION_MODIFIER", 89, 99], ["production", "OBSERVATION", 100, 110], ["HIV", "OBSERVATION", 114, 117], ["central", "ANATOMY_MODIFIER", 131, 138], ["nervous system", "ANATOMY", 139, 153]]], ["17, [24] [25] [26] Many cellular proteins and signaling pathways have been implicated in the regulation of cell fate.", [["cellular", "ANATOMY", 24, 32], ["cell", "ANATOMY", 107, 111], ["cellular", "CELL", 24, 32], ["cell", "CELL", 107, 111], ["cellular proteins", "PROTEIN", 24, 41], ["Many cellular proteins", "PROBLEM", 19, 41], ["signaling pathways", "PROBLEM", 46, 64], ["cell fate", "OBSERVATION", 107, 116]]], ["One of the most important, and best studied, is Akt.", [["Akt", "GENE_OR_GENE_PRODUCT", 48, 51], ["Akt", "PROTEIN", 48, 51], ["most important", "OBSERVATION_MODIFIER", 11, 25]]], ["27 Upon cellular stimulation, PI-3-K recruits protein kinase B/Akt to the membrane through generation of PIP3 from PIP2, where it is catalyzed via specific phosphorylation.", [["cellular", "ANATOMY", 8, 16], ["membrane", "ANATOMY", 74, 82], ["PI-3-K", "CHEMICAL", 30, 36], ["cellular", "CELL", 8, 16], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 30, 36], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 46, 62], ["Akt", "GENE_OR_GENE_PRODUCT", 63, 66], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["PIP3", "GENE_OR_GENE_PRODUCT", 105, 109], ["PIP2", "SIMPLE_CHEMICAL", 115, 119], ["PI-3-K", "PROTEIN", 30, 36], ["protein kinase B", "PROTEIN", 46, 62], ["Akt", "PROTEIN", 63, 66], ["PIP3", "PROTEIN", 105, 109], ["PIP2", "PROTEIN", 115, 119], ["cellular stimulation", "TEST", 8, 28], ["PI", "TEST", 30, 32], ["protein kinase", "TEST", 46, 60], ["PIP3 from PIP2", "TREATMENT", 105, 119]]], ["Once activated, Akt leaves the membrane to modulate the activity of its numerous targets, including GSK3\u03b2, p21, Mdm2 and Bad.", [["membrane", "ANATOMY", 31, 39], ["Akt", "GENE_OR_GENE_PRODUCT", 16, 19], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 100, 105], ["p21", "GENE_OR_GENE_PRODUCT", 107, 110], ["Mdm2", "GENE_OR_GENE_PRODUCT", 112, 116], ["Bad", "GENE_OR_GENE_PRODUCT", 121, 124], ["Akt", "PROTEIN", 16, 19], ["GSK3\u03b2", "PROTEIN", 100, 105], ["p21", "PROTEIN", 107, 110], ["Mdm2", "PROTEIN", 112, 116], ["Bad", "PROTEIN", 121, 124]]], ["[28] [29] [30] [31] The overall outcome of these events is the induction of cellular proliferation and survival.", [["cellular", "ANATOMY", 76, 84], ["[28] [29] [30] [31]", "SIMPLE_CHEMICAL", 0, 19], ["cellular", "CELL", 76, 84], ["cellular proliferation", "PROBLEM", 76, 98], ["cellular proliferation", "OBSERVATION", 76, 98]]], ["In order to prevent excess cellular proliferation and survival, especially following damage and stress, this pathway must be regulated.", [["cellular", "ANATOMY", 27, 35], ["cellular", "CELL", 27, 35], ["excess cellular proliferation", "PROBLEM", 20, 49], ["damage", "PROBLEM", 85, 91], ["stress", "PROBLEM", 96, 102], ["excess", "OBSERVATION_MODIFIER", 20, 26], ["cellular proliferation", "OBSERVATION", 27, 49]]], ["One of the wellstudied negative regulators, phosphatase and tensin homolog (PTEN), converts PIP3 to PIP2, inhibiting recruitment of Akt to the membrane and therefore preventing further activation of the PI-3-K pathway.", [["membrane", "ANATOMY", 143, 151], ["phosphatase and tensin homolog", "GENE_OR_GENE_PRODUCT", 44, 74], ["PTEN", "GENE_OR_GENE_PRODUCT", 76, 80], ["PIP3", "GENE_OR_GENE_PRODUCT", 92, 96], ["PIP2", "GENE_OR_GENE_PRODUCT", 100, 104], ["Akt", "GENE_OR_GENE_PRODUCT", 132, 135], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 203, 209], ["wellstudied negative regulators", "PROTEIN", 11, 42], ["phosphatase and tensin homolog", "PROTEIN", 44, 74], ["PTEN", "PROTEIN", 76, 80], ["PIP3", "PROTEIN", 92, 96], ["PIP2", "PROTEIN", 100, 104], ["Akt", "PROTEIN", 132, 135], ["PI-3-K", "PROTEIN", 203, 209], ["phosphatase", "TEST", 44, 55], ["PIP3 to PIP2", "TREATMENT", 92, 104], ["the PI", "TREATMENT", 199, 205]]], ["32 PTEN also can modulate proliferation and survival through reciprocal positive regulation of p53.", [["PTEN", "GENE_OR_GENE_PRODUCT", 3, 7], ["p53", "GENE_OR_GENE_PRODUCT", 95, 98], ["PTEN", "PROTEIN", 3, 7], ["p53", "PROTEIN", 95, 98], ["modulate proliferation", "PROBLEM", 17, 39], ["reciprocal positive regulation of p53", "PROBLEM", 61, 98], ["proliferation", "OBSERVATION_MODIFIER", 26, 39]]], ["PTEN binds to the C-terminal end of p53, thereby stabilizing p53 while p53 transcriptionally induces PTEN.", [["C", "CHEMICAL", 18, 19], ["PTEN", "GENE_OR_GENE_PRODUCT", 0, 4], ["p53", "GENE_OR_GENE_PRODUCT", 36, 39], ["p53", "GENE_OR_GENE_PRODUCT", 61, 64], ["p53", "GENE_OR_GENE_PRODUCT", 71, 74], ["PTEN", "GENE_OR_GENE_PRODUCT", 101, 105], ["PTEN", "PROTEIN", 0, 4], ["C-terminal end", "PROTEIN", 18, 32], ["p53", "PROTEIN", 36, 39], ["p53", "PROTEIN", 61, 64], ["p53", "PROTEIN", 71, 74], ["PTEN", "PROTEIN", 101, 105], ["PTEN binds", "PROBLEM", 0, 10], ["the C", "TEST", 14, 19]]], ["33 Both PTEN and p53 are often found mutated or deleted in cancers, alleviating the restraint on cellular survival pathways and allowing for long term survival and the subsequent establishment of a transformed phenotype.", [["cancers", "ANATOMY", 59, 66], ["cellular", "ANATOMY", 97, 105], ["cancers", "DISEASE", 59, 66], ["PTEN", "GENE_OR_GENE_PRODUCT", 8, 12], ["p53", "GENE_OR_GENE_PRODUCT", 17, 20], ["cancers", "CANCER", 59, 66], ["cellular", "CELL", 97, 105], ["PTEN", "PROTEIN", 8, 12], ["p53", "PROTEIN", 17, 20], ["cancers", "PROBLEM", 59, 66], ["the restraint", "TREATMENT", 80, 93], ["cellular survival pathways", "TREATMENT", 97, 123], ["long term survival", "TREATMENT", 141, 159], ["a transformed phenotype", "PROBLEM", 196, 219], ["cancers", "OBSERVATION", 59, 66]]], ["32 The activation of the PI-3-K/Akt cell survival signaling pathway has been observed in cells infected by several human viruses, including human T-cell leukemia virus type 1 (HTLV-1) 34, 35 and hepatitis type C virus (HCV).", [["cell", "ANATOMY", 36, 40], ["cells", "ANATOMY", 89, 94], ["K", "CHEMICAL", 30, 31], ["human T-cell leukemia virus", "DISEASE", 140, 167], ["hepatitis type C", "DISEASE", 195, 211], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 25, 31], ["Akt", "GENE_OR_GENE_PRODUCT", 32, 35], ["cells", "CELL", 89, 94], ["human", "ORGANISM", 115, 120], ["human T-cell leukemia virus type 1", "ORGANISM", 140, 174], ["HTLV-1) 34, 35", "ORGANISM", 176, 190], ["hepatitis type C virus", "ORGANISM", 195, 217], ["HCV", "ORGANISM", 219, 222], ["Akt", "PROTEIN", 32, 35], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 140, 145], ["T-cell leukemia virus type 1", "SPECIES", 146, 174], ["HTLV-1", "SPECIES", 176, 182], ["hepatitis type C virus", "SPECIES", 195, 217], ["human", "SPECIES", 115, 120], ["human T-cell leukemia virus type 1", "SPECIES", 140, 174], ["HTLV-1", "SPECIES", 176, 182], ["hepatitis type C virus", "SPECIES", 195, 217], ["HCV", "SPECIES", 219, 222], ["the PI", "TEST", 21, 27], ["Akt cell survival signaling pathway", "PROBLEM", 32, 67], ["several human viruses", "PROBLEM", 107, 128], ["human T-cell leukemia virus type", "PROBLEM", 140, 172], ["HTLV", "TEST", 176, 180], ["hepatitis type C virus (HCV)", "PROBLEM", 195, 223], ["several", "OBSERVATION_MODIFIER", 107, 114], ["human viruses", "OBSERVATION", 115, 128], ["cell leukemia", "OBSERVATION", 148, 161]]], ["36 For example, the expression of HTLV-1 Tax protein activates this survival pathway in infected cells and this event is required for its transformation activity.", [["cells", "ANATOMY", 97, 102], ["HTLV-1", "ORGANISM", 34, 40], ["Tax", "GENE_OR_GENE_PRODUCT", 41, 44], ["cells", "CELL", 97, 102], ["HTLV-1 Tax protein", "PROTEIN", 34, 52], ["infected cells", "CELL_TYPE", 88, 102], ["HTLV-1", "SPECIES", 34, 40], ["HTLV", "TEST", 34, 38], ["infected cells", "PROBLEM", 88, 102], ["its transformation activity", "PROBLEM", 134, 161], ["infected cells", "OBSERVATION", 88, 102]]], ["34 In the case of HCV, the activation of the PI-3-K/Akt pathway in HCVinfected Huh7 hepatoma cells was suggested to be involved in establishing and maintaining the latency of the virus and long-term cellular survival.", [["Huh7 hepatoma cells", "ANATOMY", 79, 98], ["cellular", "ANATOMY", 199, 207], ["HCV", "ORGANISM", 18, 21], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 45, 51], ["Akt", "GENE_OR_GENE_PRODUCT", 52, 55], ["HCVinfected Huh7 hepatoma cells", "CELL", 67, 98], ["cellular", "CELL", 199, 207], ["PI-3-K", "PROTEIN", 45, 51], ["Akt", "PROTEIN", 52, 55], ["HCVinfected Huh7 hepatoma cells", "CELL_LINE", 67, 98], ["HCV", "SPECIES", 18, 21], ["HCV", "PROBLEM", 18, 21], ["the PI", "TEST", 41, 47], ["K/Akt pathway", "TEST", 50, 63], ["HCVinfected Huh7 hepatoma cells", "PROBLEM", 67, 98], ["the virus", "PROBLEM", 175, 184], ["long-term cellular survival", "TREATMENT", 189, 216], ["HCV", "OBSERVATION", 18, 21]]], ["31 Here, we report a new biological activity of intracellular Tat that renders microglia resistant to apoptotic challenge.", [["intracellular", "ANATOMY", 48, 61], ["microglia", "ANATOMY", 79, 88], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 61], ["Tat", "GENE_OR_GENE_PRODUCT", 62, 65], ["microglia", "CELL", 79, 88], ["intracellular Tat", "PROTEIN", 48, 65], ["microglia", "CELL_TYPE", 79, 88], ["intracellular Tat", "PROBLEM", 48, 65], ["apoptotic challenge", "TREATMENT", 102, 121]]], ["We have established a human fetal microglial cell line model system to understand the cellular mechanism of the cytoprotective effect induced by expression of HIV-1 Tat.", [["fetal microglial cell line", "ANATOMY", 28, 54], ["cellular", "ANATOMY", 86, 94], ["human", "ORGANISM", 22, 27], ["fetal microglial cell line", "CELL", 28, 54], ["cellular", "CELL", 86, 94], ["HIV-1", "ORGANISM", 159, 164], ["Tat", "GENE_OR_GENE_PRODUCT", 165, 168], ["human fetal microglial cell line model", "CELL_LINE", 22, 60], ["HIV-1 Tat", "PROTEIN", 159, 168], ["human", "SPECIES", 22, 27], ["HIV-1", "SPECIES", 159, 164], ["human", "SPECIES", 22, 27], ["HIV-1", "SPECIES", 159, 164], ["a human fetal microglial cell line model system", "TREATMENT", 20, 67], ["HIV", "PROBLEM", 159, 162], ["microglial cell line", "OBSERVATION", 34, 54]]], ["Indeed, our data demonstrate that the pro-survival effect of intracellular Tat protein is mediated by the activation of the cellular proliferation pathway and the PI-3-K/Akt pathway.", [["intracellular", "ANATOMY", 61, 74], ["cellular", "ANATOMY", 124, 132], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["Tat", "GENE_OR_GENE_PRODUCT", 75, 78], ["cellular", "CELL", 124, 132], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 163, 169], ["Akt", "GENE_OR_GENE_PRODUCT", 170, 173], ["Tat protein", "PROTEIN", 75, 86], ["PI-3-K", "PROTEIN", 163, 169], ["Akt", "PROTEIN", 170, 173], ["Tat protein", "TEST", 75, 86], ["the PI", "TEST", 159, 165], ["cellular proliferation", "OBSERVATION", 124, 146]]], ["This effect of HIV-1 Tat is consistent with the recent finding that infected microglia in HIV-1 patients display prolonged survival, and it suggests a previously unrecognized role for HIV-1 Tat in the establishment and maintenance of HIV-1 infected microglia as a long-lived viral reservoir within the CNS.ResultsA human fetal microglia cell line, CHME5, transduced with HIV-1 vector displays enhanced survival Limited access of primary human microglia has been a major obstacle in studying the molecular and cellular mechanisms involved in the cell fate change of microglia induced by HIV-1 infection.", [["microglia", "ANATOMY", 77, 86], ["microglia", "ANATOMY", 249, 258], ["CNS", "ANATOMY", 302, 305], ["fetal microglia cell line", "ANATOMY", 321, 346], ["CHME5", "ANATOMY", 348, 353], ["microglia", "ANATOMY", 443, 452], ["cellular", "ANATOMY", 509, 517], ["cell", "ANATOMY", 545, 549], ["microglia", "ANATOMY", 565, 574], ["HIV-1 infection", "DISEASE", 586, 601], ["HIV-1", "ORGANISM", 15, 20], ["Tat", "ORGANISM", 21, 24], ["microglia", "CELL", 77, 86], ["HIV-1", "ORGANISM", 90, 95], ["patients", "ORGANISM", 96, 104], ["HIV-1", "ORGANISM", 184, 189], ["Tat", "GENE_OR_GENE_PRODUCT", 190, 193], ["HIV-1", "ORGANISM", 234, 239], ["microglia", "CELL", 249, 258], ["CNS", "ANATOMICAL_SYSTEM", 302, 305], ["human", "ORGANISM", 315, 320], ["fetal microglia cell line", "CELL", 321, 346], ["CHME5", "CELL", 348, 353], ["HIV-1", "ORGANISM", 371, 376], ["human", "ORGANISM", 437, 442], ["microglia", "CELL", 443, 452], ["cellular", "CELL", 509, 517], ["cell", "CELL", 545, 549], ["microglia", "CELL", 565, 574], ["HIV-1", "ORGANISM", 586, 591], ["HIV-1 Tat", "PROTEIN", 15, 24], ["microglia", "CELL_TYPE", 77, 86], ["Tat", "PROTEIN", 190, 193], ["microglia", "CELL_TYPE", 249, 258], ["human fetal microglia cell line", "CELL_LINE", 315, 346], ["CHME5", "CELL_LINE", 348, 353], ["primary human microglia", "CELL_TYPE", 429, 452], ["microglia", "CELL_TYPE", 565, 574], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 90, 95], ["patients", "SPECIES", 96, 104], ["HIV-1", "SPECIES", 234, 239], ["human", "SPECIES", 315, 320], ["HIV-1", "SPECIES", 371, 376], ["human", "SPECIES", 437, 442], ["HIV-1", "SPECIES", 586, 591], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 90, 95], ["HIV-1", "SPECIES", 184, 189], ["HIV-1", "SPECIES", 234, 239], ["human", "SPECIES", 315, 320], ["HIV-1", "SPECIES", 371, 376], ["human", "SPECIES", 437, 442], ["HIV-1", "SPECIES", 586, 591], ["HIV", "PROBLEM", 15, 18], ["prolonged survival", "PROBLEM", 113, 131], ["HIV", "PROBLEM", 184, 187], ["HIV-1 infected microglia", "PROBLEM", 234, 258], ["a long-lived viral reservoir", "TREATMENT", 262, 290], ["CHME5", "TEST", 348, 353], ["HIV", "TEST", 371, 374], ["primary human microglia", "PROBLEM", 429, 452], ["HIV-1 infection", "PROBLEM", 586, 601], ["consistent with", "UNCERTAINTY", 28, 43], ["infected", "OBSERVATION_MODIFIER", 68, 76], ["microglia", "OBSERVATION", 77, 86], ["HIV", "OBSERVATION", 234, 237], ["infected microglia", "OBSERVATION", 240, 258], ["viral reservoir", "OBSERVATION", 275, 290], ["CNS", "ANATOMY", 302, 305], ["microglia cell line", "OBSERVATION", 327, 346], ["primary human microglia", "OBSERVATION", 429, 452], ["cellular mechanisms", "OBSERVATION", 509, 528], ["cell fate change", "OBSERVATION", 545, 561], ["microglia", "OBSERVATION", 565, 574], ["infection", "OBSERVATION", 592, 601]]], ["In this study, we tested whether the human fetal microglial cell line, CHME5, displays the extended survival of microglia following HIV-1 infection as previously observed in an ex vivo setting with HIV-1 infected patient samples.", [["fetal microglial cell line", "ANATOMY", 43, 69], ["CHME5", "ANATOMY", 71, 76], ["microglia", "ANATOMY", 112, 121], ["samples", "ANATOMY", 221, 228], ["HIV-1 infection", "DISEASE", 132, 147], ["HIV-1 infected", "DISEASE", 198, 212], ["human", "ORGANISM", 37, 42], ["fetal microglial cell line", "CELL", 43, 69], ["CHME5", "CELL", 71, 76], ["microglia", "CELL", 112, 121], ["HIV-1", "ORGANISM", 132, 137], ["HIV-1", "ORGANISM", 198, 203], ["patient", "ORGANISM", 213, 220], ["human fetal microglial cell line", "CELL_LINE", 37, 69], ["CHME5", "CELL_LINE", 71, 76], ["microglia", "CELL_TYPE", 112, 121], ["human", "SPECIES", 37, 42], ["HIV-1", "SPECIES", 132, 137], ["HIV-1", "SPECIES", 198, 203], ["patient", "SPECIES", 213, 220], ["human", "SPECIES", 37, 42], ["HIV-1", "SPECIES", 132, 137], ["HIV-1", "SPECIES", 198, 203], ["this study", "TEST", 3, 13], ["the human fetal microglial cell line", "TREATMENT", 33, 69], ["HIV-1 infection", "PROBLEM", 132, 147], ["HIV", "PROBLEM", 198, 201], ["microglial cell line", "OBSERVATION", 49, 69]]], ["23 First, we attempted to validate the CHME5 cell line as a target cell type of M-tropic HIV-1 by examining whether CHME5 cells can support the replication of an M-tropic HIV-1 strain, YU-2, which was cloned from HIV-1 infected human brain tissue.", [["CHME5 cell line", "ANATOMY", 39, 54], ["cell", "ANATOMY", 67, 71], ["CHME5 cells", "ANATOMY", 116, 127], ["brain tissue", "ANATOMY", 234, 246], ["CHME5 cell line", "CELL", 39, 54], ["cell", "CELL", 67, 71], ["M-tropic HIV-1", "ORGANISM", 80, 94], ["CHME5 cells", "CELL", 116, 127], ["M-tropic HIV-1", "ORGANISM", 162, 176], ["strain", "ORGANISM", 177, 183], ["YU-2", "CELL", 185, 189], ["HIV-1", "ORGANISM", 213, 218], ["human", "ORGANISM", 228, 233], ["brain tissue", "TISSUE", 234, 246], ["CHME5 cell line", "CELL_LINE", 39, 54], ["CHME5 cells", "CELL_LINE", 116, 127], ["HIV-1", "SPECIES", 89, 94], ["HIV-1", "SPECIES", 171, 176], ["HIV-1", "SPECIES", 213, 218], ["human", "SPECIES", 228, 233], ["HIV-1", "SPECIES", 89, 94], ["HIV-1", "SPECIES", 171, 176], ["HIV-1", "SPECIES", 213, 218], ["human", "SPECIES", 228, 233], ["the CHME5 cell line", "TREATMENT", 35, 54], ["M-tropic HIV", "PROBLEM", 80, 92], ["CHME5 cells", "PROBLEM", 116, 127], ["an M-tropic HIV", "PROBLEM", 159, 174], ["HIV", "PROBLEM", 213, 216], ["infected human brain tissue", "PROBLEM", 219, 246], ["cell line", "OBSERVATION", 45, 54], ["target cell", "OBSERVATION", 60, 71], ["infected human brain tissue", "OBSERVATION", 219, 246]]], ["37 As shown in Figure 1 , the CHME5 cells were able to produce and amplify M-tropic virus during serial viral passages, and the efficiency of the HIV-1 production in this cell line was similar with that in primary human peripheral blood mononuclear cells (PBMCs).", [["CHME5 cells", "ANATOMY", 30, 41], ["cell line", "ANATOMY", 171, 180], ["peripheral blood mononuclear cells", "ANATOMY", 220, 254], ["PBMCs", "ANATOMY", 256, 261], ["CHME5 cells", "CELL", 30, 41], ["M-tropic virus", "ORGANISM", 75, 89], ["HIV-1", "ORGANISM", 146, 151], ["cell line", "CELL", 171, 180], ["human", "ORGANISM", 214, 219], ["peripheral blood mononuclear cells", "CELL", 220, 254], ["PBMCs", "CELL", 256, 261], ["CHME5 cells", "CELL_LINE", 30, 41], ["primary human peripheral blood mononuclear cells", "CELL_TYPE", 206, 254], ["PBMCs", "CELL_TYPE", 256, 261], ["HIV-1", "SPECIES", 146, 151], ["human", "SPECIES", 214, 219], ["HIV-1", "SPECIES", 146, 151], ["human", "SPECIES", 214, 219], ["the CHME5 cells", "PROBLEM", 26, 41], ["amplify M-tropic virus", "PROBLEM", 67, 89], ["serial viral passages", "TEST", 97, 118], ["the HIV", "PROBLEM", 142, 149], ["this cell line", "TREATMENT", 166, 180], ["viral passages", "OBSERVATION", 104, 118], ["cell line", "OBSERVATION", 171, 180], ["mononuclear cells", "OBSERVATION", 237, 254]]], ["M-tropic HIV-1 replicates efficiently in the CHME5 microglial cell line.", [["CHME5 microglial cell line", "ANATOMY", 45, 71], ["HIV-1", "ORGANISM", 9, 14], ["CHME5 microglial cell line", "CELL", 45, 71], ["CHME5 microglial cell line", "CELL_LINE", 45, 71], ["HIV-1", "SPECIES", 9, 14], ["HIV-1", "SPECIES", 9, 14], ["tropic HIV", "PROBLEM", 2, 12], ["the CHME5 microglial cell line", "TREATMENT", 41, 71], ["microglial cell line", "OBSERVATION", 51, 71]]], ["A total of 1 \u00d7 10 6 CHME5 cells and human PBMCs were infected with M-tropic YU2 HIV-1 (2.5 \u00d7 10 5 pg of p24) and cultured for 12 days.", [["CHME5 cells", "ANATOMY", 20, 31], ["PBMCs", "ANATOMY", 42, 47], ["CHME5 cells", "CELL", 20, 31], ["human", "ORGANISM", 36, 41], ["PBMCs", "CELL", 42, 47], ["YU2 HIV-1", "ORGANISM", 76, 85], ["CHME5 cells", "CELL_LINE", 20, 31], ["human PBMCs", "CELL_TYPE", 36, 47], ["p24", "PROTEIN", 104, 107], ["human", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 80, 85], ["human", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 80, 85], ["1 \u00d7 10 6 CHME5 cells", "TREATMENT", 11, 31], ["human PBMCs", "TREATMENT", 36, 47], ["M-tropic YU2 HIV", "TREATMENT", 67, 83]]], ["As a control, T tropic NL4-3 HIV-1 (2.5 \u00d7 10 6 pg of p24) was also inoculated in the CHME5 cells.", [["CHME5 cells", "ANATOMY", 85, 96], ["T tropic NL4-3 HIV-1", "ORGANISM", 14, 34], ["p24", "GENE_OR_GENE_PRODUCT", 53, 56], ["CHME5 cells", "CELL", 85, 96], ["p24", "PROTEIN", 53, 56], ["CHME5 cells", "CELL_LINE", 85, 96], ["HIV-1", "SPECIES", 29, 34], ["HIV-1", "SPECIES", 29, 34], ["T tropic NL4", "TEST", 14, 26], ["HIV", "TEST", 29, 32], ["p24", "TEST", 53, 56]]], ["Viral supernatants were collected at 3, 6, 9 and 12 days post-infection and the p24 level in each viral sample was measured as described in Experimental Procedures .", [["supernatants", "ANATOMY", 6, 18], ["sample", "ANATOMY", 104, 110], ["Viral", "ORGANISM", 0, 5], ["p24", "GENE_OR_GENE_PRODUCT", 80, 83], ["p24", "PROTEIN", 80, 83], ["Viral supernatants", "TEST", 0, 18], ["the p24 level", "TEST", 76, 89], ["each viral sample", "TEST", 93, 110]]], ["The SD value of the p24 level in each time point was within 5%. the CHME5 cells could not support the replication of a T-tropic HIV-1 strain, NL4-3, which is known to replicate in CD4+ T cells but not in macrophages and microglia.", [["CHME5 cells", "ANATOMY", 68, 79], ["CD4+", "ANATOMY", 180, 184], ["T cells", "ANATOMY", 185, 192], ["macrophages", "ANATOMY", 204, 215], ["microglia", "ANATOMY", 220, 229], ["p24", "GENE_OR_GENE_PRODUCT", 20, 23], ["CHME5 cells", "CELL", 68, 79], ["T-tropic HIV-1", "ORGANISM", 119, 133], ["strain", "ORGANISM", 134, 140], ["NL4-3", "CELL", 142, 147], ["CD4", "GENE_OR_GENE_PRODUCT", 180, 183], ["T cells", "CELL", 185, 192], ["macrophages", "CELL", 204, 215], ["microglia", "CELL", 220, 229], ["p24", "PROTEIN", 20, 23], ["CHME5 cells", "CELL_LINE", 68, 79], ["CD4", "PROTEIN", 180, 183], ["T cells", "CELL_TYPE", 185, 192], ["macrophages", "CELL_TYPE", 204, 215], ["microglia", "CELL_TYPE", 220, 229], ["T-tropic HIV-1", "SPECIES", 119, 133], ["HIV-1", "SPECIES", 128, 133], ["The SD value", "TEST", 0, 12], ["the p24 level", "TEST", 16, 29], ["the CHME5 cells", "PROBLEM", 64, 79], ["a T-tropic HIV", "TEST", 117, 131], ["T cells", "PROBLEM", 185, 192], ["macrophages", "PROBLEM", 204, 215], ["microglia", "PROBLEM", 220, 229], ["not in", "UNCERTAINTY", 197, 203], ["macrophages", "OBSERVATION", 204, 215], ["microglia", "ANATOMY", 220, 229]]], ["Indeed, the data shown in Figure 1 validate CHME5 cells as an M-tropic HIV-1 target cell.ResultsNext, we analyzed the survival capability of HIV-1 infected CHME5 cells in response to cellular insults.", [["CHME5 cells", "ANATOMY", 44, 55], ["cell", "ANATOMY", 84, 88], ["CHME5 cells", "ANATOMY", 156, 167], ["cellular", "ANATOMY", 183, 191], ["CHME5 cells", "CELL", 44, 55], ["HIV-1", "ORGANISM", 71, 76], ["cell", "CELL", 84, 88], ["HIV-1", "ORGANISM", 141, 146], ["CHME5 cells", "CELL", 156, 167], ["cellular", "CELL", 183, 191], ["CHME5 cells", "CELL_LINE", 44, 55], ["CHME5 cells", "CELL_LINE", 156, 167], ["HIV-1", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 141, 146], ["HIV-1", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 141, 146], ["the data", "TEST", 8, 16], ["an M-tropic HIV", "TEST", 59, 74], ["HIV", "PROBLEM", 141, 144], ["1 infected CHME5 cells", "PROBLEM", 145, 167], ["cellular insults", "PROBLEM", 183, 199], ["cellular insults", "OBSERVATION", 183, 199]]], ["In order to visualize the infected CHME5 cells, we initially employed an HIV-1 pseudotyped vector expressing green fluorescent protein (GFP) as well as all HIV-1 proteins except Env and Nef.", [["CHME5 cells", "ANATOMY", 35, 46], ["CHME5 cells", "CELL", 35, 46], ["HIV-1 pseudotyped", "ORGANISM", 73, 90], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 109, 134], ["GFP", "GENE_OR_GENE_PRODUCT", 136, 139], ["HIV-1", "ORGANISM", 156, 161], ["Env", "GENE_OR_GENE_PRODUCT", 178, 181], ["CHME5 cells", "CELL_LINE", 35, 46], ["green fluorescent protein", "PROTEIN", 109, 134], ["GFP", "PROTEIN", 136, 139], ["HIV-1 proteins", "PROTEIN", 156, 170], ["Env", "PROTEIN", 178, 181], ["Nef.", "PROTEIN", 186, 190], ["HIV-1 pseudotyped", "SPECIES", 73, 90], ["HIV-1", "SPECIES", 156, 161], ["HIV-1", "SPECIES", 73, 78], ["HIV-1", "SPECIES", 156, 161], ["the infected CHME5 cells", "PROBLEM", 22, 46], ["an HIV", "TEST", 70, 76], ["green fluorescent protein (GFP", "PROBLEM", 109, 139], ["all HIV", "TEST", 152, 159], ["infected", "OBSERVATION", 26, 34]]], ["38 For a control, we used an HIV-1 transfer plasmid, pHR'-GFP, expressing eGFP under the control of the cytomegalovirus (CMV) promoter.", [["HIV-1", "ORGANISM", 29, 34], ["pHR'-GFP", "GENE_OR_GENE_PRODUCT", 53, 61], ["eGFP", "GENE_OR_GENE_PRODUCT", 74, 78], ["cytomegalovirus", "ORGANISM", 104, 119], ["CMV", "ORGANISM", 121, 124], ["HIV-1 transfer plasmid", "DNA", 29, 51], ["pHR", "DNA", 53, 56], ["GFP", "DNA", 58, 61], ["eGFP", "DNA", 74, 78], ["cytomegalovirus (CMV) promoter", "DNA", 104, 134], ["HIV-1", "SPECIES", 29, 34], ["HIV-1", "SPECIES", 29, 34], ["CMV", "SPECIES", 121, 124], ["an HIV-1 transfer plasmid", "TREATMENT", 26, 51], ["pHR'-GFP", "TREATMENT", 53, 61], ["the cytomegalovirus (CMV) promoter", "TREATMENT", 100, 134]]], ["Unlike the HIV-1 vector system, this plasmid does not express any HIV-1 proteins, since it contains only the viral LTR and packaging site.", [["plasmid", "ANATOMY", 37, 44], ["LTR", "ANATOMY", 115, 118], ["HIV-1", "ORGANISM", 11, 16], ["HIV-1", "ORGANISM", 66, 71], ["LTR", "CELLULAR_COMPONENT", 115, 118], ["HIV-1 proteins", "PROTEIN", 66, 80], ["viral LTR", "DNA", 109, 118], ["packaging site", "DNA", 123, 137], ["HIV-1", "SPECIES", 11, 16], ["HIV-1", "SPECIES", 66, 71], ["HIV-1", "SPECIES", 11, 16], ["HIV-1", "SPECIES", 66, 71], ["the viral LTR", "TREATMENT", 105, 118], ["HIV", "OBSERVATION", 11, 14], ["viral LTR", "OBSERVATION", 109, 118], ["packaging site", "OBSERVATION", 123, 137]]], ["39 CHME5 cells were either transfected with the plasmid pHR'-GFP or transduced with the eGFP expressing HIV-1 vector (HIV-GFP) at a multiplicity of infection (MOI) of 1.", [["CHME5 cells", "ANATOMY", 3, 14], ["plasmid", "ANATOMY", 48, 55], ["infection", "DISEASE", 148, 157], ["CHME5 cells", "CELL", 3, 14], ["pHR'-GFP", "GENE_OR_GENE_PRODUCT", 56, 64], ["eGFP", "GENE_OR_GENE_PRODUCT", 88, 92], ["HIV-1", "ORGANISM", 104, 109], ["HIV-GFP", "ORGANISM", 118, 125], ["CHME5 cells", "CELL_LINE", 3, 14], ["plasmid pHR'-GFP", "DNA", 48, 64], ["eGFP expressing HIV-1 vector", "DNA", 88, 116], ["HIV-1", "SPECIES", 104, 109], ["HIV-1", "SPECIES", 104, 109], ["HIV", "SPECIES", 118, 121], ["CHME5 cells", "TREATMENT", 3, 14], ["the plasmid pHR", "TEST", 44, 59], ["the eGFP", "TEST", 84, 92], ["HIV", "TEST", 104, 107], ["infection", "PROBLEM", 148, 157], ["infection", "OBSERVATION", 148, 157]]], ["Then 48 h later, cells were treated with lipopolysaccharide (LPS) to induce cell death.", [["cells", "ANATOMY", 17, 22], ["cell", "ANATOMY", 76, 80], ["lipopolysaccharide", "CHEMICAL", 41, 59], ["LPS", "CHEMICAL", 61, 64], ["death", "DISEASE", 81, 86], ["cells", "CELL", 17, 22], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 41, 59], ["LPS", "SIMPLE_CHEMICAL", 61, 64], ["cell", "CELL", 76, 80], ["lipopolysaccharide (LPS", "TREATMENT", 41, 64], ["cell death", "PROBLEM", 76, 86], ["cell death", "OBSERVATION", 76, 86]]], ["Since it has been reported that LPS-induced cell death in macrophage and microglia requires blockade of protein synthesis, 40 the cells were also treated with cycloheximide (CHX;10 \u03bcg/ml).", [["cell", "ANATOMY", 44, 48], ["macrophage", "ANATOMY", 58, 68], ["microglia", "ANATOMY", 73, 82], ["cells", "ANATOMY", 130, 135], ["LPS", "CHEMICAL", 32, 35], ["death", "DISEASE", 49, 54], ["cycloheximide", "CHEMICAL", 159, 172], ["CHX", "CHEMICAL", 174, 177], ["cycloheximide", "CHEMICAL", 159, 172], ["CHX", "CHEMICAL", 174, 177], ["LPS", "SIMPLE_CHEMICAL", 32, 35], ["cell", "CELL", 44, 48], ["macrophage", "CELL", 58, 68], ["microglia", "CELL", 73, 82], ["cells", "CELL", 130, 135], ["cycloheximide", "SIMPLE_CHEMICAL", 159, 172], ["CHX", "SIMPLE_CHEMICAL", 174, 177], ["macrophage", "CELL_TYPE", 58, 68], ["microglia", "CELL_TYPE", 73, 82], ["LPS", "TEST", 32, 35], ["cell death in macrophage", "PROBLEM", 44, 68], ["blockade of protein synthesis", "TREATMENT", 92, 121], ["cycloheximide (CHX", "TREATMENT", 159, 177], ["cell death", "OBSERVATION", 44, 54], ["macrophage", "OBSERVATION_MODIFIER", 58, 68]]], ["Cells were then analyzed by the cytotoxicity/viability assay, which uses a combination of intracellular esterase activity (a characteristic of live cells, green) and binding of the ethidium homodimer to DNA (a marker for dead cells, red).", [["Cells", "ANATOMY", 0, 5], ["intracellular", "ANATOMY", 90, 103], ["cells", "ANATOMY", 148, 153], ["cells", "ANATOMY", 226, 231], ["ethidium", "CHEMICAL", 181, 189], ["ethidium", "CHEMICAL", 181, 189], ["Cells", "CELL", 0, 5], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 103], ["cells", "CELL", 148, 153], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["cells", "CELL", 226, 231], ["intracellular esterase", "PROTEIN", 90, 112], ["live cells", "CELL_TYPE", 143, 153], ["ethidium homodimer", "PROTEIN", 181, 199], ["dead cells", "CELL_TYPE", 221, 231], ["Cells", "TEST", 0, 5], ["the cytotoxicity/viability assay", "TEST", 28, 60], ["intracellular esterase activity", "TREATMENT", 90, 121], ["live cells", "PROBLEM", 143, 153], ["the ethidium homodimer", "TREATMENT", 177, 199], ["dead cells", "PROBLEM", 221, 231], ["esterase activity", "OBSERVATION", 104, 121]]], ["Following HIV-1 vector transduction or lipofectamine-mediated plasmid transfection (for pHR'GFP), approximately 75% of the cells expressed GFP (green).", [["plasmid", "ANATOMY", 62, 69], ["cells", "ANATOMY", 123, 128], ["lipofectamine", "CHEMICAL", 39, 52], ["HIV-1", "ORGANISM", 10, 15], ["lipofectamine", "SIMPLE_CHEMICAL", 39, 52], ["pHR'GFP", "GENE_OR_GENE_PRODUCT", 88, 95], ["cells", "CELL", 123, 128], ["GFP", "GENE_OR_GENE_PRODUCT", 139, 142], ["lipofectamine-mediated plasmid", "DNA", 39, 69], ["GFP", "PROTEIN", 139, 142], ["HIV-1", "SPECIES", 10, 15], ["HIV-1", "SPECIES", 10, 15], ["HIV-1 vector transduction", "TREATMENT", 10, 35], ["lipofectamine-mediated plasmid transfection", "TREATMENT", 39, 82], ["pHR'GFP", "TEST", 88, 95]]], ["As shown in Figure 2 (a), CHME5 cells that were either transfected with the GFP expressing plasmid (pHR'-GFP) or transduced with the HIV-1 GFP vector (HIV-GFP), did not undergo cell death in the absence of LPS/CHX (as shown by the lack of red or yellow cells in the merged fields).", [["CHME5 cells", "ANATOMY", 26, 37], ["plasmid", "ANATOMY", 91, 98], ["cell", "ANATOMY", 177, 181], ["yellow cells", "ANATOMY", 246, 258], ["death", "DISEASE", 182, 187], ["LPS", "CHEMICAL", 206, 209], ["CHX", "CHEMICAL", 210, 213], ["CHX", "CHEMICAL", 210, 213], ["CHME5 cells", "CELL", 26, 37], ["GFP", "GENE_OR_GENE_PRODUCT", 76, 79], ["pHR'-GFP", "GENE_OR_GENE_PRODUCT", 100, 108], ["HIV-1", "ORGANISM", 133, 138], ["GFP", "GENE_OR_GENE_PRODUCT", 139, 142], ["HIV-GFP", "ORGANISM", 151, 158], ["cell", "CELL", 177, 181], ["LPS", "SIMPLE_CHEMICAL", 206, 209], ["CHX", "SIMPLE_CHEMICAL", 210, 213], ["cells", "CELL", 253, 258], ["CHME5 cells", "CELL_LINE", 26, 37], ["GFP expressing plasmid", "DNA", 76, 98], ["pHR", "DNA", 100, 103], ["GFP", "DNA", 105, 108], ["HIV-1 GFP vector", "DNA", 133, 149], ["red or yellow cells", "CELL_TYPE", 239, 258], ["HIV-1", "SPECIES", 133, 138], ["HIV-1", "SPECIES", 133, 138], ["HIV", "SPECIES", 151, 154], ["CHME5 cells", "PROBLEM", 26, 37], ["the GFP", "TEST", 72, 79], ["the HIV", "TEST", 129, 136], ["cell death", "PROBLEM", 177, 187], ["LPS/CHX", "PROBLEM", 206, 213], ["red or yellow cells", "PROBLEM", 239, 258]]], ["However, when cells transfected with pHR'GFP were treated with LPS/CHX, extensive cell death was induced (as shown by the red/yellow staining in the merged fields).", [["cells", "ANATOMY", 14, 19], ["cell", "ANATOMY", 82, 86], ["LPS", "CHEMICAL", 63, 66], ["CHX", "CHEMICAL", 67, 70], ["death", "DISEASE", 87, 92], ["CHX", "CHEMICAL", 67, 70], ["cells", "CELL", 14, 19], ["pHR", "GENE_OR_GENE_PRODUCT", 37, 40], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["LPS", "SIMPLE_CHEMICAL", 63, 66], ["CHX", "SIMPLE_CHEMICAL", 67, 70], ["cell", "CELL", 82, 86], ["pHR'GFP", "DNA", 37, 44], ["pHR'GFP", "TREATMENT", 37, 44], ["LPS/CHX", "TREATMENT", 63, 70], ["extensive cell death", "PROBLEM", 72, 92], ["the red/yellow staining", "PROBLEM", 118, 141], ["extensive", "OBSERVATION_MODIFIER", 72, 81], ["cell death", "OBSERVATION", 82, 92]]], ["In contrast, CHME5 cells transduced with pseudotyped HIV-1 (HIV-GFP) remained viable (no yellow staining in merged field) following treatment with LPS/CHX.", [["CHME5 cells", "ANATOMY", 13, 24], ["LPS", "CHEMICAL", 147, 150], ["CHX", "CHEMICAL", 151, 154], ["CHX", "CHEMICAL", 151, 154], ["CHME5 cells", "CELL", 13, 24], ["pseudotyped HIV-1", "ORGANISM", 41, 58], ["HIV-GFP", "ORGANISM", 60, 67], ["LPS", "SIMPLE_CHEMICAL", 147, 150], ["CHX", "SIMPLE_CHEMICAL", 151, 154], ["CHME5 cells", "CELL_LINE", 13, 24], ["HIV-1", "SPECIES", 53, 58], ["HIV", "SPECIES", 60, 63], ["HIV-1", "SPECIES", 53, 58], ["HIV", "SPECIES", 60, 63], ["CHME5 cells", "TEST", 13, 24], ["pseudotyped HIV", "TEST", 41, 56], ["HIV-GFP", "TEST", 60, 67], ["yellow staining", "PROBLEM", 89, 104], ["LPS/CHX", "TREATMENT", 147, 154]]], ["Under these conditions, only the adjacent, untransduced cells lacking HIV-GFP expression underwent cell death (Figure 2(a) ).", [["cells", "ANATOMY", 56, 61], ["cell", "ANATOMY", 99, 103], ["death", "DISEASE", 104, 109], ["cells", "CELL", 56, 61], ["HIV", "ORGANISM", 70, 73], ["GFP", "GENE_OR_GENE_PRODUCT", 74, 77], ["cell", "CELL", 99, 103], ["untransduced cells", "CELL_LINE", 43, 61], ["GFP", "PROTEIN", 74, 77], ["HIV", "SPECIES", 70, 73], ["the adjacent, untransduced cells", "PROBLEM", 29, 61], ["cell death", "PROBLEM", 99, 109]]], ["These data demonstrate that the HIV-1 vector transduced CHME5 cells, which express HIV-1 Gag, Pol, Tat, Rev, Vpr and Vif, have an extended survival phenotype.ResultsNext, we quantitated the extent of cell death in vector-transduced cultures following LPS/CHX treatment.", [["CHME5 cells", "ANATOMY", 56, 67], ["cell", "ANATOMY", 200, 204], ["cultures", "ANATOMY", 232, 240], ["death", "DISEASE", 205, 210], ["LPS", "CHEMICAL", 251, 254], ["CHX", "CHEMICAL", 255, 258], ["CHX", "CHEMICAL", 255, 258], ["HIV-1", "ORGANISM", 32, 37], ["CHME5 cells", "CELL", 56, 67], ["HIV-1 Gag", "ORGANISM", 83, 92], ["Pol", "GENE_OR_GENE_PRODUCT", 94, 97], ["Tat", "GENE_OR_GENE_PRODUCT", 99, 102], ["Rev", "GENE_OR_GENE_PRODUCT", 104, 107], ["Vpr", "GENE_OR_GENE_PRODUCT", 109, 112], ["Vif", "GENE_OR_GENE_PRODUCT", 117, 120], ["cell", "CELL", 200, 204], ["cultures", "CELL", 232, 240], ["LPS", "SIMPLE_CHEMICAL", 251, 254], ["CHX", "SIMPLE_CHEMICAL", 255, 258], ["CHME5 cells", "CELL_LINE", 56, 67], ["Pol", "PROTEIN", 94, 97], ["Tat", "PROTEIN", 99, 102], ["Rev", "PROTEIN", 104, 107], ["Vpr", "PROTEIN", 109, 112], ["Vif", "PROTEIN", 117, 120], ["vector-transduced cultures", "CELL_LINE", 214, 240], ["HIV-1", "SPECIES", 32, 37], ["HIV-1", "SPECIES", 83, 88], ["HIV-1", "SPECIES", 32, 37], ["HIV-1", "SPECIES", 83, 88], ["These data", "TEST", 0, 10], ["the HIV", "TEST", 28, 35], ["HIV", "TEST", 83, 86], ["Tat", "TEST", 99, 102], ["an extended survival phenotype", "PROBLEM", 127, 157], ["cell death", "PROBLEM", 200, 210], ["transduced cultures", "TEST", 221, 240], ["LPS/CHX treatment", "TREATMENT", 251, 268], ["survival phenotype", "OBSERVATION", 139, 157], ["cell death", "OBSERVATION", 200, 210]]], ["CHME5 cells were transduced, resulting in greater than 95% transduction (as determined by GFP expression), then treated and analyzed for viability.", [["CHME5 cells", "ANATOMY", 0, 11], ["CHME5 cells", "CELL", 0, 11], ["GFP", "GENE_OR_GENE_PRODUCT", 90, 93], ["CHME5 cells", "CELL_LINE", 0, 11], ["GFP", "PROTEIN", 90, 93], ["viability", "PROBLEM", 137, 146], ["greater", "OBSERVATION_MODIFIER", 42, 49]]], ["The cultures were then treated with LPS/ CHX at 48 h post-transduction.", [["cultures", "ANATOMY", 4, 12], ["LPS", "CHEMICAL", 36, 39], ["CHX", "CHEMICAL", 41, 44], ["CHX", "CHEMICAL", 41, 44], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["CHX", "SIMPLE_CHEMICAL", 41, 44], ["The cultures", "TEST", 0, 12], ["LPS/ CHX", "TREATMENT", 36, 44]]], ["The number of viable cells was quantitated by trypan blue exclusion assay at 24 and 96 h post-treatment.", [["cells", "ANATOMY", 21, 26], ["trypan blue", "CHEMICAL", 46, 57], ["trypan blue", "CHEMICAL", 46, 57], ["cells", "CELL", 21, 26], ["viable cells", "PROBLEM", 14, 26], ["treatment", "TREATMENT", 94, 103], ["viable cells", "OBSERVATION", 14, 26]]], ["As shown in Figure 2 (b), the control CHME5 cells (incubated with heat-inactivated HIV GFP vector) showed significant cell death upon LPS/CHX treatment, whereas the CHME5 cells transduced with the HIV-1 vector (HIV-GFP) displayed greatly increased survival under similar conditions.", [["CHME5 cells", "ANATOMY", 38, 49], ["cell", "ANATOMY", 118, 122], ["CHME5 cells", "ANATOMY", 165, 176], ["death", "DISEASE", 123, 128], ["LPS", "CHEMICAL", 134, 137], ["CHX", "CHEMICAL", 138, 141], ["CHX", "CHEMICAL", 138, 141], ["CHME5 cells", "CELL", 38, 49], ["HIV", "ORGANISM", 83, 86], ["GFP", "GENE_OR_GENE_PRODUCT", 87, 90], ["cell", "CELL", 118, 122], ["LPS", "SIMPLE_CHEMICAL", 134, 137], ["CHX", "SIMPLE_CHEMICAL", 138, 141], ["CHME5 cells", "CELL", 165, 176], ["HIV-1", "ORGANISM", 197, 202], ["HIV-GFP", "ORGANISM", 211, 218], ["CHME5 cells", "CELL_LINE", 38, 49], ["CHME5 cells", "CELL_LINE", 165, 176], ["HIV-1 vector", "DNA", 197, 209], ["HIV-1", "SPECIES", 197, 202], ["HIV", "SPECIES", 83, 86], ["HIV-1", "SPECIES", 197, 202], ["HIV", "SPECIES", 211, 214], ["the control CHME5 cells", "TREATMENT", 26, 49], ["heat", "TEST", 66, 70], ["significant cell death", "PROBLEM", 106, 128], ["LPS/CHX treatment", "TREATMENT", 134, 151], ["the CHME5 cells", "TEST", 161, 176], ["the HIV", "TEST", 193, 200], ["greatly increased survival", "PROBLEM", 230, 256], ["significant cell death", "OBSERVATION", 106, 128], ["increased", "OBSERVATION_MODIFIER", 238, 247], ["survival", "OBSERVATION", 248, 256]]], ["Further quantification of the amount of cell death induced in CHME5 cells also confirmed that transduced cells (HIV-GFP vector) exhibited much less cell death (<4%) as compared with cells incubated with heatinactivated vector (\u223c25%).", [["cell", "ANATOMY", 40, 44], ["CHME5 cells", "ANATOMY", 62, 73], ["cells", "ANATOMY", 105, 110], ["cell", "ANATOMY", 148, 152], ["cells", "ANATOMY", 182, 187], ["death", "DISEASE", 45, 50], ["death", "DISEASE", 153, 158], ["cell", "CELL", 40, 44], ["CHME5 cells", "CELL", 62, 73], ["cells", "CELL", 105, 110], ["HIV-GFP", "ORGANISM", 112, 119], ["cell", "CELL", 148, 152], ["cells", "CELL", 182, 187], ["CHME5 cells", "CELL_LINE", 62, 73], ["transduced cells", "CELL_LINE", 94, 110], ["HIV", "SPECIES", 112, 115], ["cell death", "PROBLEM", 40, 50], ["CHME5 cells", "PROBLEM", 62, 73], ["transduced cells", "PROBLEM", 94, 110], ["HIV", "TEST", 112, 115], ["much less cell death", "PROBLEM", 138, 158], ["heatinactivated vector", "TREATMENT", 203, 225], ["amount", "OBSERVATION_MODIFIER", 30, 36], ["cell death", "OBSERVATION", 40, 50], ["transduced cells", "OBSERVATION", 94, 110], ["less cell", "OBSERVATION_MODIFIER", 143, 152]]], ["Importantly, as expected, we also found that the CHME5 cells infected with infectious M-tropic HIV-1 also showed the elevated survival capability as observed in the CHME5 cells transduced with the HIV-GFP vector (data not shown).ResultsThese data demonstrate that HIV-1 infection in the microglial cell line induces a strong cytoprotective effect upon apoptotic challenge.", [["CHME5 cells", "ANATOMY", 49, 60], ["CHME5 cells", "ANATOMY", 165, 176], ["microglial cell line", "ANATOMY", 287, 307], ["HIV-1 infection", "DISEASE", 264, 279], ["CHME5 cells", "CELL", 49, 60], ["M-tropic HIV-1", "ORGANISM", 86, 100], ["CHME5 cells", "CELL", 165, 176], ["GFP", "GENE_OR_GENE_PRODUCT", 201, 204], ["HIV-1", "ORGANISM", 264, 269], ["microglial cell line", "CELL", 287, 307], ["CHME5 cells", "CELL_LINE", 49, 60], ["CHME5 cells", "CELL_LINE", 165, 176], ["HIV-GFP vector", "DNA", 197, 211], ["microglial cell line", "CELL_LINE", 287, 307], ["HIV-1", "SPECIES", 95, 100], ["HIV-1", "SPECIES", 264, 269], ["HIV-1", "SPECIES", 95, 100], ["HIV", "SPECIES", 197, 200], ["HIV-1", "SPECIES", 264, 269], ["the CHME5 cells", "PROBLEM", 45, 60], ["infectious M-tropic HIV", "TEST", 75, 98], ["the elevated survival capability", "PROBLEM", 113, 145], ["the HIV", "TEST", 193, 200], ["These data", "TEST", 236, 246], ["HIV", "PROBLEM", 264, 267], ["1 infection", "PROBLEM", 268, 279], ["the microglial cell line", "TREATMENT", 283, 307], ["apoptotic challenge", "TREATMENT", 352, 371], ["infectious", "OBSERVATION_MODIFIER", 75, 85], ["elevated", "OBSERVATION_MODIFIER", 117, 125], ["survival capability", "OBSERVATION", 126, 145], ["infection", "OBSERVATION", 270, 279], ["microglial cell line", "OBSERVATION", 287, 307], ["strong", "OBSERVATION_MODIFIER", 318, 324], ["cytoprotective effect", "OBSERVATION", 325, 346]]], ["Basically, due to difficulties and limited access in studying primary human microglia, the CHME5 system can serve as a model system, allowing us to investigate the cellular mechanism involved in the pro-survival effect of HIV-1 infection in primary human microglia.HIV-1 Tat promotes survival of the microglial cell lineFirst, using the CHME5 model system, we attempted to identify the HIV-1 protein(s) responsible for the cytoprotective effect of HIV-1 infection.", [["microglia", "ANATOMY", 76, 85], ["cellular", "ANATOMY", 164, 172], ["microglia", "ANATOMY", 255, 264], ["microglial cell", "ANATOMY", 300, 315], ["infection", "DISEASE", 228, 237], ["HIV-1 infection", "DISEASE", 448, 463], ["human", "ORGANISM", 70, 75], ["microglia", "CELL", 76, 85], ["CHME5", "GENE_OR_GENE_PRODUCT", 91, 96], ["cellular", "CELL", 164, 172], ["HIV-1", "ORGANISM", 222, 227], ["human", "ORGANISM", 249, 254], ["microglia", "CELL", 255, 264], ["HIV-1", "ORGANISM", 265, 270], ["Tat", "ORGANISM", 271, 274], ["microglial cell lineFirst", "CELL", 300, 325], ["CHME5", "GENE_OR_GENE_PRODUCT", 337, 342], ["HIV-1", "ORGANISM", 386, 391], ["HIV-1", "ORGANISM", 448, 453], ["primary human microglia", "CELL_TYPE", 62, 85], ["CHME5", "PROTEIN", 91, 96], ["primary human microglia", "CELL_TYPE", 241, 264], ["HIV-1 Tat", "PROTEIN", 265, 274], ["microglial cell lineFirst", "CELL_LINE", 300, 325], ["HIV-1 protein", "PROTEIN", 386, 399], ["human", "SPECIES", 70, 75], ["HIV-1", "SPECIES", 222, 227], ["human", "SPECIES", 249, 254], ["HIV-1", "SPECIES", 265, 270], ["HIV-1", "SPECIES", 386, 391], ["HIV-1", "SPECIES", 448, 453], ["human", "SPECIES", 70, 75], ["HIV-1", "SPECIES", 222, 227], ["human", "SPECIES", 249, 254], ["HIV-1", "SPECIES", 265, 270], ["HIV-1", "SPECIES", 386, 391], ["HIV-1", "SPECIES", 448, 453], ["HIV-1 infection in primary human microglia", "PROBLEM", 222, 264], ["HIV", "PROBLEM", 265, 268], ["the HIV", "TEST", 382, 389], ["HIV", "PROBLEM", 448, 451], ["1 infection", "PROBLEM", 452, 463], ["infection", "OBSERVATION", 228, 237], ["primary human microglia", "OBSERVATION", 241, 264], ["microglial cell", "OBSERVATION", 300, 315], ["HIV", "OBSERVATION", 448, 451], ["infection", "OBSERVATION", 454, 463]]], ["Although the HIV-1 vector used in Figures 1 and 2 expresses multiple viral proteins, we reasoned that the expressed viral accessory proteins (Tat, Vpr, Vif or Vpu) might contribute to microglial protection.", [["microglial", "ANATOMY", 184, 194], ["HIV-1", "ORGANISM", 13, 18], ["2", "GENE_OR_GENE_PRODUCT", 48, 49], ["Tat", "GENE_OR_GENE_PRODUCT", 142, 145], ["Vpr", "GENE_OR_GENE_PRODUCT", 147, 150], ["Vif", "GENE_OR_GENE_PRODUCT", 152, 155], ["Vpu", "GENE_OR_GENE_PRODUCT", 159, 162], ["microglial", "CELL", 184, 194], ["HIV-1 vector", "DNA", 13, 25], ["viral proteins", "PROTEIN", 69, 83], ["viral accessory proteins", "PROTEIN", 116, 140], ["Tat", "PROTEIN", 142, 145], ["Vpr", "PROTEIN", 147, 150], ["Vif", "PROTEIN", 152, 155], ["Vpu", "PROTEIN", 159, 162], ["HIV-1", "SPECIES", 13, 18], ["HIV-1", "SPECIES", 13, 18], ["the HIV", "TEST", 9, 16], ["multiple viral proteins", "PROBLEM", 60, 83], ["the expressed viral accessory proteins", "PROBLEM", 102, 140], ["Vpr, Vif", "TREATMENT", 147, 155], ["microglial protection", "TREATMENT", 184, 205], ["might contribute to", "UNCERTAINTY", 164, 183], ["microglial protection", "OBSERVATION", 184, 205]]], ["In particular, we sought to determine whether the expression of Tat protein, the HIV-1 transcriptional activator, plays a role in the survival of microglia.", [["microglia", "ANATOMY", 146, 155], ["Tat", "GENE_OR_GENE_PRODUCT", 64, 67], ["HIV-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["microglia", "CELL", 146, 155], ["Tat protein", "PROTEIN", 64, 75], ["HIV-1 transcriptional activator", "PROTEIN", 81, 112], ["microglia", "CELL_TYPE", 146, 155], ["HIV-1", "SPECIES", 81, 86], ["HIV-1", "SPECIES", 81, 86], ["Tat protein", "TEST", 64, 75], ["microglia", "PROBLEM", 146, 155], ["microglia", "ANATOMY", 146, 155]]], ["To test this, we developed stable sublines of the human microglial cell line CHME5 containing either an empty vector (pCDNA3.1-hygromycin; control) or a vector encoding the 101 amino acid long fulllength Tat (pTat101) previously cloned from the Mtropic YU-2 HIV-1 strain.", [["sublines", "ANATOMY", 34, 42], ["microglial cell line CHME5", "ANATOMY", 56, 82], ["pCDNA3.1-hygromycin", "CHEMICAL", 118, 137], ["amino acid", "CHEMICAL", 177, 187], ["hygromycin", "CHEMICAL", 127, 137], ["amino acid", "CHEMICAL", 177, 187], ["sublines", "CELL", 34, 42], ["human", "ORGANISM", 50, 55], ["microglial cell line CHME5", "CELL", 56, 82], ["Tat", "GENE_OR_GENE_PRODUCT", 204, 207], ["YU-2 HIV-1 strain", "ORGANISM", 253, 270], ["human microglial cell line CHME5", "CELL_LINE", 50, 82], ["101 amino acid long fulllength Tat", "PROTEIN", 173, 207], ["pTat101", "PROTEIN", 209, 216], ["human", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 258, 263], ["human", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 258, 263], ["the human microglial cell line CHME5", "TREATMENT", 46, 82], ["an empty vector (pCDNA3", "TREATMENT", 101, 124], ["hygromycin", "TREATMENT", 127, 137], ["a vector", "TREATMENT", 151, 159], ["stable", "OBSERVATION_MODIFIER", 27, 33], ["sublines", "OBSERVATION", 34, 42], ["microglial cell line", "OBSERVATION", 56, 76]]], ["The clonally selected sublines were analyzed for the presence of the Tat gene by performing PCR amplification of genomic DNA and functionally for the activation of the HIV LTR using the Magi assay (data not shown).", [["sublines", "ANATOMY", 22, 30], ["LTR", "ANATOMY", 172, 175], ["sublines", "CELL", 22, 30], ["Tat", "GENE_OR_GENE_PRODUCT", 69, 72], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["HIV", "ORGANISM", 168, 171], ["LTR", "CELLULAR_COMPONENT", 172, 175], ["Tat gene", "DNA", 69, 77], ["genomic DNA", "DNA", 113, 124], ["HIV LTR", "DNA", 168, 175], ["HIV", "SPECIES", 168, 171], ["HIV", "SPECIES", 168, 171], ["The clonally selected sublines", "TREATMENT", 0, 30], ["the Tat gene", "TREATMENT", 65, 77], ["genomic DNA", "PROBLEM", 113, 124], ["the HIV LTR", "TREATMENT", 164, 175], ["the Magi assay", "TEST", 182, 196]]], ["In order to induce cell death in the CHME5 sublines, the cells were exposed to two different concentrations of LPS (10 \u03bcg and 100 \u03bcg/ml) and CHX (10 \u03bcg/ml) for 6 h and analyzed for viability as described above.", [["cell", "ANATOMY", 19, 23], ["CHME5 sublines", "ANATOMY", 37, 51], ["cells", "ANATOMY", 57, 62], ["death", "DISEASE", 24, 29], ["LPS", "CHEMICAL", 111, 114], ["CHX", "CHEMICAL", 141, 144], ["CHX", "CHEMICAL", 141, 144], ["cell", "CELL", 19, 23], ["CHME5 sublines", "CELL", 37, 51], ["cells", "CELL", 57, 62], ["LPS", "SIMPLE_CHEMICAL", 111, 114], ["CHX", "SIMPLE_CHEMICAL", 141, 144], ["CHME5 sublines", "CELL_LINE", 37, 51], ["cell death", "PROBLEM", 19, 29], ["the CHME5 sublines", "TREATMENT", 33, 51], ["the cells", "TREATMENT", 53, 62], ["LPS", "TREATMENT", 111, 114], ["CHX", "TREATMENT", 141, 144]]], ["As shown in Figure 3 (a), the treatment of LPS at 10 \u03bcg and 100 \u03bcg/ml, together with CHX, induced 20% and 34.5% cell death, respectively, in the control CHME5 subline (pCDNA3.1), as determined by the trypan blue exclusion assay.", [["cell", "ANATOMY", 112, 116], ["CHME5 subline", "ANATOMY", 153, 166], ["LPS", "CHEMICAL", 43, 46], ["CHX", "CHEMICAL", 85, 88], ["death", "DISEASE", 117, 122], ["trypan blue", "CHEMICAL", 200, 211], ["CHX", "CHEMICAL", 85, 88], ["trypan blue", "CHEMICAL", 200, 211], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["CHX", "SIMPLE_CHEMICAL", 85, 88], ["cell", "CELL", 112, 116], ["CHME5 subline", "CELL", 153, 166], ["pCDNA3.1", "CELL", 168, 176], ["CHME5 subline", "CELL_LINE", 153, 166], ["pCDNA3.1", "CELL_LINE", 168, 176], ["the treatment of LPS", "TREATMENT", 26, 46], ["CHX", "TREATMENT", 85, 88], ["the control CHME5 subline", "TREATMENT", 141, 166]]], ["In contrast, CHME5 cells expressing Tat displayed only 2-3% cell death at both concentrations of LPS (Figure 3(a) ).", [["CHME5 cells", "ANATOMY", 13, 24], ["cell", "ANATOMY", 60, 64], ["death", "DISEASE", 65, 70], ["LPS", "CHEMICAL", 97, 100], ["CHME5 cells", "CELL", 13, 24], ["Tat", "GENE_OR_GENE_PRODUCT", 36, 39], ["cell", "CELL", 60, 64], ["LPS", "SIMPLE_CHEMICAL", 97, 100], ["CHME5 cells", "CELL_LINE", 13, 24], ["Tat", "PROTEIN", 36, 39], ["Tat", "TEST", 36, 39], ["3% cell death", "PROBLEM", 57, 70], ["LPS", "TEST", 97, 100]]], ["In these assays, CHX treatment alone failed to induce cell death in the CHME5 sublines.", [["cell", "ANATOMY", 54, 58], ["CHME5 sublines", "ANATOMY", 72, 86], ["CHX", "CHEMICAL", 17, 20], ["death", "DISEASE", 59, 64], ["CHX", "CHEMICAL", 17, 20], ["CHX", "SIMPLE_CHEMICAL", 17, 20], ["cell", "CELL", 54, 58], ["CHME5 sublines", "CELL", 72, 86], ["CHME5 sublines", "CELL_LINE", 72, 86], ["CHX treatment", "TREATMENT", 17, 30], ["cell death", "PROBLEM", 54, 64]]], ["Next, cellular viability was examined by performing the cytotoxicity assay ( Figure 3(b) ).", [["cellular", "ANATOMY", 6, 14], ["cellular", "CELL", 6, 14], ["cellular viability", "TEST", 6, 24], ["the cytotoxicity assay", "TEST", 52, 74], ["cellular viability", "OBSERVATION", 6, 24]]], ["The results confirmed the viable cell counts and revealed that cells expressing either Tat (pTat101) or the control plasmid (pCDNA3.1) remained viable (green) in the absence of LPS/CHX treatment.", [["cell", "ANATOMY", 33, 37], ["cells", "ANATOMY", 63, 68], ["plasmid", "ANATOMY", 116, 123], ["LPS", "CHEMICAL", 177, 180], ["CHX", "CHEMICAL", 181, 184], ["CHX", "CHEMICAL", 181, 184], ["cell", "CELL", 33, 37], ["cells", "CELL", 63, 68], ["Tat", "GENE_OR_GENE_PRODUCT", 87, 90], ["pTat101", "GENE_OR_GENE_PRODUCT", 92, 99], ["pCDNA3", "GENE_OR_GENE_PRODUCT", 125, 131], ["LPS", "SIMPLE_CHEMICAL", 177, 180], ["CHX", "SIMPLE_CHEMICAL", 181, 184], ["Tat", "PROTEIN", 87, 90], ["pTat101", "PROTEIN", 92, 99], ["control plasmid", "DNA", 108, 123], ["pCDNA3", "DNA", 125, 131], ["the viable cell counts", "TEST", 22, 44], ["Tat", "TEST", 87, 90], ["the control plasmid (pCDNA3", "TREATMENT", 104, 131], ["LPS/CHX treatment", "TREATMENT", 177, 194], ["viable", "OBSERVATION_MODIFIER", 144, 150]]], ["However, upon treatment, control cells (but not Tat-expressing cells) underwent extensive cell death (as shown by extensive red staining) and .", [["cells", "ANATOMY", 33, 38], ["cells", "ANATOMY", 63, 68], ["cell", "ANATOMY", 90, 94], ["death", "DISEASE", 95, 100], ["cells", "CELL", 33, 38], ["Tat", "GENE_OR_GENE_PRODUCT", 48, 51], ["cells", "CELL", 63, 68], ["cell", "CELL", 90, 94], ["control cells", "CELL_TYPE", 25, 38], ["Tat", "PROTEIN", 48, 51], ["expressing cells", "CELL_TYPE", 52, 68], ["treatment", "TREATMENT", 14, 23], ["control cells", "PROBLEM", 25, 38], ["extensive cell death", "PROBLEM", 80, 100], ["extensive red staining", "PROBLEM", 114, 136], ["cell death", "OBSERVATION", 90, 100]]], ["Treatments with LPS and CHX (both at 10 \u03bcg/ml) and the cytotoxicity assay were then performed as described using only the cell death-specific ethidium homodimer stain (red).", [["cell", "ANATOMY", 122, 126], ["LPS", "CHEMICAL", 16, 19], ["CHX", "CHEMICAL", 24, 27], ["ethidium", "CHEMICAL", 142, 150], ["CHX", "CHEMICAL", 24, 27], ["ethidium", "CHEMICAL", 142, 150], ["LPS", "SIMPLE_CHEMICAL", 16, 19], ["CHX", "SIMPLE_CHEMICAL", 24, 27], ["cell", "CELL", 122, 126], ["LPS", "TREATMENT", 16, 19], ["CHX", "TREATMENT", 24, 27], ["the cytotoxicity assay", "TEST", 51, 73], ["the cell death", "TEST", 118, 132], ["specific ethidium homodimer stain", "TEST", 133, 166]]], ["Representative bright fields (BF) and merged fields (green + red) are shown.", [["bright", "OBSERVATION_MODIFIER", 15, 21], ["fields", "OBSERVATION_MODIFIER", 22, 28]]], ["Green cells represent cells expressing GFP while red cells represent dead cells. (b) CHME-5 cells (1 \u00d7 10 5 ) were transduced with HIV-GFP (MOI 1) or incubated with heat-inactivated vector and then treated with LPS/ CHX (at the same concentration as above) for a total of 96 h.", [["Green cells", "ANATOMY", 0, 11], ["cells", "ANATOMY", 22, 27], ["red cells", "ANATOMY", 49, 58], ["cells", "ANATOMY", 74, 79], ["CHME-5 cells", "ANATOMY", 85, 97], ["LPS", "CHEMICAL", 211, 214], ["CHX", "CHEMICAL", 216, 219], ["CHX", "CHEMICAL", 216, 219], ["Green cells", "CELL", 0, 11], ["cells", "CELL", 22, 27], ["GFP", "GENE_OR_GENE_PRODUCT", 39, 42], ["red cells", "CELL", 49, 58], ["cells", "CELL", 74, 79], ["CHME-5 cells", "CELL", 85, 97], ["HIV-GFP", "ORGANISM", 131, 138], ["LPS", "SIMPLE_CHEMICAL", 211, 214], ["CHX", "SIMPLE_CHEMICAL", 216, 219], ["Green cells", "CELL_TYPE", 0, 11], ["GFP", "PROTEIN", 39, 42], ["red cells", "CELL_TYPE", 49, 58], ["dead cells", "CELL_TYPE", 69, 79], ["CHME-5 cells", "CELL_LINE", 85, 97], ["HIV", "SPECIES", 131, 134], ["HIV", "SPECIES", 131, 134], ["red cells", "TEST", 49, 58], ["dead cells", "PROBLEM", 69, 79], ["(b) CHME-5 cells", "TEST", 81, 97], ["HIV", "TEST", 131, 134], ["heat-inactivated vector", "TREATMENT", 165, 188], ["LPS/ CHX", "TREATMENT", 211, 219], ["red cells", "OBSERVATION", 49, 58], ["dead cells", "OBSERVATION", 69, 79]]], ["Cell viability (shown as a percentage of cell death) was measured at 0 h (blue), 24 h (pink) and 96 h (yellow) using the trypan blue exclusion assay.", [["Cell", "ANATOMY", 0, 4], ["cell", "ANATOMY", 41, 45], ["trypan blue", "CHEMICAL", 121, 132], ["trypan blue", "CHEMICAL", 121, 132], ["Cell", "CELL", 0, 4], ["cell", "CELL", 41, 45], ["Cell viability", "TEST", 0, 14], ["cell death", "PROBLEM", 41, 51], ["the trypan blue exclusion assay", "TEST", 117, 148]]], ["The mean percentages cell death \u00b1 SEM induced in the CHME5 cell line following LPS/CHX treatment are summarized below.", [["cell", "ANATOMY", 21, 25], ["CHME5 cell line", "ANATOMY", 53, 68], ["death", "DISEASE", 26, 31], ["LPS", "CHEMICAL", 79, 82], ["CHX", "CHEMICAL", 83, 86], ["CHX", "CHEMICAL", 83, 86], ["cell", "CELL", 21, 25], ["CHME5 cell line", "CELL", 53, 68], ["LPS", "SIMPLE_CHEMICAL", 79, 82], ["CHX", "SIMPLE_CHEMICAL", 83, 86], ["CHME5 cell line", "CELL_LINE", 53, 68], ["The mean percentages cell death", "TEST", 0, 31], ["the CHME5 cell line", "TREATMENT", 49, 68], ["LPS/CHX treatment", "TREATMENT", 79, 96], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["percentages cell death", "OBSERVATION", 9, 31], ["cell line", "OBSERVATION", 59, 68]]], ["Experiments were performed in triplicate. loss of viability (as reflected by the loss of the green esterase staining).", [["green esterase", "GENE_OR_GENE_PRODUCT", 93, 107], ["green esterase", "PROTEIN", 93, 107], ["loss of viability", "PROBLEM", 42, 59], ["the loss of the green esterase staining", "PROBLEM", 77, 116], ["viability", "OBSERVATION_MODIFIER", 50, 59]]], ["Importantly, we tested a total of three independent clonal Tat expressing CHME5 sublines, and we observed that these three CHME5 sublines displayed similar elevated survival comparable to the subline data presented in Figure 3 .", [["CHME5 sublines", "ANATOMY", 74, 88], ["CHME5 sublines", "ANATOMY", 123, 137], ["Tat", "GENE_OR_GENE_PRODUCT", 59, 62], ["CHME5 sublines", "CELL", 74, 88], ["CHME5 sublines", "CELL", 123, 137], ["Tat", "PROTEIN", 59, 62], ["CHME5 sublines", "CELL_LINE", 74, 88], ["CHME5 sublines", "CELL_LINE", 123, 137], ["similar elevated survival", "PROBLEM", 148, 173], ["the subline data", "TEST", 188, 204]]], ["Together, these results indicate that the intracellular expression of Tat may promote the survival of CHME5 microglial cells upon apoptotic challenge.HIV-1 Tat promotes survival of the microglial cell lineSince Tat can be actively secreted by cells, it remained possible that the ability of Tat-expressing cells to survive in LPS-containing media might be due to the signaling effects triggered by secreted/ extracellular Tat protein.", [["intracellular", "ANATOMY", 42, 55], ["CHME5 microglial cells", "ANATOMY", 102, 124], ["microglial cell", "ANATOMY", 185, 200], ["cells", "ANATOMY", 243, 248], ["cells", "ANATOMY", 306, 311], ["extracellular", "ANATOMY", 408, 421], ["LPS", "CHEMICAL", 326, 329], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 55], ["Tat", "GENE_OR_GENE_PRODUCT", 70, 73], ["CHME5 microglial cells", "CELL", 102, 124], ["HIV-1", "ORGANISM", 150, 155], ["Tat", "ORGANISM", 156, 159], ["microglial cell", "CELL", 185, 200], ["Tat", "GENE_OR_GENE_PRODUCT", 211, 214], ["cells", "CELL", 243, 248], ["Tat", "GENE_OR_GENE_PRODUCT", 291, 294], ["cells", "CELL", 306, 311], ["LPS", "SIMPLE_CHEMICAL", 326, 329], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 408, 421], ["Tat", "GENE_OR_GENE_PRODUCT", 422, 425], ["Tat", "PROTEIN", 70, 73], ["CHME5 microglial cells", "CELL_LINE", 102, 124], ["HIV-1 Tat", "PROTEIN", 150, 159], ["Tat", "PROTEIN", 211, 214], ["Tat", "PROTEIN", 291, 294], ["expressing cells", "CELL_TYPE", 295, 311], ["extracellular Tat protein", "PROTEIN", 408, 433], ["HIV-1", "SPECIES", 150, 155], ["HIV-1", "SPECIES", 150, 155], ["CHME5 microglial cells", "TREATMENT", 102, 124], ["apoptotic challenge", "TREATMENT", 130, 149], ["HIV", "PROBLEM", 150, 153], ["the microglial cell lineSince Tat", "TREATMENT", 181, 214], ["Tat-expressing cells", "TREATMENT", 291, 311], ["media", "TREATMENT", 341, 346], ["the signaling effects", "PROBLEM", 363, 384], ["secreted/ extracellular Tat protein", "TREATMENT", 398, 433], ["microglial cells", "OBSERVATION", 108, 124], ["microglial cell", "OBSERVATION", 185, 200]]], ["To exclude this possibility, we treated CHME5 cells with full-length recombinant Tat protein (0.2 \u03bcM, Xeptagen), and then with CHX and LPS (at 10 and 100 \u03bcg/ml) for 24 h and observed that extracellular Tat protein was unable to protect CHME5 cells from cell death (data not shown).", [["CHME5 cells", "ANATOMY", 40, 51], ["extracellular", "ANATOMY", 188, 201], ["CHME5 cells", "ANATOMY", 236, 247], ["cell", "ANATOMY", 253, 257], ["CHX", "CHEMICAL", 127, 130], ["LPS", "CHEMICAL", 135, 138], ["death", "DISEASE", 258, 263], ["CHX", "CHEMICAL", 127, 130], ["CHME5 cells", "CELL", 40, 51], ["Tat", "GENE_OR_GENE_PRODUCT", 81, 84], ["Xeptagen", "SIMPLE_CHEMICAL", 102, 110], ["CHX", "SIMPLE_CHEMICAL", 127, 130], ["LPS", "SIMPLE_CHEMICAL", 135, 138], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 201], ["Tat", "GENE_OR_GENE_PRODUCT", 202, 205], ["CHME5 cells", "CELL", 236, 247], ["cell", "CELL", 253, 257], ["CHME5 cells", "CELL_LINE", 40, 51], ["full-length recombinant Tat protein", "PROTEIN", 57, 92], ["extracellular Tat protein", "PROTEIN", 188, 213], ["CHME5 cells", "CELL_LINE", 236, 247], ["CHME5 cells", "TREATMENT", 40, 51], ["full-length recombinant Tat protein", "TREATMENT", 57, 92], ["Xeptagen", "TREATMENT", 102, 110], ["CHX", "TREATMENT", 127, 130], ["LPS", "TREATMENT", 135, 138], ["extracellular Tat protein", "TEST", 188, 213], ["cell death", "TEST", 253, 263], ["exclude this possibility", "UNCERTAINTY", 3, 27]]], ["These findings suggested that intracellular expression of Tat is required to protect human microglial cells from apoptotic challenge.HIV-1 Tat promotes survival of the microglial cell lineRole of the PI-3-kinase/AKT pathway in mediating the cytoprotective effect of intracellular Tat in CHME5 cellsHIV-1 Tat promotes survival of the microglial cell lineIn order to investigate how intracellularly expressed Tat might protect microglial cells following apoptotic challenge, we tested whether the activation of the PI-3-K/Akt pathway is involved.", [["intracellular", "ANATOMY", 30, 43], ["microglial cells", "ANATOMY", 91, 107], ["microglial cell", "ANATOMY", 168, 183], ["intracellular", "ANATOMY", 266, 279], ["microglial cell line", "ANATOMY", 333, 353], ["microglial cells", "ANATOMY", 425, 441], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["Tat", "GENE_OR_GENE_PRODUCT", 58, 61], ["human", "ORGANISM", 85, 90], ["microglial cells", "CELL", 91, 107], ["HIV-1", "ORGANISM", 133, 138], ["Tat", "GENE_OR_GENE_PRODUCT", 139, 142], ["microglial cell", "CELL", 168, 183], ["PI-3-kinase", "GENE_OR_GENE_PRODUCT", 200, 211], ["AKT", "GENE_OR_GENE_PRODUCT", 212, 215], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 266, 279], ["CHME5 cellsHIV-1 Tat", "GENE_OR_GENE_PRODUCT", 287, 307], ["microglial cell line", "CELL", 333, 353], ["Tat", "GENE_OR_GENE_PRODUCT", 407, 410], ["microglial cells", "CELL", 425, 441], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 513, 519], ["Akt", "GENE_OR_GENE_PRODUCT", 520, 523], ["Tat", "PROTEIN", 58, 61], ["human microglial cells", "CELL_TYPE", 85, 107], ["HIV-1 Tat", "PROTEIN", 133, 142], ["PI-3-kinase", "PROTEIN", 200, 211], ["AKT", "PROTEIN", 212, 215], ["intracellular Tat", "PROTEIN", 266, 283], ["CHME5 cellsHIV-1 Tat", "PROTEIN", 287, 307], ["microglial cell line", "CELL_LINE", 333, 353], ["Tat", "PROTEIN", 407, 410], ["microglial cells", "CELL_TYPE", 425, 441], ["PI-3-K", "PROTEIN", 513, 519], ["Akt", "PROTEIN", 520, 523], ["human", "SPECIES", 85, 90], ["HIV-1", "SPECIES", 133, 138], ["human", "SPECIES", 85, 90], ["HIV-1", "SPECIES", 133, 138], ["CHME5 cellsHIV-1", "SPECIES", 287, 303], ["intracellular expression of Tat", "PROBLEM", 30, 61], ["human microglial cells", "PROBLEM", 85, 107], ["apoptotic challenge", "TREATMENT", 113, 132], ["HIV", "PROBLEM", 133, 136], ["the PI", "TEST", 196, 202], ["kinase/AKT pathway", "TREATMENT", 205, 223], ["intracellular Tat in CHME5 cellsHIV", "TREATMENT", 266, 301], ["the microglial cell line", "TREATMENT", 329, 353], ["apoptotic challenge", "TREATMENT", 452, 471], ["the PI", "TEST", 509, 515], ["microglial cells", "OBSERVATION", 91, 107], ["apoptotic challenge", "OBSERVATION", 113, 132], ["microglial cell", "OBSERVATION", 168, 183], ["microglial cell line", "OBSERVATION", 333, 353], ["microglial cells", "OBSERVATION", 425, 441]]], ["This assumption was based on the fact that the expression of Tat mediates activation of this pathway in Kaposi's sarcoma cells, thereby protecting cells from apoptosis.", [["Kaposi's sarcoma cells", "ANATOMY", 104, 126], ["cells", "ANATOMY", 147, 152], ["Kaposi's sarcoma", "DISEASE", 104, 120], ["Tat", "GENE_OR_GENE_PRODUCT", 61, 64], ["Kaposi's sarcoma cells", "CELL", 104, 126], ["cells", "CELL", 147, 152], ["Tat", "PROTEIN", 61, 64], ["Kaposi's sarcoma cells", "CELL_LINE", 104, 126], ["this pathway", "PROBLEM", 88, 100], ["Kaposi's sarcoma cells", "PROBLEM", 104, 126], ["apoptosis", "PROBLEM", 158, 167], ["Kaposi", "ANATOMY", 104, 110], ["sarcoma cells", "OBSERVATION", 113, 126], ["apoptosis", "OBSERVATION_MODIFIER", 158, 167]]], ["41 To test this possibility, we exposed CHME5 sublines (containing either pTat101 or empty vector, pCDNA3.1) to LPS and CHX (at 10 \u03bcg/ml each) for 6 h.", [["CHME5 sublines", "ANATOMY", 40, 54], ["LPS", "CHEMICAL", 112, 115], ["CHX", "CHEMICAL", 120, 123], ["CHX", "CHEMICAL", 120, 123], ["CHME5 sublines", "CELL", 40, 54], ["pCDNA3", "GENE_OR_GENE_PRODUCT", 99, 105], ["LPS", "SIMPLE_CHEMICAL", 112, 115], ["CHX", "SIMPLE_CHEMICAL", 120, 123], ["CHME5 sublines", "CELL_LINE", 40, 54], ["pTat101", "DNA", 74, 81], ["empty vector", "DNA", 85, 97], ["pCDNA3", "DNA", 99, 105], ["empty vector", "TREATMENT", 85, 97], ["pCDNA3", "TREATMENT", 99, 105], ["CHX", "TREATMENT", 120, 123]]], ["Prior to LPS treatment, cells were left alone or pretreated with the PI-3-K/Akt-specific pharmacologic inhibitors Wortmannin and LY294002 (at 100 nM and 50 \u03bcM, respectively).", [["cells", "ANATOMY", 24, 29], ["LPS", "CHEMICAL", 9, 12], ["K", "CHEMICAL", 74, 75], ["Wortmannin", "CHEMICAL", 114, 124], ["LY294002", "CHEMICAL", 129, 137], ["Wortmannin", "CHEMICAL", 114, 124], ["LY294002", "CHEMICAL", 129, 137], ["LPS", "SIMPLE_CHEMICAL", 9, 12], ["cells", "CELL", 24, 29], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 69, 75], ["Akt", "GENE_OR_GENE_PRODUCT", 76, 79], ["Wortmannin", "SIMPLE_CHEMICAL", 114, 124], ["LY294002", "SIMPLE_CHEMICAL", 129, 137], ["Akt", "PROTEIN", 76, 79], ["LPS treatment", "TREATMENT", 9, 22], ["cells", "TREATMENT", 24, 29], ["the PI", "TEST", 65, 71], ["K/Akt", "TREATMENT", 74, 79], ["pharmacologic inhibitors Wortmannin", "TREATMENT", 89, 124], ["LY294002", "TREATMENT", 129, 137]]], ["Following pretreatment and incubation with LPS and CHX, cell survival was analyzed by the trypan blue exclusion assay.", [["cell", "ANATOMY", 56, 60], ["LPS", "CHEMICAL", 43, 46], ["CHX", "CHEMICAL", 51, 54], ["trypan blue", "CHEMICAL", 90, 101], ["CHX", "CHEMICAL", 51, 54], ["trypan blue", "CHEMICAL", 90, 101], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["CHX", "SIMPLE_CHEMICAL", 51, 54], ["cell", "CELL", 56, 60], ["pretreatment", "TREATMENT", 10, 22], ["incubation", "TREATMENT", 27, 37], ["LPS", "TREATMENT", 43, 46], ["CHX", "TREATMENT", 51, 54], ["cell survival", "TREATMENT", 56, 69]]], ["As shown in Figure 4 , the Tat expressing CHME5 cells still exhibited the cytoprotective effect upon LPS/CHX treatment.", [["CHME5 cells", "ANATOMY", 42, 53], ["LPS", "CHEMICAL", 101, 104], ["CHX", "CHEMICAL", 105, 108], ["CHX", "CHEMICAL", 105, 108], ["Tat", "GENE_OR_GENE_PRODUCT", 27, 30], ["CHME5 cells", "CELL", 42, 53], ["LPS", "SIMPLE_CHEMICAL", 101, 104], ["CHX", "SIMPLE_CHEMICAL", 105, 108], ["Tat", "PROTEIN", 27, 30], ["CHME5 cells", "CELL_LINE", 42, 53], ["the Tat expressing CHME5 cells", "PROBLEM", 23, 53], ["LPS/CHX treatment", "TREATMENT", 101, 118]]], ["However, when the Tatexpressing microglial cells were pre-treated with PI-3-K/Akt inhibitors, they showed restricted survival similar to that seen in the control CHME5 cells (pcDNA3.1).", [["microglial cells", "ANATOMY", 32, 48], ["CHME5 cells", "ANATOMY", 162, 173], ["PI-3-K", "CHEMICAL", 71, 77], ["microglial cells", "CELL", 32, 48], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 71, 77], ["Akt", "GENE_OR_GENE_PRODUCT", 78, 81], ["CHME5 cells", "CELL", 162, 173], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 175, 181], ["Tatexpressing microglial cells", "CELL_LINE", 18, 48], ["Akt", "PROTEIN", 78, 81], ["CHME5 cells", "CELL_LINE", 162, 173], ["pcDNA3", "PROTEIN", 175, 181], ["the Tatexpressing microglial cells", "PROBLEM", 14, 48], ["PI", "TEST", 71, 73], ["K/Akt inhibitors", "TREATMENT", 76, 92], ["restricted survival", "PROBLEM", 106, 125]]], ["These data imply that the PI-3-K/Akt inhibitors abolished the protective effect of Tat.HIV-1 Tat promotes survival of the microglial cell lineNext, since pharmacologic agents may exert effects on additional cellular pathways, we sought to confirm these results through genetic approaches.", [["microglial cell line", "ANATOMY", 122, 142], ["cellular", "ANATOMY", 207, 215], ["PI-3-K", "CHEMICAL", 26, 32], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 26, 32], ["Akt", "GENE_OR_GENE_PRODUCT", 33, 36], ["Tat", "GENE_OR_GENE_PRODUCT", 83, 86], ["HIV-1", "ORGANISM", 87, 92], ["Tat", "ORGANISM", 93, 96], ["microglial cell lineNext", "CELL", 122, 146], ["cellular", "CELL", 207, 215], ["PI-3-K", "PROTEIN", 26, 32], ["Akt", "PROTEIN", 33, 36], ["Tat", "PROTEIN", 83, 86], ["HIV-1 Tat", "PROTEIN", 87, 96], ["microglial cell line", "CELL_LINE", 122, 142], ["HIV-1", "SPECIES", 87, 92], ["HIV-1", "SPECIES", 87, 92], ["the PI", "TEST", 22, 28], ["K/Akt inhibitors", "TREATMENT", 31, 47], ["HIV", "PROBLEM", 87, 90], ["the microglial cell line", "TREATMENT", 118, 142], ["pharmacologic agents", "TREATMENT", 154, 174], ["microglial cell line", "OBSERVATION", 122, 142]]], ["To achieve this, we expressed a dominant negative and those expressing HIV-1 Tat (grey bars, pTat101) were either left untreated, or treated with LPS (10 or 100 \u03bcg/ ml) plus 10 \u03bcg/ml of cycloheximide (CHX) or CHX alone for 6 h.", [["LPS", "CHEMICAL", 146, 149], ["cycloheximide", "CHEMICAL", 186, 199], ["CHX", "CHEMICAL", 201, 204], ["CHX", "CHEMICAL", 209, 212], ["cycloheximide", "CHEMICAL", 186, 199], ["CHX", "CHEMICAL", 201, 204], ["CHX", "CHEMICAL", 209, 212], ["HIV-1", "ORGANISM", 71, 76], ["Tat", "ORGANISM", 77, 80], ["grey bars", "ORGANISM", 82, 91], ["pTat101", "CELL", 93, 100], ["LPS", "SIMPLE_CHEMICAL", 146, 149], ["cycloheximide", "SIMPLE_CHEMICAL", 186, 199], ["CHX", "SIMPLE_CHEMICAL", 201, 204], ["CHX", "SIMPLE_CHEMICAL", 209, 212], ["HIV-1 Tat", "PROTEIN", 71, 80], ["pTat101", "PROTEIN", 93, 100], ["HIV-1", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 71, 76], ["HIV", "TEST", 71, 74], ["pTat", "TEST", 93, 97], ["LPS", "TREATMENT", 146, 149], ["cycloheximide (CHX", "TREATMENT", 186, 204], ["CHX", "TREATMENT", 209, 212], ["left", "ANATOMY_MODIFIER", 114, 118]]], ["The cells were harvested and viability was assessed by trypan blue exclusion (shown as a percentage of cell death).", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 103, 107], ["trypan blue", "CHEMICAL", 55, 66], ["death", "DISEASE", 108, 113], ["trypan blue", "CHEMICAL", 55, 66], ["cells", "CELL", 4, 9], ["trypan blue", "SIMPLE_CHEMICAL", 55, 66], ["cell", "CELL", 103, 107], ["trypan blue exclusion", "TEST", 55, 76], ["cell death", "PROBLEM", 103, 113], ["cell death", "OBSERVATION", 103, 113]]], ["The data represent the mean \u00b1 SEM derived from three independent experiments. (b) Representative results from the cytotoxicity assay.", [["The data", "TEST", 0, 8], ["the cytotoxicity assay", "TEST", 110, 132]]], ["Cells were treated with 10 \u03bcg/ml of LPS + CHX for 24 h before performing the cytotoxicity assay.", [["Cells", "ANATOMY", 0, 5], ["LPS", "CHEMICAL", 36, 39], ["CHX", "CHEMICAL", 42, 45], ["CHX", "CHEMICAL", 42, 45], ["Cells", "CELL", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["CHX", "SIMPLE_CHEMICAL", 42, 45], ["LPS", "TREATMENT", 36, 39], ["CHX", "TREATMENT", 42, 45], ["the cytotoxicity assay", "TEST", 73, 95]]], ["Live cells are represented by fluorescent green staining (intracellular esterase activity) while dead cells appear fluorescent red (ethidium homodimer binding).", [["Live cells", "ANATOMY", 0, 10], ["intracellular", "ANATOMY", 58, 71], ["cells", "ANATOMY", 102, 107], ["ethidium", "CHEMICAL", 132, 140], ["ethidium", "CHEMICAL", 132, 140], ["Live cells", "CELL", 0, 10], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 71], ["cells", "CELL", 102, 107], ["intracellular esterase", "PROTEIN", 58, 80], ["dead cells", "CELL_TYPE", 97, 107], ["fluorescent red", "PROTEIN", 115, 130], ["fluorescent green staining (intracellular esterase activity", "PROBLEM", 30, 89], ["dead cells", "PROBLEM", 97, 107], ["fluorescent red (ethidium homodimer binding", "PROBLEM", 115, 158]]], ["The fields shown represent merged images.", [["merged images", "TEST", 27, 40]]], ["Three independent CHME5 subline clones were tested in this study. mutant form of Akt in the CHME5 cells.", [["CHME5 subline clones", "ANATOMY", 18, 38], ["CHME5 cells", "ANATOMY", 92, 103], ["CHME5 subline clones", "CELL", 18, 38], ["Akt", "GENE_OR_GENE_PRODUCT", 81, 84], ["CHME5 cells", "CELL", 92, 103], ["CHME5 subline clones", "CELL_LINE", 18, 38], ["Akt", "PROTEIN", 81, 84], ["CHME5 cells", "CELL_LINE", 92, 103], ["Three independent CHME5 subline clones", "TREATMENT", 0, 38], ["this study", "TEST", 54, 64], ["Akt in the CHME5 cells", "PROBLEM", 81, 103], ["subline clones", "OBSERVATION", 24, 38], ["Akt", "OBSERVATION_MODIFIER", 81, 84]]], ["This mutant molecule (Akt K179A, referred to as dn-Akt) contains a substitution of lysine residue 179 with alanine, and functions as a dominant negative inhibitor of signal-mediated Akt activation.", [["lysine residue 179", "CHEMICAL", 83, 101], ["alanine", "CHEMICAL", 107, 114], ["lysine", "CHEMICAL", 83, 89], ["alanine", "CHEMICAL", 107, 114], ["Akt", "GENE_OR_GENE_PRODUCT", 22, 25], ["dn-Akt", "GENE_OR_GENE_PRODUCT", 48, 54], ["lysine residue 179", "AMINO_ACID", 83, 101], ["alanine", "AMINO_ACID", 107, 114], ["Akt", "GENE_OR_GENE_PRODUCT", 182, 185], ["mutant molecule", "PROTEIN", 5, 20], ["Akt K179A", "PROTEIN", 22, 31], ["dn", "PROTEIN", 48, 50], ["Akt", "PROTEIN", 51, 54], ["Akt", "PROTEIN", 182, 185], ["a substitution of lysine residue", "TREATMENT", 65, 97], ["alanine", "TEST", 107, 114], ["Akt activation", "OBSERVATION", 182, 196]]], ["41 In these experiments, CHME5 sublines (containing pTat101 or pCDNA3.1) were transiently transfected with an empty vector (representing endogenous Akt) or a vector encoding dn-Akt 24 h prior to treatment.", [["CHME5 sublines", "ANATOMY", 25, 39], ["CHME5 sublines", "CELL", 25, 39], ["pTat101", "GENE_OR_GENE_PRODUCT", 52, 59], ["pCDNA3", "GENE_OR_GENE_PRODUCT", 63, 69], ["Akt", "GENE_OR_GENE_PRODUCT", 148, 151], ["dn-Akt", "GENE_OR_GENE_PRODUCT", 174, 180], ["CHME5 sublines", "CELL_LINE", 25, 39], ["pTat101", "DNA", 52, 59], ["pCDNA3", "PROTEIN", 63, 69], ["empty vector", "DNA", 110, 122], ["Akt", "PROTEIN", 148, 151], ["dn", "DNA", 174, 176], ["Akt", "PROTEIN", 177, 180], ["CHME5 sublines", "TREATMENT", 25, 39], ["pTat", "TREATMENT", 52, 56], ["pCDNA3", "TREATMENT", 63, 69], ["an empty vector", "TREATMENT", 107, 122], ["treatment", "TREATMENT", 195, 204]]], ["Cells were then exposed to LPS and CHX (100 and 10 \u03bcg/ml, respectively) for 24 h and cellular viability was analyzed.", [["Cells", "ANATOMY", 0, 5], ["cellular", "ANATOMY", 85, 93], ["LPS", "CHEMICAL", 27, 30], ["CHX", "CHEMICAL", 35, 38], ["CHX", "CHEMICAL", 35, 38], ["Cells", "CELL", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 27, 30], ["CHX", "SIMPLE_CHEMICAL", 35, 38], ["cellular", "CELL", 85, 93], ["LPS", "TEST", 27, 30], ["CHX", "TREATMENT", 35, 38], ["cellular viability", "TEST", 85, 103]]], ["As expected, we found that transfection of K179A resulted in an increase in the amount of cell death induced following LPS/CHX treatment ( Figure 5 ).", [["cell", "ANATOMY", 90, 94], ["K179A", "CHEMICAL", 43, 48], ["death", "DISEASE", 95, 100], ["LPS", "CHEMICAL", 119, 122], ["CHX", "CHEMICAL", 123, 126], ["CHX", "CHEMICAL", 123, 126], ["K179A", "GENE_OR_GENE_PRODUCT", 43, 48], ["cell", "CELL", 90, 94], ["LPS", "SIMPLE_CHEMICAL", 119, 122], ["CHX", "SIMPLE_CHEMICAL", 123, 126], ["K179A", "PROTEIN", 43, 48], ["transfection of K179A", "PROBLEM", 27, 48], ["cell death", "PROBLEM", 90, 100], ["LPS/CHX treatment", "TREATMENT", 119, 136], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["amount", "OBSERVATION_MODIFIER", 80, 86], ["cell death", "OBSERVATION", 90, 100]]], ["Transient transfection of the Akt mutant did not seem to influence the survival of untreated cells.", [["cells", "ANATOMY", 93, 98], ["Akt", "GENE_OR_GENE_PRODUCT", 30, 33], ["cells", "CELL", 93, 98], ["Akt mutant", "PROTEIN", 30, 40], ["untreated cells", "CELL_TYPE", 83, 98], ["untreated cells", "PROBLEM", 83, 98], ["untreated cells", "OBSERVATION", 83, 98]]], ["This suggests that expression of dn-Akt was able to reverse the cytoprotective effect of Tat in CHME5 cells.", [["CHME5 cells", "ANATOMY", 96, 107], ["dn-Akt", "GENE_OR_GENE_PRODUCT", 33, 39], ["Tat", "GENE_OR_GENE_PRODUCT", 89, 92], ["CHME5 cells", "CELL", 96, 107], ["dn", "PROTEIN", 33, 35], ["Akt", "PROTEIN", 36, 39], ["Tat", "PROTEIN", 89, 92], ["CHME5 cells", "CELL_LINE", 96, 107], ["dn-Akt", "PROBLEM", 33, 39], ["Tat in CHME5 cells", "TREATMENT", 89, 107]]], ["The extent of susceptibility restored in the Tatexpressing cells reflects the transfection efficiency of the dominant negative Akt mutant (\u223c75% efficiency).", [["Tatexpressing cells", "ANATOMY", 45, 64], ["Tatexpressing cells", "CELL", 45, 64], ["Akt", "GENE_OR_GENE_PRODUCT", 127, 130], ["Tatexpressing cells", "CELL_LINE", 45, 64], ["dominant negative Akt mutant", "PROTEIN", 109, 137], ["susceptibility", "PROBLEM", 14, 28], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["susceptibility restored", "OBSERVATION", 14, 37], ["Tatexpressing cells", "OBSERVATION", 45, 64], ["transfection efficiency", "OBSERVATION", 78, 101], ["dominant", "OBSERVATION_MODIFIER", 109, 117], ["negative", "OBSERVATION_MODIFIER", 118, 126], ["Akt mutant", "OBSERVATION", 127, 137]]], ["Based on the results from the pharmacological ( Figure 4 ) and genetic ( Figure 5 ) interferences of the PI-3-K/Akt pathway, we concluded that the activation of the PI-3-K/Akt pathway by intracellular Tat might be required for Tat to promote microglial survival.Regulation of PTEN and cell proliferative signals by expression of HIV-1 TatPI3-kinase activity is negatively regulated by PTEN, which dephosphorylates PIP3 to PIP2.", [["intracellular", "ANATOMY", 187, 200], ["microglial", "ANATOMY", 242, 252], ["cell", "ANATOMY", 285, 289], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 105, 111], ["Akt", "GENE_OR_GENE_PRODUCT", 112, 115], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 165, 171], ["Akt", "GENE_OR_GENE_PRODUCT", 172, 175], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 200], ["Tat", "GENE_OR_GENE_PRODUCT", 201, 204], ["Tat", "GENE_OR_GENE_PRODUCT", 227, 230], ["microglial", "CELL", 242, 252], ["PTEN", "GENE_OR_GENE_PRODUCT", 276, 280], ["cell", "CELL", 285, 289], ["HIV-1", "GENE_OR_GENE_PRODUCT", 329, 334], ["PI3-kinase", "GENE_OR_GENE_PRODUCT", 338, 348], ["PTEN", "GENE_OR_GENE_PRODUCT", 385, 389], ["PIP3", "GENE_OR_GENE_PRODUCT", 414, 418], ["PIP2", "SIMPLE_CHEMICAL", 422, 426], ["PI-3-K", "PROTEIN", 105, 111], ["Akt", "PROTEIN", 112, 115], ["PI-3-K", "PROTEIN", 165, 171], ["Akt", "PROTEIN", 172, 175], ["intracellular Tat", "PROTEIN", 187, 204], ["Tat", "PROTEIN", 227, 230], ["PTEN", "PROTEIN", 276, 280], ["PI3", "PROTEIN", 338, 341], ["PTEN", "PROTEIN", 385, 389], ["PIP3", "PROTEIN", 414, 418], ["PIP2", "PROTEIN", 422, 426], ["HIV-1", "SPECIES", 329, 334], ["HIV-1", "SPECIES", 329, 334], ["the PI", "TEST", 101, 107], ["the PI", "TEST", 161, 167], ["K/Akt pathway", "TREATMENT", 170, 183], ["intracellular Tat", "TEST", 187, 204], ["Tat", "TREATMENT", 227, 230], ["PTEN and cell proliferative signals", "PROBLEM", 276, 311], ["HIV", "TEST", 329, 332], ["TatPI3", "TEST", 335, 341], ["kinase activity", "TEST", 342, 357], ["PIP2", "TEST", 422, 426], ["microglial survival", "OBSERVATION", 242, 261], ["PTEN", "OBSERVATION", 276, 280], ["cell proliferative", "OBSERVATION", 285, 303]]], ["32 In addition, PTEN and p53 positively regulate each other.", [["PTEN", "GENE_OR_GENE_PRODUCT", 16, 20], ["p53", "GENE_OR_GENE_PRODUCT", 25, 28], ["PTEN", "PROTEIN", 16, 20], ["p53", "PROTEIN", 25, 28]]], ["More specifically, p53 upregulates the transcription of PTEN, and PTEN stabilizes p53 by directly binding to the C-T end of p53.", [["p53", "GENE_OR_GENE_PRODUCT", 19, 22], ["PTEN", "GENE_OR_GENE_PRODUCT", 56, 60], ["PTEN", "GENE_OR_GENE_PRODUCT", 66, 70], ["p53", "GENE_OR_GENE_PRODUCT", 82, 85], ["p53", "GENE_OR_GENE_PRODUCT", 124, 127], ["p53", "PROTEIN", 19, 22], ["PTEN", "PROTEIN", 56, 60], ["PTEN", "PROTEIN", 66, 70], ["p53", "PROTEIN", 82, 85], ["C-T end", "DNA", 113, 120], ["p53", "PROTEIN", 124, 127], ["PTEN", "TEST", 56, 60], ["the C", "TEST", 109, 114]]], ["33 Importantly, it has been demonstrated that HIV-1 Tat also directly interacts with the C-T region of p53.", [["HIV-1", "ORGANISM", 46, 51], ["Tat", "GENE_OR_GENE_PRODUCT", 52, 55], ["p53", "GENE_OR_GENE_PRODUCT", 103, 106], ["HIV-1 Tat", "PROTEIN", 46, 55], ["C-T region", "PROTEIN", 89, 99], ["p53", "PROTEIN", 103, 106], ["HIV-1", "SPECIES", 46, 51], ["HIV-1", "SPECIES", 46, 51]]], ["42 Therefore, we tested whether intracellular Tat may compete with PTEN for p53 binding, which may induce the destabilization of p53 and decrease of PTEN levels, ultimately facilitating activation of the PI-3-K/Akt survival pathway.", [["intracellular", "ANATOMY", 32, 45], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["Tat", "GENE_OR_GENE_PRODUCT", 46, 49], ["PTEN", "GENE_OR_GENE_PRODUCT", 67, 71], ["p53", "GENE_OR_GENE_PRODUCT", 76, 79], ["p53", "GENE_OR_GENE_PRODUCT", 129, 132], ["PTEN", "GENE_OR_GENE_PRODUCT", 149, 153], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 204, 210], ["Akt", "GENE_OR_GENE_PRODUCT", 211, 214], ["intracellular Tat", "PROTEIN", 32, 49], ["PTEN", "PROTEIN", 67, 71], ["p53", "PROTEIN", 76, 79], ["p53", "PROTEIN", 129, 132], ["PTEN", "PROTEIN", 149, 153], ["Akt", "PROTEIN", 211, 214], ["intracellular Tat", "PROBLEM", 32, 49], ["p53 binding", "PROBLEM", 76, 87], ["the destabilization of p53", "PROBLEM", 106, 132], ["PTEN levels", "PROBLEM", 149, 160], ["the PI", "TEST", 200, 206], ["K/Akt survival pathway", "TREATMENT", 209, 231], ["decrease", "OBSERVATION_MODIFIER", 137, 145]]], ["To test this possibility, we examined the PTEN level of CHME5 cells in the presence and absence of intracellular Tat expression as well as HIV-1 transduction.", [["CHME5 cells", "ANATOMY", 56, 67], ["intracellular", "ANATOMY", 99, 112], ["PTEN", "GENE_OR_GENE_PRODUCT", 42, 46], ["CHME5 cells", "CELL", 56, 67], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 112], ["Tat", "GENE_OR_GENE_PRODUCT", 113, 116], ["HIV-1", "ORGANISM", 139, 144], ["PTEN", "PROTEIN", 42, 46], ["CHME5 cells", "CELL_LINE", 56, 67], ["Tat", "PROTEIN", 113, 116], ["HIV-1", "SPECIES", 139, 144], ["intracellular Tat expression", "PROBLEM", 99, 127]]], ["As shown in Figure 6 (a), the PTEN level significantly decreased upon transduction with the HIV-GFP vector.", [["PTEN", "GENE_OR_GENE_PRODUCT", 30, 34], ["GFP", "GENE_OR_GENE_PRODUCT", 96, 99], ["PTEN", "PROTEIN", 30, 34], ["HIV-GFP vector", "DNA", 92, 106], ["HIV", "SPECIES", 92, 95], ["the PTEN level", "TEST", 26, 40]]], ["More interestingly, the expression of HIV-1 Tat in CHME5 microglial cells also led to a drastic decrease in PTEN levels.", [["CHME5 microglial cells", "ANATOMY", 51, 73], ["HIV-1", "ORGANISM", 38, 43], ["Tat", "GENE_OR_GENE_PRODUCT", 44, 47], ["CHME5 microglial cells", "CELL", 51, 73], ["PTEN", "GENE_OR_GENE_PRODUCT", 108, 112], ["HIV-1 Tat", "PROTEIN", 38, 47], ["CHME5 microglial cells", "CELL_LINE", 51, 73], ["PTEN", "PROTEIN", 108, 112], ["HIV-1", "SPECIES", 38, 43], ["HIV-1", "SPECIES", 38, 43], ["HIV", "PROBLEM", 38, 41], ["microglial cells", "PROBLEM", 57, 73], ["a drastic decrease in PTEN levels", "PROBLEM", 86, 119], ["microglial cells", "OBSERVATION", 57, 73], ["drastic", "OBSERVATION_MODIFIER", 88, 95], ["decrease", "OBSERVATION_MODIFIER", 96, 104], ["PTEN levels", "OBSERVATION", 108, 119]]], ["This suggests that the down-regulation of PTEN by intracellular Tat and HIV-1 infection may be a potential mechanism for stimulation of the PI-3-K/Akt survival pathway.Regulation of PTEN and cell proliferative signals by expression of HIV-1 TatNext, since the decrease of PTEN levels induces the destabilization of p53, 43 we tested whether Tat expression may induce the decrease of p53 transcriptional activity in CHME5 cells.", [["intracellular", "ANATOMY", 50, 63], ["cell", "ANATOMY", 191, 195], ["CHME5 cells", "ANATOMY", 415, 426], ["infection", "DISEASE", 78, 87], ["PTEN", "GENE_OR_GENE_PRODUCT", 42, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["Tat", "GENE_OR_GENE_PRODUCT", 64, 67], ["HIV-1", "ORGANISM", 72, 77], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 140, 146], ["Akt", "GENE_OR_GENE_PRODUCT", 147, 150], ["PTEN", "GENE_OR_GENE_PRODUCT", 182, 186], ["cell", "CELL", 191, 195], ["HIV-1 TatNext", "ORGANISM", 235, 248], ["PTEN", "GENE_OR_GENE_PRODUCT", 272, 276], ["p53", "GENE_OR_GENE_PRODUCT", 315, 318], ["Tat", "GENE_OR_GENE_PRODUCT", 341, 344], ["p53", "GENE_OR_GENE_PRODUCT", 383, 386], ["CHME5 cells", "CELL", 415, 426], ["PTEN", "PROTEIN", 42, 46], ["intracellular Tat", "PROTEIN", 50, 67], ["Akt", "PROTEIN", 147, 150], ["PTEN", "PROTEIN", 182, 186], ["PTEN", "PROTEIN", 272, 276], ["p53", "PROTEIN", 315, 318], ["Tat", "PROTEIN", 341, 344], ["p53", "PROTEIN", 383, 386], ["CHME5 cells", "CELL_LINE", 415, 426], ["HIV-1", "SPECIES", 72, 77], ["HIV-1", "SPECIES", 235, 240], ["HIV-1", "SPECIES", 72, 77], ["HIV-1", "SPECIES", 235, 240], ["PTEN", "PROBLEM", 42, 46], ["intracellular Tat", "TEST", 50, 67], ["HIV-1 infection", "PROBLEM", 72, 87], ["the PI", "TEST", 136, 142], ["K/Akt survival pathway", "TREATMENT", 145, 167], ["PTEN and cell proliferative signals", "PROBLEM", 182, 217], ["HIV", "PROBLEM", 235, 238], ["PTEN levels", "PROBLEM", 272, 283], ["the destabilization of p53", "PROBLEM", 292, 318], ["the decrease of p53 transcriptional activity in CHME5 cells", "PROBLEM", 367, 426], ["PTEN", "OBSERVATION", 182, 186], ["cell proliferative", "OBSERVATION", 191, 209], ["decrease", "OBSERVATION_MODIFIER", 371, 379]]], ["For this test, we transfected CHME5 cells with a p53-regulated luciferase reporter plasmid together with pcDNA-lacZ and pTat101 or pCDNA3.1.", [["CHME5 cells", "ANATOMY", 30, 41], ["CHME5 cells", "CELL", 30, 41], ["p53", "GENE_OR_GENE_PRODUCT", 49, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 63, 73], ["pcDNA", "GENE_OR_GENE_PRODUCT", 105, 110], ["lacZ", "GENE_OR_GENE_PRODUCT", 111, 115], ["pTat101", "GENE_OR_GENE_PRODUCT", 120, 127], ["pCDNA3", "GENE_OR_GENE_PRODUCT", 131, 137], ["CHME5 cells", "CELL_LINE", 30, 41], ["p53", "PROTEIN", 49, 52], ["luciferase reporter plasmid", "DNA", 63, 90], ["pcDNA-lacZ", "DNA", 105, 115], ["pTat101", "DNA", 120, 127], ["pCDNA3", "DNA", 131, 137], ["this test", "TEST", 4, 13], ["a p53", "TEST", 47, 52], ["pcDNA-lacZ", "TREATMENT", 105, 115], ["pTat101", "TREATMENT", 120, 127], ["pCDNA3", "TREATMENT", 131, 137]]], ["CHME5 cells were derived from human fetal microglia following transformation with the simian virus 40 (SV40) large T antigen.", [["CHME5 cells", "ANATOMY", 0, 11], ["fetal microglia", "ANATOMY", 36, 51], ["CHME5 cells", "CELL", 0, 11], ["human", "ORGANISM", 30, 35], ["fetal microglia", "CELL", 36, 51], ["simian virus 40", "ORGANISM", 86, 101], ["SV40", "ORGANISM", 103, 107], ["large T antigen", "GENE_OR_GENE_PRODUCT", 109, 124], ["CHME5 cells", "CELL_LINE", 0, 11], ["human fetal microglia", "CELL_TYPE", 30, 51], ["simian virus 40 (SV40) large T antigen", "PROTEIN", 86, 124], ["human", "SPECIES", 30, 35], ["simian virus", "SPECIES", 86, 98], ["human", "SPECIES", 30, 35], ["simian virus 40", "SPECIES", 86, 101], ["CHME5 cells", "PROBLEM", 0, 11], ["the simian virus", "TREATMENT", 82, 98], ["large T antigen", "PROBLEM", 109, 124], ["fetal microglia", "OBSERVATION", 36, 51]]], ["This molecule is known to directly interact with p53 and inhibit its activity.", [["p53", "GENE_OR_GENE_PRODUCT", 49, 52], ["p53", "PROTEIN", 49, 52]]], ["49 However, as shown in Figure 6 (b), we observed that CHME5 cells exhibited a basal activity of p53 which was still detectable.", [["CHME5 cells", "ANATOMY", 55, 66], ["CHME5 cells", "CELL", 55, 66], ["p53", "GENE_OR_GENE_PRODUCT", 97, 100], ["CHME5 cells", "CELL_LINE", 55, 66], ["p53", "PROTEIN", 97, 100], ["CHME5 cells", "PROBLEM", 55, 66], ["a basal activity of p53", "PROBLEM", 77, 100], ["basal", "OBSERVATION_MODIFIER", 79, 84], ["activity", "OBSERVATION_MODIFIER", 85, 93]]], ["This basal activity was comparable with the basal activity of p53 in other cell types that contain SV40 large T antigen.", [["cell", "ANATOMY", 75, 79], ["p53", "GENE_OR_GENE_PRODUCT", 62, 65], ["cell", "CELL", 75, 79], ["SV40", "ORGANISM", 99, 103], ["large T antigen", "GENE_OR_GENE_PRODUCT", 104, 119], ["p53", "PROTEIN", 62, 65], ["SV40 large T antigen", "PROTEIN", 99, 119], ["SV40 large T antigen", "PROBLEM", 99, 119], ["activity", "OBSERVATION_MODIFIER", 11, 19], ["cell types", "OBSERVATION", 75, 85], ["large", "OBSERVATION_MODIFIER", 104, 109]]], ["50 Importantly, as predicted, p53 activity was further drastically decreased (5.3% of control) following expression of Tat in CHME5 cells (Figure 6(b) ).", [["CHME5 cells", "ANATOMY", 126, 137], ["p53", "GENE_OR_GENE_PRODUCT", 30, 33], ["Tat", "GENE_OR_GENE_PRODUCT", 119, 122], ["CHME5 cells", "CELL", 126, 137], ["p53", "PROTEIN", 30, 33], ["Tat", "PROTEIN", 119, 122], ["CHME5 cells", "CELL_LINE", 126, 137], ["p53 activity", "TEST", 30, 42], ["Tat in CHME5 cells", "PROBLEM", 119, 137], ["decreased", "OBSERVATION_MODIFIER", 67, 76]]], ["As an additional control, the cells were transfected with a control p53luciferase plasmid that lacks functional p53 binding elements (p53 mt promoter) and the luciferase expression from this control mutant construct remained low following expression of HIV-1 Tat in CHME5 cells.", [["cells", "ANATOMY", 30, 35], ["CHME5 cells", "ANATOMY", 266, 277], ["cells", "CELL", 30, 35], ["p53luciferase", "GENE_OR_GENE_PRODUCT", 68, 81], ["p53", "GENE_OR_GENE_PRODUCT", 112, 115], ["p53 mt", "GENE_OR_GENE_PRODUCT", 134, 140], ["luciferase", "GENE_OR_GENE_PRODUCT", 159, 169], ["HIV-1", "ORGANISM", 253, 258], ["Tat", "GENE_OR_GENE_PRODUCT", 259, 262], ["CHME5 cells", "CELL", 266, 277], ["p53luciferase plasmid", "DNA", 68, 89], ["p53 binding elements", "DNA", 112, 132], ["p53 mt promoter", "DNA", 134, 149], ["luciferase", "PROTEIN", 159, 169], ["HIV-1 Tat", "PROTEIN", 253, 262], ["CHME5 cells", "CELL_LINE", 266, 277], ["HIV-1", "SPECIES", 253, 258], ["HIV-1", "SPECIES", 253, 258], ["an additional control", "TREATMENT", 3, 24], ["a control p53luciferase plasmid", "TREATMENT", 58, 89], ["p53 mt promoter", "TREATMENT", 134, 149], ["the luciferase expression", "TREATMENT", 155, 180], ["this control mutant construct", "PROBLEM", 186, 215], ["HIV", "PROBLEM", 253, 256], ["Tat in CHME5 cells", "TREATMENT", 259, 277], ["functional p53", "OBSERVATION", 101, 115], ["binding elements", "OBSERVATION", 116, 132]]], ["These data suggest that expression of Tat in the microglial cell line system induces the inhibition of the transcription activator function of p53, which is consistent with the decrease of PTEN in the CHME5 Tat expression model system.Regulation of PTEN and cell proliferative signals by expression of HIV-1 TatOne of the cellular consequences of p53 dysfunction is the activation of cell proliferation, 46 which is a well-characterized mechanism of cell survival.", [["microglial cell line system", "ANATOMY", 49, 76], ["cell", "ANATOMY", 258, 262], ["cellular", "ANATOMY", 322, 330], ["cell", "ANATOMY", 384, 388], ["cell", "ANATOMY", 450, 454], ["Tat", "GENE_OR_GENE_PRODUCT", 38, 41], ["microglial cell line", "CELL", 49, 69], ["p53", "GENE_OR_GENE_PRODUCT", 143, 146], ["PTEN", "GENE_OR_GENE_PRODUCT", 189, 193], ["Tat", "GENE_OR_GENE_PRODUCT", 207, 210], ["PTEN", "GENE_OR_GENE_PRODUCT", 249, 253], ["cell", "CELL", 258, 262], ["HIV-1", "ORGANISM", 302, 307], ["TatOne", "GENE_OR_GENE_PRODUCT", 308, 314], ["cellular", "CELL", 322, 330], ["p53", "GENE_OR_GENE_PRODUCT", 347, 350], ["cell", "CELL", 384, 388], ["cell", "CELL", 450, 454], ["Tat", "PROTEIN", 38, 41], ["microglial cell line", "CELL_LINE", 49, 69], ["p53", "PROTEIN", 143, 146], ["PTEN", "PROTEIN", 189, 193], ["CHME5", "PROTEIN", 201, 206], ["Tat", "PROTEIN", 207, 210], ["PTEN", "PROTEIN", 249, 253], ["p53", "PROTEIN", 347, 350], ["HIV-1", "SPECIES", 302, 307], ["HIV-1", "SPECIES", 302, 307], ["Tat in the microglial cell line system", "TREATMENT", 38, 76], ["the decrease of PTEN", "PROBLEM", 173, 193], ["PTEN and cell proliferative signals", "PROBLEM", 249, 284], ["HIV", "TEST", 302, 305], ["p53 dysfunction", "PROBLEM", 347, 362], ["cell proliferation", "PROBLEM", 384, 402], ["microglial cell line", "OBSERVATION", 49, 69], ["consistent with", "UNCERTAINTY", 157, 172], ["PTEN", "OBSERVATION", 249, 253], ["cell", "OBSERVATION", 258, 262], ["proliferative", "OBSERVATION_MODIFIER", 263, 276], ["p53 dysfunction", "OBSERVATION", 347, 362], ["cell proliferation", "OBSERVATION", 384, 402], ["cell survival", "OBSERVATION", 450, 463]]], ["One of the key molecular events involved in the promotion of cell proliferation is the activation of the E2F transcription factor which is responsible for the expression of a number of genes essential for the cell cycle exit from G1 and entry into S phase.", [["cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 209, 213], ["cell", "CELL", 61, 65], ["E2F", "GENE_OR_GENE_PRODUCT", 105, 108], ["cell", "CELL", 209, 213], ["E2F transcription factor", "PROTEIN", 105, 129], ["cell proliferation", "PROBLEM", 61, 79], ["the E2F transcription factor", "PROBLEM", 101, 129], ["cell proliferation", "OBSERVATION", 61, 79]]], ["45 Therefore, we examined E2F activity in CHME5 cells expressing HIV-1 Tat.", [["CHME5 cells", "ANATOMY", 42, 53], ["E2F", "GENE_OR_GENE_PRODUCT", 26, 29], ["CHME5 cells", "CELL", 42, 53], ["HIV-1", "ORGANISM", 65, 70], ["Tat", "ORGANISM", 71, 74], ["E2F", "PROTEIN", 26, 29], ["CHME5 cells", "CELL_LINE", 42, 53], ["HIV-1 Tat", "PROTEIN", 65, 74], ["HIV-1", "SPECIES", 65, 70], ["HIV-1", "SPECIES", 65, 70]]], ["CHME5 cells were transiently transfected with an E2F-driven luciferase reporter plasmid together with either an empty expression vector (pCDNA3.1) or pTat101.", [["CHME5 cells", "ANATOMY", 0, 11], ["CHME5 cells", "CELL", 0, 11], ["E2F", "GENE_OR_GENE_PRODUCT", 49, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 60, 70], ["pCDNA3", "GENE_OR_GENE_PRODUCT", 137, 143], ["CHME5 cells", "CELL_LINE", 0, 11], ["E2F", "PROTEIN", 49, 52], ["luciferase reporter plasmid", "DNA", 60, 87], ["empty expression vector", "DNA", 112, 135], ["pCDNA3", "DNA", 137, 143], ["CHME5 cells", "PROBLEM", 0, 11], ["an E2F", "TREATMENT", 46, 52], ["luciferase reporter plasmid", "TREATMENT", 60, 87], ["an empty expression vector", "TREATMENT", 109, 135], ["pTat", "TEST", 150, 154], ["empty expression", "OBSERVATION", 112, 128]]], ["As a positive con- trol, cells were transfected with an expression plasmid (E6/E7) that contains the human papilloma virus type 16 (HPV-16)-encoded E6/E7 proteins, which are known to increase E2F activity.", [["cells", "ANATOMY", 25, 30], ["plasmid", "ANATOMY", 67, 74], ["cells", "CELL", 25, 30], ["E6/E7", "ORGANISM", 76, 81], ["human papilloma virus type 16", "ORGANISM", 101, 130], ["HPV-16", "ORGANISM", 132, 138], ["E6", "GENE_OR_GENE_PRODUCT", 148, 150], ["E7", "GENE_OR_GENE_PRODUCT", 151, 153], ["E2F", "GENE_OR_GENE_PRODUCT", 192, 195], ["expression plasmid", "DNA", 56, 74], ["E6", "DNA", 76, 78], ["E7", "PROTEIN", 79, 81], ["E6", "PROTEIN", 148, 150], ["E7 proteins", "PROTEIN", 151, 162], ["E2F", "PROTEIN", 192, 195], ["human", "SPECIES", 101, 106], ["papilloma virus", "SPECIES", 107, 122], ["human papilloma virus type 16 (HPV-16", "SPECIES", 101, 138], ["an expression plasmid (E6/E7", "TEST", 53, 81], ["the human papilloma virus type", "TEST", 97, 127], ["HPV", "TEST", 132, 135], ["E6/E7 proteins", "TREATMENT", 148, 162], ["human papilloma", "ANATOMY", 101, 116], ["increase", "OBSERVATION_MODIFIER", 183, 191], ["E2F activity", "OBSERVATION", 192, 204]]], ["47 In all cases, pCDNA3.1-LacZ was also included as an internal control for normalization of luciferase assay results.", [["1-LacZ", "CHEMICAL", 24, 30], ["pCDNA3", "GENE_OR_GENE_PRODUCT", 17, 23], ["1-LacZ", "GENE_OR_GENE_PRODUCT", 24, 30], ["luciferase", "GENE_OR_GENE_PRODUCT", 93, 103], ["pCDNA3", "PROTEIN", 17, 23], ["1-LacZ", "DNA", 24, 30], ["luciferase", "PROTEIN", 93, 103], ["pCDNA3", "TREATMENT", 17, 23], ["LacZ", "TREATMENT", 26, 30], ["an internal control", "TREATMENT", 52, 71], ["luciferase assay", "TEST", 93, 109]]], ["After transfection, cells were incubated for 72 h in media containing either 5%, 0.1% or 0% fetal bovine serum (FBS) and luciferase activity was measured.", [["cells", "ANATOMY", 20, 25], ["fetal bovine serum", "ANATOMY", 92, 110], ["FBS", "ANATOMY", 112, 115], ["cells", "CELL", 20, 25], ["fetal", "ORGANISM_SUBSTANCE", 92, 97], ["bovine", "ORGANISM", 98, 104], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["FBS", "ORGANISM_SUBSTANCE", 112, 115], ["luciferase", "GENE_OR_GENE_PRODUCT", 121, 131], ["luciferase", "PROTEIN", 121, 131], ["bovine", "SPECIES", 98, 104], ["bovine", "SPECIES", 98, 104], ["fetal bovine serum", "TEST", 92, 110], ["FBS", "TEST", 112, 115], ["luciferase activity", "TEST", 121, 140]]], ["As expected, high luciferase activity was observed following co-expression of the E6/ E7 proteins, presumably due to the activation of E2F by E6/E7 (Figure 6(c) ).", [["luciferase", "GENE_OR_GENE_PRODUCT", 18, 28], ["E6", "GENE_OR_GENE_PRODUCT", 82, 84], ["E7", "GENE_OR_GENE_PRODUCT", 86, 88], ["E2F", "GENE_OR_GENE_PRODUCT", 135, 138], ["E6", "GENE_OR_GENE_PRODUCT", 142, 144], ["E7", "GENE_OR_GENE_PRODUCT", 145, 147], ["Figure 6(c)", "GENE_OR_GENE_PRODUCT", 149, 160], ["luciferase", "PROTEIN", 18, 28], ["E6", "PROTEIN", 82, 84], ["E7 proteins", "PROTEIN", 86, 97], ["E2F", "PROTEIN", 135, 138], ["E6", "PROTEIN", 142, 144], ["E7", "PROTEIN", 145, 147], ["Figure 6(c)", "PROTEIN", 149, 160], ["high luciferase activity", "PROBLEM", 13, 37], ["the E6/ E7 proteins", "TEST", 78, 97], ["high", "OBSERVATION_MODIFIER", 13, 17], ["luciferase activity", "OBSERVATION", 18, 37], ["presumably due to", "UNCERTAINTY", 99, 116]]], ["48 Similarly, Tat-expressing cells also displayed significantly higher luciferase activity as compared to the control cells even following the stress of serum starvation.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 118, 123], ["serum", "ANATOMY", 153, 158], ["Tat-expressing cells", "CELL", 14, 34], ["luciferase", "GENE_OR_GENE_PRODUCT", 71, 81], ["cells", "CELL", 118, 123], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["Tat-expressing cells", "CELL_LINE", 14, 34], ["luciferase", "PROTEIN", 71, 81], ["control cells", "CELL_TYPE", 110, 123], ["Tat-expressing cells", "PROBLEM", 14, 34], ["significantly higher luciferase activity", "PROBLEM", 50, 90], ["the stress of serum starvation", "PROBLEM", 139, 169], ["significantly", "OBSERVATION_MODIFIER", 50, 63], ["higher", "OBSERVATION_MODIFIER", 64, 70], ["luciferase activity", "OBSERVATION", 71, 90]]], ["These data imply that the intracellular expression of Tat contributes to the activation of E2F in the microglial cell line.", [["intracellular", "ANATOMY", 26, 39], ["microglial cell line", "ANATOMY", 102, 122], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 39], ["Tat", "GENE_OR_GENE_PRODUCT", 54, 57], ["E2F", "GENE_OR_GENE_PRODUCT", 91, 94], ["microglial cell line", "CELL", 102, 122], ["Tat", "PROTEIN", 54, 57], ["E2F", "PROTEIN", 91, 94], ["microglial cell line", "CELL_LINE", 102, 122], ["Tat", "PROBLEM", 54, 57], ["the activation of E2F", "PROBLEM", 73, 94], ["microglial cell line", "OBSERVATION", 102, 122]]], ["We also found that expression of Tat in our system stimulated enhanced proliferative activity and DNA synthesis capability compared with control cells (data not shown).Regulation of PTEN and cell proliferative signals by expression of HIV-1 TatIn summary, employing the CHME5 model system, we observed that HIV-1 Tat expression induces (1) a decrease in PTEN level, (2) a decrease of p53 function and (3) an increase of E2F function, which collectively facilitate cell survival by the activation of the Akt pathway and cell proliferation potential.HIV-1 infection induces a cytoprotective effect in primary human monocyte-derived macrophagesEvidence suggests that HIV-1 infected microglia survive longer as compared to uninfected microglia in AIDS patients.", [["cells", "ANATOMY", 145, 150], ["cell", "ANATOMY", 191, 195], ["cell", "ANATOMY", 464, 468], ["cell", "ANATOMY", 519, 523], ["monocyte", "ANATOMY", 613, 621], ["macrophages", "ANATOMY", 630, 641], ["microglia", "ANATOMY", 679, 688], ["microglia", "ANATOMY", 730, 739], ["infection", "DISEASE", 554, 563], ["AIDS", "DISEASE", 743, 747], ["Tat", "GENE_OR_GENE_PRODUCT", 33, 36], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["cells", "CELL", 145, 150], ["PTEN", "GENE_OR_GENE_PRODUCT", 182, 186], ["cell", "CELL", 191, 195], ["HIV-1 TatIn", "ORGANISM", 235, 246], ["CHME5", "GENE_OR_GENE_PRODUCT", 270, 275], ["HIV-1", "ORGANISM", 307, 312], ["Tat", "GENE_OR_GENE_PRODUCT", 313, 316], ["PTEN", "GENE_OR_GENE_PRODUCT", 354, 358], ["p53", "GENE_OR_GENE_PRODUCT", 384, 387], ["E2F", "GENE_OR_GENE_PRODUCT", 420, 423], ["cell", "CELL", 464, 468], ["Akt", "GENE_OR_GENE_PRODUCT", 503, 506], ["cell", "CELL", 519, 523], ["HIV-1", "ORGANISM", 548, 553], ["human", "ORGANISM", 607, 612], ["monocyte-derived macrophages", "CELL", 613, 641], ["HIV-1", "ORGANISM", 664, 669], ["microglia", "CELL", 679, 688], ["microglia", "CELL", 730, 739], ["patients", "ORGANISM", 748, 756], ["Tat", "PROTEIN", 33, 36], ["control cells", "CELL_TYPE", 137, 150], ["PTEN", "PROTEIN", 182, 186], ["Tat", "PROTEIN", 313, 316], ["PTEN", "PROTEIN", 354, 358], ["p53", "PROTEIN", 384, 387], ["E2F", "PROTEIN", 420, 423], ["Akt", "PROTEIN", 503, 506], ["primary human monocyte", "CELL_TYPE", 599, 621], ["macrophages", "CELL_TYPE", 630, 641], ["microglia", "CELL_TYPE", 679, 688], ["uninfected microglia", "CELL_TYPE", 719, 739], ["HIV-1", "SPECIES", 307, 312], ["HIV-1", "SPECIES", 548, 553], ["human", "SPECIES", 607, 612], ["HIV-1", "SPECIES", 664, 669], ["patients", "SPECIES", 748, 756], ["HIV-1", "SPECIES", 235, 240], ["HIV-1", "SPECIES", 307, 312], ["HIV-1", "SPECIES", 548, 553], ["human", "SPECIES", 607, 612], ["HIV-1", "SPECIES", 664, 669], ["Tat in our system", "PROBLEM", 33, 50], ["enhanced proliferative activity", "PROBLEM", 62, 93], ["DNA synthesis capability", "PROBLEM", 98, 122], ["PTEN and cell proliferative signals", "PROBLEM", 182, 217], ["a decrease in PTEN level", "PROBLEM", 340, 364], ["a decrease of p53 function", "PROBLEM", 370, 396], ["an increase of E2F function", "PROBLEM", 405, 432], ["the Akt pathway", "TREATMENT", 499, 514], ["cell proliferation potential", "PROBLEM", 519, 547], ["HIV", "PROBLEM", 548, 551], ["1 infection", "PROBLEM", 552, 563], ["a cytoprotective effect", "PROBLEM", 572, 595], ["primary human monocyte", "TEST", 599, 621], ["HIV-1 infected microglia", "PROBLEM", 664, 688], ["proliferative activity", "OBSERVATION", 71, 93], ["PTEN", "OBSERVATION", 182, 186], ["cell proliferative", "OBSERVATION", 191, 209], ["decrease", "OBSERVATION_MODIFIER", 342, 350], ["increase", "OBSERVATION_MODIFIER", 408, 416], ["E2F function", "OBSERVATION", 420, 432], ["cell proliferation", "OBSERVATION", 519, 537], ["infection", "OBSERVATION", 554, 563], ["cytoprotective effect", "OBSERVATION_MODIFIER", 574, 595], ["macrophages", "ANATOMY", 630, 641], ["HIV", "OBSERVATION", 664, 667], ["infected", "OBSERVATION_MODIFIER", 670, 678], ["microglia", "OBSERVATION", 679, 688]]], ["23 Furthermore, since our CHME5 model system also displays an elevated survival capability upon HIV-1 infection, 16, 17 we attempted to confirm whether HIV-1 infection influences the survival of primary human monocyte-derived macrophage upon cytotoxic challenge.", [["monocyte", "ANATOMY", 209, 217], ["macrophage", "ANATOMY", 226, 236], ["HIV-1 infection", "DISEASE", 96, 111], ["infection", "DISEASE", 158, 167], ["CHME5", "GENE_OR_GENE_PRODUCT", 26, 31], ["HIV-1", "ORGANISM", 96, 101], ["HIV-1", "ORGANISM", 152, 157], ["human", "ORGANISM", 203, 208], ["monocyte-derived macrophage", "CELL", 209, 236], ["CHME5", "PROTEIN", 26, 31], ["primary human monocyte", "CELL_TYPE", 195, 217], ["HIV-1", "SPECIES", 96, 101], ["HIV-1", "SPECIES", 152, 157], ["human", "SPECIES", 203, 208], ["HIV-1", "SPECIES", 96, 101], ["HIV-1", "SPECIES", 152, 157], ["human", "SPECIES", 203, 208], ["an elevated survival capability", "PROBLEM", 59, 90], ["HIV-1 infection", "PROBLEM", 96, 111], ["HIV-1 infection", "PROBLEM", 152, 167], ["primary human monocyte", "TEST", 195, 217], ["cytotoxic challenge", "TREATMENT", 242, 261], ["elevated", "OBSERVATION_MODIFIER", 62, 70], ["survival", "OBSERVATION_MODIFIER", 71, 79], ["capability", "OBSERVATION_MODIFIER", 80, 90], ["infection", "OBSERVATION", 158, 167]]], ["Macrophages were infected with M-tropic HIV-1 Bal (1.1 \u00d7 10 7 pg, equivalent to vector MOI 40) and treated with LPS (15 \u03bcg/ml) and CHX (10 \u03bcg/ml) at 48 h post-infection.", [["Macrophages", "ANATOMY", 0, 11], ["LPS", "CHEMICAL", 112, 115], ["CHX", "CHEMICAL", 131, 134], ["infection", "DISEASE", 159, 168], ["CHX", "CHEMICAL", 131, 134], ["Macrophages", "CELL", 0, 11], ["HIV-1 Bal", "ORGANISM", 40, 49], ["LPS", "SIMPLE_CHEMICAL", 112, 115], ["CHX", "SIMPLE_CHEMICAL", 131, 134], ["Macrophages", "CELL_TYPE", 0, 11], ["HIV-1", "SPECIES", 40, 45], ["HIV-1", "SPECIES", 40, 45], ["Macrophages", "PROBLEM", 0, 11], ["M-tropic HIV", "TEST", 31, 43], ["Bal", "TEST", 46, 49], ["LPS", "TREATMENT", 112, 115], ["CHX", "TREATMENT", 131, 134], ["infection", "PROBLEM", 159, 168], ["infection", "OBSERVATION", 159, 168]]], ["The live (green) and dead (red) cells were monitored at 24 h post-treatment.", [["dead (red) cells", "ANATOMY", 21, 37], ["dead (red) cells", "CELL", 21, 37], ["live (green) and dead (red) cells", "CELL_TYPE", 4, 37], ["dead (red) cells", "PROBLEM", 21, 37], ["treatment", "TREATMENT", 66, 75]]], ["As shown in Figure 7 (a), macrophage infected with HIV-1 Bal displayed a decreased number of dead cells (red), as compared to uninfected macrophage (incubated with heat-inactivated virus).", [["macrophage", "ANATOMY", 26, 36], ["cells", "ANATOMY", 98, 103], ["macrophage", "ANATOMY", 137, 147], ["macrophage", "CELL", 26, 36], ["HIV-1 Bal", "ORGANISM", 51, 60], ["cells", "CELL", 98, 103], ["macrophage", "CELL", 137, 147], ["heat-inactivated virus", "ORGANISM", 164, 186], ["dead cells", "CELL_TYPE", 93, 103], ["uninfected macrophage", "CELL_TYPE", 126, 147], ["HIV-1", "SPECIES", 51, 56], ["HIV-1", "SPECIES", 51, 56], ["HIV", "TEST", 51, 54], ["dead cells", "PROBLEM", 93, 103], ["uninfected macrophage", "PROBLEM", 126, 147], ["heat-inactivated virus", "PROBLEM", 164, 186], ["decreased", "OBSERVATION_MODIFIER", 73, 82], ["number", "OBSERVATION_MODIFIER", 83, 89], ["dead cells", "OBSERVATION", 93, 103], ["macrophage", "OBSERVATION_MODIFIER", 137, 147]]], ["This suggests that infection with HIV-1 Bal induces a protective effect in primary human macrophage following cytotoxic challenge.", [["macrophage", "ANATOMY", 89, 99], ["infection", "DISEASE", 19, 28], ["HIV-1 Bal", "CHEMICAL", 34, 43], ["HIV-1", "ORGANISM", 34, 39], ["Bal", "ORGANISM", 40, 43], ["human", "ORGANISM", 83, 88], ["macrophage", "CELL", 89, 99], ["primary human macrophage", "CELL_TYPE", 75, 99], ["HIV-1", "SPECIES", 34, 39], ["human", "SPECIES", 83, 88], ["HIV-1", "SPECIES", 34, 39], ["human", "SPECIES", 83, 88], ["infection", "PROBLEM", 19, 28], ["HIV", "PROBLEM", 34, 37], ["primary human macrophage", "TREATMENT", 75, 99], ["cytotoxic challenge", "TREATMENT", 110, 129], ["infection", "OBSERVATION", 19, 28], ["protective effect", "OBSERVATION_MODIFIER", 54, 71], ["human macrophage", "OBSERVATION", 83, 99]]], ["Next, we employed an HIV-1 vector pseudotyped with the VSV-G envelope protein.", [["HIV-1", "ORGANISM", 21, 26], ["pseudotyped", "ORGANISM", 34, 45], ["VSV-G envelope", "GENE_OR_GENE_PRODUCT", 55, 69], ["VSV-G envelope protein", "PROTEIN", 55, 77], ["HIV-1", "SPECIES", 21, 26], ["HIV-1", "SPECIES", 21, 26], ["an HIV-1 vector pseudotyped", "TREATMENT", 18, 45], ["the VSV", "TREATMENT", 51, 58]]], ["This HIV-1 vector system expresses eGFP and all HIV-1 viral proteins except the Env and Nef proteins.", [["HIV-1", "ORGANISM", 5, 10], ["eGFP", "GENE_OR_GENE_PRODUCT", 35, 39], ["HIV-1", "ORGANISM", 48, 53], ["Env", "GENE_OR_GENE_PRODUCT", 80, 83], ["Nef", "GENE_OR_GENE_PRODUCT", 88, 91], ["eGFP", "PROTEIN", 35, 39], ["HIV-1 viral proteins", "PROTEIN", 48, 68], ["Env and Nef proteins", "PROTEIN", 80, 100], ["HIV-1", "SPECIES", 5, 10], ["HIV-1", "SPECIES", 48, 53], ["HIV-1", "SPECIES", 5, 10], ["HIV-1", "SPECIES", 48, 53], ["This HIV", "TEST", 0, 8], ["all HIV", "TEST", 44, 51], ["viral proteins", "TEST", 54, 68]]], ["39 Following transduction with the pseudotyped HIV-1 vector (HIV-GFP), macrophages were treated with LPS (25 \u03bcg/ml) and CHX (10 \u03bcg/ml), and cell viability was examined.", [["macrophages", "ANATOMY", 71, 82], ["cell", "ANATOMY", 140, 144], ["LPS", "CHEMICAL", 101, 104], ["CHX", "CHEMICAL", 120, 123], ["CHX", "CHEMICAL", 120, 123], ["pseudotyped", "ORGANISM", 35, 46], ["HIV-1", "ORGANISM", 47, 52], ["HIV", "ORGANISM", 61, 64], ["-GFP", "ORGANISM", 64, 68], ["macrophages", "CELL", 71, 82], ["LPS", "SIMPLE_CHEMICAL", 101, 104], ["CHX", "SIMPLE_CHEMICAL", 120, 123], ["cell", "CELL", 140, 144], ["macrophages", "CELL_TYPE", 71, 82], ["HIV-1", "SPECIES", 47, 52], ["HIV", "SPECIES", 61, 64], ["HIV-1", "SPECIES", 47, 52], ["HIV", "SPECIES", 61, 64], ["the pseudotyped HIV", "TEST", 31, 50], ["macrophages", "PROBLEM", 71, 82], ["LPS", "TREATMENT", 101, 104], ["CHX", "TREATMENT", 120, 123], ["cell viability", "TEST", 140, 154], ["macrophages", "ANATOMY", 71, 82]]], ["In this assay, we used only the cell death specific ethidium homodimer to detect dead cells (red).", [["cell", "ANATOMY", 32, 36], ["cells", "ANATOMY", 86, 91], ["ethidium", "CHEMICAL", 52, 60], ["ethidium", "CHEMICAL", 52, 60], ["cell", "CELL", 32, 36], ["cells", "CELL", 86, 91], ["dead cells", "CELL_TYPE", 81, 91], ["the cell death specific ethidium homodimer", "PROBLEM", 28, 70], ["dead cells", "PROBLEM", 81, 91], ["dead cells", "OBSERVATION", 81, 91]]], ["As shown in Figure 7 (b), human macrophage Ratios of PTEN level normalized by the \u03b1-tubulin level are marked. (b) CHME5 cells were transfected with pcDNA3.1 or pTat101, pcDNA-LacZ and a p53-dependent luciferase reporter construct.", [["macrophage", "ANATOMY", 32, 42], ["CHME5 cells", "ANATOMY", 114, 125], ["human", "ORGANISM", 26, 31], ["macrophage", "CELL", 32, 42], ["PTEN", "GENE_OR_GENE_PRODUCT", 53, 57], ["\u03b1-tubulin", "GENE_OR_GENE_PRODUCT", 82, 91], ["CHME5 cells", "CELL", 114, 125], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 148, 156], ["pTat101", "GENE_OR_GENE_PRODUCT", 160, 167], ["pcDNA", "GENE_OR_GENE_PRODUCT", 169, 174], ["LacZ", "GENE_OR_GENE_PRODUCT", 175, 179], ["p53", "GENE_OR_GENE_PRODUCT", 186, 189], ["luciferase", "GENE_OR_GENE_PRODUCT", 200, 210], ["PTEN", "PROTEIN", 53, 57], ["\u03b1-tubulin", "PROTEIN", 82, 91], ["CHME5 cells", "CELL_LINE", 114, 125], ["pcDNA3.1", "DNA", 148, 156], ["pTat101", "DNA", 160, 167], ["pcDNA-LacZ and a p53-dependent luciferase reporter construct", "DNA", 169, 229], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["human macrophage Ratios", "TEST", 26, 49], ["PTEN level", "TEST", 53, 63], ["(b) CHME5 cells", "TEST", 110, 125], ["pTat", "TEST", 160, 164], ["pcDNA", "TEST", 169, 174], ["PTEN", "OBSERVATION", 53, 57], ["marked", "OBSERVATION_MODIFIER", 102, 108]]], ["Activity from the wild-type p53 promoter construct is shown in gray while the activity from the mutated p53 promoter construct is shown in white.", [["p53", "GENE_OR_GENE_PRODUCT", 28, 31], ["p53", "GENE_OR_GENE_PRODUCT", 104, 107], ["wild-type p53 promoter construct", "DNA", 18, 50], ["mutated p53 promoter construct", "DNA", 96, 126], ["type p53 promoter construct", "TREATMENT", 23, 50], ["the mutated p53 promoter construct", "TREATMENT", 92, 126]]], ["The cells were then harvested 24 h later, at which time lysates were prepared and luciferase assays were performed.", [["cells", "ANATOMY", 4, 9], ["lysates", "ANATOMY", 56, 63], ["cells", "CELL", 4, 9], ["lysates", "ORGANISM_SUBSTANCE", 56, 63], ["luciferase", "GENE_OR_GENE_PRODUCT", 82, 92], ["luciferase", "PROTEIN", 82, 92], ["lysates", "TEST", 56, 63], ["luciferase assays", "TEST", 82, 99]]], ["The data represent p53 luciferase activity in relative light units (RLUs) and denote mean data values \u00b1 SEM from three independent experiments. (c) CHME5 cells were transiently transfected with pcDNA3.1 (gray), pTat101 (white) or E6/E7 (black) along with an E2Fdependent luciferase reporter construct and pcDNA3.1-LacZ.", [["(c) CHME5 cells", "ANATOMY", 144, 159], ["p53", "GENE_OR_GENE_PRODUCT", 19, 22], ["luciferase", "GENE_OR_GENE_PRODUCT", 23, 33], ["CHME5 cells", "CELL", 148, 159], ["pcDNA3.1 (gray), pTat101", "GENE_OR_GENE_PRODUCT", 194, 218], ["E6", "GENE_OR_GENE_PRODUCT", 230, 232], ["E7", "GENE_OR_GENE_PRODUCT", 233, 235], ["luciferase", "GENE_OR_GENE_PRODUCT", 271, 281], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 305, 313], ["LacZ", "GENE_OR_GENE_PRODUCT", 314, 318], ["p53", "PROTEIN", 19, 22], ["luciferase", "PROTEIN", 23, 33], ["CHME5 cells", "CELL_LINE", 148, 159], ["pcDNA3.1", "DNA", 194, 202], ["pTat101", "DNA", 211, 218], ["E6", "DNA", 230, 232], ["E7", "DNA", 233, 235], ["E2Fdependent luciferase reporter construct", "DNA", 258, 300], ["pcDNA3.1", "DNA", 305, 313], ["LacZ", "DNA", 314, 318], ["The data", "TEST", 0, 8], ["p53 luciferase activity", "PROBLEM", 19, 42], ["mean data values", "TEST", 85, 101], ["(c) CHME5 cells", "TEST", 144, 159], ["pTat", "TEST", 211, 215], ["E6/E7", "TEST", 230, 235], ["an E2Fdependent luciferase reporter construct", "TREATMENT", 255, 300], ["p53 luciferase activity", "OBSERVATION", 19, 42]]], ["The cells were then incubated in DMEM containing 5%, 0.1% or 0% fetal bovine serum.", [["cells", "ANATOMY", 4, 9], ["fetal bovine serum", "ANATOMY", 64, 82], ["cells", "CELL", 4, 9], ["bovine", "ORGANISM", 70, 76], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["bovine", "SPECIES", 70, 76], ["bovine", "SPECIES", 70, 76]]], ["72 h later, the cells were lysed and luciferase activity was measured.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["luciferase", "GENE_OR_GENE_PRODUCT", 37, 47], ["luciferase", "PROTEIN", 37, 47], ["the cells", "PROBLEM", 12, 21], ["luciferase activity", "TEST", 37, 56], ["luciferase activity", "OBSERVATION", 37, 56]]], ["All luciferase activities were normalized to equal amounts of \u03b2-galactose activity.", [["\u03b2-galactose", "CHEMICAL", 62, 73], ["\u03b2-galactose", "CHEMICAL", 62, 73], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["\u03b2-galactose", "SIMPLE_CHEMICAL", 62, 73], ["luciferase", "PROTEIN", 4, 14], ["All luciferase activities", "TEST", 0, 25]]], ["Data were compared to the level of luciferase activity in control cells (pcDNA3.1, gray).", [["cells", "ANATOMY", 66, 71], ["luciferase", "GENE_OR_GENE_PRODUCT", 35, 45], ["cells", "CELL", 66, 71], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 73, 81], ["luciferase", "PROTEIN", 35, 45], ["control cells", "CELL_TYPE", 58, 71]]], ["Results shown represent fold induction; data denotes mean values \u00b1 SEM from three experiments. transduced by the HIV-1 vector system (green) exhibited greatly diminished levels of cell death (red) than the control macrophage (incubated with heat-inactivated vector).", [["cell", "ANATOMY", 180, 184], ["macrophage", "ANATOMY", 214, 224], ["HIV-1", "ORGANISM", 113, 118], ["cell", "CELL", 180, 184], ["macrophage", "CELL", 214, 224], ["control macrophage", "CELL_TYPE", 206, 224], ["HIV-1", "SPECIES", 113, 118], ["HIV-1", "SPECIES", 113, 118], ["fold induction", "PROBLEM", 24, 38], ["mean values", "TEST", 53, 64], ["greatly diminished levels of cell death", "PROBLEM", 151, 190], ["heat-inactivated vector", "TREATMENT", 241, 264], ["fold induction", "OBSERVATION", 24, 38], ["HIV", "OBSERVATION", 113, 116], ["greatly", "OBSERVATION_MODIFIER", 151, 158], ["diminished", "OBSERVATION", 159, 169], ["cell death", "OBSERVATION", 180, 190]]], ["It is important to point out that none of the transduced cells (green) showed characteristics of cell death (as shown by distinct red or green staining in the merged field).", [["cells", "ANATOMY", 57, 62], ["cell", "ANATOMY", 97, 101], ["death", "DISEASE", 102, 107], ["cells", "CELL", 57, 62], ["cell", "CELL", 97, 101], ["transduced cells", "CELL_LINE", 46, 62], ["the transduced cells", "TEST", 42, 62], ["cell death", "PROBLEM", 97, 107], ["distinct red or green staining", "PROBLEM", 121, 151], ["cell death", "OBSERVATION", 97, 107]]], ["These data demonstrate that HIV-1 infection induces a cytoprotective effect in human monocyte-derived macrophage.", [["monocyte", "ANATOMY", 85, 93], ["macrophage", "ANATOMY", 102, 112], ["HIV-1 infection", "DISEASE", 28, 43], ["HIV-1", "ORGANISM", 28, 33], ["human", "ORGANISM", 79, 84], ["monocyte-derived macrophage", "CELL", 85, 112], ["human monocyte", "CELL_TYPE", 79, 93], ["macrophage", "CELL_TYPE", 102, 112], ["HIV-1", "SPECIES", 28, 33], ["human", "SPECIES", 79, 84], ["HIV-1", "SPECIES", 28, 33], ["human", "SPECIES", 79, 84], ["These data", "TEST", 0, 10], ["HIV-1 infection", "PROBLEM", 28, 43], ["a cytoprotective effect", "PROBLEM", 52, 75], ["human monocyte", "TEST", 79, 93], ["infection", "OBSERVATION", 34, 43], ["cytoprotective effect", "OBSERVATION", 54, 75], ["macrophage", "OBSERVATION_MODIFIER", 102, 112]]], ["Interestingly, the data with the HIV-1 vector system also suggest that Env and Nef, which are deleted in the pseudotyped vector, are not involved in this HIV-1 induced cell survival effect.HIV-1 infection induces a cytoprotective effect in primary human monocyte-derived macrophagesSince microglial cells are long-lived cells known for their role in immune surveillance of the CNS, there is little known about natural mechanisms involved in apoptosis of these cells.", [["cell", "ANATOMY", 168, 172], ["monocyte", "ANATOMY", 254, 262], ["macrophages", "ANATOMY", 271, 282], ["microglial cells", "ANATOMY", 288, 304], ["cells", "ANATOMY", 320, 325], ["CNS", "ANATOMY", 377, 380], ["cells", "ANATOMY", 460, 465], ["infection", "DISEASE", 195, 204], ["HIV-1", "ORGANISM", 33, 38], ["Env", "GENE_OR_GENE_PRODUCT", 71, 74], ["Nef", "GENE_OR_GENE_PRODUCT", 79, 82], ["pseudotyped", "ORGANISM", 109, 120], ["HIV-1", "ORGANISM", 154, 159], ["cell", "CELL", 168, 172], ["HIV-1", "ORGANISM", 189, 194], ["human", "ORGANISM", 248, 253], ["monocyte-derived macrophages", "CELL", 254, 282], ["microglial cells", "CELL", 288, 304], ["cells", "CELL", 320, 325], ["CNS", "ANATOMICAL_SYSTEM", 377, 380], ["cells", "CELL", 460, 465], ["Env", "PROTEIN", 71, 74], ["Nef", "PROTEIN", 79, 82], ["primary human monocyte", "CELL_TYPE", 240, 262], ["macrophages", "CELL_TYPE", 271, 282], ["microglial cells", "CELL_TYPE", 288, 304], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 154, 159], ["HIV-1", "SPECIES", 189, 194], ["human", "SPECIES", 248, 253], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 154, 159], ["HIV-1", "SPECIES", 189, 194], ["human", "SPECIES", 248, 253], ["the data", "TEST", 15, 23], ["HIV", "PROBLEM", 189, 192], ["1 infection", "PROBLEM", 193, 204], ["a cytoprotective effect", "PROBLEM", 213, 236], ["primary human monocyte", "TEST", 240, 262], ["microglial cells", "PROBLEM", 288, 304], ["Env", "OBSERVATION", 71, 74], ["cell survival", "OBSERVATION", 168, 181], ["infection", "OBSERVATION", 195, 204], ["cytoprotective effect", "OBSERVATION_MODIFIER", 215, 236], ["macrophages", "ANATOMY", 271, 282], ["microglial cells", "OBSERVATION", 288, 304], ["CNS", "ANATOMY", 377, 380]]], ["One of the known ways to induce microglial apoptosis is through increased nitric oxide (NO) production.", [["microglial", "ANATOMY", 32, 42], ["nitric oxide", "CHEMICAL", 74, 86], ["NO", "CHEMICAL", 88, 90], ["nitric oxide", "CHEMICAL", 74, 86], ["NO", "CHEMICAL", 88, 90], ["microglial", "CELL", 32, 42], ["nitric oxide", "SIMPLE_CHEMICAL", 74, 86], ["NO", "SIMPLE_CHEMICAL", 88, 90], ["microglial apoptosis", "PROBLEM", 32, 52], ["increased nitric oxide", "TREATMENT", 64, 86], ["microglial apoptosis", "OBSERVATION", 32, 52], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["nitric oxide", "OBSERVATION", 74, 86]]], ["44 In fact, HIV-1 infection is known to activate microglia, which leads to the production of nitric oxide.", [["microglia", "ANATOMY", 49, 58], ["infection", "DISEASE", 18, 27], ["nitric oxide", "CHEMICAL", 93, 105], ["nitric oxide", "CHEMICAL", 93, 105], ["HIV-1", "ORGANISM", 12, 17], ["microglia", "CELL", 49, 58], ["nitric oxide", "SIMPLE_CHEMICAL", 93, 105], ["microglia", "CELL_TYPE", 49, 58], ["HIV-1", "SPECIES", 12, 17], ["HIV-1", "SPECIES", 12, 17], ["HIV-1 infection", "PROBLEM", 12, 27], ["microglia", "PROBLEM", 49, 58], ["nitric oxide", "TREATMENT", 93, 105], ["HIV", "OBSERVATION", 12, 15], ["infection", "OBSERVATION", 18, 27], ["nitric oxide", "OBSERVATION", 93, 105]]], ["45 Another source of NO during HIV-1 infection is through the secretion of gp120, the viral envelope glycoprotein, which can induce production from bystander CNS cell types.", [["CNS cell", "ANATOMY", 158, 166], ["NO", "CHEMICAL", 21, 23], ["HIV-1 infection", "DISEASE", 31, 46], ["NO", "CHEMICAL", 21, 23], ["NO", "GENE_OR_GENE_PRODUCT", 21, 23], ["HIV-1", "ORGANISM", 31, 36], ["gp120", "GENE_OR_GENE_PRODUCT", 75, 80], ["bystander CNS cell", "CELL", 148, 166], ["gp120", "PROTEIN", 75, 80], ["viral envelope glycoprotein", "PROTEIN", 86, 113], ["bystander CNS cell types", "CELL_TYPE", 148, 172], ["HIV-1", "SPECIES", 31, 36], ["HIV-1", "SPECIES", 31, 36], ["1 infection", "PROBLEM", 35, 46], ["the secretion of gp120", "PROBLEM", 58, 80], ["the viral envelope glycoprotein", "PROBLEM", 82, 113], ["bystander CNS cell types", "TREATMENT", 148, 172], ["infection", "OBSERVATION", 37, 46], ["CNS cell types", "OBSERVATION", 158, 172]]], ["46 This additive effect on NO production by HIV-1 infection induces apoptosis in neighboring cells such as neurons.", [["cells", "ANATOMY", 93, 98], ["neurons", "ANATOMY", 107, 114], ["NO", "CHEMICAL", 27, 29], ["infection", "DISEASE", 50, 59], ["NO", "CHEMICAL", 27, 29], ["NO", "SIMPLE_CHEMICAL", 27, 29], ["HIV-1", "ORGANISM", 44, 49], ["cells", "CELL", 93, 98], ["neurons", "CELL", 107, 114], ["neighboring cells", "CELL_TYPE", 81, 98], ["neurons", "CELL_TYPE", 107, 114], ["HIV-1", "SPECIES", 44, 49], ["HIV-1", "SPECIES", 44, 49], ["HIV-1 infection", "PROBLEM", 44, 59], ["apoptosis in neighboring cells", "PROBLEM", 68, 98], ["infection", "OBSERVATION", 50, 59], ["neurons", "ANATOMY", 107, 114]]], ["Normally, the overactivation of microglia sensitizes them to undergo apoptosis through a feedback mechanism.", [["microglia", "ANATOMY", 32, 41], ["microglia", "CELL", 32, 41], ["microglia", "CELL_TYPE", 32, 41], ["apoptosis", "PROBLEM", 69, 78], ["microglia sensitizes", "OBSERVATION", 32, 52]]], ["47 However, despite the large amounts of NO produced during HIV-1 infection, microglia still exhibit an extended survival phenotype.", [["microglia", "ANATOMY", 77, 86], ["NO", "CHEMICAL", 41, 43], ["HIV-1 infection", "DISEASE", 60, 75], ["NO", "CHEMICAL", 41, 43], ["NO", "SIMPLE_CHEMICAL", 41, 43], ["HIV-1", "ORGANISM", 60, 65], ["microglia", "CELL", 77, 86], ["microglia", "CELL_TYPE", 77, 86], ["HIV-1", "SPECIES", 60, 65], ["HIV-1", "SPECIES", 60, 65], ["HIV-1 infection", "PROBLEM", 60, 75], ["an extended survival phenotype", "PROBLEM", 101, 131], ["large", "OBSERVATION_MODIFIER", 24, 29], ["survival phenotype", "OBSERVATION", 113, 131]]], ["Therefore, we next tested whether primary human macrophages infected with HIV-1 exhibited this cytoprotective effect following exposure to sodium nitroprusside, an NO donor.", [["macrophages", "ANATOMY", 48, 59], ["sodium nitroprusside", "CHEMICAL", 139, 159], ["NO", "CHEMICAL", 164, 166], ["sodium nitroprusside", "CHEMICAL", 139, 159], ["NO", "CHEMICAL", 164, 166], ["human", "ORGANISM", 42, 47], ["macrophages", "CELL", 48, 59], ["HIV-1", "ORGANISM", 74, 79], ["sodium nitroprusside", "SIMPLE_CHEMICAL", 139, 159], ["NO", "SIMPLE_CHEMICAL", 164, 166], ["primary human macrophages", "CELL_TYPE", 34, 59], ["human", "SPECIES", 42, 47], ["HIV-1", "SPECIES", 74, 79], ["human", "SPECIES", 42, 47], ["HIV-1", "SPECIES", 74, 79], ["primary human macrophages", "PROBLEM", 34, 59], ["HIV", "PROBLEM", 74, 77], ["sodium nitroprusside", "TREATMENT", 139, 159]]], ["48 As shown in Figure 7 (c), macrophage exposed to heat-inactivated virus exhibited significant cell death (red cells) upon exposure to sodium nitroprusside (SNP).", [["macrophage", "ANATOMY", 29, 39], ["cell", "ANATOMY", 96, 100], ["red cells", "ANATOMY", 108, 117], ["death", "DISEASE", 101, 106], ["sodium nitroprusside", "CHEMICAL", 136, 156], ["SNP", "CHEMICAL", 158, 161], ["sodium nitroprusside", "CHEMICAL", 136, 156], ["SNP", "CHEMICAL", 158, 161], ["macrophage", "CELL", 29, 39], ["cell", "CELL", 96, 100], ["red cells", "CELL", 108, 117], ["sodium nitroprusside", "SIMPLE_CHEMICAL", 136, 156], ["red cells", "CELL_TYPE", 108, 117], ["inactivated virus", "PROBLEM", 56, 73], ["significant cell death", "PROBLEM", 84, 106], ["red cells", "PROBLEM", 108, 117], ["sodium nitroprusside (SNP)", "TREATMENT", 136, 162], ["significant cell death", "OBSERVATION", 84, 106]]], ["However, macrophage infected with HIV-1 BAL did not display any significant induction in cell death even under the conditions of increased NO production.", [["macrophage", "ANATOMY", 9, 19], ["cell", "ANATOMY", 89, 93], ["death", "DISEASE", 94, 99], ["NO", "CHEMICAL", 139, 141], ["NO", "CHEMICAL", 139, 141], ["macrophage", "CELL", 9, 19], ["HIV-1", "ORGANISM", 34, 39], ["BAL", "ORGANISM", 40, 43], ["cell", "CELL", 89, 93], ["NO", "SIMPLE_CHEMICAL", 139, 141], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 34, 39], ["macrophage infected", "PROBLEM", 9, 28], ["HIV-1 BAL", "TEST", 34, 43], ["cell death", "PROBLEM", 89, 99], ["increased NO production", "PROBLEM", 129, 152], ["macrophage", "OBSERVATION_MODIFIER", 9, 19], ["infected", "OBSERVATION", 20, 28], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["increased", "OBSERVATION_MODIFIER", 129, 138]]], ["Consistent with this, primary macrophage transduced using our pseudotyped vector system (green cells) also exhibited a survival effect following SNP treatment (Figure 7(d) ), whereas macrophages incubated with heat-inactivated vector displayed significant cell death upon SNP treatment.", [["primary macrophage", "ANATOMY", 22, 40], ["green cells", "ANATOMY", 89, 100], ["macrophages", "ANATOMY", 183, 194], ["cell", "ANATOMY", 256, 260], ["SNP", "CHEMICAL", 145, 148], ["death", "DISEASE", 261, 266], ["SNP", "CHEMICAL", 272, 275], ["SNP", "CHEMICAL", 145, 148], ["SNP", "CHEMICAL", 272, 275], ["macrophage", "CELL", 30, 40], ["pseudotyped", "ORGANISM", 62, 73], ["green cells", "CELL", 89, 100], ["macrophages", "CELL", 183, 194], ["cell", "CELL", 256, 260], ["primary macrophage", "CELL_TYPE", 22, 40], ["green cells", "CELL_TYPE", 89, 100], ["macrophages", "CELL_TYPE", 183, 194], ["primary macrophage transduced", "TREATMENT", 22, 51], ["our pseudotyped vector system", "TREATMENT", 58, 87], ["SNP treatment", "TREATMENT", 145, 158], ["heat-inactivated vector", "TREATMENT", 210, 233], ["significant cell death", "PROBLEM", 244, 266], ["SNP treatment", "TREATMENT", 272, 285], ["survival effect", "OBSERVATION", 119, 134], ["significant cell death", "OBSERVATION", 244, 266]]], ["It is also important to emphasize that although SNP treatment resulted in a greater stress than LPS, inducing higher amounts of cell death, HIV-1 infected macrophages still exhibited a potent cytoprotective effect (the absence of red cells in Figure 7 (c) and (d)).HIV-1 infection induces a cytoprotective effect in primary human monocyte-derived macrophagesTo measure the extent of cell death induced in primary human macrophage, the mean percentages of cell death were obtained by counting the number of dead cells (red) out of the number of total cells from various fields.", [["cell", "ANATOMY", 128, 132], ["macrophages", "ANATOMY", 155, 166], ["red cells", "ANATOMY", 230, 239], ["monocyte", "ANATOMY", 330, 338], ["macrophages", "ANATOMY", 347, 358], ["cell", "ANATOMY", 383, 387], ["macrophage", "ANATOMY", 419, 429], ["cell", "ANATOMY", 455, 459], ["cells", "ANATOMY", 511, 516], ["cells", "ANATOMY", 550, 555], ["SNP", "CHEMICAL", 48, 51], ["LPS", "CHEMICAL", 96, 99], ["infection", "DISEASE", 271, 280], ["death", "DISEASE", 388, 393], ["death", "DISEASE", 460, 465], ["SNP", "CHEMICAL", 48, 51], ["LPS", "SIMPLE_CHEMICAL", 96, 99], ["cell", "CELL", 128, 132], ["HIV-1", "ORGANISM", 140, 145], ["macrophages", "CELL", 155, 166], ["red cells", "CELL", 230, 239], ["HIV-1", "ORGANISM", 265, 270], ["human", "ORGANISM", 324, 329], ["monocyte-derived macrophages", "CELL", 330, 358], ["cell", "CELL", 383, 387], ["human", "ORGANISM", 413, 418], ["macrophage", "CELL", 419, 429], ["cell", "CELL", 455, 459], ["cells", "CELL", 511, 516], ["cells", "CELL", 550, 555], ["macrophages", "CELL_TYPE", 155, 166], ["red cells", "CELL_TYPE", 230, 239], ["primary human monocyte", "CELL_TYPE", 316, 338], ["macrophages", "CELL_TYPE", 347, 358], ["primary human macrophage", "CELL_TYPE", 405, 429], ["dead cells", "CELL_TYPE", 506, 516], ["total cells", "CELL_TYPE", 544, 555], ["HIV-1", "SPECIES", 140, 145], ["HIV-1", "SPECIES", 265, 270], ["human", "SPECIES", 324, 329], ["human", "SPECIES", 413, 418], ["HIV-1", "SPECIES", 140, 145], ["HIV-1", "SPECIES", 265, 270], ["human", "SPECIES", 324, 329], ["human", "SPECIES", 413, 418], ["SNP treatment", "TREATMENT", 48, 61], ["a greater stress than LPS", "PROBLEM", 74, 99], ["cell death", "PROBLEM", 128, 138], ["HIV", "PROBLEM", 140, 143], ["1 infected macrophages", "PROBLEM", 144, 166], ["a potent cytoprotective effect", "PROBLEM", 183, 213], ["red cells", "PROBLEM", 230, 239], ["HIV", "PROBLEM", 265, 268], ["1 infection", "PROBLEM", 269, 280], ["a cytoprotective effect", "PROBLEM", 289, 312], ["primary human monocyte", "TEST", 316, 338], ["cell death", "PROBLEM", 383, 393], ["cell death", "PROBLEM", 455, 465], ["dead cells", "PROBLEM", 506, 516], ["cell death", "OBSERVATION", 128, 138], ["potent cytoprotective", "OBSERVATION_MODIFIER", 185, 206], ["infection", "OBSERVATION", 271, 280], ["cytoprotective effect", "OBSERVATION_MODIFIER", 291, 312], ["macrophages", "ANATOMY", 347, 358], ["cell death", "OBSERVATION", 383, 393], ["primary human macrophage", "OBSERVATION", 405, 429], ["cell death", "OBSERVATION", 455, 465], ["dead cells", "OBSERVATION", 506, 516], ["total cells", "OBSERVATION", 544, 555]]], ["In the case of pseudotyped vector transduced cells, the number of dead cells (red) out of GFP-expressing cells was determined.", [["cells", "ANATOMY", 45, 50], ["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 105, 110], ["pseudotyped", "ORGANISM", 15, 26], ["cells", "CELL", 45, 50], ["cells", "CELL", 71, 76], ["GFP", "GENE_OR_GENE_PRODUCT", 90, 93], ["cells", "CELL", 105, 110], ["pseudotyped vector transduced cells", "CELL_LINE", 15, 50], ["dead cells", "CELL_TYPE", 66, 76], ["GFP", "PROTEIN", 90, 93], ["expressing cells", "CELL_TYPE", 94, 110], ["pseudotyped vector transduced cells", "TREATMENT", 15, 50], ["dead cells", "PROBLEM", 66, 76], ["GFP", "TEST", 90, 93], ["expressing cells", "PROBLEM", 94, 110], ["dead cells", "OBSERVATION", 66, 76], ["expressing cells", "OBSERVATION", 94, 110]]], ["As shown in Figure 8 , primary human macrophage infected with M-tropic HIV-1 Bal or transduced with pseudotyped GFP vector showed significantly less cell death than the uninfected macrophage (incubated with heat-inactivated virus or heatinactivated vector) following treatment with either the LPS or SNP apoptotic stimulus.", [["macrophage", "ANATOMY", 37, 47], ["cell", "ANATOMY", 149, 153], ["macrophage", "ANATOMY", 180, 190], ["LPS", "CHEMICAL", 293, 296], ["SNP", "CHEMICAL", 300, 303], ["SNP", "CHEMICAL", 300, 303], ["human", "ORGANISM", 31, 36], ["macrophage", "CELL", 37, 47], ["M-tropic HIV-1 Bal", "ORGANISM", 62, 80], ["pseudotyped", "ORGANISM", 100, 111], ["GFP", "GENE_OR_GENE_PRODUCT", 112, 115], ["cell", "CELL", 149, 153], ["macrophage", "CELL", 180, 190], ["LPS", "SIMPLE_CHEMICAL", 293, 296], ["primary human macrophage", "CELL_TYPE", 23, 47], ["pseudotyped GFP vector", "DNA", 100, 122], ["uninfected macrophage", "CELL_TYPE", 169, 190], ["human", "SPECIES", 31, 36], ["HIV-1", "SPECIES", 71, 76], ["human", "SPECIES", 31, 36], ["HIV-1", "SPECIES", 71, 76], ["primary human macrophage infected", "PROBLEM", 23, 56], ["M-tropic HIV", "TEST", 62, 74], ["pseudotyped GFP vector", "TEST", 100, 122], ["significantly less cell death", "PROBLEM", 130, 159], ["the uninfected macrophage", "PROBLEM", 165, 190], ["heat-inactivated virus", "PROBLEM", 207, 229], ["heatinactivated vector", "TREATMENT", 233, 255], ["treatment", "TREATMENT", 267, 276], ["the LPS", "TREATMENT", 289, 296], ["SNP apoptotic stimulus", "TREATMENT", 300, 322], ["macrophage", "ANATOMY", 37, 47], ["significantly less", "OBSERVATION_MODIFIER", 130, 148], ["cell death", "OBSERVATION", 149, 159], ["uninfected macrophage", "OBSERVATION", 169, 190], ["apoptotic stimulus", "OBSERVATION", 304, 322]]], ["These data demonstrate that as observed with HIV-1 infected primary microglia 23 and our CHME5 model system, HIV-1 infection of primary human macrophage also leads to increased cell survival upon apoptotic challenge.DiscussionThe interaction of HIV-1 with CD4+ T cells has been well studied, and typically results in cell cycle arrest and cytolysis.", [["primary microglia", "ANATOMY", 60, 77], ["macrophage", "ANATOMY", 142, 152], ["cell", "ANATOMY", 177, 181], ["CD4+ T cells", "ANATOMY", 256, 268], ["cell", "ANATOMY", 317, 321], ["infection", "DISEASE", 115, 124], ["HIV-1", "ORGANISM", 45, 50], ["microglia 23", "CELL", 68, 80], ["CHME5", "GENE_OR_GENE_PRODUCT", 89, 94], ["HIV-1", "ORGANISM", 109, 114], ["human", "ORGANISM", 136, 141], ["macrophage", "CELL", 142, 152], ["cell", "CELL", 177, 181], ["HIV-1", "ORGANISM", 245, 250], ["CD4", "GENE_OR_GENE_PRODUCT", 256, 259], ["cell", "CELL", 317, 321], ["primary microglia 23", "CELL_LINE", 60, 80], ["primary human macrophage", "CELL_TYPE", 128, 152], ["CD4", "PROTEIN", 256, 259], ["T cells", "CELL_TYPE", 261, 268], ["HIV-1", "SPECIES", 45, 50], ["HIV-1", "SPECIES", 109, 114], ["human", "SPECIES", 136, 141], ["HIV-1", "SPECIES", 245, 250], ["HIV-1", "SPECIES", 45, 50], ["HIV-1", "SPECIES", 109, 114], ["human", "SPECIES", 136, 141], ["HIV-1", "SPECIES", 245, 250], ["These data", "TEST", 0, 10], ["HIV-1 infected primary microglia", "PROBLEM", 45, 77], ["HIV", "PROBLEM", 109, 112], ["primary human macrophage", "PROBLEM", 128, 152], ["increased cell survival", "TREATMENT", 167, 190], ["apoptotic challenge", "TREATMENT", 196, 215], ["HIV", "TEST", 245, 248], ["CD4+ T cells", "PROBLEM", 256, 268], ["cell cycle arrest", "PROBLEM", 317, 334], ["cytolysis", "PROBLEM", 339, 348], ["primary human macrophage", "OBSERVATION", 128, 152], ["increased cell survival", "OBSERVATION", 167, 190], ["apoptotic challenge", "OBSERVATION", 196, 215], ["cell cycle arrest", "OBSERVATION", 317, 334]]], ["In contrast, the cellular effects following HIV-1 infection in macrophage and microglia are much less clearly understood.", [["cellular", "ANATOMY", 17, 25], ["macrophage", "ANATOMY", 63, 73], ["microglia", "ANATOMY", 78, 87], ["infection", "DISEASE", 50, 59], ["cellular", "CELL", 17, 25], ["HIV-1", "ORGANISM", 44, 49], ["macrophage", "CELL", 63, 73], ["microglia", "CELL", 78, 87], ["macrophage", "CELL_TYPE", 63, 73], ["microglia", "CELL_TYPE", 78, 87], ["HIV-1", "SPECIES", 44, 49], ["HIV-1", "SPECIES", 44, 49], ["the cellular effects", "PROBLEM", 13, 33], ["HIV-1 infection in macrophage and microglia", "PROBLEM", 44, 87], ["cellular effects", "OBSERVATION", 17, 33], ["infection", "OBSERVATION", 50, 59], ["macrophage", "OBSERVATION_MODIFIER", 63, 73], ["microglia", "ANATOMY", 78, 87]]], ["Hence, we set out to conduct experiments that might shed light on this interaction, based on an intriguing recent report demonstrating that HIV-1 infection may promote the survival of primary human microglia.", [["microglia", "ANATOMY", 198, 207], ["infection", "DISEASE", 146, 155], ["HIV-1", "ORGANISM", 140, 145], ["human", "ORGANISM", 192, 197], ["microglia", "CELL", 198, 207], ["primary human microglia", "CELL_TYPE", 184, 207], ["HIV-1", "SPECIES", 140, 145], ["human", "SPECIES", 192, 197], ["HIV-1", "SPECIES", 140, 145], ["human", "SPECIES", 192, 197], ["HIV-1 infection", "PROBLEM", 140, 155], ["primary human microglia", "PROBLEM", 184, 207], ["infection", "OBSERVATION", 146, 155], ["primary human microglia", "OBSERVATION", 184, 207]]], ["23 However, a major obstacle for approaching this question is the limited access to primary human microglia.", [["microglia", "ANATOMY", 98, 107], ["human", "ORGANISM", 92, 97], ["microglia", "CELL", 98, 107], ["primary human microglia", "CELL_TYPE", 84, 107], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["primary human microglia", "PROBLEM", 84, 107], ["human microglia", "OBSERVATION", 92, 107]]], ["In addition, it is technically challenging to study primary human microglia because many experimental approaches often require large quantities of cells.", [["microglia", "ANATOMY", 66, 75], ["cells", "ANATOMY", 147, 152], ["human", "ORGANISM", 60, 65], ["microglia", "CELL", 66, 75], ["cells", "CELL", 147, 152], ["primary human microglia", "CELL_TYPE", 52, 75], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["large quantities of cells", "PROBLEM", 127, 152]]], ["Here, we attempted to develop a new cell line model that mimics the interplay between HIV-1 and microglia in terms of cell survival.DiscussionWe initially demonstrated that this cell line model system using the CHME5 microglial cell line can support the replication and amplification of Mtropic HIV-1, and displays a potent cytoprotective effect upon HIV-1 infection.", [["cell line", "ANATOMY", 36, 45], ["microglia", "ANATOMY", 96, 105], ["cell", "ANATOMY", 118, 122], ["cell line", "ANATOMY", 178, 187], ["CHME5 microglial cell line", "ANATOMY", 211, 237], ["HIV-1 infection", "DISEASE", 351, 366], ["cell line", "CELL", 36, 45], ["HIV-1", "CELL", 86, 91], ["microglia", "CELL", 96, 105], ["cell", "CELL", 118, 122], ["cell line", "CELL", 178, 187], ["CHME5 microglial cell line", "CELL", 211, 237], ["Mtropic HIV-1", "ORGANISM", 287, 300], ["HIV-1", "ORGANISM", 351, 356], ["microglia", "CELL_TYPE", 96, 105], ["CHME5 microglial cell line", "CELL_LINE", 211, 237], ["HIV-1", "SPECIES", 86, 91], ["HIV-1", "SPECIES", 295, 300], ["HIV-1", "SPECIES", 351, 356], ["HIV-1", "SPECIES", 86, 91], ["HIV-1", "SPECIES", 295, 300], ["HIV-1", "SPECIES", 351, 356], ["a new cell line model", "PROBLEM", 30, 51], ["HIV", "PROBLEM", 86, 89], ["microglia", "PROBLEM", 96, 105], ["cell survival", "TREATMENT", 118, 131], ["this cell line model system", "TREATMENT", 173, 200], ["the CHME5 microglial cell line", "TREATMENT", 207, 237], ["the replication", "TREATMENT", 250, 265], ["Mtropic HIV", "TEST", 287, 298], ["HIV-1 infection", "PROBLEM", 351, 366], ["new", "OBSERVATION_MODIFIER", 32, 35], ["cell line", "OBSERVATION", 36, 45], ["microglia", "ANATOMY", 96, 105], ["cell survival", "OBSERVATION", 118, 131], ["microglial cell line", "OBSERVATION", 217, 237], ["infection", "OBSERVATION", 357, 366]]], ["Importantly, we demonstrated that the intracellular expression of the HIV-1 Tat protein was able to induce a strong cytoprotective effect in CHME5 cells.", [["intracellular", "ANATOMY", 38, 51], ["CHME5 cells", "ANATOMY", 141, 152], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["HIV-1", "ORGANISM", 70, 75], ["Tat", "GENE_OR_GENE_PRODUCT", 76, 79], ["CHME5 cells", "CELL", 141, 152], ["HIV-1 Tat protein", "PROTEIN", 70, 87], ["CHME5 cells", "CELL_LINE", 141, 152], ["HIV-1", "SPECIES", 70, 75], ["HIV-1", "SPECIES", 70, 75], ["the HIV", "TEST", 66, 73], ["Tat protein", "TEST", 76, 87], ["a strong cytoprotective effect in CHME5 cells", "PROBLEM", 107, 152], ["CHME5 cells", "OBSERVATION", 141, 152]]], ["The possibility that secreted Tat protein from the CHME5 cells expressing Tat may also induce the same effect was eliminated when we observed that CHME5 cells treated with recombinant Tat protein (0.2 \u03bcM) did not show increased cell survival (data not shown).", [["CHME5 cells", "ANATOMY", 51, 62], ["CHME5 cells", "ANATOMY", 147, 158], ["cell", "ANATOMY", 228, 232], ["Tat", "GENE_OR_GENE_PRODUCT", 30, 33], ["CHME5 cells", "CELL", 51, 62], ["Tat", "GENE_OR_GENE_PRODUCT", 74, 77], ["CHME5 cells", "CELL", 147, 158], ["Tat", "GENE_OR_GENE_PRODUCT", 184, 187], ["cell", "CELL", 228, 232], ["Tat protein", "PROTEIN", 30, 41], ["CHME5 cells", "CELL_LINE", 51, 62], ["Tat", "PROTEIN", 74, 77], ["CHME5 cells", "CELL_LINE", 147, 158], ["recombinant Tat protein", "PROTEIN", 172, 195], ["secreted Tat protein", "PROBLEM", 21, 41], ["the CHME5 cells", "TREATMENT", 47, 62], ["CHME5 cells", "PROBLEM", 147, 158], ["recombinant Tat protein", "TEST", 172, 195], ["increased cell survival", "PROBLEM", 218, 241], ["possibility", "UNCERTAINTY", 4, 15], ["increased cell survival", "OBSERVATION", 218, 241]]], ["Furthermore, we later confirmed that primary human monocyte-derived macrophages infected with HIV-1 also exhibited prolonged survival upon cytotoxic challenges, further validating the CHME5 microglial cells as a model system to study the molecular mechanisms involved with the cytoprotective effect.DiscussionOne of the most extensively studied survival pathways is the PI-3-K/Akt pathway.", [["monocyte", "ANATOMY", 51, 59], ["macrophages", "ANATOMY", 68, 79], ["CHME5 microglial cells", "ANATOMY", 184, 206], ["human", "ORGANISM", 45, 50], ["monocyte", "CELL", 51, 59], ["macrophages", "CELL", 68, 79], ["HIV-1", "ORGANISM", 94, 99], ["CHME5 microglial cells", "CELL", 184, 206], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 370, 376], ["Akt", "GENE_OR_GENE_PRODUCT", 377, 380], ["primary human monocyte", "CELL_TYPE", 37, 59], ["macrophages", "CELL_TYPE", 68, 79], ["CHME5 microglial cells", "CELL_LINE", 184, 206], ["PI-3-K", "PROTEIN", 370, 376], ["Akt", "PROTEIN", 377, 380], ["human", "SPECIES", 45, 50], ["HIV-1", "SPECIES", 94, 99], ["human", "SPECIES", 45, 50], ["HIV-1", "SPECIES", 94, 99], ["primary human monocyte", "TEST", 37, 59], ["HIV", "PROBLEM", 94, 97], ["cytotoxic challenges", "TREATMENT", 139, 159], ["the CHME5 microglial cells", "TREATMENT", 180, 206], ["the cytoprotective effect", "TREATMENT", 273, 298], ["the PI", "TEST", 366, 372], ["microglial cells", "OBSERVATION", 190, 206], ["cytoprotective effect", "OBSERVATION", 277, 298]]], ["32, 49 We therefore tested the possible involvement of the PI-3-K/ Akt pathway using Wortmannin and LY294002, two unrelated inhibitors specific for PI-3-K.", [["Wortmannin", "CHEMICAL", 85, 95], ["LY294002", "CHEMICAL", 100, 108], ["Wortmannin", "CHEMICAL", 85, 95], ["LY294002", "CHEMICAL", 100, 108], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 59, 65], ["Akt", "GENE_OR_GENE_PRODUCT", 67, 70], ["Wortmannin", "SIMPLE_CHEMICAL", 85, 95], ["LY294002", "SIMPLE_CHEMICAL", 100, 108], ["PI-3", "GENE_OR_GENE_PRODUCT", 148, 152], ["PI-3-K", "PROTEIN", 59, 65], ["Akt", "PROTEIN", 67, 70], ["the PI", "TEST", 55, 61], ["Wortmannin", "TREATMENT", 85, 95], ["LY294002", "TREATMENT", 100, 108], ["two unrelated inhibitors", "TREATMENT", 110, 134], ["PI", "TEST", 148, 150]]], ["Both of these inhibitors reversed the survival effect induced by the expression of Tat, suggesting that the PI-3-K pathway is indeed involved in the pro-survival effect of Tat in CHME5 cells.", [["CHME5 cells", "ANATOMY", 179, 190], ["Tat", "GENE_OR_GENE_PRODUCT", 83, 86], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 108, 114], ["Tat", "GENE_OR_GENE_PRODUCT", 172, 175], ["CHME5 cells", "CELL", 179, 190], ["Tat", "PROTEIN", 83, 86], ["PI-3-K", "PROTEIN", 108, 114], ["Tat", "PROTEIN", 172, 175], ["CHME5 cells", "CELL_LINE", 179, 190], ["these inhibitors", "TREATMENT", 8, 24], ["the PI", "TEST", 104, 110], ["Tat in CHME5 cells", "TREATMENT", 172, 190]]], ["This interpretation was confirmed using an independent genetic test in which cells were transfected with a dominant negative (kinase inactive) Akt mutant; 41 this led to the restoration of cell death in Tat-expressing cells.", [["cells", "ANATOMY", 77, 82], ["cell", "ANATOMY", 189, 193], ["cells", "ANATOMY", 218, 223], ["cells", "CELL", 77, 82], ["Akt", "GENE_OR_GENE_PRODUCT", 143, 146], ["cell", "CELL", 189, 193], ["Tat", "GENE_OR_GENE_PRODUCT", 203, 206], ["cells", "CELL", 218, 223], ["dominant negative (kinase inactive", "PROTEIN", 107, 141], ["Akt", "PROTEIN", 143, 146], ["Tat", "PROTEIN", 203, 206], ["expressing cells", "CELL_TYPE", 207, 223], ["an independent genetic test", "TEST", 40, 67], ["cell death", "PROBLEM", 189, 199], ["cell death", "OBSERVATION", 189, 199]]], ["This mutant, however, did not affect the sensitivity of the control cells to cell death in response to LPS and CHX.", [["cells", "ANATOMY", 68, 73], ["cell", "ANATOMY", 77, 81], ["death", "DISEASE", 82, 87], ["LPS", "CHEMICAL", 103, 106], ["CHX", "CHEMICAL", 111, 114], ["CHX", "CHEMICAL", 111, 114], ["cells", "CELL", 68, 73], ["cell", "CELL", 77, 81], ["LPS", "SIMPLE_CHEMICAL", 103, 106], ["CHX", "SIMPLE_CHEMICAL", 111, 114], ["control cells", "CELL_TYPE", 60, 73], ["cell death", "PROBLEM", 77, 87], ["LPS", "TEST", 103, 106], ["CHX", "TREATMENT", 111, 114]]], ["These data strongly suggest that Tat promotes survival in microglia via activation of the PI-3-K/Akt pathway.DiscussionThe same phenotype has been observed in cells infected by oncogenic viruses or cells that express viral oncogenes such as the E6/E7 gene products of human papilloma virus type 16 (HPV-16).", [["microglia", "ANATOMY", 58, 67], ["cells", "ANATOMY", 159, 164], ["cells", "ANATOMY", 198, 203], ["human papilloma virus", "DISEASE", 268, 289], ["Tat", "GENE_OR_GENE_PRODUCT", 33, 36], ["microglia", "CELL", 58, 67], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 90, 96], ["Akt", "GENE_OR_GENE_PRODUCT", 97, 100], ["cells", "CELL", 159, 164], ["cells", "CELL", 198, 203], ["E6", "GENE_OR_GENE_PRODUCT", 245, 247], ["E7", "GENE_OR_GENE_PRODUCT", 248, 250], ["human papilloma virus type 16", "ORGANISM", 268, 297], ["HPV-16", "ORGANISM", 299, 305], ["Tat", "PROTEIN", 33, 36], ["microglia", "CELL_TYPE", 58, 67], ["PI-3-K", "PROTEIN", 90, 96], ["Akt", "PROTEIN", 97, 100], ["viral oncogenes", "DNA", 217, 232], ["E6/E7 gene products", "PROTEIN", 245, 264], ["human papilloma virus", "SPECIES", 268, 289], ["human papilloma virus type 16 (HPV-16", "SPECIES", 268, 305], ["the PI", "TEST", 86, 92], ["K/Akt pathway", "TREATMENT", 95, 108], ["oncogenic viruses or cells", "PROBLEM", 177, 203], ["viral oncogenes", "PROBLEM", 217, 232], ["the E6/E7 gene products", "TREATMENT", 241, 264], ["human papilloma virus type", "PROBLEM", 268, 294], ["HPV", "TEST", 299, 302], ["oncogenic viruses", "OBSERVATION", 177, 194]]], ["50, 51 Consistent with the activation of the PI-3-K/Akt pathway, expression of HIV-1 Tat protein in CHME5 cells also repressed the transcription activation activity of p53, while stimulating that of E2F.", [["CHME5 cells", "ANATOMY", 100, 111], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 45, 51], ["Akt", "GENE_OR_GENE_PRODUCT", 52, 55], ["HIV-1", "ORGANISM", 79, 84], ["Tat", "GENE_OR_GENE_PRODUCT", 85, 88], ["CHME5 cells", "CELL", 100, 111], ["p53", "GENE_OR_GENE_PRODUCT", 168, 171], ["E2F", "GENE_OR_GENE_PRODUCT", 199, 202], ["PI-3-K", "PROTEIN", 45, 51], ["Akt", "PROTEIN", 52, 55], ["HIV-1 Tat protein", "PROTEIN", 79, 96], ["CHME5 cells", "CELL_LINE", 100, 111], ["p53", "PROTEIN", 168, 171], ["E2F", "PROTEIN", 199, 202], ["HIV-1", "SPECIES", 79, 84], ["HIV-1", "SPECIES", 79, 84], ["the PI", "TEST", 41, 47], ["K/Akt pathway", "TREATMENT", 50, 63], ["HIV", "TEST", 79, 82], ["Tat protein in CHME5 cells", "PROBLEM", 85, 111]]], ["These changes are reflective of enhanced proliferative activity likely without actual cell division since primary microglia are terminally differentiated/ non-dividing cells.DiscussionBased on the data presented in Figure 6 , the expression of HIV-1 Tat induced the (1) decrease of PTEN, (2) the decrease of p53 function and (3) increase of E2F activity.", [["cell", "ANATOMY", 86, 90], ["primary microglia", "ANATOMY", 106, 123], ["cells", "ANATOMY", 168, 173], ["cell", "CELL", 86, 90], ["microglia", "CELL", 114, 123], ["cells", "CELL", 168, 173], ["HIV-1", "ORGANISM", 244, 249], ["Tat", "ORGANISM", 250, 253], ["PTEN", "GENE_OR_GENE_PRODUCT", 282, 286], ["p53", "GENE_OR_GENE_PRODUCT", 308, 311], ["E2F", "GENE_OR_GENE_PRODUCT", 341, 344], ["primary microglia", "CELL_TYPE", 106, 123], ["terminally differentiated/ non-dividing cells", "CELL_TYPE", 128, 173], ["HIV-1 Tat", "PROTEIN", 244, 253], ["PTEN", "PROTEIN", 282, 286], ["p53", "PROTEIN", 308, 311], ["E2F", "PROTEIN", 341, 344], ["HIV-1", "SPECIES", 244, 249], ["HIV-1", "SPECIES", 244, 249], ["enhanced proliferative activity", "PROBLEM", 32, 63], ["primary microglia", "PROBLEM", 106, 123], ["terminally differentiated/ non-dividing cells", "PROBLEM", 128, 173], ["HIV", "PROBLEM", 244, 247], ["decrease of PTEN", "PROBLEM", 270, 286], ["the decrease of p53 function", "PROBLEM", 292, 320], ["E2F activity", "TREATMENT", 341, 353], ["enhanced", "OBSERVATION_MODIFIER", 32, 40], ["proliferative activity", "OBSERVATION", 41, 63], ["likely without", "UNCERTAINTY", 64, 78], ["actual cell division", "OBSERVATION", 79, 99], ["primary microglia", "OBSERVATION", 106, 123], ["non-dividing cells", "OBSERVATION", 155, 173], ["E2F activity", "OBSERVATION", 341, 353]]], ["We therefore modeled the mechanism of intracellular HIV-1 Tat and HIV-1 infection-induced cell survival in the CHME5 human microglia system (Figure 9 ).", [["intracellular", "ANATOMY", 38, 51], ["cell", "ANATOMY", 90, 94], ["microglia system", "ANATOMY", 123, 139], ["infection", "DISEASE", 72, 81], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["HIV-1 Tat", "ORGANISM", 52, 61], ["HIV-1", "ORGANISM", 66, 71], ["cell", "CELL", 90, 94], ["human", "ORGANISM", 117, 122], ["microglia", "CELL", 123, 132], ["HIV-1", "SPECIES", 52, 57], ["HIV-1", "SPECIES", 66, 71], ["human", "SPECIES", 117, 122], ["HIV-1", "SPECIES", 52, 57], ["HIV-1", "SPECIES", 66, 71], ["human", "SPECIES", 117, 122], ["intracellular HIV", "PROBLEM", 38, 55], ["HIV", "PROBLEM", 66, 69], ["1 infection", "PROBLEM", 70, 81], ["cell survival", "PROBLEM", 90, 103], ["cell survival", "OBSERVATION", 90, 103]]], ["It is known that both Tat and PTEN bind to the C-terminal region of p53, and therefore these two proteins may compete with each other for p53.", [["C", "CHEMICAL", 47, 48], ["Tat", "GENE_OR_GENE_PRODUCT", 22, 25], ["PTEN", "GENE_OR_GENE_PRODUCT", 30, 34], ["p53", "GENE_OR_GENE_PRODUCT", 68, 71], ["p53", "GENE_OR_GENE_PRODUCT", 138, 141], ["Tat", "PROTEIN", 22, 25], ["PTEN", "PROTEIN", 30, 34], ["C-terminal region", "PROTEIN", 47, 64], ["p53", "PROTEIN", 68, 71], ["p53", "PROTEIN", 138, 141], ["both Tat and PTEN bind", "PROBLEM", 17, 39], ["p53", "PROBLEM", 138, 141], ["terminal", "ANATOMY_MODIFIER", 49, 57]]], ["Importantly, PTEN binding to p53 stabilizes p53, and p53 upregulates PTEN expression transcriptionally.", [["PTEN", "GENE_OR_GENE_PRODUCT", 13, 17], ["p53", "GENE_OR_GENE_PRODUCT", 29, 32], ["p53", "GENE_OR_GENE_PRODUCT", 44, 47], ["p53", "GENE_OR_GENE_PRODUCT", 53, 56], ["PTEN", "GENE_OR_GENE_PRODUCT", 69, 73], ["PTEN", "PROTEIN", 13, 17], ["p53", "PROTEIN", 29, 32], ["p53", "PROTEIN", 44, 47], ["p53", "PROTEIN", 53, 56], ["PTEN", "PROTEIN", 69, 73]]], ["43 Therefore, expression of Tat and HIV-1 infection possibly induce the destabilization of p53 by competing with PTEN, and this ultimately leads to the decrease of PTEN levels, which we observed in Figure 6 (a).", [["infection", "DISEASE", 42, 51], ["Tat", "GENE_OR_GENE_PRODUCT", 28, 31], ["HIV-1", "ORGANISM", 36, 41], ["p53", "GENE_OR_GENE_PRODUCT", 91, 94], ["PTEN", "GENE_OR_GENE_PRODUCT", 113, 117], ["PTEN", "GENE_OR_GENE_PRODUCT", 164, 168], ["Tat", "PROTEIN", 28, 31], ["p53", "PROTEIN", 91, 94], ["PTEN", "PROTEIN", 113, 117], ["PTEN", "PROTEIN", 164, 168], ["HIV-1", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 36, 41], ["Tat and HIV-1 infection", "PROBLEM", 28, 51], ["the destabilization of p53", "PROBLEM", 68, 94], ["PTEN", "PROBLEM", 113, 117], ["the decrease of PTEN levels", "PROBLEM", 148, 175], ["decrease", "OBSERVATION_MODIFIER", 152, 160]]], ["The decreased PTEN level is known to facilitate the activation of the PI-3-K/Akt pathway, which directly promotes cell proliferation and cell survival (pathway A in Figure 9 ).", [["cell", "ANATOMY", 114, 118], ["cell", "ANATOMY", 137, 141], ["PTEN", "GENE_OR_GENE_PRODUCT", 14, 18], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 70, 76], ["Akt", "GENE_OR_GENE_PRODUCT", 77, 80], ["cell", "CELL", 114, 118], ["cell", "CELL", 137, 141], ["PTEN", "PROTEIN", 14, 18], ["PI-3-K", "PROTEIN", 70, 76], ["Akt", "PROTEIN", 77, 80], ["The decreased PTEN level", "PROBLEM", 0, 24], ["the PI", "TEST", 66, 72], ["K/Akt pathway", "TREATMENT", 75, 88], ["decreased", "OBSERVATION_MODIFIER", 4, 13], ["PTEN", "OBSERVATION", 14, 18], ["cell proliferation", "OBSERVATION", 114, 132], ["cell survival", "OBSERVATION", 137, 150]]], ["In addition, the decrease of p53 function by HIV-1 Tat expression may also lead to the activation of cell proliferation signals such as the E2F transcription factor, following release from Rb (pathway B in Figure 9 ).", [["cell", "ANATOMY", 101, 105], ["p53", "GENE_OR_GENE_PRODUCT", 29, 32], ["HIV-1", "ORGANISM", 45, 50], ["Tat", "GENE_OR_GENE_PRODUCT", 51, 54], ["cell", "CELL", 101, 105], ["E2F", "GENE_OR_GENE_PRODUCT", 140, 143], ["Rb", "GENE_OR_GENE_PRODUCT", 189, 191], ["p53", "PROTEIN", 29, 32], ["Tat", "PROTEIN", 51, 54], ["E2F transcription factor", "PROTEIN", 140, 164], ["Rb", "PROTEIN", 189, 191], ["pathway B", "PROTEIN", 193, 202], ["HIV-1", "SPECIES", 45, 50], ["HIV-1", "SPECIES", 45, 50], ["the decrease of p53 function", "PROBLEM", 13, 41], ["HIV", "PROBLEM", 45, 48], ["cell proliferation signals", "PROBLEM", 101, 127], ["decrease", "OBSERVATION_MODIFIER", 17, 25], ["cell proliferation", "OBSERVATION", 101, 119]]], ["The free E2F can then Figure 9 .", [["E2F", "GENE_OR_GENE_PRODUCT", 9, 12], ["E2F", "PROTEIN", 9, 12]]], ["Model for the cytoprotective mechanism exerted by HIV-1 infection and intracellular HIV-1 Tat expression in microglial cells.", [["intracellular", "ANATOMY", 70, 83], ["microglial cells", "ANATOMY", 108, 124], ["infection", "DISEASE", 56, 65], ["HIV-1", "ORGANISM", 50, 55], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 83], ["HIV-1", "ORGANISM", 84, 89], ["Tat", "GENE_OR_GENE_PRODUCT", 90, 93], ["microglial cells", "CELL", 108, 124], ["Tat", "PROTEIN", 90, 93], ["microglial cells", "CELL_TYPE", 108, 124], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 84, 89], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 84, 89], ["the cytoprotective mechanism", "PROBLEM", 10, 38], ["HIV-1 infection", "PROBLEM", 50, 65], ["intracellular HIV", "PROBLEM", 70, 87], ["Tat expression in microglial cells", "PROBLEM", 90, 124], ["microglial cells", "OBSERVATION", 108, 124]]], ["HIV-1 infection or expression of intracellular HIV-1 Tat results in decreased PTEN expression which alleviates the restraint on activation of the PI-3-K/Akt pathway.", [["intracellular", "ANATOMY", 33, 46], ["infection", "DISEASE", 6, 15], ["HIV-1", "ORGANISM", 0, 5], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["HIV-1", "ORGANISM", 47, 52], ["Tat", "GENE_OR_GENE_PRODUCT", 53, 56], ["PTEN", "GENE_OR_GENE_PRODUCT", 78, 82], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 146, 152], ["Akt", "GENE_OR_GENE_PRODUCT", 153, 156], ["Tat", "PROTEIN", 53, 56], ["PTEN", "PROTEIN", 78, 82], ["PI-3-K", "PROTEIN", 146, 152], ["Akt", "PROTEIN", 153, 156], ["HIV-1", "SPECIES", 0, 5], ["HIV", "SPECIES", 47, 50], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 47, 52], ["HIV", "PROBLEM", 0, 3], ["1 infection", "PROBLEM", 4, 15], ["intracellular HIV", "PROBLEM", 33, 50], ["decreased PTEN expression", "PROBLEM", 68, 93], ["the PI", "TEST", 142, 148], ["K/Akt pathway", "TREATMENT", 151, 164], ["infection", "OBSERVATION", 6, 15], ["intracellular HIV", "OBSERVATION", 33, 50], ["decreased", "OBSERVATION_MODIFIER", 68, 77], ["PTEN expression", "OBSERVATION", 78, 93]]], ["The increased activation of PI-3-K and Akt leads to long-term cellular survival.", [["cellular", "ANATOMY", 62, 70], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 28, 34], ["Akt", "GENE_OR_GENE_PRODUCT", 39, 42], ["cellular", "CELL", 62, 70], ["PI-3-K", "PROTEIN", 28, 34], ["Akt", "PROTEIN", 39, 42], ["PI", "TEST", 28, 30], ["long-term cellular survival", "TREATMENT", 52, 79], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["long-term", "OBSERVATION_MODIFIER", 52, 61], ["cellular survival", "OBSERVATION", 62, 79]]], ["85 Intracellular Tat can also decrease activity of p53, which in turn leads to progression through the cell cycle, activating the E2F transcription factor and proliferation-specific signals.", [["Intracellular", "ANATOMY", 3, 16], ["cell", "ANATOMY", 103, 107], ["Tat", "GENE_OR_GENE_PRODUCT", 17, 20], ["p53", "GENE_OR_GENE_PRODUCT", 51, 54], ["cell", "CELL", 103, 107], ["E2F", "GENE_OR_GENE_PRODUCT", 130, 133], ["Tat", "PROTEIN", 17, 20], ["p53", "PROTEIN", 51, 54], ["E2F", "PROTEIN", 130, 133], ["transcription factor", "PROTEIN", 134, 154], ["Intracellular Tat", "TEST", 3, 20], ["decrease activity of p53", "PROBLEM", 30, 54], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["activity", "OBSERVATION_MODIFIER", 39, 47]]], ["86 E2F also regulates survival by transcriptionally activating an upstream adaptor protein involved in the activation of the PI-3-K/Akt pathway.", [["E2F", "GENE_OR_GENE_PRODUCT", 3, 6], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 125, 131], ["Akt", "GENE_OR_GENE_PRODUCT", 132, 135], ["E2F", "PROTEIN", 3, 6], ["upstream adaptor protein", "PROTEIN", 66, 90], ["PI-3-K", "PROTEIN", 125, 131], ["Akt", "PROTEIN", 132, 135], ["an upstream adaptor protein", "TREATMENT", 63, 90], ["the PI", "TEST", 121, 127], ["K/Akt pathway", "TREATMENT", 130, 143]]], ["52 The combined modulation of PTEN and p53 by expression of Tat leads to the increased activation of proliferation and long-term cellular survival exhibited in microglia during HIV-1 infection: dotted lines, negative regulation; thick arrows, positive regulation; thin arrows, effects of intracellular Tat expression and HIV-1 infection.Discussionup-regulate a number of genes essential for G1/S transition and cell proliferation, which is a key mechanism in cellular survival.", [["cellular", "ANATOMY", 129, 137], ["microglia", "ANATOMY", 160, 169], ["intracellular", "ANATOMY", 288, 301], ["cell", "ANATOMY", 411, 415], ["cellular", "ANATOMY", 459, 467], ["infection", "DISEASE", 183, 192], ["HIV-1 infection", "DISEASE", 321, 336], ["PTEN", "GENE_OR_GENE_PRODUCT", 30, 34], ["p53", "GENE_OR_GENE_PRODUCT", 39, 42], ["Tat", "GENE_OR_GENE_PRODUCT", 60, 63], ["cellular", "CELL", 129, 137], ["microglia", "CELL", 160, 169], ["HIV-1", "ORGANISM", 177, 182], ["lines", "CELL", 201, 206], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 288, 301], ["Tat", "GENE_OR_GENE_PRODUCT", 302, 305], ["HIV-1", "ORGANISM", 321, 326], ["cell", "CELL", 411, 415], ["cellular", "CELL", 459, 467], ["PTEN", "PROTEIN", 30, 34], ["p53", "PROTEIN", 39, 42], ["Tat", "PROTEIN", 60, 63], ["microglia", "CELL_TYPE", 160, 169], ["Tat", "PROTEIN", 302, 305], ["HIV-1", "SPECIES", 177, 182], ["HIV-1", "SPECIES", 321, 326], ["HIV-1", "SPECIES", 177, 182], ["HIV-1", "SPECIES", 321, 326], ["PTEN and p53", "PROBLEM", 30, 42], ["the increased activation of proliferation", "PROBLEM", 73, 114], ["long-term cellular survival", "PROBLEM", 119, 146], ["microglia during HIV-1 infection", "PROBLEM", 160, 192], ["thick arrows", "PROBLEM", 229, 241], ["positive regulation", "PROBLEM", 243, 262], ["thin arrows", "PROBLEM", 264, 275], ["intracellular Tat expression", "PROBLEM", 288, 316], ["HIV-1 infection", "PROBLEM", 321, 336], ["G1/S transition", "PROBLEM", 391, 406], ["cell proliferation", "PROBLEM", 411, 429], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["proliferation", "OBSERVATION_MODIFIER", 101, 114], ["long-term cellular", "OBSERVATION_MODIFIER", 119, 137], ["Tat expression", "OBSERVATION", 302, 316], ["infection", "OBSERVATION", 327, 336], ["cell proliferation", "OBSERVATION", 411, 429], ["cellular survival", "OBSERVATION", 459, 476]]], ["E2F also transcriptionally induces expression of an adaptor protein involved in the activation of the Akt pathway, an upstream mechanism of regulating this survival pathway.", [["E2F", "GENE_OR_GENE_PRODUCT", 0, 3], ["Akt", "GENE_OR_GENE_PRODUCT", 102, 105], ["E2F", "PROTEIN", 0, 3], ["adaptor protein", "PROTEIN", 52, 67], ["Akt", "PROTEIN", 102, 105], ["an adaptor protein", "TREATMENT", 49, 67], ["this survival pathway", "TREATMENT", 151, 172]]], ["52 Future studies on downstream cellular factors involved in Akt cellular survival (i.e. GSK3\u03b2, Bad) and cell cycle control pathways (p53, MDM2, p21 Cip1 , CyclinD and Rb) may reveal more precisely the point at which Tat influences cell signaling cascades in microglia, in order to elicit its protective effect.", [["cellular", "ANATOMY", 32, 40], ["cellular", "ANATOMY", 65, 73], ["cell", "ANATOMY", 105, 109], ["cell", "ANATOMY", 232, 236], ["microglia", "ANATOMY", 259, 268], ["cellular", "CELL", 32, 40], ["Akt", "GENE_OR_GENE_PRODUCT", 61, 64], ["cellular", "CELL", 65, 73], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 89, 94], ["Bad", "GENE_OR_GENE_PRODUCT", 96, 99], ["cell", "CELL", 105, 109], ["p53", "GENE_OR_GENE_PRODUCT", 134, 137], ["MDM2", "GENE_OR_GENE_PRODUCT", 139, 143], ["p21 Cip1", "GENE_OR_GENE_PRODUCT", 145, 153], ["CyclinD", "GENE_OR_GENE_PRODUCT", 156, 163], ["Rb", "GENE_OR_GENE_PRODUCT", 168, 170], ["Tat", "GENE_OR_GENE_PRODUCT", 217, 220], ["cell", "CELL", 232, 236], ["microglia", "CELL", 259, 268], ["downstream cellular factors", "PROTEIN", 21, 48], ["Akt", "PROTEIN", 61, 64], ["GSK3\u03b2", "PROTEIN", 89, 94], ["Bad", "PROTEIN", 96, 99], ["p53", "PROTEIN", 134, 137], ["MDM2", "PROTEIN", 139, 143], ["p21 Cip1", "PROTEIN", 145, 153], ["CyclinD", "PROTEIN", 156, 163], ["Rb", "PROTEIN", 168, 170], ["Tat", "PROTEIN", 217, 220], ["microglia", "CELL_TYPE", 259, 268], ["Future studies", "TEST", 3, 17], ["Akt cellular survival", "TREATMENT", 61, 82], ["GSK3\u03b2", "TEST", 89, 94], ["cell cycle control pathways", "TEST", 105, 132], ["p53", "TEST", 134, 137], ["MDM2", "TEST", 139, 143], ["Cip1", "TEST", 149, 153], ["Tat influences cell signaling cascades in microglia", "PROBLEM", 217, 268]]], ["29, 30, [53] [54] [55] In addition to HIV-1, many viruses have developed mechanisms of hijacking the PI-3-K/Akt pathway to benefit their particular needs, whether it is for enhancement of viral replication, cellular proliferation or aiding in the establishment of a persistent infection.", [["cellular", "ANATOMY", 207, 215], ["infection", "DISEASE", 277, 286], ["[53] [54] [55", "SIMPLE_CHEMICAL", 8, 21], ["HIV-1", "ORGANISM", 38, 43], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 101, 107], ["Akt", "GENE_OR_GENE_PRODUCT", 108, 111], ["cellular", "CELL", 207, 215], ["PI-3-K", "PROTEIN", 101, 107], ["Akt", "PROTEIN", 108, 111], ["HIV-1", "SPECIES", 38, 43], ["HIV", "TEST", 38, 41], ["many viruses", "PROBLEM", 45, 57], ["the PI", "TEST", 97, 103], ["viral replication", "PROBLEM", 188, 205], ["cellular proliferation", "PROBLEM", 207, 229], ["a persistent infection", "PROBLEM", 264, 286], ["viruses", "OBSERVATION", 50, 57], ["viral replication", "OBSERVATION", 188, 205], ["cellular proliferation", "OBSERVATION", 207, 229], ["persistent", "OBSERVATION_MODIFIER", 266, 276], ["infection", "OBSERVATION", 277, 286]]], ["For example, tumor-causing viruses such as human papilloma virus (HPV), 56 Epstein Barr virus (EBV) 57 and polyoma virus 58 employ viral genes to activate proliferation through this pathway, resulting in cellular transformation.", [["tumor", "ANATOMY", 13, 18], ["cellular", "ANATOMY", 204, 212], ["tumor", "DISEASE", 13, 18], ["human papilloma virus", "DISEASE", 43, 64], ["tumor", "CANCER", 13, 18], ["human papilloma virus", "ORGANISM", 43, 64], ["HPV", "ORGANISM", 66, 69], ["56", "ORGANISM", 72, 74], ["Epstein Barr virus", "ORGANISM", 75, 93], ["EBV) 57", "ORGANISM", 95, 102], ["polyoma virus 58", "ORGANISM", 107, 123], ["cellular", "CELL", 204, 212], ["viral genes", "DNA", 131, 142], ["human", "SPECIES", 43, 48], ["papilloma virus", "SPECIES", 49, 64], ["Epstein Barr virus", "SPECIES", 75, 93], ["polyoma virus", "SPECIES", 107, 120], ["human papilloma virus", "SPECIES", 43, 64], ["HPV", "SPECIES", 66, 69], ["Epstein Barr virus", "SPECIES", 75, 93], ["EBV", "SPECIES", 95, 98], ["polyoma virus 58", "SPECIES", 107, 123], ["tumor", "PROBLEM", 13, 18], ["viruses", "PROBLEM", 27, 34], ["human papilloma virus (HPV)", "PROBLEM", 43, 70], ["Epstein Barr virus (EBV)", "TEST", 75, 99], ["polyoma virus", "PROBLEM", 107, 120], ["viral genes", "PROBLEM", 131, 142], ["cellular transformation", "PROBLEM", 204, 227], ["tumor", "OBSERVATION", 13, 18], ["papilloma virus", "OBSERVATION", 49, 64], ["cellular transformation", "OBSERVATION", 204, 227]]], ["Other viruses such as human cytomegalovirus (HCMV), 59 herpes simplex virus type 1(HSV-1) 60 and EBV 61 utilize viral proteins and downstream effectors of Akt to increase viral replication.", [["human cytomegalovirus (HCMV)", "DISEASE", 22, 50], ["herpes simplex virus", "DISEASE", 55, 75], ["human cytomegalovirus", "ORGANISM", 22, 43], ["HCMV", "ORGANISM", 45, 49], ["59 herpes simplex virus type 1", "ORGANISM", 52, 82], ["HSV-1) 60", "ORGANISM", 83, 92], ["EBV 61", "ORGANISM", 97, 103], ["Akt", "GENE_OR_GENE_PRODUCT", 155, 158], ["viral proteins", "PROTEIN", 112, 126], ["downstream effectors", "PROTEIN", 131, 151], ["Akt", "PROTEIN", 155, 158], ["human", "SPECIES", 22, 27], ["herpes simplex virus type 1", "SPECIES", 55, 82], ["HSV-1", "SPECIES", 83, 88], ["human cytomegalovirus", "SPECIES", 22, 43], ["HCMV", "SPECIES", 45, 49], ["herpes simplex virus type 1", "SPECIES", 55, 82], ["HSV-1", "SPECIES", 83, 88], ["Other viruses", "PROBLEM", 0, 13], ["human cytomegalovirus", "TEST", 22, 43], ["HCMV", "TEST", 45, 49], ["herpes simplex virus type", "TEST", 55, 80], ["HSV", "TEST", 83, 86], ["EBV", "TEST", 97, 100], ["viral proteins", "TREATMENT", 112, 126], ["viral replication", "TREATMENT", 171, 188], ["viruses", "OBSERVATION", 6, 13], ["viral replication", "OBSERVATION", 171, 188]]], ["However, as is the case with our HIV-1 Tat results, most viruses hijack this particular pathway to promote cellular survival and therefore establish a persistent infection.", [["cellular", "ANATOMY", 107, 115], ["infection", "DISEASE", 162, 171], ["HIV-1", "ORGANISM", 33, 38], ["Tat", "ORGANISM", 39, 42], ["cellular", "CELL", 107, 115], ["Tat", "PROTEIN", 39, 42], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["cellular survival", "TREATMENT", 107, 124], ["a persistent infection", "PROBLEM", 149, 171], ["persistent", "OBSERVATION_MODIFIER", 151, 161], ["infection", "OBSERVATION", 162, 171]]], ["Hepatitis C virus (HCV), 36 SARS CoV 62 and EBV 63 activate Akt to establish persistence and latency.DiscussionEvidence suggests that PI-3-K/Akt activation prevents cellular death by modulating functions of pro-apoptotic molecules such as GSK-3\u03b2, 64 Bad and the BH3-interacting domain death agonist BID.", [["cellular", "ANATOMY", 165, 173], ["Hepatitis C", "DISEASE", 0, 11], ["SARS", "DISEASE", 28, 32], ["PI-3-K", "CHEMICAL", 134, 140], ["death", "DISEASE", 174, 179], ["death", "DISEASE", 285, 290], ["BID", "CHEMICAL", 299, 302], ["Hepatitis C virus", "ORGANISM", 0, 17], ["HCV", "ORGANISM", 19, 22], ["SARS CoV 62", "ORGANISM", 28, 39], ["EBV", "ORGANISM", 44, 47], ["63", "ORGANISM", 48, 50], ["Akt", "GENE_OR_GENE_PRODUCT", 60, 63], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 134, 140], ["Akt", "GENE_OR_GENE_PRODUCT", 141, 144], ["cellular", "CELL", 165, 173], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 239, 245], ["Bad", "GENE_OR_GENE_PRODUCT", 250, 253], ["BH3", "GENE_OR_GENE_PRODUCT", 262, 265], ["BID", "SIMPLE_CHEMICAL", 299, 302], ["Akt", "PROTEIN", 60, 63], ["PI-3-K", "PROTEIN", 134, 140], ["Akt", "PROTEIN", 141, 144], ["pro-apoptotic molecules", "PROTEIN", 207, 230], ["GSK-3\u03b2", "PROTEIN", 239, 245], ["64 Bad", "PROTEIN", 247, 253], ["BH3", "PROTEIN", 262, 265], ["Hepatitis C virus", "SPECIES", 0, 17], ["Hepatitis C virus", "SPECIES", 0, 17], ["HCV", "SPECIES", 19, 22], ["SARS CoV 62", "SPECIES", 28, 39], ["Hepatitis C virus (HCV)", "PROBLEM", 0, 23], ["SARS CoV", "TEST", 28, 36], ["EBV", "TEST", 44, 47], ["latency", "PROBLEM", 93, 100], ["PI", "TEST", 134, 136], ["K/Akt activation", "TREATMENT", 139, 155], ["cellular death", "PROBLEM", 165, 179], ["pro-apoptotic molecules", "PROBLEM", 207, 230], ["latency", "OBSERVATION_MODIFIER", 93, 100], ["cellular death", "OBSERVATION", 165, 179]]], ["65 This leads to the inhibition of caspase 1, 3, and 9-like activity and the modulation of mitochondrial membrane potential and cytochrome c release.", [["mitochondrial membrane", "ANATOMY", 91, 113], ["caspase 1", "GENE_OR_GENE_PRODUCT", 35, 44], ["3", "GENE_OR_GENE_PRODUCT", 46, 47], ["9", "GENE_OR_GENE_PRODUCT", 53, 54], ["mitochondrial membrane", "CELLULAR_COMPONENT", 91, 113], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 128, 140], ["caspase 1, 3, and 9", "PROTEIN", 35, 54], ["cytochrome c", "PROTEIN", 128, 140], ["caspase", "TREATMENT", 35, 42], ["cytochrome c release", "TREATMENT", 128, 148], ["mitochondrial membrane", "OBSERVATION", 91, 113]]], ["66, 67 The cytoprotective actions of PI-3-K/Akt also involve the upregulated expression of survivalpromoting genes such as Bcl-2, Bcl-xL, and c-IAP.", [["PI-3-K", "CHEMICAL", 37, 43], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 37, 43], ["Akt", "GENE_OR_GENE_PRODUCT", 44, 47], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 123, 128], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 130, 136], ["c-IAP", "GENE_OR_GENE_PRODUCT", 142, 147], ["PI-3-K", "PROTEIN", 37, 43], ["Akt", "PROTEIN", 44, 47], ["survivalpromoting genes", "DNA", 91, 114], ["Bcl-2", "DNA", 123, 128], ["Bcl-xL", "DNA", 130, 136], ["c", "DNA", 142, 143], ["IAP", "DNA", 144, 147], ["PI", "TEST", 37, 39], ["survivalpromoting genes", "PROBLEM", 91, 114], ["Bcl", "TEST", 123, 126], ["Bcl", "TEST", 130, 133], ["IAP", "ANATOMY", 144, 147]]], ["65, 68, 69 Akt may regulate the expression of these genes via the activation of transcription factors including NF-\u03baB, CREB and Forkhead (FKHR).", [["Akt", "GENE_OR_GENE_PRODUCT", 11, 14], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 112, 117], ["CREB", "GENE_OR_GENE_PRODUCT", 119, 123], ["Forkhead", "GENE_OR_GENE_PRODUCT", 128, 136], ["FKHR", "GENE_OR_GENE_PRODUCT", 138, 142], ["Akt", "PROTEIN", 11, 14], ["transcription factors", "PROTEIN", 80, 101], ["NF-\u03baB", "PROTEIN", 112, 117], ["CREB", "PROTEIN", 119, 123], ["Forkhead", "PROTEIN", 128, 136], ["FKHR", "PROTEIN", 138, 142], ["NF", "TEST", 112, 114]]], ["[70] [71] [72] [73] Indeed, intracellular expression of HIV-1 Tat is known to activate NF-\u03baB and CREB transcription factors in other cell types, [74] [75] [76] [77] suggesting that intracellular Tat might employ these signaling events in microglial cells to promote survival.DiscussionIt has been reported that the secretion of NO is one of the major in vivo toxic effects induced during HIV-1 infection, which contributes to AIDS-induced neuronal cell death.", [["intracellular", "ANATOMY", 28, 41], ["cell", "ANATOMY", 133, 137], ["intracellular", "ANATOMY", 181, 194], ["microglial cells", "ANATOMY", 238, 254], ["neuronal cell", "ANATOMY", 439, 452], ["NO", "CHEMICAL", 328, 330], ["HIV-1 infection", "DISEASE", 388, 403], ["AIDS", "DISEASE", 426, 430], ["neuronal cell death", "DISEASE", 439, 458], ["NO", "CHEMICAL", 328, 330], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 41], ["HIV-1", "ORGANISM", 56, 61], ["Tat", "GENE_OR_GENE_PRODUCT", 62, 65], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 87, 92], ["CREB", "GENE_OR_GENE_PRODUCT", 97, 101], ["cell", "CELL", 133, 137], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 194], ["Tat", "GENE_OR_GENE_PRODUCT", 195, 198], ["microglial cells", "CELL", 238, 254], ["NO", "GENE_OR_GENE_PRODUCT", 328, 330], ["HIV-1", "ORGANISM", 388, 393], ["neuronal cell", "CELL", 439, 452], ["HIV-1 Tat", "PROTEIN", 56, 65], ["NF-\u03baB", "PROTEIN", 87, 92], ["CREB", "PROTEIN", 97, 101], ["transcription factors", "PROTEIN", 102, 123], ["intracellular Tat", "PROTEIN", 181, 198], ["microglial cells", "CELL_TYPE", 238, 254], ["HIV-1", "SPECIES", 56, 61], ["HIV-1", "SPECIES", 388, 393], ["HIV-1", "SPECIES", 56, 61], ["HIV-1", "SPECIES", 388, 393], ["HIV", "PROBLEM", 56, 59], ["NF", "TEST", 87, 89], ["intracellular Tat", "PROBLEM", 181, 198], ["microglial cells", "TREATMENT", 238, 254], ["HIV-1 infection", "PROBLEM", 388, 403], ["AIDS", "PROBLEM", 426, 430], ["neuronal cell death", "PROBLEM", 439, 458], ["neuronal cell death", "OBSERVATION", 439, 458]]], ["Interestingly, we have also observed that primary human macrophages infected with HIV-1 display a strong cytoprotective effect upon treatment with SNP, an NO donor (Figure 7 (c) and (d); Figure 8 ).", [["macrophages", "ANATOMY", 56, 67], ["SNP", "CHEMICAL", 147, 150], ["NO", "CHEMICAL", 155, 157], ["SNP", "CHEMICAL", 147, 150], ["NO", "CHEMICAL", 155, 157], ["human", "ORGANISM", 50, 55], ["macrophages", "CELL", 56, 67], ["HIV-1", "ORGANISM", 82, 87], ["NO", "SIMPLE_CHEMICAL", 155, 157], ["primary human macrophages", "CELL_TYPE", 42, 67], ["human", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 82, 87], ["human", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 82, 87], ["HIV", "PROBLEM", 82, 85], ["SNP", "TREATMENT", 147, 150]]], ["Another well characterized cytotoxic extracellular protein secreted from HIV-1 infected macrophages is TRAIL (TNF related apoptosis inducing ligand), which can directly induce cell death in not only neighboring neuron cells but also the infected microglia in CNS.", [["extracellular", "ANATOMY", 37, 50], ["macrophages", "ANATOMY", 88, 99], ["cell", "ANATOMY", 176, 180], ["neuron cells", "ANATOMY", 211, 223], ["microglia", "ANATOMY", 246, 255], ["CNS", "ANATOMY", 259, 262], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["HIV-1", "ORGANISM", 73, 78], ["macrophages", "CELL", 88, 99], ["TRAIL", "GENE_OR_GENE_PRODUCT", 103, 108], ["TNF related apoptosis inducing ligand", "GENE_OR_GENE_PRODUCT", 110, 147], ["cell", "CELL", 176, 180], ["neuron cells", "CELL", 211, 223], ["microglia", "CELL", 246, 255], ["CNS", "ANATOMICAL_SYSTEM", 259, 262], ["cytotoxic extracellular protein", "PROTEIN", 27, 58], ["HIV-1 infected macrophages", "CELL_TYPE", 73, 99], ["TRAIL", "PROTEIN", 103, 108], ["TNF related apoptosis inducing ligand", "PROTEIN", 110, 147], ["neighboring neuron cells", "CELL_TYPE", 199, 223], ["infected microglia", "CELL_TYPE", 237, 255], ["HIV-1", "SPECIES", 73, 78], ["HIV-1", "SPECIES", 73, 78], ["Another well characterized cytotoxic extracellular protein secreted", "PROBLEM", 0, 67], ["HIV", "PROBLEM", 73, 76], ["infected macrophages", "PROBLEM", 79, 99], ["cell death", "PROBLEM", 176, 186], ["the infected microglia in CNS", "PROBLEM", 233, 262], ["cytotoxic", "OBSERVATION_MODIFIER", 27, 36], ["extracellular protein secreted", "OBSERVATION", 37, 67], ["infected", "OBSERVATION_MODIFIER", 79, 87], ["macrophages", "OBSERVATION", 88, 99], ["neuron cells", "OBSERVATION", 211, 223], ["infected", "OBSERVATION_MODIFIER", 237, 245], ["microglia", "OBSERVATION", 246, 255], ["CNS", "ANATOMY", 259, 262]]], ["[78] [79] [80] It has been demonstrated that HIV-1 infected macrophages become sensitive to TRAIL, whereas uninfected macrophages are resistant to TRAIL.", [["macrophages", "ANATOMY", 60, 71], ["macrophages", "ANATOMY", 118, 129], ["TRAIL", "CHEMICAL", 92, 97], ["TRAIL", "CHEMICAL", 147, 152], ["HIV-1", "ORGANISM", 45, 50], ["macrophages", "CELL", 60, 71], ["TRAIL", "GENE_OR_GENE_PRODUCT", 92, 97], ["macrophages", "CELL", 118, 129], ["TRAIL", "GENE_OR_GENE_PRODUCT", 147, 152], ["macrophages", "CELL_TYPE", 60, 71], ["TRAIL", "PROTEIN", 92, 97], ["uninfected macrophages", "CELL_TYPE", 107, 129], ["TRAIL", "PROTEIN", 147, 152], ["HIV-1", "SPECIES", 45, 50], ["HIV-1", "SPECIES", 45, 50], ["HIV", "PROBLEM", 45, 48], ["infected macrophages", "PROBLEM", 51, 71], ["TRAIL", "TREATMENT", 92, 97], ["infected", "OBSERVATION_MODIFIER", 51, 59], ["macrophages", "OBSERVATION", 60, 71]]], ["79 In addition, it was reported that the TRAIL levels in HIV-1 infected patients are elevated, compared to uninfected healthy individuals.", [["TRAIL", "CHEMICAL", 41, 46], ["HIV-1 infected", "DISEASE", 57, 71], ["TRAIL", "GENE_OR_GENE_PRODUCT", 41, 46], ["HIV-1", "ORGANISM", 57, 62], ["patients", "ORGANISM", 72, 80], ["TRAIL", "PROTEIN", 41, 46], ["HIV-1", "SPECIES", 57, 62], ["patients", "SPECIES", 72, 80], ["HIV-1", "SPECIES", 57, 62], ["the TRAIL levels", "TEST", 37, 53], ["HIV", "PROBLEM", 57, 60], ["elevated", "PROBLEM", 85, 93], ["elevated", "OBSERVATION_MODIFIER", 85, 93]]], ["79 Indeed, this finding led to the testing of TRAIL as an agent to specifically kill infected macrophages.", [["macrophages", "ANATOMY", 94, 105], ["TRAIL", "CHEMICAL", 46, 51], ["TRAIL", "GENE_OR_GENE_PRODUCT", 46, 51], ["macrophages", "CELL", 94, 105], ["TRAIL", "PROTEIN", 46, 51], ["infected macrophages", "CELL_TYPE", 85, 105], ["TRAIL", "TREATMENT", 46, 51], ["an agent", "TREATMENT", 55, 63]]], ["Unexpectedly, however, the treatment with recombinant TRAIL did not reduce viral production and cell death.", [["cell", "ANATOMY", 96, 100], ["TRAIL", "CHEMICAL", 54, 59], ["death", "DISEASE", 101, 106], ["TRAIL", "GENE_OR_GENE_PRODUCT", 54, 59], ["cell", "CELL", 96, 100], ["TRAIL", "PROTEIN", 54, 59], ["recombinant TRAIL", "TREATMENT", 42, 59], ["viral production", "PROBLEM", 75, 91], ["cell death", "PROBLEM", 96, 106], ["cell death", "OBSERVATION", 96, 106]]], ["80 One possible explanation for this failure was that the local concentration of TRAIL near infected microglia may not reach a high enough concentration to induce the apoptosis of infected macrophage and microglia.", [["microglia", "ANATOMY", 101, 110], ["macrophage", "ANATOMY", 189, 199], ["microglia", "ANATOMY", 204, 213], ["TRAIL", "CHEMICAL", 81, 86], ["TRAIL", "GENE_OR_GENE_PRODUCT", 81, 86], ["microglia", "CELL", 101, 110], ["macrophage", "CELL", 189, 199], ["microglia", "CELL", 204, 213], ["TRAIL", "PROTEIN", 81, 86], ["microglia", "CELL_TYPE", 101, 110], ["infected macrophage", "CELL_TYPE", 180, 199], ["microglia", "CELL_TYPE", 204, 213], ["this failure", "PROBLEM", 32, 44], ["TRAIL near infected microglia", "PROBLEM", 81, 110], ["infected macrophage and microglia", "PROBLEM", 180, 213], ["possible explanation for", "UNCERTAINTY", 7, 31], ["infected macrophage", "OBSERVATION", 180, 199], ["microglia", "ANATOMY", 204, 213]]], ["80, 81 Alternatively, HIV-1 might have already evolved to escape efficiently from the cytotoxic effect of TRAIL in microglia and macrophages as implied by the observation of persistent HIV-1 infection in the CNS.DiscussionIn summary, using the CHME5 cell line model, we demonstrated that intracellular expression of HIV-1 Tat has an unexpected pro-survival effect in microglia.", [["microglia", "ANATOMY", 115, 124], ["macrophages", "ANATOMY", 129, 140], ["CNS", "ANATOMY", 208, 211], ["CHME5 cell line", "ANATOMY", 244, 259], ["intracellular", "ANATOMY", 288, 301], ["microglia", "ANATOMY", 367, 376], ["TRAIL", "CHEMICAL", 106, 111], ["HIV-1 infection", "DISEASE", 185, 200], ["HIV-1", "ORGANISM", 22, 27], ["TRAIL", "GENE_OR_GENE_PRODUCT", 106, 111], ["microglia", "CELL", 115, 124], ["macrophages", "CELL", 129, 140], ["HIV-1", "ORGANISM", 185, 190], ["CNS", "ANATOMICAL_SYSTEM", 208, 211], ["CHME5 cell line", "CELL", 244, 259], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 288, 301], ["HIV-1", "ORGANISM", 316, 321], ["Tat", "GENE_OR_GENE_PRODUCT", 322, 325], ["microglia", "CELL", 367, 376], ["TRAIL", "PROTEIN", 106, 111], ["microglia", "CELL_TYPE", 115, 124], ["macrophages", "CELL_TYPE", 129, 140], ["CHME5 cell line model", "CELL_LINE", 244, 265], ["HIV-1 Tat", "PROTEIN", 316, 325], ["microglia", "CELL_TYPE", 367, 376], ["HIV-1", "SPECIES", 22, 27], ["HIV-1", "SPECIES", 185, 190], ["HIV-1", "SPECIES", 316, 321], ["HIV-1", "SPECIES", 22, 27], ["HIV-1", "SPECIES", 185, 190], ["HIV-1", "SPECIES", 316, 321], ["HIV", "PROBLEM", 22, 25], ["TRAIL in microglia and macrophages", "TREATMENT", 106, 140], ["persistent HIV", "PROBLEM", 174, 188], ["1 infection in the CNS", "PROBLEM", 189, 211], ["the CHME5 cell line model", "TREATMENT", 240, 265], ["HIV", "PROBLEM", 316, 319], ["cytotoxic effect", "OBSERVATION", 86, 102], ["persistent", "OBSERVATION_MODIFIER", 174, 184], ["HIV", "OBSERVATION", 185, 188], ["infection", "OBSERVATION", 191, 200], ["CNS", "ANATOMY", 208, 211], ["pro-survival effect", "OBSERVATION", 344, 363], ["microglia", "ANATOMY", 367, 376]]], ["This may have important implications for the pathogenesis of HIV-associated dementia, since virally infected microglia represent an important source of soluble effector molecules that can lead to the dysfunction and death of neurons.", [["microglia", "ANATOMY", 109, 118], ["neurons", "ANATOMY", 225, 232], ["dementia", "DISEASE", 76, 84], ["death", "DISEASE", 216, 221], ["HIV", "ORGANISM", 61, 64], ["microglia", "CELL", 109, 118], ["neurons", "CELL", 225, 232], ["microglia", "CELL_TYPE", 109, 118], ["soluble effector molecules", "PROTEIN", 152, 178], ["HIV", "SPECIES", 61, 64], ["HIV", "SPECIES", 61, 64], ["HIV-associated dementia", "PROBLEM", 61, 84], ["virally infected microglia", "PROBLEM", 92, 118], ["soluble effector molecules", "PROBLEM", 152, 178], ["the dysfunction and death of neurons", "PROBLEM", 196, 232], ["dementia", "OBSERVATION", 76, 84], ["soluble effector molecules", "OBSERVATION", 152, 178]]], ["Finally, our studies show that Tat manipulates Akt signaling and cell cycle regulatory pathways in such a way as to extend cell survival.", [["cell", "ANATOMY", 65, 69], ["cell", "ANATOMY", 123, 127], ["Tat", "GENE_OR_GENE_PRODUCT", 31, 34], ["Akt", "GENE_OR_GENE_PRODUCT", 47, 50], ["cell", "CELL", 65, 69], ["cell", "CELL", 123, 127], ["Tat", "PROTEIN", 31, 34], ["Akt", "PROTEIN", 47, 50], ["our studies", "TEST", 9, 20], ["Akt signaling", "PROBLEM", 47, 60], ["cell cycle regulatory pathways", "PROBLEM", 65, 95], ["cell cycle", "OBSERVATION", 65, 75], ["cell survival", "OBSERVATION", 123, 136]]], ["This in turn may lead to the establishment of long-lived cellular reservoirs of HIV-1 infection in the CNS.", [["cellular", "ANATOMY", 57, 65], ["CNS", "ANATOMY", 103, 106], ["HIV-1 infection", "DISEASE", 80, 95], ["cellular", "CELL", 57, 65], ["HIV-1", "ORGANISM", 80, 85], ["CNS", "ANATOMICAL_SYSTEM", 103, 106], ["HIV-1", "SPECIES", 80, 85], ["HIV-1", "SPECIES", 80, 85], ["HIV", "PROBLEM", 80, 83], ["1 infection in the CNS", "PROBLEM", 84, 106], ["reservoirs", "OBSERVATION_MODIFIER", 66, 76], ["infection", "OBSERVATION", 86, 95], ["CNS", "ANATOMY", 103, 106]]], ["Furthermore, our cell line model can serve as a useful tool for elucidating the molecular, cellular and virological elements that contribute to persistent HIV-1 infection in the CNS.Experimental Procedures Plasmids and cellsThe p53 and E2F luciferase reporter plasmids (wildtype and mutant), the HPV-16 E6/E7 expression plasmid and the K179A dominant-negative Akt, were gifts from Drs Dennis McCance and Robert Freeman (University of Rochester).", [["cell line", "ANATOMY", 17, 26], ["cellular", "ANATOMY", 91, 99], ["CNS", "ANATOMY", 178, 181], ["cells", "ANATOMY", 219, 224], ["HIV-1 infection", "DISEASE", 155, 170], ["cell line", "CELL", 17, 26], ["cellular", "CELL", 91, 99], ["HIV-1", "ORGANISM", 155, 160], ["CNS", "ANATOMICAL_SYSTEM", 178, 181], ["cells", "CELL", 219, 224], ["p53", "GENE_OR_GENE_PRODUCT", 228, 231], ["E2F luciferase reporter plasmids", "GENE_OR_GENE_PRODUCT", 236, 268], ["HPV-16 E6", "ORGANISM", 296, 305], ["E7", "ORGANISM", 306, 308], ["K179A", "GENE_OR_GENE_PRODUCT", 336, 341], ["Akt", "GENE_OR_GENE_PRODUCT", 360, 363], ["cellular and virological elements", "DNA", 91, 124], ["p53 and E2F luciferase reporter plasmids", "DNA", 228, 268], ["HPV-16 E6/E7 expression plasmid", "DNA", 296, 327], ["K179A dominant-negative Akt", "PROTEIN", 336, 363], ["HIV-1", "SPECIES", 155, 160], ["HIV-1", "SPECIES", 155, 160], ["our cell line model", "TREATMENT", 13, 32], ["the molecular, cellular and virological elements", "PROBLEM", 76, 124], ["persistent HIV-1 infection in the CNS", "PROBLEM", 144, 181], ["Experimental Procedures Plasmids", "TREATMENT", 182, 214], ["The p53", "TEST", 224, 231], ["E2F luciferase reporter plasmids", "TEST", 236, 268], ["the HPV", "TEST", 292, 299], ["E6/E7 expression plasmid", "TEST", 303, 327], ["cell line", "OBSERVATION", 17, 26], ["virological elements", "OBSERVATION", 104, 124], ["persistent", "OBSERVATION_MODIFIER", 144, 154], ["HIV", "OBSERVATION", 155, 158], ["infection", "OBSERVATION", 161, 170], ["CNS", "ANATOMY", 178, 181], ["negative Akt", "OBSERVATION", 351, 363]]], ["82 The HIV-1 Tat cDNA derived from the YU-2 M-tropic HIV-1 strain, 83 was sub-cloned into pcDNA3.1+/ Hygromycin (Invitrogen).", [["Hygromycin", "CHEMICAL", 101, 111], ["Hygromycin", "CHEMICAL", 101, 111], ["HIV-1", "ORGANISM", 7, 12], ["Tat", "GENE_OR_GENE_PRODUCT", 13, 16], ["YU-2 M-tropic HIV-1 strain", "ORGANISM", 39, 65], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 90, 96], ["1+/ Hygromycin", "SIMPLE_CHEMICAL", 97, 111], ["Invitrogen", "SIMPLE_CHEMICAL", 113, 123], ["HIV-1 Tat cDNA", "DNA", 7, 21], ["pcDNA3", "DNA", 90, 96], ["HIV-1", "SPECIES", 7, 12], ["HIV-1", "SPECIES", 53, 58], ["HIV-1", "SPECIES", 7, 12], ["HIV-1", "SPECIES", 53, 58], ["The HIV", "TEST", 3, 10], ["Tat cDNA", "TEST", 13, 21], ["the YU", "TEST", 35, 41], ["tropic HIV", "TEST", 46, 56], ["Hygromycin (Invitrogen", "TREATMENT", 101, 123]]], ["To do this, the full-length Tat cDNA (101 amino acid residues) was amplified by polymerase chain reaction and a hemagglutinin (HA) epitopetag sequence (2\u00d7) was cloned at its N terminus using specific primers.", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 42, 52], ["Tat", "GENE_OR_GENE_PRODUCT", 28, 31], ["amino acid", "AMINO_ACID", 42, 52], ["Tat cDNA", "DNA", 28, 36], ["hemagglutinin (HA) epitopetag sequence", "DNA", 112, 150], ["N terminus", "PROTEIN", 174, 184], ["the full-length Tat cDNA (101 amino acid residues", "TREATMENT", 12, 61], ["polymerase chain reaction", "PROBLEM", 80, 105], ["a hemagglutinin (HA) epitopetag sequence", "TREATMENT", 110, 150], ["specific primers", "TREATMENT", 191, 207]]], ["The purified Tat-HA-tag segment was then inserted into a pcDNA3.1 vector using the KpnI and XbaI restriction sites, placing it under control of the CMV promoter.", [["Tat", "GENE_OR_GENE_PRODUCT", 13, 16], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 57, 65], ["KpnI", "GENE_OR_GENE_PRODUCT", 83, 87], ["XbaI", "GENE_OR_GENE_PRODUCT", 92, 96], ["CMV", "ORGANISM", 148, 151], ["purified Tat-HA-tag segment", "DNA", 4, 31], ["pcDNA3.1 vector", "DNA", 57, 72], ["KpnI and XbaI restriction sites", "DNA", 83, 114], ["CMV promoter", "DNA", 148, 160], ["The purified Tat-HA-tag segment", "TREATMENT", 0, 31], ["a pcDNA3.1 vector", "TREATMENT", 55, 72], ["the KpnI", "TREATMENT", 79, 87], ["XbaI restriction sites", "TREATMENT", 92, 114], ["the CMV promoter", "TREATMENT", 144, 160], ["KpnI", "ANATOMY", 83, 87], ["CMV promoter", "OBSERVATION", 148, 160]]], ["The generated plasmid was designated as pTat101.", [["plasmid", "ANATOMY", 14, 21], ["pTat101", "DNA", 40, 47], ["The generated plasmid", "TREATMENT", 0, 21], ["pTat", "TEST", 40, 44]]], ["An HIV-1 transfer plasmid, pHR-GFP, which expresses green fluorescent protein (eGFP) from the CMV promoter was obtained from Dr Vicente Planelles (University of Utah).", [["HIV-1", "ORGANISM", 3, 8], ["pHR-GFP", "GENE_OR_GENE_PRODUCT", 27, 34], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 52, 77], ["eGFP", "GENE_OR_GENE_PRODUCT", 79, 83], ["CMV", "ORGANISM", 94, 97], ["HIV-1 transfer plasmid", "DNA", 3, 25], ["pHR", "DNA", 27, 30], ["GFP", "DNA", 31, 34], ["green fluorescent protein", "PROTEIN", 52, 77], ["eGFP", "PROTEIN", 79, 83], ["CMV promoter", "DNA", 94, 106], ["HIV-1", "SPECIES", 3, 8], ["HIV-1", "SPECIES", 3, 8], ["An HIV", "TEST", 0, 6], ["pHR-GFP", "TEST", 27, 34], ["the CMV promoter", "TREATMENT", 90, 106], ["HIV", "OBSERVATION", 3, 6], ["CMV promoter", "OBSERVATION", 94, 106]]], ["38 The CHME5 cell line, 84 a human fetal microglial cell line, was obtained from Dr David Mock (University of Rochester).", [["CHME5 cell line", "ANATOMY", 7, 22], ["fetal microglial cell line", "ANATOMY", 35, 61], ["CHME5 cell line", "CELL", 7, 22], ["human", "ORGANISM", 29, 34], ["fetal microglial cell line", "CELL", 35, 61], ["CHME5 cell line", "CELL_LINE", 7, 22], ["84", "CELL_LINE", 24, 26], ["human fetal microglial cell line", "CELL_LINE", 29, 61], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["The CHME5 cell line", "TEST", 3, 22], ["a human fetal microglial cell line", "TREATMENT", 27, 61], ["cell line", "OBSERVATION", 13, 22], ["microglial cell line", "OBSERVATION", 41, 61]]], ["To establish a CHME5 cell line that stably expresses full-length Tat, cells were transfected with the plasmid pTat101 using Lipofectamine 2000 (Invitrogen) and Hygromycin-resistant cells were clonally selected in 1 mg/ml of Hygromycin (Invitrogen) for 15 days.", [["CHME5 cell line", "ANATOMY", 15, 30], ["cells", "ANATOMY", 70, 75], ["cells", "ANATOMY", 181, 186], ["Lipofectamine 2000", "CHEMICAL", 124, 142], ["Hygromycin", "CHEMICAL", 160, 170], ["Hygromycin", "CHEMICAL", 224, 234], ["Invitrogen", "CHEMICAL", 236, 246], ["Hygromycin", "CHEMICAL", 160, 170], ["Hygromycin", "CHEMICAL", 224, 234], ["CHME5 cell line", "CELL", 15, 30], ["Tat", "GENE_OR_GENE_PRODUCT", 65, 68], ["cells", "CELL", 70, 75], ["Invitrogen)", "ORGANISM", 144, 155], ["Hygromycin", "SIMPLE_CHEMICAL", 160, 170], ["cells", "CELL", 181, 186], ["Hygromycin", "SIMPLE_CHEMICAL", 224, 234], ["Invitrogen", "SIMPLE_CHEMICAL", 236, 246], ["CHME5 cell line", "CELL_LINE", 15, 30], ["Tat", "PROTEIN", 65, 68], ["plasmid pTat101", "DNA", 102, 117], ["Hygromycin-resistant cells", "CELL_LINE", 160, 186], ["a CHME5 cell line", "TREATMENT", 13, 30], ["the plasmid pTat", "TREATMENT", 98, 114], ["Lipofectamine", "TREATMENT", 124, 137], ["Invitrogen", "TREATMENT", 144, 154], ["Hygromycin-resistant cells", "TREATMENT", 160, 186], ["Hygromycin (Invitrogen", "TREATMENT", 224, 246], ["cell line", "OBSERVATION", 21, 30]]], ["The control cells were transfected with an empty vector (pCDNA3.1-Hygro, Invitrogen) and subjected to drug selection as indicated above.", [["cells", "ANATOMY", 12, 17], ["1-Hygro", "CHEMICAL", 64, 71], ["1-Hygro", "CHEMICAL", 64, 71], ["cells", "CELL", 12, 17], ["pCDNA3", "GENE_OR_GENE_PRODUCT", 57, 63], ["1-Hygro", "SIMPLE_CHEMICAL", 64, 71], ["Invitrogen", "SIMPLE_CHEMICAL", 73, 83], ["empty vector", "DNA", 43, 55], ["pCDNA3", "DNA", 57, 63], ["The control cells", "TREATMENT", 0, 17], ["an empty vector (pCDNA3", "TREATMENT", 40, 63], ["drug selection", "TREATMENT", 102, 116]]], ["The parental CHME5 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; CellGro) containing 5% fetal bovine serum (FBS; HyClone) and maintained as described, 84 whereas the stable subline media was supplemented with 500 \u03bcg/ml of Hygromycin.", [["CHME5 cells", "ANATOMY", 13, 24], ["fetal bovine serum", "ANATOMY", 107, 125], ["FBS", "ANATOMY", 127, 130], ["Hygromycin", "CHEMICAL", 241, 251], ["Hygromycin", "CHEMICAL", 241, 251], ["CHME5 cells", "CELL", 13, 24], ["bovine", "ORGANISM", 113, 119], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["FBS", "ORGANISM_SUBSTANCE", 127, 130], ["HyClone", "ORGANISM_SUBSTANCE", 132, 139], ["Hygromycin", "SIMPLE_CHEMICAL", 241, 251], ["parental CHME5 cells", "CELL_LINE", 4, 24], ["bovine", "SPECIES", 113, 119], ["bovine", "SPECIES", 113, 119], ["The parental CHME5 cells", "TEST", 0, 24], ["CellGro", "TEST", 84, 91], ["fetal bovine serum", "TEST", 107, 125], ["FBS", "TEST", 127, 130], ["Hygromycin", "TREATMENT", 241, 251], ["stable", "OBSERVATION_MODIFIER", 185, 191]]], ["The presence of Tat was confirmed by PCR amplification of Tat DNA sequences using genespecific primers and functionally by activation of the viral LTRs.Experimental Procedures Plasmids and cellsHIV-1 replication assay CHME5 microglial cells were infected with M-tropic HIV-1 YU-2 (2.5 \u00d7 10 5 pg of p24) or T tropic HIV-1 NL4-3 (2.5 \u00d7 10 6 pg of p24).", [["CHME5 microglial cells", "ANATOMY", 218, 240], ["Tat", "GENE_OR_GENE_PRODUCT", 16, 19], ["Tat", "GENE_OR_GENE_PRODUCT", 58, 61], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["cellsHIV-1", "GENE_OR_GENE_PRODUCT", 189, 199], ["CHME5 microglial cells", "CELL", 218, 240], ["M-tropic HIV-1", "ORGANISM", 260, 274], ["YU-2", "ORGANISM", 275, 279], ["p24", "GENE_OR_GENE_PRODUCT", 298, 301], ["p24", "GENE_OR_GENE_PRODUCT", 345, 348], ["Tat", "PROTEIN", 16, 19], ["Tat DNA sequences", "DNA", 58, 75], ["genespecific primers", "DNA", 82, 102], ["viral LTRs", "DNA", 141, 151], ["CHME5 microglial cells", "CELL_LINE", 218, 240], ["p24", "PROTEIN", 298, 301], ["p24", "PROTEIN", 345, 348], ["HIV-1", "SPECIES", 269, 274], ["T tropic HIV-1", "SPECIES", 306, 320], ["cellsHIV-1", "SPECIES", 189, 199], ["HIV-1", "SPECIES", 269, 274], ["HIV-1", "SPECIES", 315, 320], ["Tat", "PROBLEM", 16, 19], ["PCR amplification", "TEST", 37, 54], ["Tat DNA sequences", "TEST", 58, 75], ["genespecific primers", "TREATMENT", 82, 102], ["the viral LTRs", "TREATMENT", 137, 151], ["Experimental Procedures Plasmids", "TREATMENT", 152, 184], ["cellsHIV", "TEST", 189, 197], ["microglial cells", "TEST", 224, 240], ["M-tropic HIV", "TEST", 260, 272], ["p24", "TEST", 298, 301], ["T tropic HIV", "TEST", 306, 318], ["NL4", "TEST", 321, 324], ["viral LTRs", "OBSERVATION", 141, 151]]], ["Viral supernatants were collected every three days for a period of 12 days before they were subjected to the p24 HIV-1 capsid-enzyme linked immunosorbent assay as per the manufacturer's protocol (Beckman-Coulter).Isolation of primary human macrophagePrimary human monocyte-derived macrophage were isolated and differentiated as described.", [["supernatants", "ANATOMY", 6, 18], ["macrophage", "ANATOMY", 240, 250], ["monocyte", "ANATOMY", 264, 272], ["macrophage", "ANATOMY", 281, 291], ["Viral", "ORGANISM", 0, 5], ["human", "ORGANISM", 234, 239], ["macrophage", "CELL", 240, 250], ["human", "ORGANISM", 258, 263], ["monocyte", "CELL", 264, 272], ["macrophage", "CELL", 281, 291], ["primary human macrophage", "CELL_TYPE", 226, 250], ["human monocyte", "CELL_TYPE", 258, 272], ["HIV-1", "SPECIES", 113, 118], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 258, 263], ["HIV-1", "SPECIES", 113, 118], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 258, 263], ["Viral supernatants", "PROBLEM", 0, 18], ["the p24 HIV", "TEST", 105, 116], ["primary human macrophage", "TREATMENT", 226, 250], ["Primary human monocyte", "TEST", 250, 272], ["primary human macrophage", "OBSERVATION", 226, 250], ["human monocyte", "OBSERVATION", 258, 272], ["macrophage", "OBSERVATION_MODIFIER", 281, 291]]], ["39 Macrophage were maintained in culture in RPMI 1640 (CellGro) supplemented with 10% fetal bovine serum (HyClone).Pseudotyped HIV-1 vector productionPseudotyped HIV-1 expressing EGFP was prepared as described.", [["Macrophage", "ANATOMY", 3, 13], ["fetal bovine serum", "ANATOMY", 86, 104], ["RPMI 1640", "CHEMICAL", 44, 53], ["Macrophage", "CELL", 3, 13], ["bovine", "ORGANISM", 92, 98], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["HyClone", "ORGANISM_SUBSTANCE", 106, 113], ["HIV-1", "ORGANISM", 127, 132], ["Pseudotyped HIV-1", "ORGANISM", 150, 167], ["EGFP", "GENE_OR_GENE_PRODUCT", 179, 183], ["EGFP", "DNA", 179, 183], ["bovine", "SPECIES", 92, 98], ["HIV-1", "SPECIES", 127, 132], ["HIV-1", "SPECIES", 162, 167], ["bovine", "SPECIES", 92, 98], ["HIV-1", "SPECIES", 127, 132], ["HIV-1", "SPECIES", 162, 167], ["culture", "TEST", 33, 40], ["10% fetal bovine serum (HyClone)", "TREATMENT", 82, 114], ["Pseudotyped HIV", "TEST", 115, 130], ["Pseudotyped HIV", "PROBLEM", 150, 165]]], ["39 Primary human macrophage were transduced with the HIV-1 vector at a MOI of 40 (1.1 \u00d7 10 7 pg) while an MOI of 1 was used to transduce the CHME5 microglial cell line.Preparation of M-tropic HIV-1M-tropic HIV-1 BAL (NIH Aids Reagent Program) was propagated in human PBMCs for 14 days.", [["macrophage", "ANATOMY", 17, 27], ["CHME5 microglial cell line", "ANATOMY", 141, 167], ["PBMCs", "ANATOMY", 267, 272], ["human", "ORGANISM", 11, 16], ["macrophage", "CELL", 17, 27], ["HIV-1", "ORGANISM", 53, 58], ["CHME5 microglial cell line", "CELL", 141, 167], ["M-tropic HIV-1M", "ORGANISM", 183, 198], ["HIV", "ORGANISM", 206, 209], ["-1", "ORGANISM", 209, 211], ["BAL", "ORGANISM", 212, 215], ["NIH", "ORGANISM", 217, 220], ["human", "ORGANISM", 261, 266], ["PBMCs", "CELL", 267, 272], ["Primary human macrophage", "CELL_TYPE", 3, 27], ["CHME5 microglial cell line", "CELL_LINE", 141, 167], ["human PBMCs", "CELL_TYPE", 261, 272], ["human", "SPECIES", 11, 16], ["HIV-1", "SPECIES", 53, 58], ["HIV-1M-tropic HIV-1", "SPECIES", 192, 211], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 11, 16], ["HIV-1", "SPECIES", 53, 58], ["HIV-1", "SPECIES", 206, 211], ["human", "SPECIES", 261, 266], ["Primary human macrophage", "TEST", 3, 27], ["the HIV", "TEST", 49, 56], ["a MOI", "TEST", 69, 74], ["an MOI", "TEST", 103, 109], ["M-tropic HIV", "TEST", 183, 195], ["tropic HIV", "TEST", 199, 209], ["human macrophage", "OBSERVATION", 11, 27], ["microglial cell line", "OBSERVATION", 147, 167]]], ["Viral supernatants were pooled and the p24 activity of the virus was determined using the p24 enzyme-linked immunosorbent assay (Beckman-Coulter) according to the manufacturer's protocol.", [["supernatants", "ANATOMY", 6, 18], ["Viral", "ORGANISM", 0, 5], ["p24", "GENE_OR_GENE_PRODUCT", 39, 42], ["p24", "PROTEIN", 39, 42], ["p24 enzyme", "PROTEIN", 90, 100], ["Viral supernatants", "TEST", 0, 18], ["the p24 activity of the virus", "PROBLEM", 35, 64], ["the p24 enzyme", "TEST", 86, 100], ["immunosorbent assay", "TEST", 108, 127], ["the manufacturer's protocol", "TREATMENT", 159, 186]]], ["The p24 levels were normalized to p24 levels equivalent to a vector MOI of 40 and primary human macrophage were infected with HIV-1 BAL (1.1 \u00d7 10 7 pg) for 48 h prior to treatment.", [["macrophage", "ANATOMY", 96, 106], ["p24", "GENE_OR_GENE_PRODUCT", 4, 7], ["p24", "GENE_OR_GENE_PRODUCT", 34, 37], ["human", "ORGANISM", 90, 95], ["macrophage", "CELL", 96, 106], ["HIV-1", "ORGANISM", 126, 131], ["BAL", "ORGANISM_SUBSTANCE", 132, 135], ["p24", "PROTEIN", 4, 7], ["p24", "PROTEIN", 34, 37], ["primary human macrophage", "CELL_TYPE", 82, 106], ["human", "SPECIES", 90, 95], ["HIV-1", "SPECIES", 126, 131], ["human", "SPECIES", 90, 95], ["HIV-1", "SPECIES", 126, 131], ["The p24 levels", "TEST", 0, 14], ["p24 levels", "TEST", 34, 44], ["a vector MOI", "TEST", 59, 71], ["primary human macrophage", "TEST", 82, 106], ["HIV", "TEST", 126, 129], ["treatment", "TREATMENT", 170, 179]]], ["CHME5 cells were infected with HIV-1 YU-2 (1.38 \u00d7 10 6 pg) 48 h prior to treatment.Cell survival assaysCHME5 cells or primary human macrophage were exposed to CHX (10 \u03bcg/ml) and Escherichia coli serotype O26:B6 LPS (Sigma) at the concentrations indicated in the Figure legends for the specified times.", [["CHME5 cells", "ANATOMY", 0, 11], ["Cell", "ANATOMY", 83, 87], ["assaysCHME5 cells", "ANATOMY", 97, 114], ["macrophage", "ANATOMY", 132, 142], ["CHX", "CHEMICAL", 159, 162], ["LPS", "CHEMICAL", 211, 214], ["CHX", "CHEMICAL", 159, 162], ["CHME5 cells", "CELL", 0, 11], ["YU-2", "CELL", 37, 41], ["Cell", "CELL", 83, 87], ["assaysCHME5 cells", "CELL", 97, 114], ["human", "ORGANISM", 126, 131], ["macrophage", "CELL", 132, 142], ["CHX", "SIMPLE_CHEMICAL", 159, 162], ["Escherichia coli", "ORGANISM", 178, 194], ["O26", "SIMPLE_CHEMICAL", 204, 207], ["B6", "ORGANISM", 208, 210], ["LPS", "SIMPLE_CHEMICAL", 211, 214], ["Sigma", "SIMPLE_CHEMICAL", 216, 221], ["CHME5 cells", "CELL_LINE", 0, 11], ["assaysCHME5 cells", "CELL_LINE", 97, 114], ["primary human macrophage", "CELL_TYPE", 118, 142], ["HIV-1", "SPECIES", 31, 36], ["human", "SPECIES", 126, 131], ["Escherichia coli serotype", "SPECIES", 178, 203], ["HIV-1", "SPECIES", 31, 36], ["human", "SPECIES", 126, 131], ["Escherichia coli", "SPECIES", 178, 194], ["CHME5 cells", "PROBLEM", 0, 11], ["HIV", "TEST", 31, 34], ["treatment", "TREATMENT", 73, 82], ["Cell survival assaysCHME5 cells", "PROBLEM", 83, 114], ["primary human macrophage", "PROBLEM", 118, 142], ["CHX", "TEST", 159, 162], ["Escherichia coli serotype O26", "PROBLEM", 178, 207], ["Escherichia coli", "ANATOMY", 178, 194]]], ["Sodium nitroprusside (Sigma) was used at 1 mM for treatment of cells.", [["cells", "ANATOMY", 63, 68], ["Sodium nitroprusside", "CHEMICAL", 0, 20], ["Sodium nitroprusside", "CHEMICAL", 0, 20], ["Sodium nitroprusside", "SIMPLE_CHEMICAL", 0, 20], ["Sigma", "SIMPLE_CHEMICAL", 22, 27], ["cells", "CELL", 63, 68], ["Sodium nitroprusside (Sigma)", "TREATMENT", 0, 28], ["treatment of cells", "TREATMENT", 50, 68]]], ["Cells were then trypsinized and mixed with 0.4% (w/v) trypan blue solution (Gibco) at a 1:1 dilution and the number of blue (dead) cells was calculated by cell counts.", [["Cells", "ANATOMY", 0, 5], ["blue (dead) cells", "ANATOMY", 119, 136], ["cell", "ANATOMY", 155, 159], ["trypan blue", "CHEMICAL", 54, 65], ["trypan blue", "CHEMICAL", 54, 65], ["Cells", "CELL", 0, 5], ["trypan blue solution", "SIMPLE_CHEMICAL", 54, 74], ["cells", "CELL", 131, 136], ["cell", "CELL", 155, 159], ["blue (dead) cells", "CELL_TYPE", 119, 136], ["Cells", "TEST", 0, 5], ["w/v) trypan blue solution", "TREATMENT", 49, 74], ["a 1:1 dilution", "TREATMENT", 86, 100], ["blue (dead) cells", "PROBLEM", 119, 136], ["cell counts", "TEST", 155, 166]]], ["For inhibition of the PI-3-K pathway, cells were pretreated with either Wortmannin (100 nM) or LY294002 (50 \u03bcM) (Sigma) for 30 min prior to LPS/CHX treatment.", [["cells", "ANATOMY", 38, 43], ["Wortmannin", "CHEMICAL", 72, 82], ["LY294002", "CHEMICAL", 95, 103], ["LPS", "CHEMICAL", 140, 143], ["CHX", "CHEMICAL", 144, 147], ["Wortmannin", "CHEMICAL", 72, 82], ["LY294002", "CHEMICAL", 95, 103], ["CHX", "CHEMICAL", 144, 147], ["PI-3-K", "GENE_OR_GENE_PRODUCT", 22, 28], ["cells", "CELL", 38, 43], ["Wortmannin", "SIMPLE_CHEMICAL", 72, 82], ["LY294002", "SIMPLE_CHEMICAL", 95, 103], ["LPS", "SIMPLE_CHEMICAL", 140, 143], ["CHX", "SIMPLE_CHEMICAL", 144, 147], ["PI-3-K", "PROTEIN", 22, 28], ["the PI", "TEST", 18, 24], ["Wortmannin", "TREATMENT", 72, 82], ["LY294002", "TREATMENT", 95, 103], ["LPS/CHX treatment", "TREATMENT", 140, 157]]], ["For immunofluorescent detection of viable and non-viable cells, the Live/Dead-Viability/Cytotoxicity kit (Molecular Probes) was used to stain cells as per the manufacturer's protocol.", [["cells", "ANATOMY", 57, 62], ["cells", "ANATOMY", 142, 147], ["cells", "CELL", 57, 62], ["cells", "CELL", 142, 147], ["non-viable cells", "CELL_TYPE", 46, 62], ["immunofluorescent detection", "TEST", 4, 31], ["viable and non-viable cells", "PROBLEM", 35, 62], ["the manufacturer's protocol", "TREATMENT", 155, 182], ["non-viable cells", "OBSERVATION", 46, 62]]], ["Images were taken at a magnification of 200\u00d7 24 h post-treatment using a fluorescence microscope (Leica).", [["Images", "TEST", 0, 6], ["a fluorescence microscope", "TEST", 71, 96]]], ["Each assay was performed in triplicate.Cell survival assaysIn order to determine the survival of HIV-1-infected cells, approximately 1 \u00d7 10 5 cells/well were transduced with pseudotyped HIV-1 vector eGFP at various MOI values as described in the Figure legends.", [["Cell", "ANATOMY", 39, 43], ["cells", "ANATOMY", 112, 117], ["cells", "ANATOMY", 142, 147], ["Cell", "CELL", 39, 43], ["HIV-1", "ORGANISM", 97, 102], ["cells", "CELL", 112, 117], ["cells", "CELL", 142, 147], ["pseudotyped HIV-1", "ORGANISM", 174, 191], ["eGFP", "GENE_OR_GENE_PRODUCT", 199, 203], ["pseudotyped HIV-1 vector eGFP", "DNA", 174, 203], ["HIV-1", "SPECIES", 97, 102], ["HIV-1", "SPECIES", 186, 191], ["HIV-1", "SPECIES", 97, 102], ["HIV-1", "SPECIES", 186, 191], ["Each assay", "TEST", 0, 10], ["Cell survival assays", "TEST", 39, 59], ["HIV", "TEST", 97, 100], ["infected cells", "PROBLEM", 103, 117], ["pseudotyped HIV", "TEST", 174, 189]]], ["For CHME5 cells, transductions were performed in the presence of Polybrene (10 \u03bcg/ml).", [["CHME5 cells", "ANATOMY", 4, 15], ["Polybrene", "CHEMICAL", 65, 74], ["Polybrene", "CHEMICAL", 65, 74], ["CHME5 cells", "CELL", 4, 15], ["Polybrene", "SIMPLE_CHEMICAL", 65, 74], ["CHME5 cells", "CELL_LINE", 4, 15], ["CHME5 cells", "TREATMENT", 4, 15], ["transductions", "TEST", 17, 30], ["Polybrene", "TREATMENT", 65, 74]]], ["All infections and transductions were performed 48 h prior to treatments.", [["infections", "DISEASE", 4, 14], ["All infections", "PROBLEM", 0, 14], ["treatments", "TREATMENT", 62, 72], ["infections", "OBSERVATION", 4, 14]]], ["Following treatment, cellular viability was analyzed by the cytotoxicity assay.", [["cellular", "ANATOMY", 21, 29], ["cellular", "CELL", 21, 29], ["treatment", "TREATMENT", 10, 19], ["cellular viability", "TEST", 21, 39], ["the cytotoxicity assay", "TEST", 56, 78], ["cellular viability", "OBSERVATION", 21, 39]]], ["Similarly, the viability of uninfected, as well as transiently transfected cells was analyzed using identical methods.", [["cells", "ANATOMY", 75, 80], ["cells", "CELL", 75, 80], ["transiently transfected cells", "CELL_LINE", 51, 80], ["transiently transfected cells", "PROBLEM", 51, 80], ["viability", "OBSERVATION_MODIFIER", 15, 24], ["uninfected", "OBSERVATION", 28, 38], ["transfected cells", "OBSERVATION", 63, 80]]], ["For trypan blue analysis of transduced cells, cells were treated for a total of 96 h, changing media every 24 h and replacing with fresh media and LPS/CHX.", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 46, 51], ["trypan blue", "CHEMICAL", 4, 15], ["LPS", "CHEMICAL", 147, 150], ["CHX", "CHEMICAL", 151, 154], ["trypan blue", "CHEMICAL", 4, 15], ["CHX", "CHEMICAL", 151, 154], ["cells", "CELL", 39, 44], ["cells", "CELL", 46, 51], ["LPS", "SIMPLE_CHEMICAL", 147, 150], ["CHX", "SIMPLE_CHEMICAL", 151, 154], ["transduced cells", "CELL_LINE", 28, 44], ["trypan blue analysis", "TEST", 4, 24], ["transduced cells", "PROBLEM", 28, 44], ["changing media", "TREATMENT", 86, 100], ["fresh media and LPS/CHX", "TREATMENT", 131, 154], ["transduced cells", "OBSERVATION", 28, 44]]], ["Viability was measured by trypan blue exclusion every 24 h.", [["trypan blue", "CHEMICAL", 26, 37], ["trypan blue", "CHEMICAL", 26, 37], ["trypan blue exclusion", "TREATMENT", 26, 47]]], ["Each assay was performed in triplicate.Cell survival assaysFor quantitation of the percentage of cell death induced in primary human macrophage following LPS/CHX treatment, cells were infected or transduced 48 h prior to LPS/CHX treatment.", [["Cell", "ANATOMY", 39, 43], ["cell", "ANATOMY", 97, 101], ["macrophage", "ANATOMY", 133, 143], ["cells", "ANATOMY", 173, 178], ["death", "DISEASE", 102, 107], ["LPS", "CHEMICAL", 154, 157], ["CHX", "CHEMICAL", 158, 161], ["LPS", "CHEMICAL", 221, 224], ["CHX", "CHEMICAL", 225, 228], ["CHX", "CHEMICAL", 158, 161], ["CHX", "CHEMICAL", 225, 228], ["Cell", "CELL", 39, 43], ["cell", "CELL", 97, 101], ["human", "ORGANISM", 127, 132], ["macrophage", "CELL", 133, 143], ["LPS", "SIMPLE_CHEMICAL", 154, 157], ["CHX", "SIMPLE_CHEMICAL", 158, 161], ["cells", "CELL", 173, 178], ["LPS", "SIMPLE_CHEMICAL", 221, 224], ["CHX", "SIMPLE_CHEMICAL", 225, 228], ["primary human macrophage", "CELL_TYPE", 119, 143], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["Each assay", "TEST", 0, 10], ["Cell survival assays", "TEST", 39, 59], ["cell death", "PROBLEM", 97, 107], ["primary human macrophage", "TREATMENT", 119, 143], ["LPS/CHX treatment", "TREATMENT", 154, 171], ["cells", "PROBLEM", 173, 178], ["LPS/CHX treatment", "TREATMENT", 221, 238], ["cell death", "OBSERVATION", 97, 107]]], ["The mean percentages of cell death were obtained by counting the number of dead cells out of the number of total cells from various fields following staining with ethidium homodimer (described above).", [["cell", "ANATOMY", 24, 28], ["cells", "ANATOMY", 80, 85], ["cells", "ANATOMY", 113, 118], ["death", "DISEASE", 29, 34], ["ethidium", "CHEMICAL", 163, 171], ["ethidium", "CHEMICAL", 163, 171], ["cell", "CELL", 24, 28], ["cells", "CELL", 80, 85], ["cells", "CELL", 113, 118], ["ethidium homodimer", "SIMPLE_CHEMICAL", 163, 181], ["dead cells", "CELL_TYPE", 75, 85], ["total cells", "CELL_TYPE", 107, 118], ["ethidium homodimer", "PROTEIN", 163, 181], ["cell death", "PROBLEM", 24, 34], ["dead cells", "PROBLEM", 75, 85], ["ethidium homodimer", "TREATMENT", 163, 181], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["cell death", "OBSERVATION", 24, 34], ["dead cells", "OBSERVATION", 75, 85]]], ["In the case of pseudotyped vector transduced cells, the number of dead cells out of GFP-expressing cells was determined.", [["cells", "ANATOMY", 45, 50], ["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 99, 104], ["pseudotyped", "ORGANISM", 15, 26], ["cells", "CELL", 45, 50], ["cells", "CELL", 71, 76], ["GFP", "GENE_OR_GENE_PRODUCT", 84, 87], ["cells", "CELL", 99, 104], ["pseudotyped vector transduced cells", "CELL_LINE", 15, 50], ["dead cells", "CELL_TYPE", 66, 76], ["GFP", "PROTEIN", 84, 87], ["expressing cells", "CELL_TYPE", 88, 104], ["pseudotyped vector transduced cells", "TREATMENT", 15, 50], ["dead cells", "TEST", 66, 76], ["GFP", "TEST", 84, 87], ["expressing cells", "PROBLEM", 88, 104], ["dead cells", "OBSERVATION", 66, 76], ["expressing cells", "OBSERVATION", 88, 104]]], ["These numbers reflect the mean percentage of cell death from five fields (\u223c75 cells per field).Luciferase assayFor measuring p53 activity, CHME5 cells were cotransfected with pcDNA3.1/LacZ (Invitrogen), a luciferase reporter plasmid (containing either a wild-type or mutated responsive element) and either pcDNA3.1-Hygro (Invitrogen) or pTat101 using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions.", [["cell", "ANATOMY", 45, 49], ["cells", "ANATOMY", 78, 83], ["CHME5 cells", "ANATOMY", 139, 150], ["death", "DISEASE", 50, 55], ["1-Hygro", "CHEMICAL", 313, 320], ["pTat101", "CHEMICAL", 337, 344], ["1-Hygro", "CHEMICAL", 313, 320], ["pTat101", "CHEMICAL", 337, 344], ["cell", "CELL", 45, 49], ["cells", "CELL", 78, 83], ["p53", "GENE_OR_GENE_PRODUCT", 125, 128], ["CHME5 cells", "CELL", 139, 150], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 175, 181], ["LacZ", "GENE_OR_GENE_PRODUCT", 184, 188], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 190, 200], ["luciferase", "GENE_OR_GENE_PRODUCT", 205, 215], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 306, 312], ["1-Hygro", "SIMPLE_CHEMICAL", 313, 320], ["Invitrogen", "SIMPLE_CHEMICAL", 322, 332], ["pTat101", "SIMPLE_CHEMICAL", 337, 344], ["Invitrogen", "SIMPLE_CHEMICAL", 379, 389], ["p53", "PROTEIN", 125, 128], ["CHME5 cells", "CELL_LINE", 139, 150], ["pcDNA3.1", "DNA", 175, 183], ["LacZ", "DNA", 184, 188], ["Invitrogen", "DNA", 190, 200], ["luciferase reporter plasmid", "DNA", 205, 232], ["wild-type or mutated responsive element", "DNA", 254, 293], ["pcDNA3", "DNA", 306, 312], ["cell death", "PROBLEM", 45, 55], ["Luciferase assayFor", "TEST", 95, 114], ["CHME5 cells", "PROBLEM", 139, 150], ["pcDNA3", "TREATMENT", 175, 181], ["LacZ (Invitrogen", "TREATMENT", 184, 200], ["a luciferase reporter plasmid", "TREATMENT", 203, 232], ["mutated responsive element", "PROBLEM", 267, 293], ["pcDNA3", "TREATMENT", 306, 312], ["Hygro (Invitrogen", "TREATMENT", 315, 332], ["pTat", "TREATMENT", 337, 341], ["Lipofectamine 2000 reagent", "TREATMENT", 351, 377], ["Invitrogen", "TREATMENT", 379, 389], ["cell death", "OBSERVATION", 45, 55]]], ["At 24 h post-transfection, cells were washed with DPBS (CellGro), lysed in 50 \u03bcl Galacto-Light Plus lysis buffer (Tropix) for 10 min and the \u03b2-galactosidase assay was performed using the Galacto-Light Plus kit (Tropix).", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["DPBS", "SIMPLE_CHEMICAL", 50, 54], ["CellGro", "SIMPLE_CHEMICAL", 56, 63], ["Tropix", "SIMPLE_CHEMICAL", 114, 120], ["\u03b2-galactosidase", "PROTEIN", 141, 156], ["DPBS (CellGro", "TREATMENT", 50, 63], ["lysis buffer (Tropix", "TREATMENT", 100, 120], ["the \u03b2-galactosidase assay", "TEST", 137, 162], ["the Galacto-Light Plus kit (Tropix)", "TREATMENT", 183, 218]]], ["Lysates were normalized according to \u03b2-galactosidase activity and the luciferase assay was performed (Promega).", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 37, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 70, 80], ["\u03b2-galactosidase", "PROTEIN", 37, 52], ["luciferase", "PROTEIN", 70, 80], ["Lysates", "TEST", 0, 7], ["the luciferase assay", "TEST", 66, 86]]], ["Luciferase activity was then immediately measured with the Lumicount Microplate Luminometer (Packard).", [["Luciferase", "GENE_OR_GENE_PRODUCT", 0, 10], ["the Lumicount Microplate Luminometer (Packard)", "TREATMENT", 55, 101]]], ["To detect E2F activity, the transfected CHME5 cells were incubated in DMEM (CellGro) with either 5%, 0.1% or 0% FBS for 72 h post-transfection before lysing cells for the \u03b2-galactosidase and luciferase assays as described above.", [["CHME5 cells", "ANATOMY", 40, 51], ["FBS", "ANATOMY", 112, 115], ["cells", "ANATOMY", 157, 162], ["E2F", "GENE_OR_GENE_PRODUCT", 10, 13], ["CHME5 cells", "CELL", 40, 51], ["FBS", "ORGANISM_SUBSTANCE", 112, 115], ["cells", "CELL", 157, 162], ["luciferase", "GENE_OR_GENE_PRODUCT", 191, 201], ["E2F", "PROTEIN", 10, 13], ["CHME5 cells", "CELL_LINE", 40, 51], ["\u03b2-galactosidase", "PROTEIN", 171, 186], ["luciferase", "PROTEIN", 191, 201], ["the transfected CHME5 cells", "TREATMENT", 24, 51], ["lysing cells", "TREATMENT", 150, 162], ["the \u03b2-galactosidase and luciferase assays", "TEST", 167, 208], ["E2F activity", "OBSERVATION", 10, 22]]], ["As an additional control, a plasmid expressing the E6/E7 genes of human papilloma virus type 16 (HPV-16) was also used.", [["plasmid", "ANATOMY", 28, 35], ["human papilloma virus", "DISEASE", 66, 87], ["E6", "GENE_OR_GENE_PRODUCT", 51, 53], ["E7", "GENE_OR_GENE_PRODUCT", 54, 56], ["human papilloma virus type 16", "ORGANISM", 66, 95], ["HPV-16", "ORGANISM", 97, 103], ["plasmid", "DNA", 28, 35], ["E6/E7 genes", "DNA", 51, 62], ["human papilloma virus", "SPECIES", 66, 87], ["human papilloma virus type 16 (HPV-16", "SPECIES", 66, 103], ["an additional control", "TREATMENT", 3, 24], ["a plasmid", "TREATMENT", 26, 35], ["human papilloma virus type", "PROBLEM", 66, 92], ["HPV", "TEST", 97, 100], ["human papilloma", "ANATOMY", 66, 81]]], ["Each assay was performed in triplicate.Western blot analysisCell lysates were prepared in RIPA buffer supplemented with protease inhibitors (Roche) and phosphatase inhibitor cocktail (Sigma) and samples (20 \u03bcg) were run on an SDS 8% (w/v) polyacrylamide gel.", [["Cell lysates", "ANATOMY", 60, 72], ["samples", "ANATOMY", 195, 202], ["polyacrylamide", "CHEMICAL", 239, 253], ["Cell lysates", "ORGANISM_SUBSTANCE", 60, 72], ["Each assay", "TEST", 0, 10], ["blot analysis", "TEST", 47, 60], ["Cell lysates", "TREATMENT", 60, 72], ["RIPA buffer", "TREATMENT", 90, 101], ["protease inhibitors", "TREATMENT", 120, 139], ["phosphatase inhibitor cocktail", "TREATMENT", 152, 182], ["an SDS", "TREATMENT", 223, 229], ["polyacrylamide gel", "TREATMENT", 239, 257]]], ["PTEN expression was detected by probing with the PTEN (138G6) rabbit monoclonal antibody (Cell Signaling) at a dilution of 1:1000.", [["Cell", "ANATOMY", 90, 94], ["PTEN", "GENE_OR_GENE_PRODUCT", 0, 4], ["PTEN", "GENE_OR_GENE_PRODUCT", 49, 53], ["Cell", "CELL", 90, 94], ["PTEN", "PROTEIN", 0, 4], ["PTEN (138G6) rabbit monoclonal antibody", "PROTEIN", 49, 88], ["rabbit", "SPECIES", 62, 68], ["rabbit", "SPECIES", 62, 68], ["PTEN expression", "PROBLEM", 0, 15], ["the PTEN", "TEST", 45, 53], ["rabbit monoclonal antibody", "TEST", 62, 88]]], ["Donkey anti-rabbit Ig (Amersham Biosciences) was used at 1:5000 for secondary antibody followed by ECL detection using the SuperSignal West Femto kit (Pierce).", [["anti-rabbit Ig", "GENE_OR_GENE_PRODUCT", 7, 21], ["Donkey anti-rabbit Ig", "PROTEIN", 0, 21], ["Amersham Biosciences", "PROTEIN", 23, 43], ["Donkey", "SPECIES", 0, 6], ["anti-rabbit", "SPECIES", 7, 18], ["anti-rabbit", "SPECIES", 7, 18], ["Donkey anti-rabbit Ig (Amersham Biosciences", "TREATMENT", 0, 43], ["secondary antibody", "PROBLEM", 68, 86], ["ECL detection", "TEST", 99, 112]]], ["For a loading control, blots were probed for \u03b1tubulin (Cell Signaling) followed by sheep anti-mouse IgG (Amersham Biosciences).", [["Cell", "ANATOMY", 55, 59], ["\u03b1tubulin", "CHEMICAL", 45, 53], ["\u03b1tubulin", "SIMPLE_CHEMICAL", 45, 53], ["Cell", "CELL", 55, 59], ["\u03b1tubulin", "PROTEIN", 45, 53], ["sheep anti-mouse IgG", "PROTEIN", 83, 103], ["Amersham Biosciences", "PROTEIN", 105, 125], ["sheep", "SPECIES", 83, 88], ["anti-mouse", "SPECIES", 89, 99], ["sheep", "SPECIES", 83, 88], ["a loading control", "TREATMENT", 4, 21], ["blots", "PROBLEM", 23, 28], ["\u03b1tubulin (Cell Signaling)", "TREATMENT", 45, 70], ["sheep anti-mouse IgG (Amersham Biosciences", "TREATMENT", 83, 125]]], ["ECL detection was performed as described above.", [["ECL detection", "TEST", 0, 13]]], ["Expression of PTEN in each sample was normalized to alpha-tubulin levels for analysis.", [["sample", "ANATOMY", 27, 33], ["PTEN", "GENE_OR_GENE_PRODUCT", 14, 18], ["alpha-tubulin", "GENE_OR_GENE_PRODUCT", 52, 65], ["PTEN", "PROTEIN", 14, 18], ["alpha-tubulin", "PROTEIN", 52, 65], ["PTEN in each sample", "PROBLEM", 14, 33], ["alpha-tubulin levels", "TEST", 52, 72], ["analysis", "TEST", 77, 85], ["PTEN", "OBSERVATION", 14, 18]]]], "PMC7105203": [["IntroductionCystic fibrosis (CF) affects over 60,000 patients worldwide.", [["fibrosis", "DISEASE", 19, 27], ["CF", "DISEASE", 29, 31], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["IntroductionCystic fibrosis", "PROBLEM", 0, 27], ["fibrosis", "OBSERVATION", 19, 27]]], ["Bacterial infections are the main cause of recurrent pulmonary exacerbations leading to progressive lung damage with less known about the role of viral respiratory tract infections [1], [2], [3].", [["pulmonary", "ANATOMY", 53, 62], ["lung", "ANATOMY", 100, 104], ["respiratory tract", "ANATOMY", 152, 169], ["Bacterial infections", "DISEASE", 0, 20], ["lung damage", "DISEASE", 100, 111], ["viral respiratory tract infections", "DISEASE", 146, 180], ["pulmonary", "ORGAN", 53, 62], ["lung", "ORGAN", 100, 104], ["viral respiratory tract", "ORGANISM", 146, 169], ["Bacterial infections", "PROBLEM", 0, 20], ["recurrent pulmonary exacerbations", "PROBLEM", 43, 76], ["progressive lung damage", "PROBLEM", 88, 111], ["viral respiratory tract infections", "PROBLEM", 146, 180], ["infections", "OBSERVATION", 10, 20], ["main cause of", "UNCERTAINTY", 29, 42], ["recurrent", "OBSERVATION_MODIFIER", 43, 52], ["pulmonary", "ANATOMY", 53, 62], ["exacerbations", "OBSERVATION", 63, 76], ["progressive", "OBSERVATION_MODIFIER", 88, 99], ["lung", "ANATOMY", 100, 104], ["damage", "OBSERVATION", 105, 111], ["viral", "OBSERVATION_MODIFIER", 146, 151], ["respiratory tract", "ANATOMY", 152, 169]]], ["The true impact of respiratory viruses in CF may have been previously underestimated as the majority of previous studies [4], [5] used viral culture and/or immunofluorescence techniques which are relatively insensitive and restricted in breadth for viral detection [1], [2].", [["respiratory viruses", "DISEASE", 19, 38], ["CF", "DISEASE", 42, 44], ["respiratory viruses in CF", "PROBLEM", 19, 44], ["previous studies", "TEST", 104, 120], ["viral culture", "TEST", 135, 148], ["immunofluorescence techniques", "TEST", 156, 185], ["viral detection", "TEST", 249, 264], ["respiratory viruses", "OBSERVATION", 19, 38]]], ["To date, published reports of respiratory viral infections in children with CF have primarily focused on the proportion of pulmonary exacerbations associated with viruses [1], [4], [5], [6], [7], [8].", [["pulmonary", "ANATOMY", 123, 132], ["respiratory viral infections", "DISEASE", 30, 58], ["CF", "DISEASE", 76, 78], ["pulmonary exacerbations", "DISEASE", 123, 146], ["respiratory viral", "ORGANISM", 30, 47], ["children", "ORGANISM", 62, 70], ["pulmonary", "ORGAN", 123, 132], ["[4]", "SIMPLE_CHEMICAL", 176, 179], ["[5], [6]", "SIMPLE_CHEMICAL", 181, 189], ["[7]", "SIMPLE_CHEMICAL", 191, 194], ["children", "SPECIES", 62, 70], ["respiratory viral infections", "PROBLEM", 30, 58], ["CF", "PROBLEM", 76, 78], ["pulmonary exacerbations", "PROBLEM", 123, 146], ["viruses", "PROBLEM", 163, 170], ["respiratory", "ANATOMY", 30, 41], ["viral infections", "OBSERVATION", 42, 58], ["pulmonary", "ANATOMY", 123, 132], ["exacerbations", "OBSERVATION", 133, 146]]], ["The relationship between severity of these exacerbations and infection status with respiratory viruses has not been assessed.", [["exacerbations", "DISEASE", 43, 56], ["infection", "DISEASE", 61, 70], ["respiratory viruses", "DISEASE", 83, 102], ["these exacerbations", "PROBLEM", 37, 56], ["infection status", "PROBLEM", 61, 77], ["respiratory viruses", "PROBLEM", 83, 102], ["exacerbations", "OBSERVATION", 43, 56], ["infection", "OBSERVATION", 61, 70], ["respiratory viruses", "OBSERVATION", 83, 102]]], ["The extent to which these complications are mediated by direct viral effects or via potentiation of bacterial colonization and infection is unclear [5].", [["infection", "DISEASE", 127, 136], ["these complications", "PROBLEM", 20, 39], ["direct viral effects", "PROBLEM", 56, 76], ["bacterial colonization", "PROBLEM", 100, 122], ["infection", "PROBLEM", 127, 136], ["complications", "OBSERVATION", 26, 39], ["bacterial", "OBSERVATION_MODIFIER", 100, 109], ["colonization", "OBSERVATION", 110, 122], ["infection", "OBSERVATION", 127, 136]]], ["The pulmonary manifestations of CF involve both neutrophil-dominated airway inflammation and chronic bacterial infection.", [["pulmonary", "ANATOMY", 4, 13], ["neutrophil", "ANATOMY", 48, 58], ["airway", "ANATOMY", 69, 75], ["CF", "DISEASE", 32, 34], ["inflammation", "DISEASE", 76, 88], ["bacterial infection", "DISEASE", 101, 120], ["pulmonary", "ORGAN", 4, 13], ["neutrophil", "CELL", 48, 58], ["airway", "MULTI-TISSUE_STRUCTURE", 69, 75], ["neutrophil", "CELL_TYPE", 48, 58], ["The pulmonary manifestations of CF", "PROBLEM", 0, 34], ["dominated airway inflammation", "PROBLEM", 59, 88], ["chronic bacterial infection", "PROBLEM", 93, 120], ["pulmonary", "ANATOMY", 4, 13], ["both", "OBSERVATION_MODIFIER", 43, 47], ["neutrophil", "OBSERVATION", 48, 58], ["dominated", "OBSERVATION_MODIFIER", 59, 68], ["airway", "ANATOMY", 69, 75], ["inflammation", "OBSERVATION", 76, 88], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["bacterial", "OBSERVATION_MODIFIER", 101, 110], ["infection", "OBSERVATION", 111, 120]]], ["Although the temporal relationship between infection and inflammation remains unclear in early disease, later in disease there is a self-perpetuating cycle of airway obstruction, chronic bacterial infection and vigorous inflammation resulting in structural damage to the airway [9], [10], [11].", [["airway", "ANATOMY", 159, 165], ["airway", "ANATOMY", 271, 277], ["infection", "DISEASE", 43, 52], ["inflammation", "DISEASE", 57, 69], ["airway obstruction", "DISEASE", 159, 177], ["bacterial infection", "DISEASE", 187, 206], ["inflammation", "DISEASE", 220, 232], ["airway obstruction", "PATHOLOGICAL_FORMATION", 159, 177], ["infection", "PROBLEM", 43, 52], ["inflammation", "PROBLEM", 57, 69], ["early disease", "PROBLEM", 89, 102], ["airway obstruction", "PROBLEM", 159, 177], ["chronic bacterial infection", "PROBLEM", 179, 206], ["vigorous inflammation", "PROBLEM", 211, 232], ["structural damage to the airway", "PROBLEM", 246, 277], ["temporal", "OBSERVATION_MODIFIER", 13, 21], ["infection", "OBSERVATION", 43, 52], ["inflammation", "OBSERVATION", 57, 69], ["early", "OBSERVATION_MODIFIER", 89, 94], ["disease", "OBSERVATION", 95, 102], ["airway", "ANATOMY", 159, 165], ["obstruction", "OBSERVATION", 166, 177], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["bacterial", "OBSERVATION_MODIFIER", 187, 196], ["infection", "OBSERVATION", 197, 206], ["vigorous", "OBSERVATION_MODIFIER", 211, 219], ["inflammation", "OBSERVATION", 220, 232], ["structural damage", "OBSERVATION", 246, 263], ["airway", "ANATOMY", 271, 277]]], ["Less is currently known about the contribution from viral infections.", [["viral infections", "DISEASE", 52, 68], ["viral infections", "PROBLEM", 52, 68], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["infections", "OBSERVATION", 58, 68]]], ["A better understanding of the host inflammatory response following respiratory viral infections may minimize the use of prolonged antibiotic therapy.IntroductionThe primary objective of this study was to investigate the proportion of CF pulmonary exacerbations associated with a respiratory viral infection, as detected by conventional diagnostics and a commercially available multiplex molecular diagnostic assay.", [["pulmonary", "ANATOMY", 237, 246], ["respiratory viral infections", "DISEASE", 67, 95], ["pulmonary exacerbations", "DISEASE", 237, 260], ["respiratory viral infection", "DISEASE", 279, 306], ["pulmonary", "ORGAN", 237, 246], ["the host inflammatory response", "PROBLEM", 26, 56], ["respiratory viral infections", "PROBLEM", 67, 95], ["prolonged antibiotic therapy", "TREATMENT", 120, 148], ["this study", "TEST", 186, 196], ["CF pulmonary exacerbations", "PROBLEM", 234, 260], ["a respiratory viral infection", "PROBLEM", 277, 306], ["inflammatory", "OBSERVATION_MODIFIER", 35, 47], ["viral infections", "OBSERVATION", 79, 95], ["pulmonary", "ANATOMY", 237, 246], ["exacerbations", "OBSERVATION", 247, 260], ["respiratory viral", "OBSERVATION", 279, 296], ["infection", "OBSERVATION", 297, 306]]], ["Our secondary objectives were to determine the clinical severity and pulmonary inflammation due to exacerbations associated with viral infections.Participants ::: Materials and methodsFrom November 1, 2009 to March 31, 2010, we conducted an observational, cross-sectional study of children with CF seen in the setting of a pulmonary exacerbation.", [["pulmonary", "ANATOMY", 69, 78], ["pulmonary", "ANATOMY", 323, 332], ["pulmonary inflammation", "DISEASE", 69, 91], ["exacerbations", "DISEASE", 99, 112], ["viral infections", "DISEASE", 129, 145], ["CF", "DISEASE", 295, 297], ["pulmonary exacerbation", "DISEASE", 323, 345], ["pulmonary", "ORGAN", 69, 78], ["children", "ORGANISM", 281, 289], ["pulmonary", "ORGAN", 323, 332], ["Participants", "SPECIES", 146, 158], ["children", "SPECIES", 281, 289], ["the clinical severity", "PROBLEM", 43, 64], ["pulmonary inflammation", "PROBLEM", 69, 91], ["exacerbations", "PROBLEM", 99, 112], ["viral infections", "PROBLEM", 129, 145], ["CF", "PROBLEM", 295, 297], ["a pulmonary exacerbation", "PROBLEM", 321, 345], ["pulmonary", "ANATOMY", 69, 78], ["inflammation", "OBSERVATION", 79, 91], ["viral", "OBSERVATION_MODIFIER", 129, 134], ["infections", "OBSERVATION", 135, 145], ["pulmonary", "ANATOMY", 323, 332], ["exacerbation", "OBSERVATION", 333, 345]]], ["Patients were recruited from the respiratory medicine clinic at The Hospital for Sick Children, a large pediatric referral center that cares for approximately 280 CF patients.", [["CF", "DISEASE", 163, 165], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 166, 174], ["Patients", "SPECIES", 0, 8], ["Children", "SPECIES", 86, 94], ["patients", "SPECIES", 166, 174]]], ["We enrolled all CF patients who met the following inclusion criteria: age < 18 years; and clinical presentation consistent with a pulmonary exacerbation, defined as any of the following clinical symptoms: change in sputum production, increased cough or dyspnea, alone or in combination with temperature above 38 \u00b0C, and/or change in respiratory status (tachypnea, indrawing, wheezing or crackles) reported by the attending team.", [["pulmonary", "ANATOMY", 130, 139], ["sputum", "ANATOMY", 215, 221], ["respiratory", "ANATOMY", 333, 344], ["pulmonary exacerbation", "DISEASE", 130, 152], ["cough", "DISEASE", 244, 249], ["dyspnea", "DISEASE", 253, 260], ["tachypnea", "DISEASE", 353, 362], ["wheezing", "DISEASE", 375, 383], ["patients", "ORGANISM", 19, 27], ["pulmonary", "ORGAN", 130, 139], ["sputum", "ORGANISM_SUBSTANCE", 215, 221], ["patients", "SPECIES", 19, 27], ["a pulmonary exacerbation", "PROBLEM", 128, 152], ["clinical symptoms", "PROBLEM", 186, 203], ["change in sputum production", "PROBLEM", 205, 232], ["increased cough", "PROBLEM", 234, 249], ["dyspnea", "PROBLEM", 253, 260], ["temperature above 38 \u00b0C", "PROBLEM", 291, 314], ["change in respiratory status", "PROBLEM", 323, 351], ["tachypnea", "PROBLEM", 353, 362], ["indrawing", "PROBLEM", 364, 373], ["wheezing", "PROBLEM", 375, 383], ["crackles", "PROBLEM", 387, 395], ["consistent with", "UNCERTAINTY", 112, 127], ["pulmonary", "ANATOMY", 130, 139], ["exacerbation", "OBSERVATION", 140, 152], ["increased", "OBSERVATION_MODIFIER", 234, 243], ["cough", "OBSERVATION", 244, 249], ["respiratory status", "OBSERVATION", 333, 351]]], ["Informed consent (and assent from child as appropriate) was obtained from all participants and ethics approval was obtained from the Research Ethics Board at The Hospital for Sick Children.", [["participants", "SPECIES", 78, 90], ["Children", "SPECIES", 180, 188]]], ["Exclusion criteria included lack of consent and insufficient command of English or absence of translator.Collection of clinical information and specimens ::: Materials and methodsInformation on patient demographics and CF-relevant baseline characteristics such as CF-related comorbidities and bacterial colonization were abstracted from health records.", [["specimens", "ANATOMY", 144, 153], ["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 194, 201], ["CF-related comorbidities", "PROBLEM", 264, 288], ["bacterial colonization", "PROBLEM", 293, 315], ["bacterial colonization", "OBSERVATION", 293, 315]]], ["The Cystic Fibrosis Questionnaire-Revised (CFQ-R ) [12] and the Cystic Fibrosis Clinical Score (CFCS) [13] were prospectively administered to participants through standardized interviews and physical assessments.", [["Cystic Fibrosis", "DISEASE", 4, 19], ["Cystic Fibrosis", "DISEASE", 64, 79], ["participants", "SPECIES", 142, 154], ["The Cystic Fibrosis", "PROBLEM", 0, 19], ["CFQ", "TEST", 43, 46], ["the Cystic Fibrosis", "PROBLEM", 60, 79], ["physical assessments", "TEST", 191, 211], ["Cystic", "OBSERVATION_MODIFIER", 4, 10], ["Fibrosis", "OBSERVATION", 11, 19], ["Cystic", "OBSERVATION_MODIFIER", 64, 70], ["Fibrosis", "OBSERVATION", 71, 79]]], ["The CFCS is an acute clinical score, based on signs and symptoms.", [["an acute clinical score", "PROBLEM", 12, 35], ["symptoms", "PROBLEM", 56, 64], ["CFCS", "OBSERVATION", 4, 8], ["acute", "OBSERVATION_MODIFIER", 15, 20]]], ["It was chosen as a severity scale because of its reliability and its ease of use [13].", [["a severity scale", "TREATMENT", 17, 33]]], ["Body mass index (BMI) percentile was calculated for children \u2265 2 years of age and weight-for-recumbent length percentile for those under the age of 2 [14].", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["Body mass index", "TEST", 0, 15], ["weight", "TEST", 82, 88]]], ["Mid-turbinate flocked swabs (Copan Diagnostics, Murrietta, CA), collected from all enrolled patients, were placed into in 3 mL of Universal Transport Medium (UTM-RT COPAN Diagnostics, Murrieta, CA).", [["turbinate", "MULTI-TISSUE_STRUCTURE", 4, 13], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Mid-turbinate flocked swabs", "PROBLEM", 0, 27]]], ["In addition, children old enough to produce sputum provided sputum samples while FLOQ COPAN throat swabs (inoculated in UTM) were obtained from those unable to produce sputum (refer to Fig. 1for sample collection and testing).Virology studies ::: Materials and methodsMid-turbinate specimens were examined by 1) direct fluorescent antigen assay (DFA) for 8 respiratory viruses (respiratory syncytial virus (RSV), influenza virus [A,B] (INFA/INFB), parainfluenza [types 1\u20133] (PIV), adenovirus (ADV) (SimulFluor\u00ae, Millipore, Temecula, CA) and human metapneumovirus (hMPV) (Diagnostic HYBRIDS, Athens, OH); 2) a nucleic acid amplification-based assay (ResPlex II v2.0, Qiagen, Mississauga, ON, Canada) for detection of 18 respiratory viruses (RSV [A, B], coronaviruses [OC43, 229E, NL63, HKU1], rhinovirus (HRV), cocksackie/echovirus, PIV [types 1\u20134], INFA, INFB, bocavirus, ADV [B, E] and hMPV); and 3) reverse transcription polymerase chain reaction (RT-PCR) for specific identification of the pandemic 2009 influenza A H1N1 (pH1N1) virus (Astra influenza Screen and Type (Astra Diagnostics, Hamburg, Germany or RT-PCR Kit 1.0, Astra Diagnostics, Hamburg, Germany)).", [["sputum", "ANATOMY", 44, 50], ["sputum samples", "ANATOMY", 60, 74], ["throat swabs", "ANATOMY", 92, 104], ["sputum", "ANATOMY", 168, 174], ["sample", "ANATOMY", 195, 201], ["turbinate specimens", "ANATOMY", 272, 291], ["respiratory viruses", "DISEASE", 357, 376], ["respiratory syncytial virus", "DISEASE", 378, 405], ["parainfluenza", "DISEASE", 448, 461], ["human metapneumovirus", "DISEASE", 541, 562], ["nucleic acid", "CHEMICAL", 609, 621], ["respiratory viruses", "DISEASE", 719, 738], ["influenza A H1N1", "DISEASE", 1007, 1023], ["children", "ORGANISM", 13, 21], ["sputum", "ORGANISM_SUBSTANCE", 44, 50], ["sputum samples", "ORGANISM_SUBSTANCE", 60, 74], ["throat swabs", "ORGANISM_SUBSTANCE", 92, 104], ["sputum", "ORGANISM_SUBSTANCE", 168, 174], ["respiratory syncytial virus", "ORGANISM", 378, 405], ["RSV", "ORGANISM", 407, 410], ["influenza virus", "ORGANISM", 413, 428], ["A,B", "ORGANISM", 430, 433], ["INFA", "GENE_OR_GENE_PRODUCT", 436, 440], ["INFB", "GENE_OR_GENE_PRODUCT", 441, 445], ["parainfluenza", "ORGANISM", 448, 461], ["PIV", "ORGANISM", 475, 478], ["adenovirus", "ORGANISM", 481, 491], ["human", "ORGANISM", 541, 546], ["metapneumovirus", "ORGANISM", 547, 562], ["hMPV", "ORGANISM", 564, 568], ["RSV", "ORGANISM", 740, 743], ["A, B]", "ORGANISM", 745, 750], ["coronaviruses", "ORGANISM", 752, 765], ["OC43", "GENE_OR_GENE_PRODUCT", 767, 771], ["229E", "GENE_OR_GENE_PRODUCT", 773, 777], ["NL63", "GENE_OR_GENE_PRODUCT", 779, 783], ["HKU1", "GENE_OR_GENE_PRODUCT", 785, 789], ["rhinovirus", "ORGANISM", 792, 802], ["cocksackie/echovirus", "ORGANISM", 810, 830], ["INFA", "GENE_OR_GENE_PRODUCT", 849, 853], ["INFB", "GENE_OR_GENE_PRODUCT", 855, 859], ["B", "GENE_OR_GENE_PRODUCT", 877, 878], ["hMPV", "ORGANISM", 887, 891], ["2009", "ORGANISM", 1002, 1006], ["influenza A H1N1 (pH1N1) virus", "ORGANISM", 1007, 1037], ["INFA", "PROTEIN", 849, 853], ["INFB", "PROTEIN", 855, 859], ["children", "SPECIES", 13, 21], ["respiratory syncytial virus", "SPECIES", 378, 405], ["influenza virus", "SPECIES", 413, 428], ["parainfluenza", "SPECIES", 448, 461], ["human", "SPECIES", 541, 546], ["metapneumovirus", "SPECIES", 547, 562], ["influenza A H1N1", "SPECIES", 1007, 1023], ["pH1N1) virus", "SPECIES", 1025, 1037], ["respiratory syncytial virus", "SPECIES", 378, 405], ["RSV", "SPECIES", 407, 410], ["PIV", "SPECIES", 475, 478], ["adenovirus", "SPECIES", 481, 491], ["ADV", "SPECIES", 493, 496], ["human metapneumovirus", "SPECIES", 541, 562], ["hMPV", "SPECIES", 564, 568], ["RSV", "SPECIES", 740, 743], ["A", "SPECIES", 745, 746], ["HRV", "SPECIES", 804, 807], ["ADV", "SPECIES", 872, 875], ["hMPV", "SPECIES", 887, 891], ["pandemic 2009 influenza A H1N1 (pH1N1) virus", "SPECIES", 993, 1037], ["sputum", "TEST", 44, 50], ["sputum samples", "TEST", 60, 74], ["FLOQ COPAN throat swabs", "TEST", 81, 104], ["sputum", "PROBLEM", 168, 174], ["sample collection and testing", "TEST", 195, 224], ["Virology studies", "TEST", 226, 242], ["methodsMid-turbinate specimens", "TEST", 261, 291], ["direct fluorescent antigen assay", "TEST", 312, 344], ["DFA", "TEST", 346, 349], ["8 respiratory viruses (respiratory syncytial virus", "PROBLEM", 355, 405], ["RSV", "TEST", 407, 410], ["influenza virus", "PROBLEM", 413, 428], ["INFA", "TEST", 436, 440], ["INFB", "TEST", 441, 445], ["parainfluenza", "PROBLEM", 448, 461], ["types", "TEST", 463, 468], ["PIV", "TREATMENT", 475, 478], ["adenovirus (ADV) (SimulFluor\u00ae, Millipore", "TREATMENT", 481, 521], ["human metapneumovirus (hMPV", "PROBLEM", 541, 568], ["a nucleic acid amplification", "TEST", 607, 635], ["detection", "TEST", 703, 712], ["18 respiratory viruses", "PROBLEM", 716, 738], ["RSV", "TEST", 740, 743], ["coronaviruses", "PROBLEM", 752, 765], ["OC43", "TEST", 767, 771], ["NL63", "TEST", 779, 783], ["HKU1", "TEST", 785, 789], ["rhinovirus", "TEST", 792, 802], ["HRV", "TEST", 804, 807], ["cocksackie", "TEST", 810, 820], ["echovirus", "PROBLEM", 821, 830], ["PIV", "TEST", 832, 835], ["types", "TEST", 837, 842], ["INFA", "TEST", 849, 853], ["INFB", "TEST", 855, 859], ["bocavirus", "TEST", 861, 870], ["ADV", "TEST", 872, 875], ["hMPV", "PROBLEM", 887, 891], ["reverse transcription polymerase chain reaction", "PROBLEM", 901, 948], ["RT-PCR", "TEST", 950, 956], ["the pandemic 2009 influenza A H1N1 (pH1N1) virus", "PROBLEM", 989, 1037], ["Astra influenza Screen", "TEST", 1039, 1061], ["respiratory syncytial", "ANATOMY", 378, 399], ["respiratory viruses", "OBSERVATION", 719, 738]]], ["We also applied the ResPlex II v2.0 panel to FLOQ COPAN throat swabs and Sputolysin (10.14 mg/ml, CALBIOCHEM)-treated sputum sample after ensuring that Sputolysin would not affect the performance of the assay (Fig. 1).", [["sputum sample", "ANATOMY", 118, 131], ["Sputolysin", "CHEMICAL", 73, 83], ["Sputolysin", "CHEMICAL", 152, 162], ["Sputolysin", "CHEMICAL", 73, 83], ["Sputolysin", "CHEMICAL", 152, 162], ["Sputolysin", "SIMPLE_CHEMICAL", 73, 83], ["Sputolysin", "SIMPLE_CHEMICAL", 152, 162], ["ResPlex II", "PROTEIN", 20, 30], ["the ResPlex II", "TREATMENT", 16, 30], ["FLOQ COPAN throat swabs", "TREATMENT", 45, 68], ["Sputolysin", "TREATMENT", 73, 83], ["sputum sample", "TEST", 118, 131]]], ["To evaluate the potential interference of Sputolysin with the efficiency of nucleic acid extraction and performance of the assay, we randomly chose four known positive mid-turbinate samples (RSV B, PIV 1, HRV/INFA and RSVA) from another study and divided them each into two equal aliquots.", [["mid-turbinate samples", "ANATOMY", 168, 189], ["Sputolysin", "CHEMICAL", 42, 52], ["nucleic acid", "CHEMICAL", 76, 88], ["Sputolysin", "CHEMICAL", 42, 52], ["Sputolysin", "SIMPLE_CHEMICAL", 42, 52], ["nucleic acid", "SIMPLE_CHEMICAL", 76, 88], ["RSV", "ORGANISM", 191, 194], ["RSV", "SPECIES", 191, 194], ["Sputolysin", "TREATMENT", 42, 52], ["nucleic acid extraction", "TREATMENT", 76, 99], ["the assay", "TEST", 119, 128], ["positive mid-turbinate samples", "PROBLEM", 159, 189], ["PIV", "TREATMENT", 198, 201], ["HRV/INFA", "TREATMENT", 205, 213], ["RSVA", "TREATMENT", 218, 222], ["another study", "TEST", 229, 242]]], ["The potential interference of Sputolysin was tested on mid-turbinate swabs instead of sputum samples as non Sputolysin-treated sputum samples would not enable appropriate nucleic acid extraction because of the sputum viscosity.", [["mid-turbinate swabs", "ANATOMY", 55, 74], ["sputum samples", "ANATOMY", 86, 100], ["sputum samples", "ANATOMY", 127, 141], ["sputum", "ANATOMY", 210, 216], ["Sputolysin", "CHEMICAL", 30, 40], ["Sputolysin", "CHEMICAL", 108, 118], ["nucleic acid", "CHEMICAL", 171, 183], ["Sputolysin", "CHEMICAL", 30, 40], ["Sputolysin", "SIMPLE_CHEMICAL", 30, 40], ["mid-turbinate swabs", "ORGANISM_SUBSTANCE", 55, 74], ["sputum samples", "ORGANISM_SUBSTANCE", 86, 100], ["Sputolysin", "SIMPLE_CHEMICAL", 108, 118], ["sputum", "ORGANISM_SUBSTANCE", 210, 216], ["Sputolysin", "TREATMENT", 30, 40], ["mid-turbinate swabs", "TREATMENT", 55, 74], ["sputum samples", "TEST", 86, 100], ["Sputolysin", "TEST", 108, 118], ["sputum samples", "TEST", 127, 141], ["appropriate nucleic acid extraction", "TREATMENT", 159, 194], ["the sputum viscosity", "PROBLEM", 206, 226], ["sputum", "OBSERVATION", 210, 216]]], ["We mixed one aliquot with an equal volume of 10% Sputolysin in PBS (phosphate buffered saline) and the other with an equal volume of PBS alone.", [["Sputolysin", "CHEMICAL", 49, 59], ["phosphate", "CHEMICAL", 68, 77], ["Sputolysin", "CHEMICAL", 49, 59], ["phosphate", "CHEMICAL", 68, 77], ["Sputolysin", "SIMPLE_CHEMICAL", 49, 59], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 68, 93], ["an equal volume", "TREATMENT", 26, 41], ["PBS (phosphate buffered saline", "TREATMENT", 63, 93], ["an equal volume of PBS", "TREATMENT", 114, 136]]], ["After incubation for 10 min at room temperature, we extracted total nucleic acids from both aliquots with the NucliSENS easyMAG (bioMerieux, St Laurent, QC, Canada ) followed by amplification with the Resplex II v2.0 assay [15].", [["nucleic acids", "CHEMICAL", 68, 81], ["total nucleic acids", "TREATMENT", 62, 81], ["the NucliSENS easyMAG", "TREATMENT", 106, 127]]], ["A patient was classified as being virus-positive if a respiratory virus was detected in the mid-turbinate or throat or sputum sample by any one of the three assays used (DFA, Resplex II v2.0 or RT-PCR).Bacteriologic confirmation and load assessment ::: Materials and methodsSputum samples underwent bacterial density analysis for Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae based on the predominant organism isolated on the routine bacterial culture using previously described methods [16].Inflammatory markers and sputum neutrophil percentage ::: Materials and methodsLevels of IL-8 and 26 additional inflammatory cytokines (PDGF, Il-1 B, Il-1 RA, Il-2, Il-4, Il-5, Il-6, Il-7, Il-9, Il-10, Il-12, Il-13, Il-15, Il-17, Eotaxin, FGF, G_CSF, GM_CSF, IFN_G, IP_10, MCP_1, MIP_1A, MIP_1B, RANTES, TNF_alpha, VEGF) were measured on Sputolysin-treated sputum samples using a commercial multiplex bead-based assay (Bio-Plex Cytokine Assay, Bio-Rad) [17], [18].", [["mid-turbinate", "ANATOMY", 92, 105], ["throat", "ANATOMY", 109, 115], ["sputum sample", "ANATOMY", 119, 132], ["Sputum samples", "ANATOMY", 274, 288], ["sputum neutrophil", "ANATOMY", 544, 561], ["sputum samples", "ANATOMY", 876, 890], ["Staphylococcus aureus", "DISEASE", 354, 375], ["Sputolysin", "CHEMICAL", 857, 867], ["Sputolysin", "CHEMICAL", 857, 867], ["patient", "ORGANISM", 2, 9], ["mid-turbinate", "CANCER", 92, 105], ["throat", "ORGAN", 109, 115], ["Pseudomonas aeruginosa", "ORGANISM", 330, 352], ["Staphylococcus aureus", "ORGANISM", 354, 375], ["Haemophilus influenzae", "ORGANISM", 380, 402], ["sputum neutrophil", "CELL", 544, 561], ["IL-8", "GENE_OR_GENE_PRODUCT", 608, 612], ["PDGF", "GENE_OR_GENE_PRODUCT", 655, 659], ["Il-1 B", "GENE_OR_GENE_PRODUCT", 661, 667], ["Il-1 RA", "GENE_OR_GENE_PRODUCT", 669, 676], ["Il-2", "GENE_OR_GENE_PRODUCT", 678, 682], ["Il-4", "GENE_OR_GENE_PRODUCT", 684, 688], ["Il-5", "GENE_OR_GENE_PRODUCT", 690, 694], ["Il-6", "GENE_OR_GENE_PRODUCT", 696, 700], ["Il-7", "GENE_OR_GENE_PRODUCT", 702, 706], ["Il-9", "GENE_OR_GENE_PRODUCT", 708, 712], ["Il-10", "GENE_OR_GENE_PRODUCT", 714, 719], ["Il-12", "GENE_OR_GENE_PRODUCT", 721, 726], ["Il-13", "GENE_OR_GENE_PRODUCT", 728, 733], ["Il-15", "GENE_OR_GENE_PRODUCT", 735, 740], ["Il-17", "GENE_OR_GENE_PRODUCT", 742, 747], ["Eotaxin", "GENE_OR_GENE_PRODUCT", 749, 756], ["FGF", "GENE_OR_GENE_PRODUCT", 758, 761], ["G_CSF", "GENE_OR_GENE_PRODUCT", 763, 768], ["GM_CSF", "GENE_OR_GENE_PRODUCT", 770, 776], ["IFN_G", "GENE_OR_GENE_PRODUCT", 778, 783], ["IP_10", "GENE_OR_GENE_PRODUCT", 785, 790], ["MCP_1", "GENE_OR_GENE_PRODUCT", 792, 797], ["MIP_1A", "GENE_OR_GENE_PRODUCT", 799, 805], ["MIP_1B", "GENE_OR_GENE_PRODUCT", 807, 813], ["RANTES", "GENE_OR_GENE_PRODUCT", 815, 821], ["TNF_alpha", "GENE_OR_GENE_PRODUCT", 823, 832], ["VEGF", "GENE_OR_GENE_PRODUCT", 834, 838], ["Sputolysin", "SIMPLE_CHEMICAL", 857, 867], ["IL", "PROTEIN", 608, 610], ["inflammatory cytokines", "PROTEIN", 631, 653], ["PDGF", "PROTEIN", 655, 659], ["Il", "PROTEIN", 661, 663], ["Il", "PROTEIN", 669, 671], ["Il-6", "PROTEIN", 696, 700], ["Il-13", "PROTEIN", 728, 733], ["Il-15", "PROTEIN", 735, 740], ["Il-17", "PROTEIN", 742, 747], ["Eotaxin", "PROTEIN", 749, 756], ["FGF", "PROTEIN", 758, 761], ["G_CSF", "PROTEIN", 763, 768], ["GM", "PROTEIN", 770, 772], ["_CSF", "PROTEIN", 772, 776], ["IFN_G", "PROTEIN", 778, 783], ["IP_10", "PROTEIN", 785, 790], ["MCP_1", "PROTEIN", 792, 797], ["MIP_1A", "PROTEIN", 799, 805], ["MIP_1B", "PROTEIN", 807, 813], ["RANTES", "PROTEIN", 815, 821], ["TNF_alpha", "PROTEIN", 823, 832], ["VEGF", "PROTEIN", 834, 838], ["Cytokine", "PROTEIN", 947, 955], ["patient", "SPECIES", 2, 9], ["Pseudomonas aeruginosa", "SPECIES", 330, 352], ["Staphylococcus aureus", "SPECIES", 354, 375], ["Haemophilus influenzae", "SPECIES", 380, 402], ["Pseudomonas aeruginosa", "SPECIES", 330, 352], ["Staphylococcus aureus", "SPECIES", 354, 375], ["Haemophilus influenzae", "SPECIES", 380, 402], ["virus", "PROBLEM", 34, 39], ["a respiratory virus", "PROBLEM", 52, 71], ["sputum sample", "TEST", 119, 132], ["the three assays", "TEST", 147, 163], ["DFA", "TEST", 170, 173], ["Resplex II v", "TEST", 175, 187], ["RT-PCR", "TREATMENT", 194, 200], ["Bacteriologic confirmation", "TEST", 202, 228], ["load assessment", "TEST", 233, 248], ["methodsSputum samples", "TEST", 267, 288], ["bacterial density analysis", "TEST", 299, 325], ["Pseudomonas aeruginosa", "PROBLEM", 330, 352], ["Staphylococcus aureus", "PROBLEM", 354, 375], ["Haemophilus influenzae", "PROBLEM", 380, 402], ["the predominant organism", "PROBLEM", 412, 436], ["the routine bacterial culture", "TEST", 449, 478], ["Inflammatory markers", "TEST", 519, 539], ["sputum neutrophil percentage", "TEST", 544, 572], ["methodsLevels", "TEST", 591, 604], ["IL", "TEST", 608, 610], ["additional inflammatory cytokines", "TEST", 620, 653], ["PDGF", "TEST", 655, 659], ["Il", "TEST", 661, 663], ["Il", "TEST", 669, 671], ["Il", "TEST", 678, 680], ["Il", "TEST", 684, 686], ["Il", "TEST", 690, 692], ["Il", "TEST", 696, 698], ["Il", "TEST", 702, 704], ["Il", "TEST", 708, 710], ["Il", "TEST", 714, 716], ["Il", "TEST", 721, 723], ["Il", "TEST", 728, 730], ["Il", "TEST", 735, 737], ["Il", "TEST", 742, 744], ["Eotaxin", "TEST", 749, 756], ["FGF", "TEST", 758, 761], ["IFN_G", "TEST", 778, 783], ["IP", "TEST", 785, 787], ["MCP_1", "TEST", 792, 797], ["MIP_1A", "TEST", 799, 805], ["RANTES", "TEST", 815, 821], ["Sputolysin", "TEST", 857, 867], ["sputum samples", "TEST", 876, 890], ["a commercial multiplex bead", "TEST", 897, 924], ["Cytokine Assay", "TEST", 947, 961], ["throat", "ANATOMY", 109, 115], ["bacterial density", "OBSERVATION", 299, 316], ["sputum neutrophil percentage", "OBSERVATION", 544, 572], ["inflammatory", "OBSERVATION_MODIFIER", 631, 643], ["RA", "ANATOMY", 674, 676]]], ["The detection range for all cytokines was 0\u201332,000 pg/ml as per the manufacture guidelines [26].", [["cytokines", "PROTEIN", 28, 37], ["all cytokines", "TREATMENT", 24, 37]]], ["Neutrophil elastase (NE) activity was measured using a modified enzymatic assay based on NE cleavage of nitroanilide from N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide and results were reported in units/ml (1 unit = mmol/min).", [["Neutrophil", "ANATOMY", 0, 10], ["NE", "CHEMICAL", 89, 91], ["nitroanilide", "CHEMICAL", 104, 116], ["N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide", "CHEMICAL", 122, 170], ["nitroanilide", "CHEMICAL", 104, 116], ["N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide", "CHEMICAL", 122, 170], ["Neutrophil elastase", "GENE_OR_GENE_PRODUCT", 0, 19], ["NE", "SIMPLE_CHEMICAL", 21, 23], ["NE", "SIMPLE_CHEMICAL", 89, 91], ["nitroanilide", "SIMPLE_CHEMICAL", 104, 116], ["N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide", "SIMPLE_CHEMICAL", 122, 170], ["Neutrophil elastase", "PROTEIN", 0, 19], ["NE", "PROTEIN", 21, 23], ["NE", "PROTEIN", 89, 91], ["Neutrophil elastase", "TEST", 0, 19], ["a modified enzymatic assay", "TREATMENT", 53, 79], ["NE cleavage", "TREATMENT", 89, 100], ["nitroanilide", "TREATMENT", 104, 116], ["methoxysuccinyl", "TREATMENT", 124, 139], ["ala-ala", "TREATMENT", 140, 147], ["nitroanilide", "TREATMENT", 158, 170]]], ["Sputum neutrophil percentage is the percentage of neutrophils based on a count of 400 white blood cells.Lung function testing ::: Materials and methodsChildren old enough to perform spirometry had standard spirometry done at enrollment and routinely at every visit.", [["Sputum neutrophil", "ANATOMY", 0, 17], ["neutrophils", "ANATOMY", 50, 61], ["white blood cells", "ANATOMY", 86, 103], ["Lung", "ANATOMY", 104, 108], ["Sputum neutrophil", "CELL", 0, 17], ["neutrophils", "CELL", 50, 61], ["blood cells", "CELL", 92, 103], ["Lung", "ORGAN", 104, 108], ["Children", "ORGANISM", 151, 159], ["neutrophils", "CELL_TYPE", 50, 61], ["white blood cells", "CELL_TYPE", 86, 103], ["Children", "SPECIES", 151, 159], ["Sputum neutrophil percentage", "TEST", 0, 28], ["neutrophils", "TEST", 50, 61], ["a count", "TEST", 71, 78], ["white blood cells", "TEST", 86, 103], ["Lung function testing", "TEST", 104, 125], ["standard spirometry", "TREATMENT", 197, 216], ["neutrophil percentage", "OBSERVATION", 7, 28]]], ["We reported forced expiratory volume in 1 s (FEV1) as a percentage of predicted value for sex and height using the equation of Corey et al. [19].", [["forced expiratory volume", "TEST", 12, 36], ["FEV1", "TEST", 45, 49], ["forced", "OBSERVATION_MODIFIER", 12, 18], ["expiratory volume", "OBSERVATION", 19, 36]]], ["We defined baseline FEV1 as the best FEV1 in the 6 months prior to the current pulmonary exacerbation, and exacerbation FEV1 as the FEV1 at the time of presentation with a pulmonary exacerbation.Statistical analyses ::: Materials and methodsStandard descriptive and comparative statistics were used on data categorized by viral infection status (virus-positive and virus-negative patients).", [["pulmonary", "ANATOMY", 79, 88], ["pulmonary", "ANATOMY", 172, 181], ["pulmonary exacerbation", "DISEASE", 172, 194], ["viral infection", "DISEASE", 322, 337], ["pulmonary", "ORGAN", 79, 88], ["pulmonary", "ORGAN", 172, 181], ["patients", "ORGANISM", 380, 388], ["patients", "SPECIES", 380, 388], ["baseline FEV1", "TEST", 11, 24], ["the current pulmonary exacerbation", "PROBLEM", 67, 101], ["exacerbation FEV1", "PROBLEM", 107, 124], ["the FEV1", "TEST", 128, 136], ["a pulmonary exacerbation", "PROBLEM", 170, 194], ["viral infection", "PROBLEM", 322, 337], ["virus", "TEST", 346, 351], ["virus", "TEST", 365, 370], ["pulmonary", "ANATOMY", 79, 88], ["exacerbation", "OBSERVATION", 89, 101], ["pulmonary", "ANATOMY", 172, 181], ["exacerbation", "OBSERVATION", 182, 194]]], ["For normally-distributed continuous variables (total bacterial densities and bacterial densities for S. aureus, P. aeruginosa and H. influenzae), we calculated means and analyzed differences between the comparator groups using Student's t-test.", [["S. aureus", "ORGANISM", 101, 110], ["P. aeruginosa", "ORGANISM", 112, 125], ["H. influenzae", "ORGANISM", 130, 143], ["S. aureus", "SPECIES", 101, 110], ["P. aeruginosa", "SPECIES", 112, 125], ["H. influenzae", "SPECIES", 130, 143], ["S. aureus", "SPECIES", 101, 110], ["P. aeruginosa", "SPECIES", 112, 125], ["H. influenzae", "SPECIES", 130, 143], ["normally-distributed continuous variables (total bacterial densities", "PROBLEM", 4, 72], ["bacterial densities", "PROBLEM", 77, 96], ["S. aureus", "PROBLEM", 101, 110], ["P. aeruginosa", "PROBLEM", 112, 125], ["H. influenzae", "PROBLEM", 130, 143], ["Student's t-test", "TEST", 227, 243], ["distributed", "OBSERVATION_MODIFIER", 13, 24], ["total", "OBSERVATION_MODIFIER", 47, 52], ["bacterial densities", "OBSERVATION", 53, 72], ["bacterial densities", "OBSERVATION", 77, 96]]], ["For skewed data (age, obesity measures, FEV1% predicted, CFSC and CFQ-R scores, IL-8 levels, sputum neutrophil percentage and count, sputum neutrophil elastase), we derived medians and used the Mann\u2013Whitney method for comparisons.", [["sputum neutrophil", "ANATOMY", 93, 110], ["sputum neutrophil", "ANATOMY", 133, 150], ["obesity", "DISEASE", 22, 29], ["CFQ-R", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-8", "GENE_OR_GENE_PRODUCT", 80, 84], ["neutrophil", "CELL", 100, 110], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 140, 159], ["CFQ", "PROTEIN", 66, 69], ["IL", "PROTEIN", 80, 82], ["sputum neutrophil elastase", "PROTEIN", 133, 159], ["obesity measures", "PROBLEM", 22, 38], ["FEV1", "TEST", 40, 44], ["CFSC", "TEST", 57, 61], ["CFQ", "TEST", 66, 69], ["IL", "TEST", 80, 82], ["levels", "TEST", 85, 91], ["sputum neutrophil percentage", "TEST", 93, 121], ["count", "TEST", 126, 131], ["sputum neutrophil elastase", "TEST", 133, 159]]], ["The \u03c72 test or Fisher's exact test was used to compare categorical variables between groups as appropriate.", [["The \u03c72 test", "TEST", 0, 11], ["Fisher's exact test", "TEST", 15, 34]]], ["Using standard formulae, we estimated the sensitivities and specificities (with respective binomial 95% confidence intervals (CI)) of mid-turbinate swabs, sputum samples and throat swabs for virus detection relative to the combination of these sample types as the reference standard.", [["mid-turbinate swabs", "ANATOMY", 134, 153], ["sputum samples", "ANATOMY", 155, 169], ["throat swabs", "ANATOMY", 174, 186], ["sample", "ANATOMY", 244, 250], ["sputum samples", "ORGANISM_SUBSTANCE", 155, 169], ["throat", "ORGANISM_SUBDIVISION", 174, 180], ["swabs", "ORGANISM_SUBSTANCE", 181, 186], ["specificities", "TEST", 60, 73], ["mid-turbinate swabs", "TEST", 134, 153], ["sputum samples", "TEST", 155, 169], ["throat swabs", "TEST", 174, 186], ["virus detection", "TEST", 191, 206]]], ["Differences in test performance were calculated using McNemar's test.", [["test performance", "TEST", 15, 31], ["McNemar's test", "TEST", 54, 68]]], ["A p value < 0.05 was considered statistically significant.", [["A p value", "TEST", 0, 9]]], ["Data were analyzed by SPSS statistical software (version 16.0, SPSS Inc, Chicago, IL, USA).Viral detection studies ::: ResultsA total of 112 CF patients were screened for inclusion in the study between November 2009 and March 2010.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["version", "TEST", 49, 56], ["Viral detection studies", "TEST", 91, 114], ["the study", "TEST", 184, 193]]], ["Of these, 47 (42%) met eligibility criteria, 4 of whom (8.5%) declined participation in the study.", [["the study", "TEST", 88, 97]]], ["Among the 43 enrolled patients, 26 (60.5%) were classified as virus-positive: 25/26 (96.2%) from mid-turbinate swabs and 6/26 (23.0%) from either sputum samples or throat swabs by any one of the three assays used (8 by DFA, 2 by RT-PCR and 26 by multiplex PCR).", [["mid-turbinate swabs", "ANATOMY", 97, 116], ["sputum samples", "ANATOMY", 146, 160], ["throat swabs", "ANATOMY", 164, 176], ["patients", "ORGANISM", 22, 30], ["turbinate", "ORGAN", 101, 110], ["patients", "SPECIES", 22, 30], ["virus", "TEST", 62, 67], ["mid-turbinate swabs", "TEST", 97, 116], ["sputum samples", "TEST", 146, 160], ["throat swabs", "TEST", 164, 176], ["the three assays", "TEST", 191, 207], ["DFA", "TEST", 219, 222], ["RT", "TEST", 229, 231], ["PCR", "TEST", 232, 235], ["multiplex PCR", "TEST", 246, 259]]], ["Of those 26 virus-positive subjects, 17 (65.4%) tested positive for one virus and the remaining 9 (34.6%) for two or more viruses (all by ResPlex II v2.0).", [["those 26 virus", "TEST", 3, 17], ["one virus", "PROBLEM", 68, 77], ["more viruses", "PROBLEM", 117, 129], ["viruses", "OBSERVATION", 122, 129]]], ["From the 17 participants who tested positive for only one respiratory virus, coxsackie/echovirus was the most commonly identified pathogen (29.4%) (Table 1).", [["respiratory virus", "DISEASE", 58, 75], ["coxsackie/echovirus", "DISEASE", 77, 96], ["participants", "ORGANISM", 12, 24], ["coxsackie/echovirus", "ORGANISM", 77, 96], ["participants", "SPECIES", 12, 24], ["one respiratory virus", "PROBLEM", 54, 75], ["coxsackie/echovirus", "PROBLEM", 77, 96], ["pathogen", "TEST", 130, 138], ["respiratory virus", "ANATOMY", 58, 75]]], ["RSV was reported from all participants who tested positive for two viruses (6/6) (Table 1).Patient characteristics and clinical status at the time of pulmonary exacerbation ::: ResultsVirus-positive patients were significantly younger (p= 0.047) and more likely to be male (p= 0.029) than virus-negative patients.", [["pulmonary", "ANATOMY", 150, 159], ["RSV", "ORGANISM", 0, 3], ["pulmonary", "ORGAN", 150, 159], ["ResultsVirus", "GENE_OR_GENE_PRODUCT", 177, 189], ["patients", "ORGANISM", 199, 207], ["patients", "ORGANISM", 304, 312], ["participants", "SPECIES", 26, 38], ["Patient", "SPECIES", 91, 98], ["patients", "SPECIES", 199, 207], ["patients", "SPECIES", 304, 312], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["two viruses", "PROBLEM", 63, 74], ["pulmonary exacerbation", "PROBLEM", 150, 172], ["ResultsVirus", "TEST", 177, 189], ["virus", "TEST", 289, 294], ["pulmonary", "ANATOMY", 150, 159], ["exacerbation", "OBSERVATION", 160, 172]]], ["Also, they were significantly more likely to present with fever (p= 0.019) but not with upper respiratory tract infection symptoms (p= 0.941) (Table 2).", [["upper respiratory tract", "ANATOMY", 88, 111], ["fever", "DISEASE", 58, 63], ["respiratory tract infection", "DISEASE", 94, 121], ["upper", "ORGANISM_SUBDIVISION", 88, 93], ["respiratory tract", "ORGANISM_SUBDIVISION", 94, 111], ["fever", "PROBLEM", 58, 63], ["upper respiratory tract infection symptoms", "PROBLEM", 88, 130], ["not with", "UNCERTAINTY", 79, 87], ["upper", "ANATOMY_MODIFIER", 88, 93], ["respiratory tract", "ANATOMY", 94, 111], ["infection", "OBSERVATION", 112, 121]]], ["There were no other significant differences between the two groups.", [["no other", "UNCERTAINTY", 11, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["differences", "OBSERVATION", 32, 43]]], ["At the time of exacerbation, virus-positive patients had significantly higher CF clinical score (CFCS) (27 vs 24; p= 0.041) and lower quality of life (physical) CFQ-R score (53.4 vs 75.3; p= 0.030) (Table 3).", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["exacerbation", "PROBLEM", 15, 27], ["virus", "PROBLEM", 29, 34], ["significantly higher CF clinical score", "PROBLEM", 57, 95], ["CFCS", "TEST", 97, 101], ["p", "TEST", 114, 115], ["CFQ", "TEST", 161, 164], ["R score", "TEST", 165, 172], ["p", "TEST", 188, 189], ["exacerbation", "OBSERVATION", 15, 27]]], ["When the patient's viral infection status was determined without incorporating the positive rhinovirus and coxsackie/echovirus results, the physical CFQ-R score of virus-positive patients remained significantly lower (58.5 vs 194.5; p= 0.022).", [["viral infection", "DISEASE", 19, 34], ["patient", "ORGANISM", 9, 16], ["rhinovirus", "ORGANISM", 92, 102], ["coxsackie/echovirus", "ORGANISM", 107, 126], ["CFQ-R", "GENE_OR_GENE_PRODUCT", 149, 154], ["patients", "ORGANISM", 179, 187], ["patient", "SPECIES", 9, 16], ["patients", "SPECIES", 179, 187], ["the patient's viral infection status", "PROBLEM", 5, 41], ["the positive rhinovirus", "PROBLEM", 79, 102], ["coxsackie/echovirus", "PROBLEM", 107, 126], ["the physical CFQ", "TEST", 136, 152], ["virus", "TEST", 164, 169], ["p", "TEST", 233, 234]]], ["However, CFCS was no longer significantly different between virus-positive and negative patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["CFCS", "TEST", 9, 13], ["virus", "TEST", 60, 65], ["no longer", "UNCERTAINTY", 18, 27]]], ["Antibiotic use, hospitalization requirements and mean percent predicted exacerbation FEV1 were not significantly different between the two groups (Table 3).Pulmonary inflammation ::: ResultsBacterial densities were examined in sputum samples from 8/26 (30.8%) virus-positive and 7/17 (41.2%) virus-negative patients.", [["Pulmonary", "ANATOMY", 156, 165], ["ResultsBacterial", "ANATOMY", 183, 199], ["sputum samples", "ANATOMY", 227, 241], ["Pulmonary inflammation", "DISEASE", 156, 178], ["Pulmonary", "ORGAN", 156, 165], ["sputum samples", "CANCER", 227, 241], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 307, 315], ["Antibiotic use", "TREATMENT", 0, 14], ["hospitalization requirements", "TREATMENT", 16, 44], ["mean percent predicted exacerbation FEV1", "PROBLEM", 49, 89], ["Pulmonary inflammation", "PROBLEM", 156, 178], ["ResultsBacterial densities", "PROBLEM", 183, 209], ["sputum samples", "TEST", 227, 241], ["virus", "TEST", 260, 265], ["virus", "TEST", 292, 297], ["significantly different", "OBSERVATION_MODIFIER", 99, 122], ["inflammation", "OBSERVATION", 166, 178], ["densities", "OBSERVATION", 200, 209]]], ["The mean total bacterial density observed in virus-positive patients was two logs lower (albeit not statistically significant) than that found in virus-negative patients (3.9 \u00d7 107 vs 1.8 \u00d7 10 9CFU/mL; p= 0.299).", [["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 161, 169], ["The mean total bacterial density", "TEST", 0, 32], ["virus", "PROBLEM", 45, 50], ["virus", "TEST", 146, 151], ["vs", "TEST", 181, 183], ["p", "TEST", 202, 203], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["total", "OBSERVATION_MODIFIER", 9, 14], ["bacterial density", "OBSERVATION", 15, 32]]], ["Virus-positive and negative patients had similar IL-8, neutrophil percentage and neutrophil elastase levels (Table 3).", [["neutrophil", "ANATOMY", 55, 65], ["neutrophil", "ANATOMY", 81, 91], ["Virus", "ORGANISM", 0, 5], ["patients", "ORGANISM", 28, 36], ["IL-8", "GENE_OR_GENE_PRODUCT", 49, 53], ["neutrophil", "CELL", 55, 65], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 81, 100], ["IL-8", "PROTEIN", 49, 53], ["neutrophil", "CELL_TYPE", 81, 91], ["elastase", "PROTEIN", 92, 100], ["patients", "SPECIES", 28, 36], ["Virus", "TEST", 0, 5], ["similar IL", "TEST", 41, 51], ["neutrophil percentage", "TEST", 55, 76], ["neutrophil elastase levels", "TEST", 81, 107], ["neutrophil elastase", "OBSERVATION", 81, 100]]], ["There was also no difference in the 26 additional cytokines levels between both groups (Supplementary Table 1).Comparison of viral detection in mid-turbinate swabs and sputum or throat swab samples ::: ResultsA total of 21/43 (48.8%) patients had concomitant sputum samples and 11/43 (25.6%) had concomitant throat swabs tested for respiratory viruses by ResPlex II v2.0.", [["mid-turbinate swabs", "ANATOMY", 144, 163], ["sputum", "ANATOMY", 168, 174], ["throat swab samples", "ANATOMY", 178, 197], ["sputum samples", "ANATOMY", 259, 273], ["throat swabs", "ANATOMY", 308, 320], ["respiratory viruses", "DISEASE", 332, 351], ["mid-turbinate swabs", "ORGANISM_SUBSTANCE", 144, 163], ["sputum", "ORGANISM_SUBSTANCE", 168, 174], ["patients", "ORGANISM", 234, 242], ["sputum samples", "CANCER", 259, 273], ["cytokines", "PROTEIN", 50, 59], ["patients", "SPECIES", 234, 242], ["difference in the 26 additional cytokines levels", "PROBLEM", 18, 66], ["viral detection", "TEST", 125, 140], ["mid-turbinate swabs", "TEST", 144, 163], ["sputum", "TEST", 168, 174], ["throat swab samples", "TEST", 178, 197], ["concomitant sputum samples", "PROBLEM", 247, 273], ["concomitant throat swabs", "PROBLEM", 296, 320], ["respiratory viruses", "PROBLEM", 332, 351], ["no", "UNCERTAINTY", 15, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28], ["viral", "OBSERVATION", 125, 130], ["throat", "ANATOMY", 308, 314]]], ["Overall, the detection rate of respiratory viruses using mid-turbinate swabs was similar to that of throat swabs (7/11 vs 6/11) but higher than that of sputum samples (11/21 vs 6/21) (Supplementary Table 2).", [["mid-turbinate swabs", "ANATOMY", 57, 76], ["throat swabs", "ANATOMY", 100, 112], ["sputum samples", "ANATOMY", 152, 166], ["mid-turbinate swabs", "ORGANISM_SUBSTANCE", 57, 76], ["throat swabs", "ORGANISM_SUBDIVISION", 100, 112], ["sputum samples", "CANCER", 152, 166], ["the detection rate", "TEST", 9, 27], ["respiratory viruses", "PROBLEM", 31, 50], ["mid-turbinate swabs", "TREATMENT", 57, 76], ["throat swabs", "TEST", 100, 112], ["sputum samples", "TEST", 152, 166], ["respiratory viruses", "OBSERVATION", 31, 50]]], ["For classification of infection status based on detection of at least one respiratory virus, mid-turbinate swabs had a 76% (16/21) concordance rate with sputum samples (concordant pairs: 6 positive/positive, 10 negative/negative; discordant pairs: 5 positive/negative, 0 negative/positive) and 72.7% (8/11) concordance rate with throat swabs (concordant pairs: 5 positive/positive, 3 negative/negative; discordant pairs: 2 positive/negative, 1 negative/positive).", [["mid-turbinate swabs", "ANATOMY", 93, 112], ["sputum samples", "ANATOMY", 153, 167], ["throat swabs", "ANATOMY", 329, 341], ["infection", "DISEASE", 22, 31], ["mid-turbinate swabs", "ORGANISM_SUBSTANCE", 93, 112], ["sputum samples", "CANCER", 153, 167], ["infection status", "PROBLEM", 22, 38], ["one respiratory virus", "PROBLEM", 70, 91], ["mid-turbinate swabs", "TEST", 93, 112], ["concordance rate", "TEST", 131, 147], ["sputum samples", "TEST", 153, 167], ["concordance rate", "TEST", 307, 323], ["throat swabs", "TEST", 329, 341], ["infection", "OBSERVATION", 22, 31], ["respiratory virus", "OBSERVATION", 74, 91]]], ["The sensitivities of mid-turbinate swabs and sputum samples relative to the combination of mid-turbinate and/or sputum samples were 100.0% (95% CI, 67.9\u2013100.0) and 54.5% (95% CI, 24.6\u201381.9) respectively, while the specificities were both 100.0% (95% CI, 65.5\u2013100.0).", [["mid-turbinate swabs", "ANATOMY", 21, 40], ["sputum samples", "ANATOMY", 45, 59], ["mid-turbinate", "ANATOMY", 91, 104], ["sputum samples", "ANATOMY", 112, 126], ["mid-turbinate swabs", "ORGANISM_SUBSTANCE", 21, 40], ["sputum samples", "CANCER", 45, 59], ["mid-turbinate", "CANCER", 91, 104], ["The sensitivities", "TEST", 0, 17], ["mid-turbinate swabs", "TEST", 21, 40], ["sputum samples", "TEST", 45, 59], ["mid-turbinate", "TEST", 91, 104], ["sputum samples", "TEST", 112, 126], ["CI", "TEST", 144, 146], ["CI", "TEST", 175, 177], ["the specificities", "TEST", 210, 227], ["CI", "TEST", 250, 252]]], ["Mid-turbinate swabs trended toward being more sensitive than sputum samples (p= 0.0625).", [["Mid-turbinate swabs", "ANATOMY", 0, 19], ["sputum samples", "ANATOMY", 61, 75], ["Mid-turbinate swabs", "TISSUE", 0, 19], ["Mid-turbinate swabs", "TEST", 0, 19], ["sputum samples", "TEST", 61, 75]]], ["We did not calculate sensitivities and specificities for the mid-turbinate/throat swabs paired samples due to limited numbers.DiscussionThe proportion of virus-associated exacerbations documented in our study is similar to those demonstrated in recent studies using molecular-based techniques (60.0% and 49.8%) [20] and significantly higher than those found in prior studies using conventional diagnostic methods (< 15%) [4], [5].", [["throat swabs", "ANATOMY", 75, 87], ["samples", "ANATOMY", 95, 102], ["exacerbations", "DISEASE", 171, 184], ["sensitivities", "TEST", 21, 34], ["specificities", "TEST", 39, 52], ["the mid-turbinate/throat swabs paired samples", "TEST", 57, 102], ["virus", "PROBLEM", 154, 159], ["associated exacerbations", "PROBLEM", 160, 184], ["our study", "TEST", 199, 208], ["recent studies", "TEST", 245, 259], ["molecular-based techniques", "TEST", 266, 292], ["prior studies", "TEST", 361, 374], ["conventional diagnostic methods", "TEST", 381, 412], ["virus", "OBSERVATION", 154, 159], ["exacerbations", "OBSERVATION", 171, 184]]], ["These discrepancies can be attributed to the higher sensitivity and broader range of virus detection afforded by molecular-based methods leading to a better estimation of the true prevalence of respiratory viruses in CF exacerbations.DiscussionRhinoviruses have been reported as major pathogens in CF exacerbations [1], [22] with detection rates reaching 87% from samples collected both from exacerbations and routine visits [20].", [["samples", "ANATOMY", 364, 371], ["respiratory viruses", "DISEASE", 194, 213], ["CF exacerbations", "DISEASE", 298, 314], ["Rhinoviruses", "GENE_OR_GENE_PRODUCT", 244, 256], ["the higher sensitivity", "PROBLEM", 41, 63], ["virus detection", "TEST", 85, 100], ["respiratory viruses", "PROBLEM", 194, 213], ["CF exacerbations", "PROBLEM", 217, 233], ["Rhinoviruses", "PROBLEM", 244, 256], ["CF exacerbations", "PROBLEM", 298, 314], ["detection rates", "TEST", 330, 345], ["exacerbations", "PROBLEM", 392, 405], ["respiratory viruses", "OBSERVATION", 194, 213]]], ["Ours and another study [1] reported similar rates of rhinovirus detection (17.6% vs 15.9%) from samples collected during exacerbation.", [["samples", "ANATOMY", 96, 103], ["rhinovirus", "ORGANISM", 53, 63], ["another study", "TEST", 9, 22], ["rhinovirus detection", "TEST", 53, 73], ["samples", "TEST", 96, 103], ["exacerbation", "PROBLEM", 121, 133], ["rhinovirus", "OBSERVATION", 53, 63]]], ["Rhinovirus and coxsackie/echovirus comprised half of our identified viruses.", [["Rhinovirus", "CHEMICAL", 0, 10], ["coxsackie/echovirus", "DISEASE", 15, 34], ["coxsackie/echovirus", "ORGANISM", 15, 34], ["Rhinovirus", "PROBLEM", 0, 10], ["coxsackie", "PROBLEM", 15, 24], ["echovirus", "PROBLEM", 25, 34], ["coxsackie", "OBSERVATION", 15, 24], ["echovirus", "OBSERVATION", 25, 34], ["viruses", "OBSERVATION", 68, 75]]], ["Given the ResPlex II v2.0 assay's suboptimal performance in distinguishing rhinovirus from coxsackie/echovirus, our true rate of rhinovirus detection might have been even higher [21].DiscussionOur study documented a low proportion of pH1N1 (5.3%) even though it was conducted during the larger second wave of the 2009 influenza with a modest pH1N1 vaccine uptake rate (46.5%).", [["rhinovirus", "DISEASE", 75, 85], ["coxsackie/echovirus", "DISEASE", 91, 110], ["influenza", "DISEASE", 318, 327], ["rhinovirus", "ORGANISM", 75, 85], ["coxsackie/echovirus", "ORGANISM", 91, 110], ["rhinovirus", "ORGANISM", 129, 139], ["ResPlex II", "PROTEIN", 10, 20], ["coxsackie/echovirus", "SPECIES", 91, 110], ["pH1N1", "SPECIES", 234, 239], ["the ResPlex II v2.0 assay", "TEST", 6, 31], ["rhinovirus", "PROBLEM", 75, 85], ["coxsackie", "PROBLEM", 91, 100], ["echovirus", "PROBLEM", 101, 110], ["rhinovirus detection", "PROBLEM", 129, 149], ["DiscussionOur study", "TEST", 183, 202], ["H1N1", "PROBLEM", 235, 239], ["influenza", "PROBLEM", 318, 327], ["a modest pH1N1 vaccine", "TREATMENT", 333, 355], ["uptake rate", "TEST", 356, 367], ["rhinovirus", "OBSERVATION", 75, 85], ["rhinovirus", "OBSERVATION", 129, 139]]], ["Another study [1] conducted during a typical influenza season reported higher influenza A and B detection rates (25%) despite a high influenza vaccination uptake of 70%.", [["influenza", "DISEASE", 45, 54], ["influenza A and B", "DISEASE", 78, 95], ["Another study", "TEST", 0, 13], ["a typical influenza season", "PROBLEM", 35, 61], ["higher influenza A", "PROBLEM", 71, 89], ["B detection rates", "TEST", 94, 111], ["a high influenza vaccination uptake", "PROBLEM", 126, 161]]], ["These discrepancies may be related to the perfect matching of the pH1N1 vaccine to the circulating influenza viruses during our study period.DiscussionCompared to another study [1], our rate of viral coinfection was significantly higher (34.6% vs 4.3%).", [["influenza viruses", "DISEASE", 99, 116], ["viral coinfection", "DISEASE", 194, 211], ["pH1N1", "ORGANISM", 66, 71], ["These discrepancies", "PROBLEM", 0, 19], ["the pH1N1 vaccine", "TREATMENT", 62, 79], ["the circulating influenza viruses", "PROBLEM", 83, 116], ["another study", "TEST", 163, 176], ["viral coinfection", "PROBLEM", 194, 211], ["may be related to", "UNCERTAINTY", 20, 37], ["influenza viruses", "OBSERVATION", 99, 116], ["coinfection", "OBSERVATION", 200, 211]]], ["These discrepancies can be attributed to the broader range of virus detection afforded by the ResPlex II v2.0 assay compared to other molecular-based methods used in this study (detection of 18 viruses vs 9 viruses) [1].", [["ResPlex II", "PROTEIN", 94, 104], ["These discrepancies", "PROBLEM", 0, 19], ["virus detection", "TEST", 62, 77], ["the ResPlex II v2.0 assay", "TEST", 90, 115], ["this study", "TEST", 166, 176]]], ["Multiplex assays permit the improved identification of cases of infection with multiple agents although the impact of multiple viral infections on the clinical course of disease is at present unknown and worthy of further study [21].DiscussionTo our knowledge, this is the first study to assess the severity of viral-associated pulmonary exacerbations and their impact on quality of life.", [["pulmonary", "ANATOMY", 328, 337], ["infection", "DISEASE", 64, 73], ["viral infections", "DISEASE", 127, 143], ["pulmonary exacerbations", "DISEASE", 328, 351], ["pulmonary", "ORGAN", 328, 337], ["Multiplex assays", "TEST", 0, 16], ["infection", "PROBLEM", 64, 73], ["multiple agents", "TREATMENT", 79, 94], ["multiple viral infections", "PROBLEM", 118, 143], ["disease", "PROBLEM", 170, 177], ["further study", "TEST", 214, 227], ["the first study", "TEST", 269, 284], ["viral-associated pulmonary exacerbations", "PROBLEM", 311, 351], ["infection", "OBSERVATION", 64, 73], ["multiple", "OBSERVATION_MODIFIER", 118, 126], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["infections", "OBSERVATION", 133, 143], ["viral", "OBSERVATION", 311, 316], ["pulmonary", "ANATOMY", 328, 337], ["exacerbations", "OBSERVATION", 338, 351]]], ["Virus-positive subjects had significantly higher severity and lower quality of life scores.", [["Virus", "ORGANISM", 0, 5], ["Virus", "TEST", 0, 5], ["significantly higher severity", "PROBLEM", 28, 57], ["higher severity", "OBSERVATION_MODIFIER", 42, 57], ["lower quality", "OBSERVATION_MODIFIER", 62, 75]]], ["Our ability to detect a difference in severity scores between the two groups but not other metrics of pulmonary exacerbation severity may reflect the increased statistical power afforded by the quantitative nature of the severity and quality of life scores.", [["pulmonary", "ANATOMY", 102, 111], ["pulmonary", "ORGAN", 102, 111], ["a difference in severity scores", "PROBLEM", 22, 53], ["pulmonary exacerbation severity", "PROBLEM", 102, 133], ["pulmonary", "ANATOMY", 102, 111], ["exacerbation", "OBSERVATION", 112, 124], ["increased", "OBSERVATION_MODIFIER", 150, 159]]], ["Another study [22] suggested that children in whom a virus other than rhinovirus or coxsackie/echovirus was identified had a significantly greater decline in FEV1 from baseline compared to children with a rhinovirus infection.", [["rhinovirus infection", "DISEASE", 205, 225], ["children", "ORGANISM", 34, 42], ["rhinovirus", "ORGANISM", 70, 80], ["coxsackie/echovirus", "ORGANISM", 84, 103], ["children", "ORGANISM", 189, 197], ["rhinovirus", "ORGANISM", 205, 215], ["children", "SPECIES", 34, 42], ["children", "SPECIES", 189, 197], ["Another study", "TEST", 0, 13], ["a virus", "PROBLEM", 51, 58], ["rhinovirus", "PROBLEM", 70, 80], ["coxsackie/echovirus", "PROBLEM", 84, 103], ["a significantly greater decline in FEV1", "PROBLEM", 123, 162], ["a rhinovirus infection", "PROBLEM", 203, 225], ["significantly", "OBSERVATION_MODIFIER", 125, 138], ["greater", "OBSERVATION_MODIFIER", 139, 146], ["decline", "OBSERVATION_MODIFIER", 147, 154], ["rhinovirus", "OBSERVATION", 205, 215]]], ["However, our repeat analyses after excluding the rhinovirus and coxsackie/echovirus-positive patients did not change the above findings other than the difference in the CFCS which became insignificant.", [["CFCS", "DISEASE", 169, 173], ["rhinovirus", "ORGANISM", 49, 59], ["coxsackie/echovirus", "ORGANISM", 64, 83], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["our repeat analyses", "TEST", 9, 28], ["the rhinovirus", "PROBLEM", 45, 59], ["coxsackie/echovirus", "TEST", 64, 83], ["the CFCS", "TEST", 165, 173], ["insignificant", "OBSERVATION_MODIFIER", 187, 200]]], ["This might reflect a decreased discriminative ability of CFCS compared to the CFQ-R, the underpowered sample size after excluding rhinovirus and coxsackie/echovirus-positive patients, and/or a biased estimate resulting from missing CFQ-R data.DiscussionSeveral studies have correlated repeated bacterial infections in CF patients with increased airway inflammation, whereas the pathophysiology of virus-induced CF exacerbation remains unclear [9], [10], [11].", [["airway", "ANATOMY", 345, 351], ["bacterial infections", "DISEASE", 294, 314], ["CF", "DISEASE", 318, 320], ["airway inflammation", "DISEASE", 345, 364], ["CF", "DISEASE", 411, 413], ["CFQ-R", "GENE_OR_GENE_PRODUCT", 78, 83], ["rhinovirus", "ORGANISM", 130, 140], ["coxsackie/echovirus", "ORGANISM", 145, 164], ["patients", "ORGANISM", 174, 182], ["CFQ-R", "GENE_OR_GENE_PRODUCT", 232, 237], ["patients", "ORGANISM", 321, 329], ["airway", "MULTI-TISSUE_STRUCTURE", 345, 351], ["[10]", "SIMPLE_CHEMICAL", 448, 452], ["[11]", "SIMPLE_CHEMICAL", 454, 458], ["CFQ", "PROTEIN", 232, 235], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 321, 329], ["a decreased discriminative ability of CFCS", "PROBLEM", 19, 61], ["the CFQ", "TEST", 74, 81], ["rhinovirus", "PROBLEM", 130, 140], ["coxsackie/echovirus", "PROBLEM", 145, 164], ["DiscussionSeveral studies", "TEST", 243, 268], ["repeated bacterial infections in CF", "PROBLEM", 285, 320], ["increased airway inflammation", "PROBLEM", 335, 364], ["virus", "PROBLEM", 397, 402], ["CF exacerbation", "PROBLEM", 411, 426], ["decreased", "OBSERVATION_MODIFIER", 21, 30], ["discriminative", "OBSERVATION_MODIFIER", 31, 45], ["size", "OBSERVATION_MODIFIER", 109, 113], ["rhinovirus", "OBSERVATION", 130, 140], ["bacterial", "OBSERVATION_MODIFIER", 294, 303], ["infections", "OBSERVATION", 304, 314], ["increased", "OBSERVATION_MODIFIER", 335, 344], ["airway", "ANATOMY", 345, 351], ["inflammation", "OBSERVATION", 352, 364]]], ["In our study, levels of sputum IL-8, neutrophil percentage and neutrophil elastase were within ranges of published data [9], [17] whereas sputum neutrophil cell counts were lower than what have been described in the literature [9], [17].", [["neutrophil", "ANATOMY", 37, 47], ["neutrophil", "ANATOMY", 63, 73], ["sputum neutrophil cell", "ANATOMY", 138, 160], ["IL-8", "GENE_OR_GENE_PRODUCT", 31, 35], ["neutrophil", "CELL", 37, 47], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 63, 82], ["neutrophil cell", "CELL", 145, 160], ["sputum IL-8", "PROTEIN", 24, 35], ["neutrophil elastase", "PROTEIN", 63, 82], ["our study", "TEST", 3, 12], ["levels", "TEST", 14, 20], ["sputum IL", "TEST", 24, 33], ["neutrophil percentage", "TEST", 37, 58], ["neutrophil elastase", "TEST", 63, 82], ["published data", "TEST", 105, 119], ["sputum neutrophil cell counts", "TEST", 138, 167], ["neutrophil elastase", "OBSERVATION", 63, 82]]], ["Our study included outpatients with milder exacerbations and consisted of a younger patient-population which may have resulted in a milder degree of airway inflammation and therefore in lower sputum neutrophil counts.", [["airway", "ANATOMY", 149, 155], ["sputum neutrophil", "ANATOMY", 192, 209], ["airway inflammation", "DISEASE", 149, 168], ["outpatients", "ORGANISM", 19, 30], ["patient", "ORGANISM", 84, 91], ["airway", "MULTI-TISSUE_STRUCTURE", 149, 155], ["neutrophil", "CELL", 199, 209], ["outpatients", "SPECIES", 19, 30], ["patient", "SPECIES", 84, 91], ["Our study", "TEST", 0, 9], ["milder exacerbations", "PROBLEM", 36, 56], ["airway inflammation", "PROBLEM", 149, 168], ["lower sputum neutrophil counts", "TEST", 186, 216], ["milder degree", "OBSERVATION_MODIFIER", 132, 145], ["airway", "ANATOMY", 149, 155], ["inflammation", "OBSERVATION", 156, 168], ["lower", "OBSERVATION_MODIFIER", 186, 191], ["sputum neutrophil counts", "OBSERVATION", 192, 216]]], ["We also found levels of inflammatory cytokines in both groups to be similar but reported a two-log lower mean total bacterial density in virus-positive subjects compared to the virus-negative ones (albeit not significant), likely due to the younger age of virus-positive subjects.", [["inflammatory cytokines", "PROTEIN", 24, 46], ["inflammatory cytokines", "PROBLEM", 24, 46], ["a two-log lower mean total bacterial density in virus", "PROBLEM", 89, 142], ["positive subjects", "PROBLEM", 143, 160], ["the virus", "TEST", 173, 182], ["inflammatory", "OBSERVATION_MODIFIER", 24, 36], ["cytokines", "OBSERVATION", 37, 46], ["bacterial density", "OBSERVATION", 116, 133]]], ["A recent study [23] reported a trend toward lower cytokine production in CF airway epithelial cells following viral infection.", [["CF airway epithelial cells", "ANATOMY", 73, 99], ["viral infection", "DISEASE", 110, 125], ["CF airway epithelial cells", "CELL", 73, 99], ["cytokine", "PROTEIN", 50, 58], ["CF airway epithelial cells", "CELL_TYPE", 73, 99], ["A recent study", "TEST", 0, 14], ["a trend toward lower cytokine production in CF airway epithelial cells", "PROBLEM", 29, 99], ["viral infection", "PROBLEM", 110, 125], ["airway", "ANATOMY", 76, 82], ["epithelial cells", "OBSERVATION", 83, 99], ["viral", "OBSERVATION_MODIFIER", 110, 115], ["infection", "OBSERVATION", 116, 125]]], ["Whether respiratory viruses themselves or by interaction with bacteria induce the observed inflammation remains controversial and requires further investigation.DiscussionThe data available for the optimal method for respiratory viral detection is limited and controversial [1].", [["inflammation", "DISEASE", 91, 103], ["respiratory viruses", "ORGANISM", 8, 27], ["respiratory viruses themselves", "PROBLEM", 8, 38], ["bacteria", "PROBLEM", 62, 70], ["the observed inflammation", "PROBLEM", 78, 103], ["further investigation", "TEST", 139, 160], ["the optimal method", "TEST", 194, 212], ["respiratory viral detection", "TEST", 217, 244], ["viruses", "OBSERVATION", 20, 27], ["inflammation", "OBSERVATION", 91, 103]]], ["Our study reported a higher rate of viral detection with mid-turbinate swabs than with sputum samples in contrast with another recent study which reported higher concordance rates (87% for rhinoviruses detection and 92% for other virus types) [24].", [["mid-turbinate swabs", "ANATOMY", 57, 76], ["sputum samples", "ANATOMY", 87, 101], ["rhinoviruses", "DISEASE", 189, 201], ["rhinoviruses", "ORGANISM", 189, 201], ["Our study", "TEST", 0, 9], ["viral detection", "TEST", 36, 51], ["mid-turbinate swabs", "PROBLEM", 57, 76], ["sputum samples", "TEST", 87, 101], ["another recent study", "TEST", 119, 139], ["concordance rates", "TEST", 162, 179], ["rhinoviruses detection", "TEST", 189, 211]]], ["The difference in timing of sampling between this study (23% of samples collected during exacerbation) and ours (100% during exacerbation) might have contributed to these observed differences.", [["samples", "ANATOMY", 64, 71], ["this study", "TEST", 45, 55], ["samples", "TEST", 64, 71], ["exacerbation", "PROBLEM", 89, 101], ["exacerbation", "PROBLEM", 125, 137], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["A larger study comparing test performance characteristics of paired upper airway and sputum samples collected during exacerbations would provide insights into the above findings.DiscussionOur study has several limitations.", [["upper airway", "ANATOMY", 68, 80], ["sputum samples", "ANATOMY", 85, 99], ["upper airway", "MULTI-TISSUE_STRUCTURE", 68, 80], ["A larger study", "TEST", 0, 14], ["paired upper airway and sputum samples", "PROBLEM", 61, 99], ["exacerbations", "PROBLEM", 117, 130], ["DiscussionOur study", "TEST", 178, 197], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["upper", "ANATOMY_MODIFIER", 68, 73], ["airway", "ANATOMY", 74, 80], ["sputum", "OBSERVATION", 85, 91]]], ["The observational design limits our ability to exclude the effect of measured or unmeasured covariates in our analysis.", [["our analysis", "TEST", 106, 118]]], ["Despite the central importance of pulmonary exacerbations as an outcome measure in CF clinical trials, no standardized definition of pulmonary exacerbation that includes children under the age of 6 has been validated.", [["pulmonary", "ANATOMY", 34, 43], ["pulmonary", "ANATOMY", 133, 142], ["pulmonary exacerbations", "DISEASE", 34, 57], ["pulmonary exacerbation", "DISEASE", 133, 155], ["pulmonary", "ORGAN", 34, 43], ["pulmonary", "ORGAN", 133, 142], ["children", "ORGANISM", 170, 178], ["children", "SPECIES", 170, 178], ["pulmonary exacerbations", "PROBLEM", 34, 57], ["pulmonary exacerbation", "PROBLEM", 133, 155], ["central", "OBSERVATION_MODIFIER", 12, 19], ["pulmonary", "ANATOMY", 34, 43], ["exacerbations", "OBSERVATION", 44, 57], ["pulmonary", "ANATOMY", 133, 142], ["exacerbation", "OBSERVATION", 143, 155]]], ["In using a broader definition of pulmonary exacerbation which includes children managed as outpatients, our sample may have included more patients with mild exacerbations than other studies.", [["pulmonary", "ANATOMY", 33, 42], ["pulmonary exacerbation", "DISEASE", 33, 55], ["pulmonary", "ORGAN", 33, 42], ["children", "ORGANISM", 71, 79], ["patients", "ORGANISM", 138, 146], ["children", "SPECIES", 71, 79], ["patients", "SPECIES", 138, 146], ["pulmonary exacerbation", "PROBLEM", 33, 55], ["mild exacerbations", "PROBLEM", 152, 170], ["other studies", "TEST", 176, 189], ["pulmonary", "ANATOMY", 33, 42], ["exacerbation", "OBSERVATION", 43, 55], ["mild", "OBSERVATION_MODIFIER", 152, 156], ["exacerbations", "OBSERVATION", 157, 170]]], ["However, the proportion of hospitalized patients with viral infection in our study (64%) was similar to that of outpatients (58%).", [["viral infection", "DISEASE", 54, 69], ["patients", "ORGANISM", 40, 48], ["outpatients", "ORGANISM", 112, 123], ["patients", "SPECIES", 40, 48], ["outpatients", "SPECIES", 112, 123], ["viral infection", "PROBLEM", 54, 69], ["our study", "TEST", 73, 82], ["viral", "OBSERVATION_MODIFIER", 54, 59], ["infection", "OBSERVATION", 60, 69]]], ["Likewise, there are no generally accepted severity scores for pulmonary exacerbations that apply to younger children, including the CFQ-R, a validated and widely used patient-reported outcome.", [["pulmonary", "ANATOMY", 62, 71], ["pulmonary exacerbations", "DISEASE", 62, 85], ["pulmonary", "ORGAN", 62, 71], ["children", "ORGANISM", 108, 116], ["patient", "ORGANISM", 167, 174], ["children", "SPECIES", 108, 116], ["patient", "SPECIES", 167, 174], ["severity scores", "PROBLEM", 42, 57], ["pulmonary exacerbations", "PROBLEM", 62, 85], ["no", "UNCERTAINTY", 20, 22], ["pulmonary", "ANATOMY", 62, 71], ["exacerbations", "OBSERVATION", 72, 85]]], ["Despite its validation against PFTs as the gold standard, the CFCS has been infrequently used in clinical trials.", [["PFTs", "TEST", 31, 35], ["the CFCS", "TREATMENT", 58, 66]]], ["This highlights the need for further evaluation of its applicability in clinical studies.", [["further evaluation", "TEST", 29, 47], ["clinical studies", "TEST", 72, 88]]], ["Our small sample size did not permit subgroup analyses according to individual viruses.", [["Our small sample size", "PROBLEM", 0, 21], ["subgroup analyses", "TEST", 37, 54], ["small", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 17, 21], ["viruses", "OBSERVATION", 79, 86]]], ["Finally, we did not have data on viral infection status in CF children not experiencing an exacerbation as a comparator to strengthen the association between the exacerbation and viral infections.", [["viral infection", "DISEASE", 33, 48], ["viral infections", "DISEASE", 179, 195], ["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["viral infection status", "PROBLEM", 33, 55], ["an exacerbation", "PROBLEM", 88, 103], ["the exacerbation", "PROBLEM", 158, 174], ["viral infections", "PROBLEM", 179, 195], ["infection", "OBSERVATION", 39, 48], ["exacerbation", "OBSERVATION", 91, 103], ["viral", "OBSERVATION_MODIFIER", 179, 184], ["infections", "OBSERVATION", 185, 195]]], ["Compared to other viruses such as RSV, rhinoviruses can shed for a prolonged period (> 3 weeks vs < 1 week) [25] and may have been acquired before the exacerbation.", [["RSV", "ORGANISM", 34, 37], ["rhinoviruses", "ORGANISM", 39, 51], ["RSV", "SPECIES", 34, 37], ["RSV", "SPECIES", 34, 37], ["RSV", "PROBLEM", 34, 37], ["rhinoviruses", "PROBLEM", 39, 51], ["the exacerbation", "PROBLEM", 147, 163], ["rhinoviruses", "OBSERVATION", 39, 51]]], ["However, virus-positive subjects were more likely to present with fever upon exacerbation.DiscussionIn conclusion, respiratory viruses, especially coxsackie/echovirus and rhinovirus are frequently associated with pulmonary exacerbations in pediatric CF patients.", [["pulmonary", "ANATOMY", 213, 222], ["fever", "DISEASE", 66, 71], ["respiratory viruses", "DISEASE", 115, 134], ["coxsackie/echovirus and rhinovirus", "DISEASE", 147, 181], ["pulmonary exacerbations", "DISEASE", 213, 236], ["CF", "DISEASE", 250, 252], ["subjects", "ORGANISM", 24, 32], ["respiratory viruses", "ORGANISM", 115, 134], ["coxsackie/echovirus", "ORGANISM", 147, 166], ["rhinovirus", "ORGANISM", 171, 181], ["pulmonary", "ORGAN", 213, 222], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["virus", "PROBLEM", 9, 14], ["fever", "PROBLEM", 66, 71], ["exacerbation", "PROBLEM", 77, 89], ["respiratory viruses", "PROBLEM", 115, 134], ["coxsackie", "PROBLEM", 147, 156], ["echovirus", "PROBLEM", 157, 166], ["rhinovirus", "PROBLEM", 171, 181], ["pulmonary exacerbations", "PROBLEM", 213, 236], ["fever", "OBSERVATION", 66, 71], ["respiratory", "ANATOMY", 115, 126], ["viruses", "OBSERVATION", 127, 134], ["echovirus", "OBSERVATION", 157, 166], ["rhinovirus", "OBSERVATION", 171, 181], ["pulmonary", "ANATOMY", 213, 222], ["exacerbations", "OBSERVATION", 223, 236]]], ["Systematic detection of respiratory viruses by molecular techniques using mid-turbinate swabs should occur in the setting of a pulmonary exacerbation.", [["mid-turbinate swabs", "ANATOMY", 74, 93], ["pulmonary", "ANATOMY", 127, 136], ["respiratory viruses", "DISEASE", 24, 43], ["pulmonary exacerbation", "DISEASE", 127, 149], ["pulmonary", "ORGAN", 127, 136], ["respiratory viruses", "PROBLEM", 24, 43], ["mid-turbinate swabs", "TREATMENT", 74, 93], ["a pulmonary exacerbation", "PROBLEM", 125, 149], ["respiratory viruses", "OBSERVATION", 24, 43], ["pulmonary", "ANATOMY", 127, 136], ["exacerbation", "OBSERVATION", 137, 149]]], ["The relative contribution of repeated respiratory viral infections in young children to pulmonary inflammation and continuing decline in lung function seen from an early age is not known.", [["pulmonary", "ANATOMY", 88, 97], ["lung", "ANATOMY", 137, 141], ["respiratory viral infections", "DISEASE", 38, 66], ["pulmonary inflammation", "DISEASE", 88, 110], ["children", "ORGANISM", 76, 84], ["pulmonary", "ORGAN", 88, 97], ["lung", "ORGAN", 137, 141], ["children", "SPECIES", 76, 84], ["repeated respiratory viral infections", "PROBLEM", 29, 66], ["pulmonary inflammation", "PROBLEM", 88, 110], ["continuing decline in lung function", "PROBLEM", 115, 150], ["repeated", "OBSERVATION_MODIFIER", 29, 37], ["respiratory viral infections", "OBSERVATION", 38, 66], ["pulmonary", "ANATOMY", 88, 97], ["inflammation", "OBSERVATION", 98, 110], ["lung", "ANATOMY", 137, 141], ["function", "OBSERVATION", 142, 150]]], ["A longitudinal study which documents the decline in FEV1 over time and comprehensively evaluates patients for both viral and bacterial infections during exacerbations might help to clarify the contribution of respiratory viruses to progressive lung damage.DiscussionSupplementary data to this article can be found online at doi:10.1016/j.jcf.2012.04.006.Conflicts of interestThe authors had no financial or other forms of conflicts of interest.Conflicts of interestThe following are the supplementary related to this article.", [["respiratory", "ANATOMY", 209, 220], ["lung", "ANATOMY", 244, 248], ["viral and bacterial infections", "DISEASE", 115, 145], ["respiratory viruses", "DISEASE", 209, 228], ["lung damage", "DISEASE", 244, 255], ["patients", "ORGANISM", 97, 105], ["lung", "ORGAN", 244, 248], ["patients", "SPECIES", 97, 105], ["A longitudinal study", "TEST", 0, 20], ["the decline in FEV1", "PROBLEM", 37, 56], ["both viral and bacterial infections", "PROBLEM", 110, 145], ["exacerbations", "PROBLEM", 153, 166], ["respiratory viruses", "PROBLEM", 209, 228], ["progressive lung damage", "PROBLEM", 232, 255], ["decline", "OBSERVATION_MODIFIER", 41, 48], ["bacterial", "OBSERVATION_MODIFIER", 125, 134], ["infections", "OBSERVATION", 135, 145], ["respiratory viruses", "OBSERVATION", 209, 228], ["progressive", "OBSERVATION_MODIFIER", 232, 243], ["lung", "ANATOMY", 244, 248], ["damage", "OBSERVATION", 249, 255]]]]}